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Summary 
The work described in this thesis deals with three aspects of quality assurance in 
the field of forensic toxicology: proficiency testing schemes, validation of 
analytical methods for the piperazine group of abused drugs and validation of 
the police field impairment test, used at the roadside to test drivers for drug-
induced impairment. 
Proficiency Testing 
Long term reviews were performed for two forensic external quality assurance 
schemes.  Rounds 30 (in 2007) to 48 (in 2012) of the UKAS-accredited 
commercial Quartz Forensic Blood Toxicology Proficiency Testing Scheme (PTS), 
and a ten year period from 1999 to 2009 of the freely-available United Nations 
Office on Drugs and Crime (UNODC) International Collaborative Exercises (ICE).  
Only limited ICE data could be made available as much of the original data had 
been stored on a database which had become obsolete, hence the data were 
only available as the original results forms provided to UNODC by the ICE 
participants.  Data was entered to Microsoft Excel® spreadsheets and Microsoft 
Access® databases from the original forms for the years 1999, 2001 (2 rounds), 
2003 (2 rounds) and 2005 (2 rounds), and summary data was extracted from the 
UNODC round reports for the years 2007, 2008 and 2009. 
Four methods of scoring quantitative performance were reviewed and the most 
suitable, a z-score using an assigned ‘true’ value and a percentage of the true 
value as acceptable deviation, was applied to reanalyse the participants’ results 
and assess their performance.  Methods of scoring proficiency which relied upon 
participants’ data to determine acceptable variation were found merely to 
describe the data rather than challenge participants on whether or not they 
were performing fit-for-purpose analyses.   
Factors such as participation, analytes tested, participants’ methods of analysis 
and participants performance were summarised for each scheme before the 
performance of the two schemes, and that of their participants, were compared. 
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ICE tested more analytes per annum but from a smaller test menu than Quartz.  
This resulted in more repetitive testing and allowed for some trend analysis and 
performance monitoring.  It was not possible to observe performance trends 
with Quartz due to the wide variety of analytes tested.  The smaller array of 
potential analytes and more repetitive nature of ICE testing also meant that 
performance monitoring and detection of bias were easier to perform, and ICE 
was shown to be more effective as external quality assurance (EQA).  Quartz 
provided a good educational resource as it incorporated the wide range of drugs 
which a forensic toxicology laboratory could realistically encounter.  Following 
the review, however, it was recommended for QUARTZ that, to provide a 
safeguard against bias, more repetitive testing was required and this has now 
been adopted.  
 Piperazines 
All piperazine analogues are now illegal in the UK, registered as Class C of the 
Misuse of Drugs Act (1971) and schedule 2, part III of the Misuse of Drugs 
Regulations (2001).  Piperazines can elicit similar effects to some ATS and 
methods for their detection should be available in forensic toxicology 
laboratories. 
In the present study, methods were developed for the detection of a range of 
piperazines in blood using LC-MS/MS (p-MeOPP, p-FPP, BZP, o-MeOPP, p-MPP and 
TFMPP) and GC-MS (p-FPP, BZP, TFMPP, p-MPP, o-MeOPP, m-CPP, p-MeOPP and 
p-CPP).  Quality assurance required both methods to be validated.  For all 
piperazine analytes accuracy was within ±15% (20% at low concentrations) and 
precision was within 15% (20% at low concentrations).  For both methods LLOD of 
all analytes was 5 ng/ml of blood and upper limit of quantification was 2 µg/ml 
of blood.  For the GC-MS method lower limits of quantification (LLOQs) were in 
the range 20 to 30 ng/ml of blood.  For LC-MS/MS, LLOQs ranged from 50 to 60 
ng/ml of blood, although quantification by the LC-MS/MS method was restricted 
by the lack of availability of appropriate internal standards.  There were no 
apparent significant matrix effects and recovery by both methods was >60 % 
and, therefore, acceptable. 
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Short term stability of the piperazine analytes was investigated. Piperazines 
remain sufficiently stable when stored in the fridge for at least one week, and 
are stable through three freeze-thaw cycles.  There was no detectable 
degradation when blood samples were left on the bench-top or when extracted 
‘in-process’ samples were left in the autosampler for up to 72 hours. 
The LC-MS/MS method could provide a readily applicable screening method.  A 
small aliquot of a basic drug extract could be screened by LC-MS/MS for the 
presence of piperazines, leaving the majority of the extract for other analyses, 
for example, piperazines confirmation or amphetamines analysis.  The GC-MS 
method was suitably validated to provide quantification but application to 
casework samples remains to be evaluated.  It is recommended that piperazine 
testing be performed for all suspected MDMA or ‘club drug’ intoxication cases.     
The Field Impairment Test 
The detection of drugged drivers primarily depends on the current method which 
is the driver field impairment test (FIT).  FIT comprises measurement of pupil 
diameter and four physical tasks (the Romberg balance test, walk and turn test, 
one legged stand and finger to nose test) intended to simultaneously test 
comprehension, short term memory, balance and motor function.  Despite FIT 
having ISO accreditation, it has been recognised that police officers lack 
confidence with the protocol and do not apply the test as often as is necessary.  
The main difficulty arises from the requirement to make a subjective judgement 
of impairment and officers lack confidence in their ability to do so.  
FIT has never been fully validated.  The present study was designed to meet the 
urgent requirement to develop FIT into an objective measurement, by 
determining what constitutes “normal” performance in FIT by unimpaired adults 
of different ages.  FIT performance was recorded for 79 individuals, a 
statistically determined cohort size, confirmed by breath and oral fluid analysis 
not to be under the influence of impairing substances.  Each error made during 
FIT, as defined by the FIT standard operating procedure, was recorded and 
collated in a Microsoft Excel® spreadsheet for analysis.  It was found that the 
definition of ‘errors’ was too stringent as many which are required to be 
recorded are normal physiological or behavioural characteristics, such as body 
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sway, and most subjects would be unable to complete the task without 
displaying them.  A less stringent, evidence-based definition of “error” was 
developed which allowed statistically more significant analysis to be performed 
on the FIT results. 
A statistically significant difference (P=0.00578) was shown to exist between the 
FIT performance of individuals under the age of forty years and those aged forty 
and over.  Based on the principles of a PTS, robust mean and standard deviation 
were used to determine what constituted acceptable performance.  Those in the 
younger age group could be considered impaired if the police officer witnessed 
more than seven errors, or, in the older age group, more than fifteen errors.  
Using these criteria the frequency of false positives, i.e. unimpaired drivers 
being assessed as impaired is estimated to be (less than 3%). Also, the ranges of 
errors observed in both groups was large and overlapped, such that it may be 
possible for an impaired person to appear unimpaired.  This requires further 
investigation. 
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Chapter 1:  Introduction 
  
1.1 Introduction to Forensic Toxicology 
Forensic toxicology has changed dramatically over the last 20-30 years.  
Previously the forensic toxicologist dealt almost exclusively with post mortem 
samples in which substances were present in relatively high concentrations (fatal 
levels) and there was a limited number of substances of interest.1   Today 
forensic toxicology laboratories also receive a large number of clinical samples 
from which a large number of ‘relevant substances’ can be detected at very low 
concentrations.  These samples can take many forms, traditionally blood or 
urine, but less conventional matrices such as hair and oral fluid (OF) are also 
routinely encountered and research is ongoing with substances such as sweat, 
nail clippings and exhaled breath (for drugs other than alcohol).2-4  Newer 
matrices may be less useful for quantitative work due to the lack of 
interpretation data.  Literature relating to the detection of various drugs in hair 
and OF is expanding.5,6 
OF is an ultra-filtrate of plasma and substances present in blood are transferred 
to OF across epithelial membranes by passive diffusion,7 and some to a lesser 
extent by active transport.8  Drug compounds present in blood can be detected 
in oral fluid without the necessity of invasive sampling.  As a clean matrix OF 
analysis is relatively simple, although sensitive detection is required as analytes 
are present in very low concentration.  Quantification of analytes in OF is 
complicated by many factors including method of collection and rate of saliva 
production.  Large inter- and intra-individual variations in OF-to-plasma ratios 
mean that a reliable estimation of blood concentration from OF is usually not 
possible.  There are a number of detailed reviews of OF as a forensic toxicology 
specimen, including Drummer,9 Aps and Martens,10 and the DRUID 
evaluation,11and a detailed account is not provided here.   
Chapter 1  2 
 
 
 
OF can, however, indicate that a psychoactive substance was present in blood at 
the time of sampling and is an ideal sample for point-of-care testing, especially 
for the detection of driving under the influence of drugs (DUID).   
1.2 Systematic Toxicological Analysis (STA) 
Samples are generally submitted for forensic toxicology by pathologists, forensic 
medical examiners, police officers or from workplace drug testing schemes.  
These samples have most often been taken from individuals amid suspicion of 
drug use e.g. driving in an unsafe manner, pre-mortem behaviour, or post 
mortem observations.  The information supplied upon submission, together with 
inter- and intra-laboratory statistics, can help determine which substances may 
be present and which analyses should be performed.  In some instances there 
may only be one (or limited) analyte(s) of interest and testing can be directed 
towards this.  Most often, however, specimens are required to be analysed for a 
wide range of substances to obtain maximum information. 
No single analysis can yet scrutinise a specimen for all possible drugs.  A series 
of analyses, or systematic toxicological analysis (STA), is necessary.  As the 
presence of toxic substances is uncertain and their identities unknown, STA is 
designed to simultaneously detect numerous intoxicants (or confirm absence).12-
17  STA should be applied even when a priori information is available in order to 
screen for other ‘unknown’ toxic substances, particularly as poly-drug use is 
regularly encountered.1,18   
After checking paperwork and ensuring integrity of the specimen sample, pre-
treatment is usually required.  This could simply be  dilution or mixing of the 
sample but  depending upon the matrix, analyte properties and analytical 
technique to be applied other preparation such as filtration, centrifugation, 
homogenisation or pH adjustment may be necessary.19,20  To direct and narrow 
the number of detailed analyses required a relatively quick and inexpensive 
screening technique (usually one or more immunological tests) will usually be 
applied.  Caution is required with interpreting screening results.  Whilst these 
tests can be sensitive, generally they lack specificity and some analytes, 
particularly emerging designer drugs, may not be detected.  Positive results 
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must be confirmed by more detailed instrumental analysis to provide 
identification and concentration. 
To maximise discriminating power a combination of analytical systems is 
required.  The probability of correct identification is increased with the number 
and range of techniques applied.  Courts in the United Kingdom (UK) recognise 
this and require all evidential results to have been subjected to at least two 
analyses.  Integrated techniques are, therefore, beneficial for satisfying the 
court’s requirement for selectivity with minimal effort and confirmation is 
usually by gas chromatography-mass spectrometry (GC-MS) or liquid 
chromatography-tandem mass spectrometry (LC-MS/MS).17 
1.2.1 Gas Chromatography – Mass Spectrometry (GC-MS) 
In order to improve chromatographic properties (peak shape, resolution, 
retention time, etc.) or increase the sensitivity of detection, samples may 
require derivatisation prior to GC-MS.  This is primarily aimed at decreasing 
polarity (making the analyte less reactive with the stationary phase) and hence 
increasing volatility and/or thermal stability of the analyte molecule.21  
The prepared sample is introduced via an injection port, maintained at high 
temperature to cause volatilisation.  In order to prevent sample overloading the 
volume of sample injected is in the order of approximately 1 µl (containing up to 
50 ng of individual analytes), although a larger volume can be injected if a 
splitter valve within the injection port is programmed to vent a defined 
proportion.22  Volatilised analytes enter the chromatographic column and are 
swept through by an inert carrier gas.  They become separated according to 
their boiling point and partition coefficient in the column stationary phase: 
volatile and inert compounds with few polar groups elute first.  The column oven 
temperature is fundamental in ensuring that adequate separation is attained.  
Temperature programmes allow the oven temperature to be steadily increased 
at a designated rate and provide the necessary separation and resolution in the 
shortest possible time.  The column is connected to a mass spectrometer which 
records presence and abundance of eluting analytes as a chromatogram.  
Compounds are identified by their retention time, ion fragmentation patterns 
(mass spectra) and molecular weights.    
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There is a range of mass spectrometers available, all with the same three basic 
requirements: an ion source to create charged ions, a mass analyser to separate 
the ions by mass to charge ratio (m/z) and a detector to count the ions.  It is 
preferable with GC-MS to have hard ionisation in which fragmentation is induced 
by bombardment with a stream of electrons (electron ionisation, EI).  EI is 
generally favoured as it results in greater fragmentation for more reliable 
identification.  Alternatively, soft ionisation involving a reagent gas (chemical 
ionisation, CI) can be used to enhance the molecular ion region of the mass 
spectrum. 
The most common and versatile mass spectrometer uses the quadrupole mass 
analyser.23  Ion filtration is by application of an oscillating quadrupole electric 
field along four precisely parallel rods, equally spaced around a central axis.23  
Precisely controlled alternating voltages are applied to opposite sets of rods 
such that only ions with a particular m/z will reach the detector.  As the positive 
ions are introduced to the analyser they are directed at the negative rod.  The 
electric potential is then changed and ions which have not yet collided with the 
rod (and depleted) are repelled towards another rod.  This continues along the 
length of the analyser until the ions reach the detector.  At any given time only 
ions of one particular m/z will be in resonance the full length of the analyser 
and reach the detector.  The radio frequency (RF) of the voltage oscillation is 
continuously adjusted over a set range to bring ions of different m/z into focus 
on the detector at different times and build a mass spectrum.  When in full scan 
mode the analyser performs rapid scans through a range of m/z values to allow 
the full range of ions present to be detected, producing a full mass spectrum 
and total ion chromatogram (TIC).  Alternatively, selected ion monitoring (SIM) 
can be performed.  In this mode the analyser performs repeated cycles through 
selected RF values.  As more time is devoted to the ions of interest, whilst the 
others are ignored, a more sensitive detection is achieved.19,24  
1.2.2 Liquid Chromatography Tandem Mass Spectrometry (LC-
MS/MS) 
LC-MS/MS can detect lower concentrations than GC-MS,15,25 and is applicable to 
a broader range of analytes.17,19,26,27  Analytes are not required to be derivatised 
which reduces uncertainty of the result as well as sample preparation time.19,28  
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A limiting factor of LC-MS/MS, however, is that, as fragmentation depends upon 
geometric configuration of the interface and chromatographic conditions, the 
spectra produced can vary widely;27 even when operating parameters appear 
consistent.17  LC-MS/MS spectra are, therefore, considered laboratory- and 
instrument-specific and cannot be easily shared (making searching of external 
libraries unreliable).16,17,27   
LC-MS/MS operates on similar principles to GC-MS.  Rather than a carrier gas, 
analytes are swept through the system in a liquid mobile phase of highest grade 
solvents and buffers.  The mobile phase must be degassed to ensure dissolved 
gases are not present which interfere with the chromatography by producing 
bubbles.  Mobile phase is delivered at a constant rate but not necessarily 
constant (isocratic) composition.  Similar to controlling oven temperature in GC-
MS, elution can be controlled by using more than one pump, or a mixing 
chamber, to establish a mobile phase gradient system.  Properties of the mobile 
phase such as the organic solvent content, pH or ionic strength are changed.   
The sample is introduced at the injection valve and carried by mobile phase 
through a guard column to the analytical column where it interacts with 
stationary phase, which can also influence elution.  The column used will depend 
upon the properties of the analytes.  The mobile phase should be 
complementary to the stationary phase such that the chosen interactions 
strongly dominate in the stationary phase and are minimised in the mobile 
phase.  LC-MS/MS columns have smaller internal diameter than HPLC-DAD 
columns to allow for a lower flow, and less mobile phase to be evaporated at the 
MS source. 
Solvent evaporation (desolvation) and ionisation take place at the interface by 
Atmospheric Pressure Chemical Ionisation (APCI), Electrospray ionisation (ESI), 
Particle Beam ionisation (PB) or Thermospray ionisation (TS).  The interface 
involves evaporation and pressure reduction as well as ionisation to transform 
dissolved analytes to gas phase ions.24  ESI is most suited to polar compounds it 
has wide applicability and is the most frequently used system.29,30  
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1.2.2.1 Electrospray Ionisation (ESI) 
Analytes in mobile phase are introduced to the interface through a heated 
hollow needle (nebuliser) with high electrical potential (typically from 2.4-5KV) 
with respect to the cone.19  As eluent emerges from the nebuliser tip it forms a 
fine mist of highly charged droplets (positive or negatively charged depending 
upon the voltage applied).  Droplet formation is aided by drying effects of a flow 
of sheath gas, usually nitrogen.  Repelled from the charged needle tip the 
droplets migrate towards the ion sweep cone into the ion transfer capillary.31  
During this transition auxiliary gas can be used to encourage evaporation.  The 
droplets become increasingly smaller and eventually the electrostatic repulsion 
of the ions within them exceeds their surface tension (Rayleigh limit), and a 
series of coulombic explosions occurs as the droplets produce smaller droplets 
which disintegrate further until charged ions are ejected.  Ion formation can be 
influenced (enhanced or suppressed) by co-eluting substances.  These are known 
as ‘matrix effects’ (although they may arise from matrix components, mobile 
phase additives, salts, ion-pairing agents, internal standard, metabolites, 
etc.).32  
Once in the gas phase the charged analyte molecules pass through the ion 
transfer capillary to the mass spectrometer. ESI is a soft ionisation technique 
which predominantly yields only quasi-molecular ions.  Fragmentation required 
for structural elucidation necessitates tandem mass spectrometry (MS/MS).   
1.2.2.2 Triple Quadrupole Mass Analysers (QqQ) 
The single quadrupole analyses externally fragmented ions but analytes are 
fragmented and detected within the triple quadrupole.24  The first mass 
analyser, the first quadrupole, passes ions into the reaction zone, the second 
quadrupole.  Here, precursor ions are exposed to collision gas resulting in 
fragmentation to form product ions.  Product ions undergo second mass analysis 
in the third quadrupole.  There are a number of operating modes depending 
upon whether ions are filtered or scanned at the first and third quadrupole.  
Non-scanning modes are most sensitive.  Multiple reaction monitoring (MRM) 
where only selected precursor ions enter the reaction chamber, and only 
selected product ions from each precursor are detected provides sensitive 
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quantification which can be useful in forensic toxicology for the detection of low 
concentration analytes, particularly in alternative matrices.33 
1.2.3 Identification Criteria 
In order to have a reliable identification, analyte signals must be compared to a 
contemporaneously analysed reference substance.34 In chromatographic-mass 
spectrometric techniques the factors which ought to be compared are relative 
retention time and presence and abundance of monitored ions.16,17,35  
Acceptable relative retention is usually when the analyte value falls within ±2% 
of the reference value.36-38  In order to share retention time data amongst 
different instruments and laboratories, however, GC retention times can be 
standardised by comparison to n-alkanes.  With isothermal methods this is by 
conversion to Kováts index (KI).35  Linear retention index (LRI or RT) in Equation 
1-1 is required for programmed temperature analyses.39  These are approximate 
values, as it is unlikely that they would be identically reproduced between 
laboratories.39   
zttttnI TRz
T
zr
T
Rz
T
Ri
T 100)/(100 )1(       
Equation 1-1:  Linear Retention Index 
n = difference in carbon atom number of the two n-alkanes that bracket an analyte’s 
retention time, 
T
Rit = retention time of the analyte, 
T
Rzt = retention time of the n-alkane eluting 
immediately before the analyte, and 
T
zrt )1(   = retention time of the n-alkane eluting 
immediately after the analyte. 
Identification from full scan mass spectra is traditionally considered to be best, 
although SIM is acceptable.  SIM should include the molecular ion where 
possible.34  Other ions selected should originate from different parts of the 
molecule and be sufficiently characteristic of the compound structure.34,40  
Generally with GC-MS there should be three diagnostic ions giving two ratios 
within ±20% of the reference value.14,16,34,36,37,41-43  The use of two MRM 
transitions in LC-MS/MS is considered acceptable where the abundance ratio is as 
expected.16,44  LC-MS/MS is accepted to be less reproducible than GC-MS and 
ratios should agree to ±25-30%.38  
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1.2.4 Reporting Results  
Upon identification/quantification the toxicologist needs to prepare a report 
which explains the analytical results within the context of the case i.e. which 
attempts to provide answers to the questions asked upon submission of the 
sample.  All information gained should be reviewed and checked by the person(s) 
who will sign the report.  Interpretation needs to be done with utmost care for a 
variety of reasons e.g. the data may only relate to one point in time, there may 
be concentration differences depending upon sampling site, results could be 
complicated by post-mortem redistribution or decomposition and more than one 
substance may be present.1  The greatest difficulty in evaluating the results of 
forensic toxicological analysis arises from inter-individual variations.  
Adsorption, elimination and hence concentrations of drugs in various bodily 
specimens are affected by a range of factors, many of which are unpredictable.  
These include, but are not limited to, gender, race, age, illness, frequency and 
duration of substance use, tolerance, route of administration, presence of food, 
drug interactions and metabolic polymorphism (especially the polymorphic 
enzymes of the cytochrome P-450 system).  The toxicologist can usually, 
therefore, only give a general indication of how a drug might affect a person, 
based upon the changes induced in the central nervous system (CNS) (or effects 
upon other body systems).  Stimulants (e.g. amphetamine and cocaine) arouse 
the CNS to increase brain activity.  Depressants (e.g. benzodiazepines and 
heroin) inhibit brain activity, and hallucinogens (e.g. ecstasy and cannabis) 
neither stimulate nor inhibit but cause alterations in perception and mood.20  
Trends in abused drugs are witnessed to change as drugs move in and out of 
fashion according to changes in popular culture and social economics.  New 
drugs are frequently being introduced.  As new drugs are encountered new 
analytical methods are required for their detection.  It is important that all new 
methods are rigorously tested to ensure quality requirements are upheld. 
1.3 Quality 
A number of recognised and respected bodies produce guidelines of best 
practice which laboratories can incorporate in the development of an effective 
quality system.  Those directed at forensic toxicology laboratories include the 
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UNODC Recommended Guidelines for Quality Assurance and Good Laboratory 
Practice,45  The Society of Forensic Toxicologists (SOFT) and American Academy 
of Forensic Sciences (AAFS) Forensic Toxicology Laboratory Guidelines,38 
European Laboratory Guidelines for Legally Defensible Workplace Drug Testing,46 
and the United Kingdom and Ireland Association of Forensic Toxicologists 
(UKIAFT) guidelines.47  These guides are designed to help laboratories to deliver 
reliable results in accordance with ‘best practice’.  Best practice, however, will 
differ between laboratories as a result of available resources and the 
requirements of test results.  UNODC recommends ‘best practice’ is interpreted 
as “the best achievable practice within the laboratory and jurisdiction 
concerned” provided these meet minimum requirements.45  The UK Government 
Valid Analytical Measurement (VAM) Initiative, however, like many others, 
interprets best practice to be procedures sufficient to ‘satisfy an agreed 
requirement’; in other words ‘fitness for purpose’.48   
1.4 Fitness for Purpose 
It is of utmost importance to consider why the data to be generated is required 
when judging whether the chosen method will be adequate.  Use of the most 
sophisticated techniques and equipment does not guarantee quality, and may 
not be necessary to provide sufficient quality for the intended purpose.  The 
laboratory must liaise with the customer to gain a thorough understanding of 
requirements (necessary standards, legislation, sample handling, timing, etc.), 
and agree how these will best be accomplished, focusing on cost-effectiveness.49 
Fitness for purpose, therefore, answers a specific aim by selecting a method 
which can consistently detect with acceptable measurement uncertainty, the 
most appropriate target analytes to meet relevant legislative and regulatory 
demands and satisfy the needs of the client.   
Forensic toxicology investigations are conducted for a range of purposes, from 
monitoring (e.g. workplace, prisons or rehabilitation) to legal investigations (e.g. 
detection of drug-facilitated offences or cause of death).  Results entering the 
legal system must be reliable beyond doubt and command higher quality and 
expense.  To reassure clients and legal authorities that results can be trusted to 
be fit for purpose, a laboratory may wish to obtain formal accreditation.  
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Accreditation is considered to be the best means of demonstrating dedication to 
quality. 
1.5 Accreditation 
Accreditation is said to provide laboratories with increased confidence in their 
procedures by indicating that data produced is reliable for its intended use and 
comparable with data of other organisations.48  Accreditation can only be 
awarded by an approved accrediting body.  Most countries have a national body 
(e.g. United Kingdom Accreditation Service, UKAS), although those which do not 
are free to select one in any other country.48  Accrediting bodies require to be 
approved by a higher body (e.g. the European Co-operation for Accreditation in 
Europe or the Association of Crime Lab Directors in the US which is specific to 
Forensic Science Laboratories).48  This structure enables standardisation of the 
accreditation and assessment process (including conformance monitoring) to 
ensure correct application of the internationally agreed quality standards within 
the sector.50  Confirmed compliance with such standards facilitates acceptance 
and reliable sharing of results and information between laboratories.48  
Accreditation is, therefore, often equated with confidence in laboratory output.     
With such meaningful inference, achieving accreditation is a difficult process.  A 
laboratory may, therefore, seek only to accredit a select few of its services and 
perhaps gradually include more.48  This is possible as accreditation is awarded 
for a defined ‘scope’ which specifies particular combinations of analyte, matrix 
and test method.49,51  The scope can be altered, activities added or removed, to 
reflect a laboratory’s changing capabilities.  There are also different standards 
to which a company can become accredited, each with varying levels of 
demand.  A company can select one or more standards to adhere to depending 
upon the nature of its work and the level of quality they wish to demonstrate.  
In England and Wales it is a requirement of forensic toxicology laboratories 
providing services to the police authorities (and elsewhere an aim) to be 
accredited to ISO/IEC 17025 (general requirements for the competence of 
testing and calibration laboratories).48,52  This standard is published by the 
International Organisation for Standardisation (ISO) and the International 
Electrochemical Commission (IEC).  Within the UK, forensic science laboratories 
work towards the Forensic Science Regulator Standard.53  Laboratories must 
Chapter 1  11 
 
 
 
already be accredited to ISO17025 then adhere to some additional requirements 
specific to their area of analysis (including forensic toxicology).  The European 
Network of Forensic Science Institutes (ENSFI) also requires members to be 
accredited to, or working towards ISO 17025.52,54  Despite many ENSFI 
laboratories having quality management systems only 13 of the 53 members have 
any accreditation and only 9 of these had ISO 17025 in 2007.52  This could reflect 
the expense and effort accreditation requires or it could be a lack of confidence 
in the merit of accreditation within a sector which does not have standard 
methods.   
With many criteria to satisfy, the International Laboratory Accreditation 
Cooperation (ILAC) provides procedures to help laboratories embarking on 
accreditation.55  In general terms the process is straightforward.  The laboratory 
will define their accreditation scope and contact their national body to arrange 
a pre-assessment visit.  A lead assessor will visit and make recommendations 
related to the overall quality management system within the laboratory, whilst 
one or more technical assessors will comment on the activities to be 
accredited.48  The same assessors will return six to twelve months later to 
perform a detailed audit.  Anything found lacking is termed a ‘non-conformity’.  
Non-conformities are listed and the laboratory given a timescale in which they 
must be addressed.  When corrected to the satisfaction of the assessors, 
accreditation is awarded.  Regular announced assessments will continue to 
ensure the required standards are maintained, and re-assessment is required 
every four to five years.  Within forensic toxicology, however, the assessor 
cannot monitor the application of standard methods (there are none), and is 
unqualified to judge the ‘fitness-for-purpose’ or acceptability of methods 
(although they may try).  Conformity with the laboratory stipulated standard 
operating procedure is what will be confirmed.   
There is increased confidence in analytical output, however, due to the 
requirements for Quality Assurance (QA), including internal quality control (IQC) 
activities, participation in external quality assessment (EQA) and the necessity 
to define measurement uncertainty (MU).56  The degree of rigor applied to 
calculation of MU will depend upon the purpose of the testing,56 although it is 
typically determined through internal quality control studies.57-59  This is 
regarded as a simple indication of whether or not a protocol is fit for purpose, as 
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it describes the range of values within which the true value is asserted to 
lie.49,59,60  It is compulsory for all QA procedures and systems to be meticulously 
documented within the various manuals of the laboratory Quality Management 
System (QMS).  
It is possible for procedures to be accredited to non-technical standards, 
typically ISO 9001 (Quality Management Systems).  Laboratories are required to 
demonstrate that management, operations, personnel, procedures, equipment, 
accommodation, security and health and safety procedures meet defined quality 
standards.48,56  In support of this the laboratory must operate a stringent, 
documented QMS.  As the ISO 9000 series standards do not address technical 
competence, accreditation to these standards does not provide confidence in 
analytic output, rather, dedication to quality.48,52,56   
1.6 Quality Management System (QMS) 
The QMS is a series of manuals which clearly stipulate criteria, methods and 
systems of laboratory operation.  It is a means of safeguarding confidence in 
consistent production of fit-for-purpose results, and is therefore subject to 
periodic review.56  It recognises that every action within the laboratory can 
impact upon quality and is therefore designed to encompass every aspect of 
laboratory activities where errors could be introduced.38,51,61  Ferrara et al 62 
provide a good summary of QMS, suggesting it operates on three levels:  logistic 
(e.g. laboratory environment, reagents, equipment, personnel and chain-of 
custody), analytical (e.g. sampling, storage, reference materials and report 
format), and control (monitoring of laboratory performance and the Quality 
Assurance system).  With technical standards the QMS must additionally ensure 
and document the validity, reliability, accuracy, precision, and performance 
characteristics of each test.63  This requires that all analytical methods have 
suitably validated standard operating procedures (SOPs) 13 and mechanisms for 
monitoring of the overall performance of the laboratory by both internal and 
external proficiency testing programs.62     
Analytical Quality Assurance (AQA) is the documented programme of activities 
necessary to verify that the system is operating within acceptable limits.50,64  It 
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provides a configuration for correct implementation and documentation of a 
laboratory’s Quality Control (QC) to ensure (and demonstrate) continuous 
production of data within defined reliability;51 QC being the practical activities 
performed day-to-day to test the system and ensure the quality of individual 
batches/samples.45,49-51,64  Such monitoring of the stability of the measurement 
process determines whether results are reliable enough to be released.45,50,51  
It is important to recognise that although AQA ensures measurements are valid 
and fit-for-purpose it does not guarantee every result will be reliable.  Good 
AQA will manage the frequency of these failures such that they are rare but they 
cannot be completely eliminated.49  There are two main sources: mistakes (e.g. 
sample mix-ups), and random or systematic errors. 
To establish AQA procedures for a method it must first be established what the 
acceptable performance criteria are for the intended purpose, and it must be 
ensured that the selected method can reproducibly attain them.  Such method 
evaluation is achieved through validation studies.  All ISO 17025 accredited 
procedures must be fully validated before application.56 
1.7 Validation 
Not every method based on sound theory will, in practice, produce results which 
satisfy acceptance criteria.  In order to accurately identify an analyte, its 
response must be related to a single chemical species and in order to quantify an 
analyte its response must be consistent.24  Method validation demonstrates 
suitability for an intended purpose and ability to provide the correct result;  
precision, limits and susceptibility to variation in parameters must be 
scrutinised.50,55,65-68 
The specific end use of the protocol should be well defined in advance of 
validation.  Experiments are designed to appraise only the aspects of analytical 
performance agreed to be relevant for provision of fitness for purpose.  Results 
are documented to support attainment of necessary analytical performance for 
identification (or quantification) of analytes in the given matrix with suitable 
reliability and reproducibility, and to additionally demonstrate the exploration 
and characterisation of any parameters which could influence this.  Validation 
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can, therefore, require a large series of analyses and be very time consuming 
and costly.   
Careful planning can minimise the effort and cost required but it is imperative, 
particularly where high quality is demanded, that reliability of the validation is 
not compromised.    Essential parameters for validation of quantitative analyses 
are largely agreed to be specificity, calibration model (e.g. linearity), lower 
limit of quantification (LLOQ), accuracy (bias), precision (repeatability, 
intermediate precision) and analyte stability, outlined in Table 1-1A and B.  
There are additional, optional parameters such as limit of detection (LOD), 
recovery and ruggedness.  Validation cannot consist of spiked samples alone. 69  
The analysis of real samples is necessary to demonstrate that the method works 
in practice, is selective, sufficiently sensitive, and has the required dynamic 
range to cover the concentrations encountered.  Unfortunately this is not always 
possible and it is important to perform many additional replicates during method 
validation to test as many assumptions as possible.   
Where the determined fitness-for-purpose requirements are not satisfied the 
analysis needs to be adapted until confirmation is achieved.70  Pre-validation, or 
first phase validation, can help to avoid the requirement for adaptations 
following (or during) validation.  It is focused on method optimisation, 
identifying and minimising sources of error.71  Validation measures the remaining 
error 72 and must be performed for every method used, however, if this has 
previously been done but the method is adapted to be suitable for a different 
use (e.g. different matrix) only measurements sufficient to demonstrate that the 
factors changed do not bring the analytical results outside of the acceptable 
limits are required.54,73   
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 Table 1-1(A):    Validation exercises…/Cont. 
Measurement Ref
Selectivity 49,57,58,
68,72-76
Calibration 
(Response 
Function)
54,57,58,
60,67,68,
70,73-75,
78,79,84
34,38,41,
50,57,58,
60,67,68,
70,80-83
Bias 50,57,58,
67,68,73,
75,79,80
Lower lever of 
Quantification 
(LLOQ) 
Level of 
Detection
(LOD)
Description
Selectivity is the ability of an analytical method to differentiate the analyte in the presence of other components in the sample 
(including the IS). The generally accepted test for selectivity is to analyse six sources of blank matrix.  As specificity is of primary 
importance, however, it is recommended that this be increased to 10-20 matrix sources.  Dosing of subjects with the substance of 
interest is regarded as the best method of investigating selectivity.  Often this is not possible and the favoured alternative is the 
analysis of real casework samples submitted for routine testing.  Samples determined to contain other drugs (and their 
metabolites), together with negative (‘blank’) samples, are spiked with the analyte of interest and analysed to demonstrate there is 
no interfering response.  
Calibration during validation is intended to verify a reproducible relationship between instrument response and analyte 
concentration.  This enables calibration with fewer determinations (concentration and replications) in subsequent routine analyses.  
A calibration response function is determined for each analyte using blank matrix spiked with known concentrations.  Where 
possible authenticated reference standards of known purity should be used to spike calibrators.
Recommendations for the number of concentration levels vary, most are for a minimum of 6 to 8 concentrations (although 5 may 
be sufficient), a ‘blank’ (matrix) and ‘zero’ (matrix plus internal standard), with no fewer than two independent determinations of 
each.  Duplicate analysis may be insufficient, however, statistical evaluation would be improved with more replicates (perhaps with 
fewer concentration levels to reduce the total number of analyses required); six replicates at six levels could be more appropriate.  
Outliers will be more reliably detected.  No more than two outliers can be removed (and must leave at least five non-zero 
standards).  
LOD is the lowest concentration of analyte which can be differentiated from background noise although not quantified as an exact 
value.  LLOQ is the lowest concentration that can be quantified with acceptable precision (20% RSD) and accuracy (±20% RSD).  
LOD and LLOQ are often defined by signal to noise ratios of less than or equal to three and ten, respectively.  Visual 
measurement of s/n ratio is not recommended because it is generally not possible to obtain a peak area for a blank sample (and 
some analytes may be present in the blank matrix).  Rather, it is recommended that the equation below be applied to a calibration 
produced from ten independent samples with concentrations close to LOD/Q.  Calculated concentrations need to be validated with 
5 replicates within ±20% of nominal value and CV<20%.
LLOQ = k.SDlow/S
SDlow = the standard deviation of the response (residual standard deviation of the regression line or the standard deviation of the y-
intercepts), S = the slope of the calibration curve, and k = k factor (LOD 3.3 and LLOQ 10)
Bias describes the closeness of mean test results to the true concentration.  It should be determined at a low, medium and high 
concentration through 3 to 5 replicates at each, depending upon the variability expected.  Bias is typically reported as the percent 
deviation from the accepted reference value which should be within ±15% (20% at LLOQ).
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 Table 1-1(B):    Validation exercises continued
Measurement Ref
54,57,58,
68,79,80
57,73
  
Recovery 50,54,57,
58,67,68,
73,74,79
Ruggedness 
(Robustness)
50,54,57,
60,68,80,
84,85
Ruggedness determinations establish susceptibility to small changes (e.g. mobile phase composition, reagent supplier or pH of a 
solution).  The factors selected for study should be those that are most likely to be changed during routine application of the 
method.  Changes should be made individually and the effects of each on bias and precision investigated.  Any factors which are 
found to show a significant alteration in performance need to be investigated further.  These factors will require the greatest care in 
performing the method routinely and it may be necessary to define a permitted operating interval. It is generally accepted that 
ruggedness need only be investigated if the method is intended to be transferred to another laboratory.
Long-term storage:  Maximum expected storage time is the period for which the laboratory is required to retain samples.
Description
Stability
Recovery relates the efficiency of a method to detect all of the analyte present.  It is the percentage of the detector response 
obtained from analytes extracted from spiked matrix compared to the response of a reference standard not prepared in matrix and, 
therefore, not subject to any sample pre-treatment.  (Thus it cannot be determined where derivatisation is required.)  It is 
investigated at low, medium and high concentration, but is expected to be an overrepresentation as there would be greater affinity 
between analyte and matrix within real samples.  Where it is not possible to directly measure recovery, acceptable recovery is 
demonstrated in attaining good bias and precision.  It is therefore often accepted that recovery is not required as part of a 
validation study.
It is essential that the presence and magnitude of matrix effects are evaluated for LC-MS/MS methods.  This can be determined 
during recovery studies.
Repeatability is precision over a short period of time, under the same operating conditions.  Between-batch variation requires 
measurement of at least three concentrations (low, medium and high) over a number of rounds of testing (variability should be < 
15%, 20% near LLOQ).
Intermediate precision describes variations under changing conditions (e.g. different operators or days).  Reproducibility is 
precision achieved between different laboratories (only necessary for methods used across different laboratories.)
Stability studies are required for various stages of sample analysis and storage.   Investigated at low and high concentrations in 
triplicate
Bench-top/In-process stability:  Stability at laboratory ambient temperature over time required for sample-preparation (or longer) 
Freeze/thaw stability:  Samples may be required to be removed from the freezer and re-analysed.  It must be ensured that the 
analyte concentration is not significantly affected by freezing and thawing (over 3 freeze/thaw cycles).
Processed sample stability:  Stability in the auto-sampler is investigated for the maximum time specimens might be expected to 
be present (e.g 24 hours for overnight and 72 hours for a weekend).
Precision Precision is closeness (degree of scatter) of individual measures to each other, not a reference value.  It relates the extent of 
random error components in the analytical technique; expressed as relative standard deviation (RSD), or increasingly as coefficient 
of variation.  There are three levels of precision; repeatability, intermediate-precision and reproducibility.  
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1.8 Internal Quality Control 
Internal quality control (IQC) is an expansion of validation.  It monitors method 
performance during routine processing, rather than the performance achieved 
through vigilant application at validation.  Routine performance measures are 
compared with acceptance criteria to ensure fitness for purpose is 
maintained.50,54,62  Simple IQC procedures are incorporated in every analytical 
batch.  Minimum requirements are a negative control (to confirm signals 
produced are originating from the samples), and at least one positive control at 
LLOQ (to confirm correct working order).38,62  It is good practice to have more 
quality control samples (those at high concentration should be followed by a 
blank to detect carry-over).38,62  Where possible these should be prepared with 
certified reference standards.62,86   
Results are monitored within batches as well as over time.  Statistical criteria 
are applied to the IQC determinations in order to determine stable variations 
which can be expected within the system and acceptability is based on where a 
result lies relative to these.12,50,62  For example, when the co-efficient of 
variation is selected this should generally remain below 15%.38  A common 
method for evaluating precision and immediately identifying departures from 
statistical control is to plot the results of control measurements on a Shewhart 
control chart (variable of interest on the y-axis, run-number on the x-axis).  The 
chart is marked with guidelines to denote the expected value for the control, 
the control limits within which the measured values should fall and the warning 
limits outside of which the analytical result must be rejected.  
If results are found to consecutively plot outside of the warning limits this 
indicates a problem with the protocol and remedial action must be taken.62  The 
QMS will stipulate corrective actions appropriate to the error identified.56  Any 
problems experienced, remedial actions, servicing and maintenance are 
logged.38 
IQC monitors consistency of results rather than quality of results.48,50,57,62,68  This 
is particularly relevant for analyses which do not make use of certified reference 
standards.  Satisfying IQC alone does not directly imply good quality, rather, it 
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demonstrates that the analytical protocol is stabilised.48,62  A system is under 
control if no more than 5% of the measured values exceed the control limits.50  
Close agreement of results does not infer that this is a ‘true’ or accurate value, 
however, as biased data can be consistently produced.  Systematic errors arising 
from permanent factors (e.g. wrong instrument set-up, source of reagents or 
reference material) will be consistent and will not be identified as no statistical 
variation will be expressed.62,86,87  Thus, although IQC ensures day-to-day 
consistency of results external quality assurance (EQA) is an additional 
requirement as a less frequent but regular check of method accuracy.48,49,62  
Undetected errors lead to over- or under-estimations which can have serious 
consequences.  
1.9 External Quality Assessment (EQA) 
EQA encourages development of IQC.  It is an independent measure of testing 
capability, intended to guard against bias.62  EQA should ideally take the form of 
a proficiency test (PT) 88 as there are ISO guides available which aid 
standardisation of testing (ISO 17043:2010,89 intended to replace ISO Guide 43: 
1997 Parts one 90 and two 91).  Standardisation ensures adequate scrutiny of 
results and an interpretation and reporting format which allows ready 
comparison.  The ISO guide to proficiency testing, however, offers a selection of 
methods and the testing body must extract the recommendations relevant to 
their measurement.86  Thus the International Harmonised Protocol for The 
Proficiency Testing of Analytical Chemistry Laboratories, compiled in 
collaboration between ISO and IUPAC (revised 2006) 86 is typically the guide of 
choice.   
A proficiency test is ideally designed and co-ordinated by an independent 
body.50,62,92  In designing the PT organisers should strive to adopt the VAM 
principles of good practice for proficiency testing.48  The aims of the scheme 
(e.g. to test that participants reach a specific required level of performance or 
to educate participants) should be established to ensure that the final protocol 
will be fit-for-purpose.  This may also influence whether or not the testing is 
declared to the laboratory or performed ‘blind’. 
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When samples received by the laboratory are known to them to be PTS samples, 
it can only be assumed that test materials are truly being processed as routine 
samples.61  There is some suspicion, however, that not all laboratories are 
committed to the PT philosophy of an honest check of performance.  Doubt 
arises from laboratories having good performance in declared trials yet failing 
blind trials indicating that declared test materials frequently receive a degree of 
special treatment (more determinations performed than usual or a more 
experienced scientist replacing the routine scientist).62 
PTS providers UKNEQAS demonstrated disloyalty amongst participants to routine 
method application through monitoring of false positives (inclusion of drugs 
similar to the target in ‘negative’ samples e.g. ephedrine for an amphetamine 
test).18  A high incidence of false positives was encountered.  Participants noted 
this from feedback and the following year there was a significant reduction in 
false positives when the same similar analyte was included.  The analyte was 
then omitted from subsequent test rounds.  It was later re-tested and a high 
occurrence of false positives was reported once again.  This demonstrated that 
rather than learning from the feedback and improving QC to prevent reporting of 
false positives laboratories were simply extra vigilant in the round immediately 
following their poor performance.  Undeclared PT is, therefore, a more realistic 
indication of performance.  Testers can be assured that the laboratory will not 
depart form routine protocol as the test material cannot be distinguished from 
routine samples.61,63   
Where there is no suitable PTS available laboratories should organise inter-
laboratory testing and submit samples to each other as a useful means of 
comparative performance evaluation 12,93 (or round-robin testing where the same 
sample is analysed by each laboratory in turn and the results compared 94,95).  
The main function of EQA is error diagnosis but it additionally enables 
laboratories to evaluate their performance against their own targets, and the 
capabilities of their peers.49,62,63,88  Where performance is unsatisfactory the 
laboratory should have a written procedure of action to be taken.  As a 
requirement of accreditation ISO guide 13528 provides a checklist for error 
diagnosis.96 
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1.10 Research Background 
The results of forensic toxicology analyses can have far-reaching consequences.  
They must, therefore, be legally defensible which demands analytical techniques 
(and reports generated) be demonstrably reliable, with verifiable sample 
integrity.  Quality Management is, therefore, vitally important in forensic 
toxicology.  In the absence of accreditation standards specific to forensic 
toxicology it is difficult to establish whether quality management is adequate 
within this sector.  Additionally, as standardised analytical methods are not 
applied across laboratories there must be a means of verifying that methods are 
being suitably validated.  This could perhaps be assessed through an evaluation 
of the performance of laboratories in PTSs.  This would require sufficient 
availability of PTSs which effectively test routine forensic toxicology procedures.  
It is unknown whether laboratories have access to PTS which can effectively 
reflect their work-load to demonstrate fitness-for-purpose in an adequate range 
of their analyses.  Are laboratories able to be discerning in their choice of PTS to 
usefully monitor and safeguard their results, or has participation become a 
function of accreditation?  And does the accreditation of a PTS assist selection 
by endorsing its fitness-for-purpose? 
Performance monitoring and quality control is more difficult for procedures 
which are not performed within the laboratory.  Issues have been raised in 
relation to the fitness-for-purpose of one such test, the driver field impairment 
test for the detection of drugged drivers.  Results from these tests can be 
presented as evidence in court, often as ‘scientific’ findings.  Results must, 
therefore, be scientifically reliable.  Tests based in science are standardised to 
ensure reproducibility; i.e. the same principles are being applied, and tested to 
the same extent during every application (by different operators).  
Interpretation of results must be part of this standard operating procedure.  This 
is where the driver field impairment test is known to be lacking.  It has not been 
fully validated and an objective means of interpreting results is required.
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Chapter 2:  Proficiency Testing 
  
2.1 Introduction 
Participants in PTS are expected to process test materials as they would an 
everyday sample using their laboratory routine methods.  It is not expected for 
laboratories to be required to make special arrangements to participate, 
although if the laboratory does not regularly perform the required analysis, it is 
accepted that education rather than quality monitoring is the objective, as the 
laboratory can gain from staff training, maintenance of expertise, etc.48  As the 
chemical properties of the target analyte are unknown the choice of detection 
methods to employ can be difficult.  Regular PT is, therefore, recommended to 
ensure the credibility of the laboratory’s systematic toxicological analysis 
(STA).14   
Successful STA should identify, beyond a reasonable doubt, all substances of 
relevance regardless of their structure or chemical properties.12  In order to 
uphold cost and time efficiency, sustain good sample recovery and to keep 
contamination potential low, the STA method should involve as few steps as 
possible to first establish if there is a potentially harmful substance present 
(screen) then confirm its presence, identity and if necessary provide 
quantification.  It is usual for laboratory performance to be most dramatic in 
early rounds of a PTS and to improve with length of participation before 
reaching a plateau.48    
Laboratories are supplied with individual portions of a homogeneous test 
material.48,50,62  Homogeneity and stability over the test period must be 
ensured.95,97  It is recommended that at least ten random samples are analysed, 
in duplicate and under repeatable conditions.97  Some analytes deteriorate with 
time.  In these instances the closing date for completion of analysis must cover 
only the period for which the analyte concentration is known to remain 
relatively stable.38,85,86   
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To monitor true performance, test materials which very closely resemble routine 
samples are essential,18,48,62,98 especially where analytes are not available as 
certified reference standards.48,62  IQC for these analytes is less reliable and 
external monitoring is of increased importance.  Provision of ‘routine’ specimens 
is particularly difficult within forensic toxicology: most samples are spiked drug-
free matrices.  To more accurately imitate routine samples, matrices should be 
spiked with the drug of interest together with relative proportions of 
metabolites and other likely interferences such as other therapeutic or abused 
drugs.62  These could still be unlike casework samples, however, as they will be 
of good quality compared to those which might normally be received (e.g. 
degradation of the analyte, condition or volume of matrix supplied, the presence 
of many interferences).  This is particularly true of post mortem samples, the 
analysis and interpretation of which can be very complicated.  Results of PT 
should, therefore, be regarded as a guideline and diminished performance may 
be experienced from real samples.  
2.2 Performance Scoring in a PTS 
A qualitative and, where possible, quantitative statistical evaluation is 
performed.  Qualitative summary gives the proportion of correct identifications 
with some account of false positives.  Quantitative summary gives the proportion 
of acceptable measurements: this requires each participant to be assigned a 
competency score which scales the difference between their measured value 
and the true value.  This can be achieved by forming a z-score, q-score or 
standard deviation index (SDI).  None of these have been found to be entirely 
suitable for competence scoring, however, z-score is the generally preferred 
method.  The main advantage of z-score is that a suitably fit-for-purpose 
‘standard error’ value can be determined in advance.  By translating 
quantifications to a z-score the adequacy of laboratories’ measurements are 
immediately apparent (irrespective of the nature of the test e.g. different 
analytes, units of measurement).  This makes it much easier for participants to 
monitor their performance through time.99   
Z-scoring rates performance by using the maximum variation within which data 
is deemed valid to define the limits of satisfactory measurements.48,62,93  Z 
scores are calculated using Equation 2-1 where ‘x’ is the participant measured 
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value, ‘xa’ is the true value and σ represents acceptable deviation.  |z| <2 is 
satisfactory; 2<|z|<3 is questionable; and |z| >3 is unacceptable, perhaps 
symptomatic of a non-random event for which corrective action is necessary.48,87  
This is based on the expectance that in a well-behaved system, in which data 
will be normally distributed around the mean, less than 5% of the data will be ±2 
standard deviations from the mean and the chance of falling outside ±3 standard 
deviations is remote (0.3%).48,100  This assumes PT data is well-behaved, with 
central tendency around the true value (which may not be true when different 
methods, with varying biases, are applied).  In order that competence is not 
directed by the data, but fitness-for-purpose, the true value and acceptable 
variation are not necessarily equal to the mean and standard deviation of the 
data.  These can be derived by a number of routes, each of which has its 
particular strengths and weaknesses. 
z = (x-xa)/σ 
Equation 2-1:  formula for calculating z-score    
 
Participants should be advised of the scoring system and target of variance in 
advance.48,86,95  It is essential that participants are provided details as to how 
these have been calculated, as the various methods of assigning them mean that 
the performance of a laboratory can be good in one PTS but unacceptable in 
another.101 
2.2.1 Determining the true value 
The use of the participants’ mean as the true value is discouraged as a PTS 
should be strictly external and independent of the test laboratories.  If large 
proportions of participants are operating biased methods, the ‘true’ value 
generated by their mean will be biased (unless there is an equal share of 
different methods and the biases are normally distributed around the true 
value).48,62,94  Using the participants’ mean monitors consistency across 
laboratories rather than accuracy, and impedes error detection.48,62  If one or 
two participants operate with greater accuracy than the majority, this would not 
be recognised.  As minorities, their measurements might be further from the 
mean and their performance score would not reflect their excellent 
performance.48,62  If these laboratories then adapt their methods to improve 
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their score in the PTS, they could be introducing bias to their method.94  
Participant mean is, therefore, likely to be unsuitable for performance 
assessment, with a reference value being preferable.97,102 
The reference value may be a consensus of measurements from specialist 
reference laboratories with a proven ability to carry out the measurements of 
interest to a high level of performance, using validated methods and reporting 
their uncertainty with their results.48,62,94,97  Reference laboratories must be 
accepted as such by all PTS participants.95  It can be difficult to gather a group 
of laboratories all agreed by the participants to perform measurements beyond 
doubt, and the expense of reference measurements may be too great for some 
PTSs.94 
If there is no alternative but to use the participants’ mean value, however, it 
must be ensured that they are sufficient in number that the uncertainty 
associated with their mean is acceptable (more than 20-30 participants;92 below 
30 the statistics applied become increasingly unreliable 102,103).  Also, it is 
recommended that results are separated into ‘peer groups’ according to 
measurement procedure (mean calculated and acceptable variation assigned for 
each group), due to different methods having various associated biases.48 
2.2.2 Defining Acceptable Variation (σ Value) 
There are many methods by which acceptable variation can be defined as due to 
the diverse nature of analytical laboratories, one universal method would not be 
appropriate.  ISO surmises that these methods fall into five categories:96 
1. Prescribed value 
2. Statistical Model 
3. Precision Experiment  
4. Participants’ results 
5. Perception 
 
2.2.2.1 Prescribed Value 
In regulatory schemes the acceptable variation is defined by the regulating body 
as the level of performance required in order for a laboratory to be certified as 
competent, or permitted, to perform a particular analysis. 
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2.2.2.2 Statistical Model 
Acceptable variation is derived from a general model for the reproducibility of 
the measurement method, usually the Horwitz Equation or Thompson’s 
modification of the Horwitz function.  This model is intended for use in inter-
laboratory collaborative studies to test the performance of a particular method, 
although it is applicable to datasets which do not have normal distributions 
(which may be true of PT results).  The Horwitz equation, Equation 2-2, predicts 
reproducibility relative standard deviation (RSDR), which should be achieved with 
analyte concentration ‘C’ as a mass fraction.  The RSDR (as a percentage of the 
true value) or Thomson’s σ value 104 can be used as acceptable standard 
deviation. 
RSDR [%] = 2(1-0.5log10 C)  
Thompson’s modification:104 
σ = 0.22c if c<1.2 x10-7 
σ = 0.02c0.8495 if 1.2 x10-7 < c > 0.138 
σ = 0.01c0.5 if c > 0.138 
Equation 2-2:  Horwitz Equation 
 
Horwitz predictions are contradicted by everyday laboratory experiences which 
indicate that reproducibility is not solely dependent upon concentration but on 
factors such as analyte, matrix, method and time; significant deviations from 
the predicted values are frequently experienced.95  Additionally, with such a 
model, participants would have an indication of analyte concentration from the 
acceptable variance provided.  Horwitz values are, therefore, not ideal for a 
forensic toxicology PTS.  
2.2.2.3 Precision Experiment 
Acceptable variance is established from reproducibility and repeatability studies 
by a standard method.  This is not appropriate for forensic toxicology where 
participants use a variety of methods.  
2.2.2.4 Participants’ results 
Participants’ standard deviation is not suitable for PT.  Often results are non-
normally distributed,98 and when the aim is to establish variability, outlier 
Chapter 2  26 
 
 
rejection, essential for calculation of standard deviation, should not be 
performed.105  The more acceptable alternative is a robust standard deviation, 
which incorporates outliers but assigns them less importance, and is thereby 
insensitive to deviating results or non-normal distribution.94,105,106  Removal of 
outlying values due to a recognisable error (e.g. transcription) is still 
performed.107 
The robust measurement of variance is typically the median of absolute 
deviations, MAD; the median of the differences between the data and median.  
For robust standard deviation to be an equivalent measure to classic standard 
deviation MADe is calculated which equals 1.483 x MAD 99 (alternatively 
MAD/0.6745).108  Robust statistics require an appropriately large dataset to 
minimise the influence of the spread of results and have a true picture of 
laboratory performance.107  Even so, as the acceptable variation is not an 
independent value, robust statistics are said to describe a data set rather than 
assess participant performance.  Regardless of the relative deviations from the 
true value around 95% of participants will always have acceptable scores.86  Thus 
an acceptable z-score derived from a robust standard deviation is not an 
indication of good performance, rather it supports that the laboratory 
performance is in-line with the ‘norm’.   
Depending upon participants’ performance, acceptability can vary substantially 
between rounds, for example, a higher z-score could be achieved for a 
determination closer to the true value than the z-score achieved in another 
round for a value which is further from the true value, depending upon the 
spread of participant results.  This complicates comparison of results between 
rounds, making trend analysis impossible.104  Thus, determination of acceptable 
variation from participant results should be avoided if possible.99   
Despite these concerns, a robust calculation remains the ISO recommended 
method for use in an accredited PTS.  ISO provides instruction on their iterative 
method for robust mean and robust standard deviation in ISO Standard 13528.96 
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2.2.2.5 Perception 
Ideally acceptable variation is stipulated by the PTS steering committee, through 
relevant professional experience, at a level generally accepted within the sector 
to represent fitness-for-purpose.85,99  In some PTSs a level which reflects the 
organiser’s perception of participants’ capabilities may be selected instead.  
Only a value determined by the end use, however, can truly demonstrate 
proficiency.  Acceptable variation should challenge participants and encourage 
improvement.   
A fixed variation is preferable to allow performance comparison between 
rounds.  The use of a fixed value would be inappropriate in toxicology, however, 
where drug/metabolite concentrations vary considerably.  Rather, a fixed 
percentage of the true value which describes the level of accuracy to be 
achieved, is more suitable.86,99,109  Generally a measurement within ±10% of the 
true value would be desirable (higher at low concentration), therefore, setting 
acceptable variation at 5% of the true value (such that an acceptable result 
would have a z-score of less than 2).99   
A z-score based on standard uncertainty which represents fitness-for-purpose is 
the only method recommended by The Harmonised Protocol For Proficiency 
Testing in Analytical Chemistry Laboratories 1995 revised in 2006.86  Other 
models are expected to produce falsely reassuring results.  This has been 
partially demonstrated by Rosario et al.110  However, they recommend more 
work be performed to include non-normally distributed (heavy tailed/skewed) 
data with outliers.   
Whilst z-scoring with perceived acceptable variation provides a good estimate of 
proficiency and enables round-to-round comparison for performance monitoring, 
it does not take account of measurement uncertainty (MU) for either the true 
value or the laboratory values.  ISO suggests five means of performance 
assessment: z-score, En-score, zeta-score, z’-score and Ez-score.96  Although the 
z-score remains the most widely used,97,104 there are some suggestions that the 
others may be better measures of competence as there is some recognition of 
uncertainty.104  This may be true in theory, however, in practice laboratories 
that have not accurately estimated their MU (expected to be quite frequent due 
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to the lack of standardised methods for calculation) would not receive a true 
reflection of performance.104  It would also be inappropriate to apply these ISO 
methods where participants’ MU values differ by several orders of magnitude.111  
Thus, it would be necessary for the PTS to not only consider the accuracy of 
results returned but also the reliability (i.e. the consistency and accuracy of the 
measurement).  With all ISO accredited laboratories required to calculate and 
report MU, this would be a logical future progression.  
2.3 Performance Appraisal 
It is not enough to participate in a PTS: attention must be given to the feedback.  
Laboratory directors should review summary reports to check that the 
information submitted has been properly transcribed and to question 
performance, comparing it to previous rounds.  The review should be thorough 
and address whether results deemed acceptable for the conditions of the PTS 
are truly acceptable for maintenance of fitness for purpose within the 
laboratory.  A z-score can be re-calculated if necessary (particularly if a 
participant-dependent scoring method has been applied).   
PTS results provide limited information as a single result simply reflects the 
performance of the laboratory on that particular day.  Also results may be 
received a significant time post testing, during which there may have been 
changes to the SOP.48,61   A laboratory receiving a satisfactory result in a single 
round cannot use this to claim reliable results have been produced on any other 
occasion.  Where a laboratory operates a QMS and consistently achieves 
satisfactory PT results, however, they can use this as evidence of their 
competence to produce reliable data in that particular test.96  Laboratories are 
therefore encouraged to frequently participate in PT and monitor their 
performance over time.  Where the same analysis or the same analytes are being 
tested in each round, rolling performance indicators (RPIs) may be reported with 
each set of results to convey performance over a number of rounds.94  Recording 
z-scores as a graph is thought to be the best monitoring method as it provides a 
clear overview and is less prone to misinterpretation than numerical methods. 
Performance monitoring is particularly important where MU has not been 
considered.  Performance z-score slightly >3 (or <-3) should be considered 
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together with MU as  when the uncertainty is incorporated the range of values, 
and hence possible z-scores, could extend to less than 2 (or >-2), an acceptable 
performance.  Reference to previous performance scores will help to decide 
whether a z-score in excess of 3 (or >-3) is truly unacceptable.97,112  
Unacceptable results should always be investigated, although immediate 
corrective actions may not be necessary.  When the source of the error cannot 
be traced (clerical error, method problem, equipment, operator, the proficiency 
testing material, etc.) the best course of action is to repeat the test, as trying to 
correct an unidentified problem could introduce further errors.85  An aliquot of 
retained test material can be re-analysed to determine whether a random error 
has occurred.  If corrective actions are taken, the test material should be re-
analysed to check they have been effective.38,85  Serious errors (for example, 
false positives) may require re-validation.38   
2.4 Availability of Proficiency Tests 
In some countries, to practice within a particular discipline a laboratory requires 
a license which they are only awarded if they can demonstrate that they 
maintain appropriate quality standards; participation and good performance in a 
PTS are essential.18,62  This is a legal requirement of toxicology laboratories in 
the United States.38  Elsewhere, participation in a PTS is frequently a 
requirement, or at least a strong recommendation, for accreditation to technical 
standards.48,62,88  SOFT/AAFS Laboratory Guidelines stipulate that toxicology 
laboratories should participate in quantitative proficiency testing.38  The Asia 
Pacific Laboratory Accreditation Cooperation (APLAC) recommends participation 
in one round of testing per year.  ISO accreditation does not have any particular 
requirement, although they suggest biannual testing is usually appropriate.     
Most proficiency testing schemes (PTS) are voluntary and have an educational 
ethos.  Their aims are usually along the lines of facilitation of learning and 
improvement, through sharing of participants’ experiences and knowledge, and 
provision of technical and scientific guidance.62,94  With the majority of 
laboratories free to select the PTS in which they participate, it must be noted 
that some are better (more appropriate to the laboratory routine, or more 
rigorous) than others.  In selecting a proficiency testing scheme it should be 
ensured that a reliable test protocol is being applied and that the method of 
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performance scoring is clearly defined and appropriate.  Accredited schemes and 
those which achieve good peer review are generally preferred.49  Identifying 
suitable schemes in which to participate can be troublesome, however, as there 
are relatively few; some countries having no opportunities for participation.113 
2.4.1 United States 
The American Association for Laboratory Accreditation (A2LA) stipulates that 
PTSs approved and accredited by them are required where available.  There do 
not appear to be any forensic toxicology schemes listed.  As an alternative the 
website for ASCLAD LAB lists PTSs which they accredit.114  There are very few 
schemes for toxicology.  It appears that there are only three registered 
providers:  College of American Pathologists (CAP) (which can provide ISO 
accreditation), Research Triangle Institute (RTI) International, and Collaborative 
Testing Services (CTS). 
2.4.1.1 College of American Pathologists 
CAP is recognised to be a worldwide leader in providing quality improvement 
programs to pathologists and laboratory professionals.  Forensic toxicology is not 
their main focus, however they do offer Forensic Toxicology (Criminalistics) and 
Forensic Urine Drug Testing (Confirmatory) programmes.115   
2.4.1.2 RTI International (North Carolina, US). 
Since 2001 a drugs of abuse in ‘neat’ (synthetic) oral fluid PTS has been 
available in the US.  Laboratories receive five frozen specimens three times per 
year and are given two weeks to submit their results.  A European programme 
has been in operation since 2007 (only two rounds per annum).  Samples may 
contain substances from a large selection of drugs of abuse. 
Toxicology quality assurance/quality control samples prepared with relevant 
drug analytes at appropriate concentrations for the analysis of drugs in human 
specimens (urine, oral fluid, hair, sweat or serum) are available to purchase.   
These are intended to be used by laboratories as a check of quality/calibration 
although they are responsible for monitoring their own results and comparison 
with peers is not possible.116 
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2.4.1.3 CTS – Collaborative Testing Services, Inc.  US 
In 2014 CTS introduced two forensic toxicology proficiency testing schemes - 
drugs of abuse in blood and drugs of abuse in urine.  These are intended to 
mimic casework samples with realistic drug/metabolite compositions in natural 
human matrices, routine sample vials, and a case scenario.  These tests are 
directed at US laboratories but could be accessed anywhere (provided relevant 
import and export documentation is obtained, thus, not blind but an 
independent check of bias). 
A breath alcohol analysis programme (with a breath alcohol quality control 
simulator solution) is also available.   
2.4.2 Asia and Pacific 
Asia Pacific Laboratory Accreditation Cooperation (APLAC), covering the entire 
Asia Pacific area but based in Melbourne Australia, accredits laboratories, 
inspection bodies and reference material producers in the Asia Pacific region.  
One of APLAC’s primary roles is to organise overseeing a large number of 
proficiency tests.  They list 84 different PT schemes, however forensic 
toxicology is not included as an approved scheme.117  They also produce a list of 
available, not necessarily APLAC endorsed, PTSs.118  There are two relevant to 
forensic toxicology.  Austox Urine Toxicology Proficiency Program Drugs of Abuse 
– Qualitative/Quantitative provides monthly urine samples and is accredited to 
Australian Standard AS4308.119  This is a general laboratory standard, however it 
is not specific to PTSs.  The second PTS featured in the directory is blood alcohol 
and drivers toxicology from Division of Analytical Laboratories, Australia.  This is 
an unaccredited PTS and no detailed information could be found. 
2.4.3 Europe 
PTSs available to European laboratories have become increasing accessible 
thanks to the European Proficiency Testing Information System, EPTIS,59 funded 
by the Standards, Measurement and Testing (SMT) Programme and supported by 
the European Cooperation for Accreditation (EA), European Federation of 
National Associations of Measurement, Testing and Analytical Laboratories 
(EUROLAB) and Analytical Chemistry in Europe (EUROCHEM).  This database lists 
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more than 1200 schemes from 300 providers in 24 countries worldwide.  There 
are 31 different schemes listed under the product group ‘drugs’.  With the 
majority of these aimed at therapeutic drug monitoring, there are few which are 
of interest to laboratories providing forensic toxicology, demonstrated by the 
much reduced list of only fourteen on the ENFSI website (listed in Table 2-1).59  
The schemes represented on the ENSFI website can be considered to have good 
peer review, however few are accredited.120  A list of accredited PT schemes is 
available from the UKAS website.120  There are only two; QUARTZ (drugs in 
blood) and Tackler Analytical PT Scheme for Point of Collection Testing (PoCT) 
Devices (drugs of abuse in urine).  RANDOX is listed as an accredited provider of 
proficiency testing, however their toxicology programme does not currently (as 
of May 2014) appear to be part of their accreditation scope.   
2.4.3.1 QUARTZ – LGC Standards Proficiency Testing UK 
The forensic blood PTS is UKAS accredited (originally based on ISO Guide 43-1) 
and has been in operation since 2000, providing quarterly assessments.  The list 
of drugs included in samples is extensive, with around eighty possible analytes. 
Participants’ performance is rated by a z-score derived from a perceived fixed 
value for acceptable variation.  Participants are provided an electronic report 
for each round which contains the composition of test materials, the assigned 
values, and tabular and/or graphical representations of participants’ results.
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Table 2-1:  European Proficiency Testing Schemes
Provider Scheme Accreditation x/a
ENSFI approved schemes
DGKC Reference Institute for Bioanalytics Germany Drugs and Alcohol Analysis In process
Institute of Legal Medicine and Traffic Medicine 
for Society of Toxicological and Forensic 
Chemistry (GTFCh)
Germany Forensic Alcohol Analysis, Forensic Toxicology, Forensic Hair Testing, In preparation
Institut Municipal d'Investigacio Medica (IMIM) Spain Modality A: 3 urine samples for screening In process 6
Modality B: 6 urine samples for identification and quantification analysis 4
KKGT The Hague Drugs of Abuse (urine) and alcohol analysis
Norwegian Institute of Public Health Division of 
Forensic Toxicology and Drug Abuse
Norway Quantification of 15 drugs in whole blood No 2
Universität Zürich (Scientific Forensic Service 
Zurich) 
Members only
Switzerland
Alcohol Analysis, Toxicology, Drugs
(Accredited as a member of the Swiss Society of Legal Medicine but not 
to an international standard)
1 or 2
UK Alcohol Breath  Analysis No 1
Toxicology 1
Members only Drugs 2
Alcohol Analysis 4
Drug of abuse in urine 4
Drugs of abuse in urine
Drugs in blood and autopsy blood
Other European Schemes
NORDQUANT:  Norwegian Institute of Public 
Health 
Norway Drug quantitation in blood 1
Equalis AB Sweden No
U.O.C. Tossicologia Forense Antidoping Italy In Progress
UKFSLG (United Kingdom Forensic Science 
Drugs Liaison Group), LGC
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2.4.3.2 UKNEQAS 
The Network of United Kingdom National External Quality Assessment Schemes 
(UKNEQAS) provides educational schemes, mainly for laboratories monitoring 
therapeutic drug levels.18  Although they do not appear on the UKAS 
accreditation list, their schemes are fully approved in the UK by Clinical 
Pathology Accreditation (EQA) Ltd (a subsidiary of UKAS) and have over 450 
participants from 36 countries.  UKNEQAS offers a forensic toxicology PTS for 
ethanol (established 1993), paracetamol, salicylate and carboxyhaemoglobin 
(1991) and various drugs of abuse schemes as detailed below. 
2.4.3.2.1 Drugs of abuse in urine  
UKNEQAS for drugs of abuse in urine commenced in 1986 and now has over 250 
participants from 26 countries (149 UK-based).18  Participants are quarterly 
provided 3 specimens of lyophilised urine which reflect real specimens 
containing complex mixtures of interferences, and therapeutic and abused 
drugs/metabolites (including emerging drugs of abuse). 
Abilities of participating laboratories range from offering point of care testing to 
more accurate legal or clinical analyses.  Participants can select how their 
performance will be rated, qualitatively or quantitatively.  There are two 
thresholds by which quantitative determinations can be scored: cut-off values 
assigned by UKNEQAS for routine clinical investigations or the more rigorous 
values outlined in the UK Laboratory Guidelines for Legally Defensible Workplace 
Drug Testing.121  Participants should also report notes on sample integrity 
(qualitatively or through measurement).   
2.4.3.2.2 Quantitative blood scheme  
Each quarter two blood samples are provided with named analytes for 
quantification.  Analytes are those typically associated with death by overdose 
(many requested by participants). 
2.4.3.2.3 Toxicology cases  
With the majority of PTS a results form is supplied to participants which prompts 
for information required.  Only the level of detail routinely provided to clients 
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should be given, although the method used (including LLOQ or cut-off) should be 
completed.62  A results proforma aids evaluation but can impede valuable 
comment and may not reflect everyday performance.95  In 1995 UKNEQAS 
launched a special ‘toxicology cases’ PTS designed to monitor interpretation of 
analytical results which is a key aspect of forensic toxicology.18  Participants are 
supplied with a test material (serum/urine) accompanied by a case scenario.  
The laboratory considers time and cost requirements before following what they 
believe to be the best course of action.  They are free to make enquiries, 
including requests for further samples as they would with real cases.  Results are 
returned as a case report and interpretation is also scored out of a maximum of 
twenty by an independent panel of toxicologists.  This type of testing more 
closely satisfies the requirement of a PTS, to obtain a genuine perception of 
routine performance.  However, forensic toxicology laboratories most often work 
with blood and do not routinely process serum samples.18  Thus, this scheme is 
more applicable to clinical toxicology but with the inclusion of interpretation it 
is taking PTS to the next level.  Forensic toxicology schemes could benefit from 
the inclusion of interpretation but the most beneficial advance would be a PTS 
catering for the non-traditional matrices which are increasingly being 
encountered.    
2.4.4 Oral Fluid PT Schemes 
2.4.4.1 UKNEQAS Oral Fluid Scheme 
In 2009 UKNEQAS commenced an accredited scheme for drugs of abuse in oral 
fluid.  They have quarterly distributions of three oral fluid samples (collected 
from volunteers, patients and drug misusers) which may be spiked with 
additional drug compounds and metabolites.  Participants are expected to 
complete integrity tests. 
2.4.4.2 ORALVEQ 
The first external Quality Assessment performed for drugs of abuse in oral fluid 
was ORALVEQ.  Organised in cooperation between the Institut Municipal 
d’Investigacio Medica (Spain) and the Instituto Superiore di Sanita (Italy), the 
first round of testing was performed in 2007 with three samples sent to 
seventeen European and four US laboratories (including three reference 
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laboratories).  The results of this round of testing have been summarised and 
published by Ventura et al.122  Participants provided quantitative analysis and 
evaluation was performed by converting measurements to z-scores using robust 
mean and robust standard deviation of participants’ results.  Participants’ 
dispersion was high (CV around 40%, reference laboratories <10%) although 
accuracy was quite good (the standard error, ERR, was never above 20%).  High 
dispersion could be the result of using robust statistics for z-scoring as no 
outliers were rejected.  High dispersion may have influenced the high 
percentage of satisfactory z-scores.122 
2.4.5 HAIR PT Schemes 
2.4.5.1 Society of Hair Testing PT 
The Society Of Hair Testing (SOHT) provides an annual proficiency test 
(qualitative/quantitative), which is for their members only.123 
2.4.5.2 HAIRVEQ 
The same institutions which were involved in ORALVEQ collaborated to provide 
an external assessment scheme to evaluate testing of illicit drugs in hair within 
the Italian National Health Service and Institutes of Forensic Medicine.  First 
testing was performed in 2002, with 23 participant and three reference 
laboratories, and a round of testing was conducted once in each of the three 
subsequent years before long term review revealed that participants’ 
performance had deteriorated.  As a definite source of error could not be 
uncovered, method validation and evaluation of analytical results was deemed 
responsible.  Support and training in these areas was therefore given over three 
test rounds in 2006.  Organisers held workshops and supplied SOPs with hair 
samples of known drug composition to help improve participant performance.  
Participation had increased in 2006 to 32 participants and four reference 
laboratories.  Although a small group of laboratories persisted in showing 
unsatisfactory qualitative performance, overall there was improvement.  
Quantitative performance was also much improved in terms of dispersion of 
results (although this remained relatively high).124 
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For z-score calculation the robust mean of the participant values (not reference 
labs) was used in combination with two values of acceptable deviation to 
provide two scores.  One by robust standard deviation of participants’ results 
and another by the expected relative standard deviation given by Horwitz’s 
equation.  This was considered necessary as by the first method all participants 
received satisfactory z-scores (-2 to 2) which was unrealistic.  By Horwitz’s 
method only a few laboratories received satisfactory scores.  This highlights the 
importance of having an appropriate scoring system.  By using an independent 
scoring method it was clear that, although there had been improvement, 
participants were still not performing adequately.  A further workshop identified 
two analytical method problems responsible for the laboratories struggling with 
qualitative analysis.  The scheme continues to support participants by providing 
guidance in these areas.  
2.4.6 Specialist Forensic Toxicology Testing 
2.4.6.1 Federal Aviation Association (FAA) PT, USA   
FAA provides specialist proficiency testing for forensic toxicology laboratories in 
the USA.  The scheme was created to provide ‘true’ post-mortem samples as 
other toxicology programmes do not take account of tissues or putrid samples.125  
They supply whole blood, plasma and urine samples as well as tissues (kidney 
and liver), to be more reflective of the samples routinely received by 
participants.  Test material matrix and analyte/concentration are selected on 
the basis of current analytical/toxicological issues.  These could be informed by 
published research, suggestions from participants/other toxicologists, including 
those at the Civil Aerospace Medical Institute providing forensic toxicology, or 
data from aircraft accident research.125  Testing is quarterly and free of charge 
although information exchange is expected in return.  It is performed on a 
voluntary basis and participants need only do as they would routinely - 
qualitative or quantitative analysis.   
2.5 Alternative EQA available to all:  UNODC ICE 
In the 1990s the United Nations Office on Drugs and Crime (UNODC, previously 
the United Nations Drug Control Programme, UNDCP) investigated global 
provision of PTSs for forensic toxicology laboratories.  It was concluded that they 
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were significantly lacking and many member states were without access to any 
form of EQA, for example, in South America, the Middle East and Africa.  Many 
of the schemes discussed above have since been created, although the 
laboratories that could benefit most from participation, those in developing 
countries, remain without. 
In recognition of the power of PTS to improve quality, and the absolute necessity 
for all laboratories to have access to EQA, UNODC created free-of-charge, 
accessible to all, International Collaborative Exercises (ICE) for drugs of abuse in 
urine and for drugs of abuse in seized drug materials.  Not a collaborative trial in 
the traditional sense, ICE follows the principles of proficiency testing to assess 
trueness (closeness of agreement between the measured and true values) 
achieved from various protocols operating within laboratories of differing 
competencies and resources.  It is not yet a true PTS but biannually provides 
laboratories four test specimens to allow an independent check of performance.   
2.6 PTS Quality Assurance:  Long Term Review 
It is recommended that every PTS should monitor the performance of their 
participants and the effectiveness of the PTS through long-term review.  This is 
essential for accredited schemes.  These are conducted after each year or 
twelve rounds of testing, whichever is longer.48  The percentage of participants 
producing acceptable results (known as the first efficacy measure EMa) is 
calculated and reported for each round, often as a chart for ease of 
interpretation.48  To determine the degree to which a PTS satisfies the objective 
of bringing participants’ performance closer to the target performance level, a 
second efficacy measure EMb can be calculated.  This is equal to the defined 
target variation divided by the observed inter-laboratory robust standard 
deviation.48  The target values to suggest that the majority of participants are 
performing satisfactorily are EMa >95% and EMb >1. 
As previously mentioned, Ferrara et al 62 caution that whilst proficiency testing 
is the best means of assessing laboratory performance it should not, in itself, be 
considered an endorsement of quality.  The limitations of the protocol previously 
discussed (genuine routine processing of test materials, uncertainty in statistical 
interpretation of data and delay in reporting results) can be too great for the 
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PTS to be effective.62  Hence the encouragement for laboratories to aim to 
participate in a good quality PTS.  With accreditation often associated with 
quality, many laboratories will opt for schemes which carry some form of 
endorsement, particularly ISO accreditation.  This begs the questions of whether 
this approach is correct and of whether fitness-for-purpose is ensured by 
accreditation.  Results of long term review can provide participants and 
laboratories considering participation with an indication of the scheme’s fitness-
for–purpose.   
With relatively few forensic toxicology PTS available, long-term review was 
performed in the present study for two quite different schemes, the LGC 
Standards International UKAS-accredited commercial scheme, “Quartz Forensic 
Blood Toxicology PTS”, and the freely-available International Collaborative 
Exercises (ICE), which does not evaluate performance against a quality standard 
such as ISO/IEC 17025.  Detailed reviews of both schemes are given in the 
following chapters.  The two were compared to evaluate effectiveness of the 
schemes in improving laboratory performance and to establish the level at which 
participants perform.   
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Chapter 3:  United Nations Office on Drugs and 
Crime (UNODC) International Collaborative 
Exercise (ICE), within the International Quality 
Assurance Programme (IQAP) 
  
3.1 Introduction 
In 1988 a meeting was held by the United Nations Commission on Narcotic Drugs 
(CND) which directs the United Nations Office on Drugs and Crime, UNODC, to 
discuss with member states mounting concern over the expansion of drug abuse 
in developing countries.  At this meeting the requirement for member states to 
be educated, trained and provided with resources for the testing of drugs 
(particularly in body fluids, considered the more difficult task 63) was recognised 
as an essential factor in reducing drug abuse at national and international levels.  
In developing countries at this time there was a lack of technical knowledge and 
support services required for effective control.63  UNODC aimed to ensure that 
every member state had adequate drug testing facilities.  The necessity for 
proficiency testing to improve laboratory performance was quickly identified.   
In the 1990s UNODC investigated the provision of EQA and PTSs.  They concluded 
that available schemes were very much lacking with many of their member 
states  without access.  Thus, UNODC created an initiative to promote 
improvements of quality in routine analytical measurements, the International 
Quality Assurance Programme, which in turn instituted the International 
Collaborative Exercises (ICE).  These are not collaborative trials in the 
traditional sense, as they do not study precision of specified methods performed 
by equally competent laboratories.  Rather, ICE follows the principles of 
proficiency testing to assess trueness achieved from various protocols within 
laboratories with differing competencies and resources.  It is intended, that in 
time, ICE will develop into an international PTS, available to all.
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3.2 International Quality Assurance Programme (IQAP) 
Rapid dissemination of information internationally between laboratories, and 
from laboratories to the various authorities engaged in drug control, is 
considered critically important for the effective control of international illegal 
drugs activities.63  This information must be reliable and comparable between 
nations. 
Laboratories with strong IQC cultures demonstrate a greater level of reliability.79  
The IQAP of UNODC, therefore, helps drug testing laboratories to raise their 
level of performance by teaching Analytical Quality Assurance and promoting its 
use.  IQAP encourages laboratories to expand their capabilities and strive to 
perform quantitative analysis, as this has been shown to achieve consistently 
better laboratory performance.126  Developed in 1995 the Standing Panel of IQAP 
aimed to: 
“Develop a programme of work to harmonise the standards of quality 
assurance for national laboratories and to set up an international 
proficiency testing programme”.63 
Development of a PT programme was an obvious aim as participation in PT is 
known to improve laboratory performance 50,61 and many member states of the 
UN were without such a resource.  Creating an international PTS is a massive 
endeavour, however, and perhaps not the best means of IQAP achieving its 
target of improving quality in the poorest performing laboratories.  These 
laboratories would have been unlikely to participate in a PTS with their 
performance often far below acceptable limits.  Thus, UNODC offered help 
which included manuals, training equipment, standards, regional meetings, and 
the introduction of ICE, as a preliminary to a PTS.  ICE was intended to help 
rather than regulate participants, eventually to evolve to a PTS when participant 
performance reached sufficiency.  The overall aim of ICE is to determine an  
“internationally accepted standard against which the performance of 
laboratories could eventually be monitored and assessed”.63   
It was anticipated that ICE would aid laboratory quality improvement by 
enabling laboratories to demonstrate and compare the quality of their work.  
Participant laboratories’ recognition of their improved competence, together 
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with their awareness of how they perform relative to their peers was expected 
to inspire laboratories to improve.  Improvement would not be possible, 
however, without creation of laboratory quality management systems.   
Setting up a QMS is not simple but participants would be directed in the 
development of effective system by using their performance results to assess the 
strengths of their systems and identify necessary corrective actions.  IQAP was 
available to assist.  It was hoped that ultimately participants would seek to have 
their efforts and commitment to quality internationally recognised by becoming 
accredited.  The disadvantage of not being a formal PTS is that ICE may not be 
recognised as such for laboratories required to participate in a PTS for 
accreditation.  Where PTSs are unavailable, however, ICE could be used as an 
alternative form of EQA, with verification to demonstrate commitment to 
quality.   
The process of certification is a commercial activity which can be performed by 
any organisation (unlike accreditation).  Certification can be accredited by an 
accrediting body on International Certification Standards such as ISO 17043.  
UNODC seeks to become an accredited Certifying Body which will enable them to 
provide a Certificate of Participation in ICE. 
3.3 International Collaborative Exercises (ICE) 
Although ICE was primarily instigated for laboratories in developing countries, it 
welcomed participation from all laboratories recognised (“gazetted”) for the 
analysis of drugs of abuse by the appropriate governing body in their country.63  
ICE was the only EQA system available to many participants and, therefore, their 
only means of detecting if performance was less than fit-for-purpose.  Poor 
performance from these laboratories would have a significant negative effect on 
the Human Rights of those facing drugs charges and also on worldwide exchange 
and co-ordination of drugs information.  Despite this, participation was voluntary 
and partial participation was possible with no penalties for opting out of certain 
analyses, with participation at any level appreciated as ambition to improve 
quality.   
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In order to allow maximum participation from laboratories in developing nations 
the introductory requirements of ICE were simplistic.  Organisers were aware, 
however, that an over-simplified scheme would not have any developmental or 
educational benefits.  Participants were to be challenged to demonstrate that 
the scheme was sufficiently discriminating.  In order to achieve this, the 
requirements of the scheme were gradually increased to reflect the 
advancement of the laboratories.  Initially there was no requirement to identify 
a specific substance; screening was the only requirement, with confirmatory 
testing introduced in later stages.   
Analytical methods for analysis were never stipulated.  Some laboratories return 
results obtained from simple methods such as thin layer chromatography and 
ultra violet spectrophotometry whilst others employ sophisticated techniques 
like LC-MS/MS.127  If confirmatory analysis is not routine in a laboratory only a 
screening result will be returned.  The provision of more reliable confirmatory 
results is a fundamental step in quality improvement, however, many ICE 
participants’ resources could be so limited that they are unable to attain 
reference standards, rendering confirmatory testing impossible.  UNODC 
demonstrated their commitment to these laboratories by distributing drug 
standards and publishing recommended analytical methods for the most 
prevalent illicit drugs to aid method development.63  Initially the range of drugs 
included in test materials was limited to those for which manuals were 
available.  Progressively the range has expanded and more substances have been 
added to the core test menu (and an optional supplementary list created) to 
reflect international and regional trends in illicit use of controlled substances.   
The experts on the ICE Standing Panel travel to UNODC (Vienna) annually to 
review the programme and advise recommendations for its future development 
and management.  Resources are required for this yet participation is free of 
charge, to appeal to laboratories truly in need of help.  Participation is 
therefore restricted to 150 per round.  If demand for participation were to 
exceed this limit, fees could be imposed on laboratories in developed countries, 
particularly commercial laboratories. 
With such financial demands on UNODC compromises have been necessary.  
Biannual provision of samples was cut to annual and for a period no samples 
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were sent out and there were no meetings of the Standing Panel.  Biannual 
testing returned in 2009 as the panel agreed that laboratory performance should 
be tested more than once a year.  In order for ICE to become a PTS for the 
purposes of ISO 17025, a minimum of two rounds per year must be maintained.  
3.3.1 Test Materials 
There are two types of testing available, the analysis of seized materials (SM) or 
biological specimens (BS).  Laboratories can participate in either or both.  A 
round of each test comprises four samples.  One bottle can contain an analyte 
which is not on the main menu and some bottles may be drug-free.  SM are 
usually samples of drugs which have been recovered from illegal trade.  As the 
precise nature of these materials is unknown they are analysed by 5-6 accredited 
reference laboratories prior to testing. 
BS are prepared as spiked urine samples.  To avoid bacterial growth on standing 
and transportation these are supplied freeze-dried for reconstitution (which 
could introduce errors not encountered in routine casework 85).  With less 
uncertainty related to their content, external verification of the 
drug/metabolite concentrations is performed in parallel with the test 
laboratories by three to five reference laboratories.63   
As an international scheme, variations between laboratory routine protocols 
have caused some problems.  In many countries testing is prioritised and is 
stopped at the first controlled drug detected, while other countries identify 
everything present above trace levels and others still report everything 
regardless of abundance.  Additional constituents and trace substances are 
therefore not included in the assessment of performance but are simply reported 
in the laboratory feedback.  There is some concern, however, that laboratories 
operating at this level may be disappointed that their additional work does not 
get formal recognition. 
3.3.2 Import/Export Certificates 
One of the difficulties which must be overcome with an international scheme is 
obtaining permission for SM and reference standards to be transported between 
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countries (no such requirement exists for biological specimens).  Participants 
must obtain an import certificate to permit the entry of the substance into their 
country and an export certificate to allow the drugs samples to leave Austria.  
Import certificates must be issued by the national competent authority under 
International Drug Control Treaties.  When problems are experienced obtaining 
import certificates UNODC can contact the International Narcotics Control Board 
(INCB) which writes to the appropriate authorities to establish what problems 
exist and help to rectify them.   
As the composition of the test materials is unknown, permission for all possible 
substances must be obtained.  The Austrian export certificate, however, is more 
complicated.  In order to satisfy international drug control conventions it must 
indicate the full contents of each sample.  Provision of truly unknown samples is 
therefore difficult and sometime impossible.  It is recommended to participants 
that the ICE test materials are delivered to an intermediary.  Where possible the 
intermediary will be an UNODC Field Office, alternatively an independent 
laboratory.  Upon receiving the test materials they are immediately forwarded 
to the participant whilst the export certificate is retained.  However, if only the 
receiving laboratory can be named as the importer, a manager should receive 
the export certificate and agree not to disclose the contents to the analysts.   
This system was demonstrated to be effectively maintaining confidentiality 
when, in 2001, LSD coated on codeine and paracetamol tablets was released as 
an SM sample.  Only five of sixty laboratories correctly identified the presence of 
LSD. 
3.3.1 Returning Results 
Laboratories are given eight weeks from notification of dispatch of samples to 
return their results.  Results are returned on a special form provided with the 
test bottles. The results form has a separate area to record the results for each 
of the three phases of testing: 
Phase 1: Screening (classification only) 
Phase 2: Identification (specific compound) 
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Phase3: Quantification (only reported if this forms part of the laboratory 
routine procedure) 
 
In order to make the task as simple as possible for participants, the results form 
contains a list of the substances which are potentially contained within the 
bottles – this is referred to as the ‘menu’.  It is possible that other substances 
may be present in one of these bottles but they do not appear on the menu.  
This is because the menu only contains those substances that would be expected 
to be detected and reported in general routine work.  Participating laboratories 
should treat the test materials as they would routine samples, thus all three 
phases of testing are not compulsory.  If they detect a substance not on the 
menu following their standard procedure, there is a comments area where this 
can be recorded and this is a bonus point for that laboratory.  This comments 
area can also be used to record any other relevant details e.g. difficulties 
encountered during the analysis of the test materials. 
The results sheet also prompts the laboratory to detail the analysis methods 
used.  This is recorded as a code number according to the list provided in the 
test documentation.  Laboratories can use up to two methods at each stage.  It 
is expected that a different method will be applied to screening and 
confirmation, thus at least two methods are expected to be reported by each 
laboratory. 
3.3.2 Reporting Performance  
At the end of each round individual laboratories are provided with an evaluation 
of their own performance and are advised of the correct content of the test 
materials.  Participants also receive an annual certificate of competence in the 
analysis of SM or BS, provided the following criteria have been fulfilled:126 
 Return of all results for all samples (for both rounds where applicable) 
 Correct identification of at least one controlled drug (and/or its metabolite 
where appropriate) in all samples that contained controlled drugs. 
 At least 90% correct results 
 
Z-scores are not calculated for participants, only for reference laboratories.  
These are anonymised and supplied to participants to allow them to become 
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familiar with the data presentation format.  Participants’ performances are not 
shared, although any pertinent information arising from the comments section is 
disseminated to alert laboratories for new substances likely to be encountered. 
UNODC uses ICE results in determining how best to focus their support.  
Laboratories which fail to return results or present high instances of incorrect 
results are approached and offered assistance.  Mentoring and advice is available 
to any laboratory that seeks this.  It is hoped that this long term review will 
provide greater focus of assistance.  
3.4 Aim 
The University of Glasgow Department of Forensic Medicine and Science has 
actively supported UNODC in the global improvement of drug testing facilities 
since 1989.  This exercise aimed to further UNODC’s target to develop an 
accessible PTS through evaluation of ten years of data generated by ICE (1999 – 
2009).  It was intended to appraise whether ICE had improved participants’ 
analytical quality, and establish the level at which they operate.  In order for 
ICE to advance to a PTS recognised by ISO 17025, criteria for acceptable 
quantitative results must be stipulated.  Long term review of ICE aimed to 
inform what constitutes an international measure of achievable, yet challenging, 
acceptable variation against which to measure performance. 
3.5 Long Term Review 
3.5.1 Summary of Available Results 
The results received over the first ten years of testing were recorded to a 
database which used software now obsolete.  Unfortunately it was impossible to 
reliably retrieve the required data and everything had to be manually entered 
from the original hard-copy participants’ results forms to a specially designed 
Excel spreadsheet.  This was extremely time-consuming and only some years 
could be made available for re-entry.  Data for the more recent rounds were 
provided as summary reports prepared for coordinators’ review and were, 
therefore, more limited.  Data reviewed and summarised is listed in Table 3-1. 
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Table 3-1:  Available data by year  
(BS = Biological Specimens, SM = seized materials).  No testing was performed in 2006 
(2000, 2002 and 2004 data is unavailable) 
 
3.5.2 General protocol 
 
Figure 1  Frequency of testing of specific substances in biological specimens 
 
Year Round Samples Data
1999 1 BS Complete
2001 1 BS and SM Complete
2001 2 BS and SM Complete
2003 1 BS and SM Complete
2003 2 BS and SM Complete
2005 1 BS and SM Complete
2005 2 BS and SM Complete
2007 1 BS and SM Limited
2008 1 BS and SM Limited
2009 1 BS and SM Limited
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Figure 2:  Frequency of testing of specific substances in seized materials 
 
Figure 1 (BS) and Figure 2 (SM) depict the frequency with which specific drugs 
were included in the programme over the years profiled.   
3.5.3 Participation 
In general participation was unstable (Figure 3), with SM tending to be favoured 
over BS, Figure 4 (2009 data did not allow laboratories participating in both SM 
and BS to be distinguished). 
 
Figure 3:  Number of laboratories participating in ICE for each round 
There was only one round in 2007 and 2008 
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Figure 4:  Number of laboratories participating in BS testing, SM testing and total number of 
participants.  
 
Continuous participation in ICE could not be fully assessed with information 
available only for the 8 BS and 6 SM rounds in years 1999, 2001, 2003 and 2005 
(Table 3-2).  65 laboratories performed at least one ICE BS round and 111 
laboratories participated in at least one SM round.  Only 10 laboratories 
participated in all 8 BS rounds and 14 in all 6 SM rounds.   
 
Table 3-2:  Consistency of laboratories’ participation 
 
There was no data to relate the number of laboratories that were invited to 
participate but declined, or that enrolled in a round but did not return results.  
Review of such data could have diagnosed issues which prevented keen 
laboratories from participating (for example, difficulties with export certificates 
or insufficient time allotted for completion of testing) and any requisite 
procedural adaptations to maximise participation. 
Number of 
rounds
Number of 
Laboratories
Number of 
rounds
Number of 
Laboratories
8 10
7 1
6 10 6 14
5 2 5 13
4 4 4 24
3 13 3 19
2 12 2 25
1 13 1 16
BS SM
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3.5.4 Qualitative Summary 
Figure 5 (BS) and Figure 6 (SM) illustrate proportions of correct detections for 
years 1999, 2001, 2003 and 2005. 
In the absence of individual laboratory data for the whole period of the review a 
compromise of looking at detections for each particular substance was used as a 
general performance measure (summarised in Table 3-4 BS and Table 3-6 SM).  
As a consequence of inconsistent laboratory participation, however, it is 
unknown whether the percentages of correct identifications given in these 
tables are a true reflection of participants’ general performance through time.  
It is unknown whether any dips in performance are due to poorer performance 
by new or periodic participants bringing down performance as a whole, whilst 
improvement in regular participants is perhaps obscured. 
Details for occurrences of false negatives and positives could only be deciphered 
from 1999, 2001, 2003 and 2005 data, with details of the analyte errors and the 
laboratories that reported them.  All that was provided for 2007, 2008 and 2009 
was the sum total of ‘participants with a wrong response’ per round.  It was 
unclear whether they had failed to detect the substance of interest or if they 
had identified a substance which was not present.  Incorrect results are 
presented in Table 3-3 BS in and Table 3-5 for SM. 
Overall, identification was better for SM than BS.  A laboratory failed to identify 
an analyte present in a BS sample on 137 occasions (some samples had multiple 
analytes) compared with 23 unidentified analytes in SM samples. 
3.5.4.1 Biological Specimens 
BS codeine false negatives were very frequent.  As this drug is not controlled 
worldwide, it may not have been part of a large number of participants’ routine 
test battery.  Failure to detect codeine could not, therefore, be confidently 
attributed as a quality issue and was not given further consideration.   
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Figure 5:  Correct identifications of biological specimens from 1999 to 2005 
 
 
 
Table 3-3:  Overview of BS results 
 
Benzodiazepines had the highest incidence of incorrect BS results (although this 
could be because it was the most frequently tested group).  Investigation of the 
laboratories failing to detect benzodiazepines identified 3 laboratories with a 
particularly high share (laboratory 330 had 12, 349 had 10 and 521 had 9 errors).  
These were recurrent participants (330 and 521 participated in all 8 BS rounds 
and 349 in 7) which could explain their higher rate, although there was a 
common feature of their analytical method.  They all applied TLC.  
Total tests
Participants
New participants
No of analytes
Failed to identify:
ATS * * 20 50% 9 33% 16 53% 17 50% 8 22% 5 23% 8 18% 234 83 35%
Barbiturates * * * * * * * * 9 26% * * * * * * 34 9 26%
Benzodiazepines 68 46% * * 16 59% 71 59% * * 48 43% 12 55% 5 23% 484 220 45%
Delta-9-THC - COOH 14 19% * * 9 33% * * * * 6 16% 4 18% * * 160 33 21%
Cocaine Group 37 50% 32 40% * * 8 27% 17 25% 27 36% * * 2 9% 348 123 35%
opiates * * 19 24% 10 19% 15 25% * * 12 32% 10 23% 24 55% 319 90 28%
Total 119 40% 71 36% 44 33% 110 46% 43 32% 101 34% 31 28% 39 30%
ATS 1 17
Barbiturates * 4
Benzodiazepines 6 30
Delta-9-THC - COOH * 3
Cocaine Group * 3
Hallucinogens 1 2
opiates * 22
Total
2005_1 2005_2 Total failed to ID
37 40 27 30 34 37 22
1999_1 1999_2 2001_1 2001_2 2003_1 2003_2
22
37 9 4 5 2 1 4 0
110 132
False positives
296 200 135 240 136 296
1 2 3 3 3 2 2
*
4 3 6 3 * 4 4
2 2 * * * *
*
1 * 1 1 * * *
2 1 * * * *
*
* 3 6 8 * 4 1
* * * 1 * *
7 88 11 10 16 3 16
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Amphetamine Type Stimulants
MDMA
Amphetamine
Methamphetamine
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11-nor-delta-9-THC-9-carboxylic acid
Cocaine
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3.5.4.2 Seized Materials 
Results for 2001 Round 1 SM involving LSD were disregarded as this Round 
probably had an error in the sample composition.   
 
Figure 6:  Correct identifications of seized materials from 1999 to 2005  
*  LSD in bottle 3 2001 Round 1 has been omitted.  2003 R1 bottle 4 contained EDDP which 
only four laboratories correctly identified  
Amphetamine-type stimulants (ATS) accounted for 11(65%) of all relevant SM 
false negatives.  Opiate false negatives were all for the adulterant codeine and 
all but 3 of the hallucinogen false negatives related to the disregarded LSD 
sample in Round 1.  With the highest proportion of false negatives, ATS proved 
to be the greatest challenge to SM participants (Table 3-5 counts those 
laboratories who did not attempt the analysis together with false negatives as 
‘failed to identify’, Table 3-8  differentiates between these).  The false 
negatives were dispersed across different laboratories and therefore appeared to 
be random errors (although 3 laboratories had 2).  In 2 instances no screening 
had been performed and in 6 screening was negative (5 using colorimetric 
reactions and 1 TLC).  In the remaining 3 instances another substance was 
identified (2 correctly and 1 falsely) and it may have been the routine procedure 
of the laboratories concerned simply to stop the analysis when the first drug was 
identified rather than continue to test for all substances present.   
All bar one of the other 8 false negatives (4 hallucinogens, 3 benzodiazepines,1 
opiate) were the result of negative screening (3 by colorimetric reactions, 3 by 
TLC and one GCMS, the other was not screened).
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Table 3-5:  Overview of SM results
Total tests
Participants
New participants
number of possible identifications
Failed to identify:
ATS 8 10% 5 6% * * 5 8% 4 9% 10 23% 508 32 6%
Benzodiazepines 7 0.09 * * * * * * * * * * 34 7 21%
Delta-9-THC - COOH * * * * * * 4 7% * * * * 484 4 1%
Cocaine Group * * 2 2% 1 2% 0 0% 0 0% 0 0% 160 3 2%
Hallucinogens 72 47% * * * * * * 8 19% 3 7% 348 83 24%
opiates * * 32 19% 56 55% * * 0 0 * * 319 88 28%
Total 87 28% 39 11% 57 12% 9 4% 12 7% 13 6%
ATS
Barbturates
Benzodiazepines
Delta-9-THC - COOH
Cocaine Group
Hallucinogens
opiates
Total
4
4 7 3 2 3 8
* 1 1 * * 2
3
1 * * * * * 1
* 3 * * * *
2
* 1 2 * * * 3
1 1 * * * *
13
1 * * * * * 1
1 1 * 2 3 6
False positives
220
18 5 5 0 0
308 340 459 240 172
Total failed to ID
77 85 51 60 43 44
2001_1 2001_2 2003_1 2003_2 2005_1 2005_2
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Amphetamine 
Type Stimulants
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3.5.5 Methods 
3.5.5.1 Biological Specimens 
The analytical methods used for BS determinations are detailed for each 
substance group in Table 3-7.  As barbiturates were only tested once method 
assessment would have been unreliable.  With the greatest proportion of correct 
identifications (87%), HPLC appeared to be the best method for benzodiazepine 
identification, closely followed by GC-MS (82% correct).  GC/NPD was generally 
acceptable (greater than 80% correct identifications), however, GC-FID as well 
as TLC were unreliable.  
At 7%, cannabis had the lowest BS frequency of false negatives (others ranged 
13% to 16%); participants were therefore most competent with this 
identification.  With a 100% identification rate, HPLC transpired to be the best 
identification method.  There were fewer HPLC identifications than GC-MS, 
however, which was most popular and extremely effective (97% correct).  TLC 
was also frequently applied.  Overall TLC had unacceptable performance as just 
over half of analyses resulted in a correct identification.  However, with 
cannabis it was relatively good (74%).  Perhaps a consequence of the fewer 
cannabinoid analytes impacting on specificity.  If this were true, TLC would be 
expected to perform well with other substance groups with few analytes, for 
example cocaine.  However, TLC cocaine identifications were poor (55%).   
All instrumental methods applied to cocaine, ATS, and opiates provided 
acceptable performance with the exception of GC-FID with ATS.  It was clear 
that BS identification was most successful by LC-MS(/MS) (infrequently used 
methods were not considered).  Only 1 of 40 analyses was a false negative.  
However, LC-MS/MS accounted for only a small fraction of analyses (3%), which 
reflects the lower availability of instruments in poorer countries.  GC-MS was the 
most popular method for a large proportion of analyses (63%) and its proficiency 
was, therefore, more extensively tested.  GC-MS attained 87% correct 
identifications, relatively good given the mixed abilities of the participants, 
although a higher rate would be desirable. 
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Table 3-7:  Analytical methods used for biological specimens.   
(c = correct, c+ = correct identification with an additional false positive, fn = failed to 
identify, fn+ = failed to identify the correct substance but wrongly detected another)  
3.5.5.2 Seized Materials 
SM analytical methods are detailed in Table 3-8 (poor hallucinogen performance 
resulted from sample preparation error and poor opiate performance was due to 
codeine, as mentioned earlier).  In general terms no SM methods appeared to 
Unknown EIA FPIA TLC HPLC GC/NPD GC/FID GC-ECD GC-MS FTIR UV-VIS LC-MS
ATS
No Analysis 41 - - - - - - - - - - - 41
c 2 - - 13 3 7 6 - 113 - - 9 153
c + - - - 1 - 1 - - 2 - - - 4
fn - - - 7 1 1 5 - 10 - - - 24
fn+ - - - 3 - 1 2 - 5 - 1 - 12
Total 43 - - 24 4 10 13 - 130 - 1 9 234
Barbiturates
No Analysis 7 - - - - - - - - - - - 7
c - - - 3 1 - 2 - 17 - - 1 24
c + - - - - - - 1 - - - - - 1
fn - - - - - - - - 2 - - - 2
fn+ - - - - - - - - - - - - 0
Total 7 - - 3 1 - 3 - 19 - - 1 34
Benzodiazepines
No Analysis 142 - - - - - - - - - - - 142
c 6 - - 22 20 9 3 2 153 1 1 10 227
c + - - - 3 - - 1 - 1 1 - - 6
fn 2 - - 21 3 1 4 - 28 - - - 59
fn+ 1 - - 7 - - 3 1 4 - - - 16
Total 151 - - 53 23 10 11 3 186 2 1 10 450
Cannabinoids
No Analysis 19 - - - - - - - - - - - 55
c 2 1 - 23 11 1 7 - 80 1 - - 91
c + - - - - - - 1 - 1 - - - 2
fn - - - 8 - - 2 - 1 - - - 11
fn+ - - - - - - 1 - - - - - 1
Total 22 1 - 31 11 1 11 - 82 1 - - 160
Cocaine
No Analysis 72 - - - - - - - - - - - 72
c 8 1 - 20 14 9 11 - 157 - - 7 227
c + - - - - - 1 - - - - - - 1
fn - - - 16 1 2 4 - 25 - - - 48
fn+ - - - - - - - - - - - - 0
Total 80 1 - 36 15 12 15 - 182 - - 7 348
Opiates
No Analysis 44 - - - - - - - - - - - 44
c 4 3 1 25 7 9 17 - 148 2 1 12 229
c + 0 - - 1 - - - - - - - - 1
fn 0 - - 12 - - 4 2 21 - - 1 40
fn+ 0 - - 2 2 1 - - - - - - 5
Total 48 3 1 40 9 10 21 2 169 2 1 13 319
All Groups
No Analysis 325 - - - - - - - - - - - 325
c 22 5 1 106 56 35 46 2 668 4 2 39 986
c + - - - 5 - 2 3 - 4 1 - - 15
fn 2 - - 64 5 4 19 2 87 - - 1 184
fn+ 1 - - 12 2 2 6 1 9 - 1 - 34
Total 351 5 1 187 63 43 74 5 768 5 3 40 1545
Substance Group Result
Method
Total
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have unacceptable performance.  GC-MS was the most frequently applied 
method (69% of analyses) with a relatively good rate of correct identifications 
(92%) 
.  
Table 3-8:  Analytical methods used for seized materials.   
(c = correct, c+ = correct identification with an additional false positive, fn = failed to 
identify, fn+ = failed to identify the correct substance but wrongly detected another) 
Unknown
Colour 
Reactions TLC HPLC GC/NPD GC/FID GC-MS FTIR UV-VIS
ATS
No Analysis 8 - - - - - - - - 8
c 3 - 14 10 3 60 312 19 4 425
c + - - - - - 1 9 - - 10
fn - - 4 - - 5 2 - - 11
fn+ - - - - - 2 1 - - 3
Total 11 - 18 10 3 68 324 19 4 457
Benzodiazepines
No Analysis 4 - - - - - - - - 4
c 1 - 3 2 1 12 49 2 - 70
c + - - - - - - - - - 0
fn - - - - - 1 1 1 - 3
fn+ - - - - - - - - - 0
Total 5 - 3 2 1 13 50 3 - 77
Cannabinoids
No Analysis 3 - - - - - - - - 3
c 3 - 5 - 1 10 37 - - 56
c + - - - - - - - - - 0
fn - - - - - - 1 - - 1
fn+ - - - - - - - - - 0
Total 6 - 5 - 1 10 38 - - 60
Cocaine
No Analysis 2 - - - - - - - - 2
c 4 - 7 5 2 47 198 14 1 278
c + - - 2 - - 1 - - - 3
fn - - - - - - - - - 0
fn+ - - - - - - - - - 0
Total 6 - 9 5 2 48 198 14 1 283
Hallucinogens
No Analysis 37 - - - - - - - - 37
c 2 - 13 16 1 18 103 7 - 160
c + - - - - - - 1 - - 1
fn 1 - 11 2 - 3 22 - - 39
fn+ 1 - 1 - - - 2 - - 4
Total 41 - 25 18 1 21 128 7 - 241
Opiates
No Analysis 61 - - - - - - - - 61
c 3 1 5 2 3 25 135 10 2 186
c + - - - - - 2 - - - 2
fn 3 - 3 4 1 18 32 4 1 66
fn+ - - - - - - - - - 0
Total 67 1 8 6 4 45 167 14 3 315
All Groups
No Analysis 115 - - - - - - - - 115
c 16 1 47 35 11 172 834 52 7 1175
c + - - 2 - - 4 10 - - 16
fn 4 - 18 6 1 27 58 5 1 120
fn+ 1 - 1 - - 2 3 - - 7
Total 136 1 68 41 12 205 905 57 8 1433
Substance Group Result
Method
Total
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3.5.6 Quantitative Summary  
To evaluate if ICE influenced participants to progress to quantification, a 
detailed study was required which identified whether the same laboratories 
quantified in each round or laboratories progressed from qualitative 
participation to returning quantifications.  This was conducted by dividing the 
laboratories into three groups according to 1999-2005 participation in less than 
four rounds, participation in four rounds, or participation in more than four 
rounds of testing.  When values unsuitable for performance evaluation were 
returned (e.g. zero, ‘less than’, ‘more than’, ‘trace’, incorrect units and errors 
where an explanation was apparent), laboratories were still considered to have 
performed quantitative analysis.   
Quantification was least common amongst laboratories that did not participate 
often (23% of ‘less than four rounds’ and 56% of ‘four rounds’ participants), and 
greatest amongst those that participated in more than four rounds (79%).  
Regular participants, therefore, appeared most likely to quantify, although their 
quantification could not be linked to their regular participation.  There were 106 
laboratories performing quantification.  Only 6 started to return quantitative 
results subsequent to their first round and these were equally distributed 
amongst the three levels of participation frequency.  Regular participation did 
not appear to progress participants towards quantification.   
Thus, it had to be addressed whether or not ICE improved quantification 
performance of regular participants.  This required performance scoring.  To 
avoid the possibility of sporadic participation influencing performance statistics, 
the appraisal only considered laboratories that regularly participated.  This was 
defined as more than four rounds for which complete information was available.  
A further 5 SM laboratories were included as they had participated in four such 
rounds and quantified in two or more of the later rounds.  This equated to 21 BS 
and 26 SM participants, of which 13 BS and 26 SM had returned quantifications, 
as detailed in Table 3-9 (BS) and Table 3-10 (SM).   
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Table 3-9:  Laboratories performing quantification by BS substance group 
 
Substance Group Year/Round
No of 
Laboratories Comments
10
MDMA 2005/2 3
Amphetamine 2001/1 9
2003/2 8 no reference value
Methamphetamine 2003/2 10
2007/1 4
MBDB 1999/2 6
Norephedrine 2001/2 6 one wrong units
Phenylpropanolamine 2003/1 7 no reference value
Tenamphetamine 2005/1 2
2005/2 3
4
10
Alprazolam 2001/1 4
2005/2 3
Nordazepam 1999/1 9
1999/1 9
2003/2 7 Does not correspond to ref value
Oxazepam 1999/1 8
1999/1 8
2003/2 7 one “traces”
Temazepam 2001/2 8 Does not correspond to ref value
2001/2 3 one wrong units
2003/2 5 one “traces”
12
1999/1 10 Does not correspond to ref value
1999/1 9 Does not correspond to ref value
2001/1 8
2003/2 11
2005/1 3
2007/1 4
13
Benzoylecgonine 1999/1 9
1999/2 9 Does not correspond to ref value
2001/2 9
2003/1 9 no reference value
2003/2 11
2005/2 4
12
Codeine 1999/2 11 Eight wrong units
Methadone 2001/1 7
2001/2 6 Does not correspond to ref value
2005/2 4
Morphine (free) 1999/2 8 no reference value
2001/1 8
2001/2 6
2003/2 7
2007/1 4
Morphine (total) 1999/2 10 no reference value
2001/1 8 no reference value
2001/2 9 no reference value
2003/2 7 no reference value
2007/1 4 no reference value
Opiates
Amphetamines
Barbiturates
Benzodiazepines
Cannabinoids
Cocaine
Chapter 3  62 
 
 
 
 
Table 3-10:  Laboratories performing quantification by SM substance group 
 
Data sets were only further analysed when they contained at least eight 
estimations and there was a known reference value.  They were each plotted 
and evaluated for central tendency of the reference value.  Datasets where the 
given reference value did not appear to be reasonably central to the measured 
values were not considered further.  The reference value may have been 
incorrect and none of the datasets were large enough to reliably apply a 
consensus value from the participants’ results.  It was also impossible to assign 
consensus values to the total morphine data for which no reference values were 
provided (many laboratories had provided this rather than free morphine which 
Year/Round
No of 
Laboratories Comments
22
MDMA 2001/2 21
2005/1 19 one wrong units
2005/2 22 one wrong units
2005/2 21 one wrong units
Amphetamine (Base) 2001/1 17
2007/1 12
2009/1 15
Methamphetamine 2003/2 20
2005/2 13 Does not correspond to ref value
2008/1 11
MDEA 2003/2 19 Does not correspond to ref value
22
2001/2 22
2003/1 16
2003/2 20
2005/1 21 one wrong units
2005/2 23 one wrong units
2007/1 13
2009/1 15
21
Codeine 2001/1 9 no reference value
2001/2 8 no reference value
Heroin 2001/2 20
2003/1 15
2005/1 19 one wrong units
2007/1 11 no reference value
2008/1 12 Does not correspond to ref value
2009/1 15
  6
Substance Group
Amphetamines
Cocaine
Opiates 
Hallucinogens 
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was the given reference value but could not be used as the metabolite 
morphine-6-glucuronide was also present in these morphine samples).  
No quantitative scoring had been performed by UNODC.  For review, a 
proficiency score (z-score) was calculated by five different methods: 
 Classical statistics using the known reference value with the standard 
deviation and the mean value with the standard deviation.  (A 2-sided-Grubbs 
test was used to detect outliers.  The Grubbs test considers the difference 
between the extreme values of the dataset and the mean together with the 
standard deviation to determine whether the extreme values are likely to 
belong to the same population.  A table of critical values will identify 
whether the difference is significant which depends on the size of the 
dataset. Outliers at a 95% confidence level were not considered in the 
determination of the mean/standard deviation but were scored using the 
values calculated from the other data in the set, in accordance with ISO 
guidance.90) 
 Using the known value with a perceived variation of 5% (10% for very low 
concentrations), 
 Robust statistics using the known value with robust standard deviation 
(Median absolution deviation estimate of standard deviation, MADe), and the 
median value with MADe 
 ISO iterative robust method.96 
 
Considerable variation was observed in the scores when calculated by each 
method.  The International Harmonised Protocol states that the only acceptable 
means of PT scoring is by using a fixed percentage of the true value as the 
acceptable variation.86  Due to the low participation in each data set the best 
method according to the ISO guide 90 was fixed acceptable deviation.  In addition 
this was the only suitable means of performing round-to-round comparison and 
trend analysis and negated any requirement for data to be separated by peer 
groups (for example, because of the various methods applied having differing 
influences upon participant dependant scoring methods).  Thus, scores derived 
by the reference value with variation up to 5% (or 10%) of this were considered 
further.   
The z-scores for each dataset were plotted to view distribution of performance 
and substances for which there were multiple datasets were plotted together to 
try and identify whether general performance had improved with time.  The 
data were too few to reliably draw conclusions, however there were indications 
of improvement with slightly reduced range of z-scores with progressive rounds 
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(with the exception of some ATS SM analyses, most notably MDMA).  
Performance parameters (coefficient of variation (CV%), accuracy as standard 
error (ERR%) referred to the true value and first (EMa) and second (EMb) efficacy 
measures) for each suitable round were calculated, Table 3-11.  BS laboratories 
appeared to have struggled more with quantification than SM participants.   
Grouped participant performance proved unsuitable for evaluation of 
improvement.  Individual participant performance, however, was also 
insufficient.  Only 11 BS laboratories had quantified 6 or more of the data sets.  
Of these, 5 laboratories regularly produced unacceptable z-scores, with the z-
score of one being excessively high (>15).  It would seem that the quality 
management system within these laboratories needs to be strengthened, 
although with the others it could be that a less stringent scoring system is 
necessary if so few laboratories satisfy these requirements.  Poor quantification 
performance may be indicative of participants not being competent in preparing 
reference standards.  It is also possible that the extra step of reconstitution of 
the freeze dried urine, (not part of routine procedure), is introducing a 
significant error to some BS participants’ analysis.   
For such a large scheme, the level of participation in quantification level was 
low.  It is accepted that this is largely a result of the mixed abilities of the 
participants, many being poorly-resourced laboratories.  Poor uptake of 
quantification, however, could be as a result of it not being routine practice in 
some laboratories.  Quantification of SM materials may not be required by the 
legal system. Even in the UK, purity analysis of SM is only done for large 
seizures. And generally with BS, analyte concentration is of greatest interest for 
blood samples rather than urine.  It is understood that the difficulties involved in 
providing blood specimens in a sizable international PTS would be too great for 
an incentive such as ICE which has limited resources and is provided free-of-
charge to participants who may also face financial difficulty.  Perhaps as a 
compromise dried standards could be provided for reconstitution with blank 
blood in place of or in addition to dried urine samples. 
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Table 3-11:  Performance Statistics 
Substance Year/Round Outliers CV% ERR% EMa EMb
BS
ATS
Amphtamine 2001_1 1 11.93 3.83 55.60 0.44
Methamphetamine 2003_2 - 16.38 5.05 54.60 0.30
Benzodiazepines
Nordazepam 1999_1 - 30.05 10.30 44.40 0.16
Nordazepam 1999_1 - 25.89 9.06 77.80 0.18
Oxazepam 1999_1 - 31.56 8.82 12.50 0.20
Oxazepam 1999_1 - 33.02 9.96 37.50 0.18
Cannabinoids
Cannabis 2001_1 - 19.46 7.51 62.50 0.24
Cannabis 2003_2 1 17.19 4.25 36.36 0.35
Cocaine
Benzoylecgonine 1999_1 - 12.92 4.56 66.67 0.37
Benzoylecgonine 2001_2 - 18.29 5.11 44.44 0.33
Benzoylecgonine 2003_2 - 14.77 4.23 63.64 0.36
Opiates
Morphine (free) 2001_1 1 67.48 27.07 12.50 0.07
SM
ATS
MDMA 2001_2 - 3.22 0.71 87.50 1.53
MDMA 2005_1 2 5.47 1.34 88.90 0.88
MDMA 2005_2 - 15.14 3.35 71.40 0.33
MDMA 2005_2 - 9.99 2.24 75.00 0.50
Amphetamine (base) 2001_1 1 31.45 6.80 47.06 0.15
Amphetamine (base) 2007_1 1 9.88 3.03 75.00 0.48
Amphetamine (base) 2009_1 - 6.99 1.82 86.67 0.71
Methamphetamine 2003_2 - 2.33 0.55 85.00 2.04
Methamphetamine 2008_1 1 8.59 2.55 90.91 0.59
Cocaine
Benzoylecgonine 2001_2 - 5.66 1.26 77.27 0.84
Benzoylecgonine 2003_1 - 12.76 3.30 75.00 0.38
Benzoylecgonine 2003_2 2 10.00 2.24 75.00 0.70
Benzoylecgonine 2005_1 4 5.46 1.20 85.00 0.93
Benzoylecgonine 2005_2 - 6.14 1.30 81.82 0.82
Benzoylecgonine 2007_1 3 6.92 1.88 76.92 0.74
Benzoylecgonine 2009_1 - 5.48 1.43 86.67 0.90
Opiates
Heroin 2001_2 - 4.00 0.91 100.00 1.23
Heroin 2003_1 - 5.84 1.60 73.33 0.81
Heroin 2005_1 1 4.52 1.05 94.44 1.12
Heroin 2009_1 - 4.32 1.13 100.00 1.14
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3.5.6.1 Biological Specimens 
BS quantification was best for the analyte which had been most frequently 
included in test samples, benzoylecgonine, perhaps indicating that good 
performance is as a result of familiarity with the application of the analytical 
method.  This could be misguided, however, as the poorest performance was for 
morphine which had been included in test samples almost as often.  86% of 
laboratories reported opiate identifications (only 79% for cocaine) but much 
fewer performed quantification (only one round contained enough appropriate 
data for review).  Laboratories may be struggling with the quantification of 
opiates, although this cannot be fully explored without reference values for the 
total morphine content which was often the preferred measurement. 
There were three outlying values amongst the BS dataset; two were produced by 
LC-MS methods (cannabis and morphine) and the other by GC-MS 
(amphetamine).  Almost all of the BS laboratories used GCMS for quantification, 
a small number used HPLC and one used GC-NPD (GC-ECD for benzodiazepines).  
The instrumental method used was not observed to influence the z-score apart 
from the quantification of benzodiazepines in which the use of HPLC resulted in 
higher scores relative to GC-MS.  Scores for benzodiazepine quantification by 
GC-NPD/GC-ECD were outside of the acceptable range but this could not be 
attributed to unsuitability of the instrumentation as this laboratory also scored 
highly with substances analysed by GC-MS.  It seems more likely that this 
participant required some help with internal quality standards.   
3.5.6.2 Seized Materials 
SM performance contrasted BS performance, as quantification of opiates was the 
most successful SM analysis performed, with highest ratings of accuracy and 
satisfactory scores.  No trends could be observed although it was apparent that 
improvement was required with ATS.  Although the most frequently tested SM 
substance group, it contained the largest number of analytes with each 
individual drug being tested infrequently. 
Similar to BS the majority of SM laboratories used GC-MS for quantification.    A 
small number used GC-FID, FTIR, HPLC or GC-IRD (gas chromatography with 
vapour phase infrared spectrophotometric detection).  (Data only available up to 
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2005 and assumed the same methods until 2009.)  All instrumentation performed 
equally well.  Often the poorest scores related to GC-MS, which had the greatest 
number of unacceptable results.  Thus, the scores for performance of other 
methods were within that of GC-MS.  There were 13 outliers: 10 of these were 
produced by GC-MS (2 MDMA, 1 amphetamine, 1 methamphetamine and 6 
cocaine), 2 by FTIR (cocaine) and 1 by GC-FID (cocaine).  None of the 21 SM 
laboratories that had quantified in at least six datasets were found to have poor 
performance, although one laboratory did appear to struggle slightly with MDMA 
and another with cocaine. 
3.5.7 Variation in Results 
With a large dispersion and the presence of outliers it was considered that ICE 
data was suited to further review of scoring methods recommended by Rosario 
et al.110    It was determined how many laboratories achieved acceptable scores 
by each of the methods previously outlined, in addition to perceived variation of 
20% of the true value for BS samples.  (This was deemed fit-for-purpose variation 
for forensic toxicology laboratories by the Panel of Experts for the LGC QUARTZ 
Forensic Blood Toxicology Proficiency Testing Scheme, described in Chapter 4 
page 78).  This is reported in Table 3-12 (BS) and Table 3-13 (SM).  The data for 
participant dependent scoring methods were not separated into peer groups as a 
large majority of laboratories used GC-MS for quantification, leaving too few for 
sub-grouping. 
With the SM data there was not a great deal of difference in the number of 
acceptable scores achieved by each of the various methods of calculating the 
performance scores, as there was no significant variance in the SM laboratory 
determinations, bar some outliers.  The BS laboratories, however, did not 
perform as well (the increased difficulty with such analyses is recognised in the 
increased acceptable variance in the LGC QUARTZ scheme).  The effects of using 
different scoring systems can be more readily detected with the BS results. 
In agreement with Rossario et al, classical statistics produced the highest 
number of acceptable z-scores, with 4 exceptions in which robust statistics had 
resulted in more acceptable z-scores due to the broadening of the acceptable 
range by inclusion of outliers.  This confirms previous findings that robust 
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methods which do not reject outliers produce an unrealistically high percentage 
of satisfactory z-scores.110,122,124  Comparison of the known reference value with 
the laboratory determinations demonstrated that both classical and robust 
statistics generated a falsely elevated number of acceptable z-scores.  EMa was 
not influenced by use of mean compared to true value. 
The large variation in participant determinations influenced participant-
dependent scoring systems such that a true reflection of participant 
performance was only obtained with perceived variation.  This was evident when 
EMa by the perceived method was much lower than with other methods.  For 
example, for morphine in Round 2001_1 (Table 3-14) only one laboratory, with a 
determination close to the true value, received an acceptable z-score within 5% 
perceived.  Yet by the other methods, 7 laboratories with determinations far 
from the true value have been awarded very good performance scores.  This is 
clearly unhelpful as participants appear to have no cause for concern although 
one laboratory has detected less than one tenth of the morphine present and 
may be in need of corrective actions.   
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Table 3-14:  Laboratory performance scores by various calculation methods for BS 
Morphine 2001 round 1 
 
 
Table 3-15:  Laboratory performance scores by various calculation methods for BS Delt-9-
THC-COOH 2003 round 2 
 
Relying on participants’ determinations to define ‘acceptable’ can, therefore, 
be very misguided.  This was well demonstrated by THC-COOH in Round 2003_2 
(Table 3-15), even though variation within this dataset was less than in many 
others, which it illustrated the effect of many inaccurate measurements on a 
few accurate measurements.  One laboratory (751) returned a result equal to 
the true value but a z-score of 0 was only awarded by a perceived protocol.  
Morphine
2001_1  
(290ng/ml) Classic Robust ISO
Perceived 
(5%)
Perceived 
(20%)
264.8 329 347.4 290 290
192.6 222 232.1 14.5 58
Laboratory ID
529 27.8 -1.2 -1.4 -1.4 -18.1 -4.5
526 195.5 -0.4 -0.6 -0.7 -6.5 -1.6
751 220 -0.2 -0.5 -0.5 -4.8 -1.2
757 318 0.3 0 -0.1 1.9 0.5
328 340 0.4 0 0 3.4 0.9
754 495 1.2 0.7 0.6 14.1 3.5
752 521 1.3 0.9 0.7 15.9 4
527 (outlier) 1678 7.3 6.1 5.7 95.7 23.9
Ema (%) 87.5 87.5 87.5 12.5 50
Laboratory 
Determinations 
(ng/ml)
Z-score Calculation Method
Participant 'true' value
Acceptable Deviation
Classic Robust ISO
Perceived 
(5%)
Perceived 
(20%)
121 114.7 122.4 140 140
18.7 19.7 20.4 7 28
Laboratory ID
758 100.2 -1.1 -0.7 -1.1 -5.7 -1.4
526 104 -0.9 -0.5 -0.9 -5.1 -1.3
759 107.1 -0.7 -0.4 -0.7 -4.7 -1.2
525 108 -0.7 -0.3 -0.7 -4.6 -1.1
757 111.4 -0.5 -0.2 -0.5 -4.1 -1
752 114.7 -0.3 0 -0.4 -3.6 -0.9
529 128 0.4 0.7 0.3 -1.7 -0.4
751 140 1 1.3 0.9 0 0
754 144.9 1.3 1.5 1.1 0.7 0.2
328 152 1.7 1.9 1.5 1.7 0.4
527 247 (Outlier) 6.7 6.7 6.1 15.3 3.8
EMa 90.9 90.9 90.9 36.6 90.9
Delta-9-THC-COOH 
2003_2  (140ng/ml)
Laboratory 
Determinations 
(ng/ml)
Z-score Calculation Method
Participant 'true' value
Acceptable Deviation
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Whilst the scores determined by other scoring methods were good acceptable 
scores, more than half the other participants, who measured further from the 
true value, appear to have performed better than they actually did.   
Perceived variation scoring is, therefore, more appropriate and worthwhile for a 
PTS to ensure participants are operating without significant error.  The fixed 
percentage used, however, must be given careful consideration.  At 20% some 
acceptable scores were questionable.  This was well demonstrated with 
oxazepam in round 1999_1 (Table 3-16) in which all 20% perceived scores were 
satisfactory, however, at the extremes one laboratory quantified 50% over the 
true value and another 50% less than was present.  An analytical result of less 
than half the concentration of an analyte present in a good quality sample is not 
fit for the purpose of legally defensible forensic toxicology.   
 
Table 3-16:  Laboratory performance scores by various calculation methods for BS 
Oxazepam 1999 round 1 
 
It is recommended for consensus scoring systems that there should be at least 
20-30 participants.48,92  There were no datasets in the BS group which satisfied 
this and, although variance was much less extreme within the SM group, the 
dataset with the most determinations was SM cocaine 2001 round 2 (Table 3-17), 
which contained 22 quantifications.  Unlike the studies by Ventura et al. there 
were no outliers in this data and dispersion was reasonably good (CV 5.6%).  
Oxazepam
1999_1 
(1150ng/ml) Classic Robust ISO
Perceived 
(5%)
Perceived 
(20%)
1051.4 909 1017.4 1150 1150
385.3 286.9 364.7 57.5 230
Laboratory ID
527 560 -1.3 -1.2 -1.3 -10.3 -2.6
525 793 -0.7 -0.4 -0.6 -6.2 -1.6
526 870 -0.5 -0.1 -0.4 -4.9 -1.2
328 878 -0.4 -0.1 -0.4 -4.7 -1.2
759 940 -0.3 0.1 -0.2 -3.7 -0.9
754 1180 0.3 0.9 0.4 0.5 0.1
752 1440 1 1.9 1.2 5 1.3
751 1750 1.8 2.9 2 10.4 2.6
EMa (%) 100 100 100 12.5 100
Laboratory 
Determinations 
(ng/ml)
Z-score Calculation Method
Participant 'true' value
Acceptable Deviation
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There was nothing to suggest that unrealistic scores would be achieved by 
participant-dependent scoring.   
Two laboratories (allowing for small unknown uncertainty) measured the true 
percentage of cocaine in the sample (506 and 113).  They did not achieve 
cautionary scores by any method, however it was only perceived scoring which 
recognised the accuracy of these participants (ranking them 1st/2nd compared 
with 12th/13th by classic, robust and ISO robust methods).  By the classical 
approach there were no unacceptable values and only two approached 
cautionary scores.  Quite a different interpretation is given by perceived scoring, 
where there were five participants with unsatisfactory scores.  By the ISO 
recommended robust method there were only three unacceptable values, in 
contrast to the scores that would have been awarded by a perceived method.  
Even with a larger data set, the use of scoring systems which rely upon 
participant data should be avoided. 
 
Table 3-17:  Laboratory performance scores by various calculation methods for SM Cocaine 
2001 round 2 
Classic Robust ISO Perceived (5%)
68.5 68.1 67.8 65
7.2 3.9 4.3 3.3
Laboratory ID
521 51.6 -2.3 -4.3 -3.8 -4.1
139 61.1 -1 -1.8 -1.5 -1.2
703 62.2 -0.9 -1.5 -1.3 -0.9
140 62.8 -0.8 -1.4 -1.2 -0.7
527 64.5 -0.5 -0.9 -0.8 -0.2
506 65 -0.5 -0.8 -0.6 0
113 65.3 -0.4 -0.7 -0.6 0.1
713 66.3 -0.3 -0.5 -0.3 0.4
110 66.8 -0.2 -0.3 -0.2 0.6
101 67.2 -0.2 -0.2 -0.1 0.7
213 68 -0.1 0 0.1 0.9
206 68.1 -0.1 0 0.1 1
141 68.6 0 0.1 0.2 1.1
215 68.6 0 0.1 0.2 1.1
526 68.7 0 0.2 0.2 1.1
108 69 0.1 0.2 0.3 1.2
187 69.5 0.1 0.4 0.4 1.4
530 70.5 0.3 0.6 0.6 1.7
135 76 1 2.1 1.9 3.4
149 80 1.6 3.1 2.8 4.6
208 81.5 1.8 3.5 3.2 5.1
151 85 2.3 4.4 4 6.2
EMa (%) 100 81.8 86.4 77.3
Cocaine 
2001_2 
(65%)
Laboratory 
Determinations 
(ng/ml)
Z-score Calculation Method
Participant 'true' value
Acceptable Deviation
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3.6 CONCLUSIONS 
Long term review of ICE was impeded by issues related to degree of 
participation and data retrieval.  The nature of the data available did not 
facilitate elucidation of year-by-year improvements in participants’ 
performance.  However, some limited trend analysis was possible, as 
summarised below.  
3.6.1 Qualitative Summary 
SM laboratories performed much better in providing identifications than BS 
laboratories.  The substance group which was most successfully analysed was 
cannabinoids (BS and SM).  The amphetamine-type stimulants group proved most 
challenging to SM laboratories whilst the benzodiazepine group posed the 
greatest challenge to BS laboratories.  Difficulties experienced with 
benzodiazepines were due to the large number of laboratories using TLC. 
3.6.2 Methods 
For BS screening, immunoassay techniques performed better than TLC or 
colorimetric reactions, which should not be relied upon.   
TLC is unsuitable for identification with both BS and SM samples.  GC-MS was the 
most used identification method and no problems identified with the use of this 
method for either BS or SM.  LC-MS(/MS) performed most reliably for 
identification of BS and SM, however, it was not tested to the same extend as 
GC-MS. 
3.6.3 Quantitative Summary 
An extremely small proportion of laboratories showed progression from 
identification to quantification for at least one substance.  The vast majority of 
those performing quantifications had done so from their first round of testing. 
Quantification was much better amongst the SM laboratories than BS.  No 
general problems of quantification could be identified.  BS laboratories were 
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most proficient in quantifying benzoylecgonine but may have struggled with free 
morphine which was rarely quantified (total morphine which could not be 
evaluated).  Conversely SM quantification was best for opiates.  SM laboratories 
had difficulty with ATS. 
The truest reflection of performance was achieved using a defined true value 
and a perceived acceptable variation (percentage of the defined true value).  
The perceived value should be greater than 5% for BS laboratories as many z-
scores were unacceptable at 5%.  Perceived acceptable variation need not 
represent best performance but should reflect acceptable performance such that 
it is a realistically achievable target.86,104  It should be clear to participants, 
however, that pass or fail is not the outcome of such a developmental 
educational scheme.  Successful participation means learning from the 
experience.  How a laboratory responds to an unsatisfactory result can infer 
better dedication to quality than a laboratory that consistently achieves 
satisfactory results.94   
One BS participant was observed to be in need of assistance in strengthening 
their internal quality procedures but no SM laboratories were identified with 
general quality issues, although one laboratory did appear to struggle with MDMA 
and another with cocaine. 
3.6.4 ICE Review Summary 
There was some limited support from BS z-score plots to suggest that 
participants’ accuracy had improved slightly over time.  The laboratories 
profiled were consistent ICE participants and this small improvement could be 
related.   
The review has highlighted that assistance should be directed toward BS 
laboratory performance.   
3.6.5 VARIATION  
Scoring PT results with participant-dependent mechanisms, including the ISO 
recommended robust method, can be most misleading (even with ‘well-behaved’ 
data).  Performance indicators determined from participant results are 
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unrealistic.  Only a perceived variation approach provides a true reflection of 
performance, although careful consideration is required as to how large the 
permitted variance should be. 
3.7 Future Work 
In order that the next review be a more effective evaluation of the ICE 
programme, efforts should be directed towards laboratory participation, not to 
enrol more laboratories, but to ensure that laboratories participate regularly.  
From the limited data available it appears that few laboratories have committed 
to the scheme with participation over these first years being very erratic.  
Recoding and addressing reasons for non-participation/not returning results 
could help to resolve this issue. 
It should also be stressed to participants that ICE is an assessment of their 
routine procedure and this is what they must apply to test materials.  
Observation of sporadic quantification suggests that many participants do not 
consistently follow routine.  Some participants only provided identification for a 
substance in Rounds which were flanked by others in which quantification had 
been performed for that same substance.   
Lack of clear progression amongst ICE participants could be related to 
insufficient feed-back.  Participants were unaware of how they performed 
relative to others and had no means of gauging whether or not their 
performance was acceptable.  As ISO identified, participants in PTS should know 
where they are within the range of capabilities, in order to aim higher.  It is 
therefore important that efforts to provide quantification are recognised and 
rewarded by scoring quantification and anonymously reporting all scores to all 
participants.  It is understood that this recommendation has been actioned by 
UNODC and reports for each ICE Round are now published on-line to provide 
anonymous feedback of all participants’ performance at all levels including z-
scores.128  The reports also now provide methods analysis and are introducing 
relevant emerging drugs to maintain the challenge to participants.  Ketamine 
was included in BS samples in 2008 (performance unknown) and again in 2011 
where performance appeared to be generally good.  Participant laboratories are 
officially invited to report any new substances encountered every six months.129 
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It was clear that BS assessments were more difficult than SM.  In order to 
accelerate improvements in laboratories observed to be struggling, when 
consecutive unacceptable results have been returned, the participant could be 
asked to submit additional data for review such as calibration results and 
calculations, to allow the experts at UNODC to assist with corrective actions.   
It is also suggested that, in order to maintain the educational, challenging ethos 
of ICE, participants should be encouraged to submit an uncertainty measurement 
with their result (in line with ISO recommendations 56).  This would also require 
UNODC to report the standard uncertainty associated with the ‘true’ 
concentration of each analyte.  This information could be useful to all 
participants as, when the uncertainty is large in relation to acceptable 
deviation, some participants may wish to consider their action and warning 
limits relative to this.96  
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Chapter 4:  LGC Quartz Forensic Blood Toxicology 
Proficiency Testing Scheme; Long Term Review  
  
4.1 Introduction 
LGC Standards is an international provider of proficiency testing schemes with 
many years of experience in various fields of testing (chemical, microbial and 
physical measurements).  The scheme which is generally applicable to 
laboratories analysing blood samples for toxicology within a forensic setting 
(post mortem and other samples) is the UKAS-accredited Forensic Blood 
Toxicology Proficiency Testing Scheme which has been in operation for over ten 
years.  This scheme is intended to provide laboratories with a means of 
safeguarding against undetected errors, enable laboratories to compare their 
performance with that of their peers and, additionally, provide information to 
participants on technical issues and methodologies via their scheme-specific 
advisory group.130  All aspects of the scheme are overseen by an LGC Standards 
Proficiency Testing Coordinator. 
4.1.1 Scheme Details 
In order to ensure confidentiality, participants are allocated a unique laboratory 
reference number against which results are reported.  Reference numbers are 
assigned and changed from round to round.  There are four rounds offered each 
year and participants must apply for each round in which they wish to 
participate.  All rounds contain forensic toxicology samples 1 and 2, whilst every 
other round (two per annum) contains a third forensic toxicology sample, sample 
3, and a driving impairment sample, sample 4, as detailed below: 
Sample 1 Identification: 10 ml blood sample 
 Qualitative results only.  The sample will always contain one Group 
A substance plus up to three other drugs from either Group A or B 
(Table 4-1). 
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Sample 2 Quantification: 10 ml blood sample 
 Participants are provided the identity or generic classification of 
the drugs present and should measure their concentrations in the 
sample.  The results should be reported together with an 
interpretation relating to case information provided with the 
sample.  There will always be at least one Group A substance 
present. 
 
 Samples 1 and 2 are accompanied by a case study providing details that 
would generally be submitted with a sample to a toxicology laboratory, 
stating the circumstances which necessitate toxicological testing and 
providing information such as the clinical symptoms, post mortem 
observations, cause of death and history of drug use. 
 
Sample 3 Standard Solution   
 A prepared drug solution to assess instrumental analysis. 
Sample 4 Alcohol: 10 ml blood 
 A blood sample with a known amount of ethanol present.  
Participants are requested to measure and report the alcohol 
content. 
 
Participants specify upon application which samples they wish to receive, 
forensic toxicology (1, 2, and 3), driving impairment (4), or both.  It is not 
necessary to participate in the analysis of all samples provided.  Test samples 
may contain up to four analytes from a list provided which is regularly updated; 
Table 4-1 is the list from 2012.131 
Participants are asked to process the test samples as they would a routine 
sample and are, therefore, free to select any method of analysis which they 
believe to be technically appropriate.  The analytical method should be reported 
with the result. 
Before samples are provided to participants, ten randomly selected aliquots are 
analysed to ensure that there were no drugs present in the blood before spiking 
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and that the concentration of the spiked analytes is homogeneous throughout 
the blood samples. 
 
Table 4-1:  Drugs included in LGC QUARTZ Forensic Blood Toxicology Scheme.  
(NSAID = Non-steroidal anti-inflammatory drugs) 
4.1.2 Returning Results 
Participants log their results through an electronic reporting software, PORTAL, 
before the given deadline (around six weeks post-dispatch).  Ten working days 
following round closure all participants’ results are available for secure on-line 
viewing.  Results not received before the deadline will not be included in the 
report but these laboratories can still access the report, and can calculate their 
own z-score using the programme available on PORTAL.  Laboratories are 
permitted to submit more than one result (up to thirteen) in order to compare 
Anesthetic Ketamine Midazolam Propafenone
Paracetamol Temazepam Flecainide
Salicylate Zolpidem Clonazepam
Anticholinergic Procyclidine Zopiclone Gabapentin
Carbamazepine Diclofenac Antidepressant Trazodone
Lamotrigine Ibuprofen Antidiabetic Metformin
Phenytoin Buprenorphine Bronchodilator Theophylline
Amitriptyline Codiene Calcium antagonist Amlodipine
Citalopram Dihydrocodeine Benzylpiperazine
Clomipramine Fentanyl Methylphenidate
Dosulepin Methadone Amobarbital
Fluoxetine Morphine Butobarbital
Imipramine 6MAM (MACM) Clomethiazole
Mitrazapine Oxycodone Gamma hydroxy butyrate
Paroxetine Pethidine Lormetazepam
Sertraline Propoxyphene Pentobarbital
Venlafaxine Tramadol Secobarbital
Cyclizine THC Zaleplon
Diphenhydramine THC-COOH Dextromoramide
Promethazine Chlordiazepoxide Dipipanone
Amisulpride Diazepam Opioid antagonist Naltrexone
Chlorpromazine Desmethyldiazepam Clobazam
Clozapine Oxazepam Loprazolam
Olanzapine Lorazepam
Quetiapine Phenazepam
Risperidone Vasodilator Sildenafil
Amfetamine Atenolol
Cocaine Propranolol
Benzylecgonine Other Substances Carboxyhaemoglobin
MDA
MDMA
Methamfetamine
Mephedrone
Group A Group B
Hypnotic
Anti-arrhythmic
Analgesic
Anticonvulsant
Central Stimulant
Metabolites of Group A and B substances 
can also be included
Β-Blocker
Anticonvulsant
NSAID
Opioid 
AnalgesicAntidepressant
Central Stimulant
Antihistamine
Hypnotic
Psychotropic
Tranquilliser
Antipsychotic
Opioid analgesic
Tranquilliser
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the results obtained by different analysts or methods.  Only three of these, 
however, can be nominated as official results to be included in the statistical 
analysis and report. 
Additional test materials can be provided after each test round to allow 
participants to repeat testing as necessary, for example, to check the 
effectiveness of corrective actions. 
4.1.3 Calculating Proficiency  
The qualitative data (sample 1) is simply scored by correctly determining 
presence/absence of analytes.  False positive identifications are noted but do 
not influence scoring.  Correctly identifying the analyte present is considered a 
satisfactory performance, with each analyte scored individually.  For 
quantitative samples, where a performance z-score is calculated for each 
analyte, values which are clearly in error are omitted from the overall statistics 
but are scored and reported as transcription to the final report is considered to 
be part of the proficiency assessment.  A reported concentration of zero is 
regarded as unsatisfactory and is not accepted (the concentration should be 
reported as less than the lower limit of quantification).  In common with other 
schemes a z score equal to or greater than three (or equal to or less than minus 
three) is considered unsatisfactory and a z-score greater than two (or less than 
minus two) may require attention.  Scoring methods can vary depending on the 
nature and concentrations of the analytes. 
4.1.3.1 True Value 
The true value, termed the “assigned value”, is derived by one of three 
methods.  The simplest is a formulation value, where the true value is known 
from sample preparation.  An expert value, measured by an agreed reference 
laboratory could be used, otherwise a robust mean of the participants results 
will be used (from all methods unless the measurement is known to be method-
dependent). 
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4.1.3.2 Acceptable Variation 
Referred to in QUARTZ schemes as the ‘standard deviation for proficiency 
assessment’ (SDPA), it can take the form of a fixed value (which would be 
stated), a percentage of the assigned value, or robust standard deviation of the 
participant results. 
4.1.3.3 Scoring Samples 2 and 3 
Originally the SDPA was the robust standard deviation.  From round 34, however, 
scoring was largely performed with SDPA as a percentage of the formulation 
value.  The percentage used was dependent on analyte concentration, <0.1 
mg/L = 25%, 1 to 10 mg/L = 20%, and >10 mg/L = 15%.  These percentages were 
derived through a combination of in-house assessment to establish participant 
capability and expert consultation to determine fitness for purpose.  Fixed fit-
for-purpose SDPA with formulation value are preferred as it allows scores to be 
compared across rounds, and enables traceability and estimation of uncertainty.  
Where necessary the standard uncertainty of the assigned value will be 
incorporated in the scoring system, i.e. when the standard uncertainty of the 
assigned value is greater than 0.3 x SDPA.  In these instances a z′ (z prime) score 
is calculated by Equation 4-1 and is interpreted following the same convention as 
used for z-scores.  Uncertainties of the participant measurements are not 
considered by the scoring system but participants are provided with enough 
information to allow calculation of their performance using one of the 
metrological methods described by ISO 96 if they wish. 
 
 z′ = (x-X) / √ (SDPA2 + ux2) 
Equation 4-1:  z prime score 
Where:  x = measured value, X = assigned value, and Ux = uncertainty of assigned value 
If the analyte of interest is not found to have satisfactory homogeneity 
throughout the test material, this would be reflected by a more lenient SDPA.  
Acceptable homogeneity is defined as a sample variance, from duplicate 
measurements of ten randomly selected aliquots, which is less than a calculated 
critical value.  This is based on IUPAC International Harmonized Protocol for the 
proficiency testing of analytical chemistry laboratories and meets the 
requirements of ISO/IEC 17043.130 
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4.1.4 Efficacy Measures 
There must be eight or more participant results before analyte statistics and 
efficacy scores will be officially reported.  These provide the percentage of 
satisfactory, questionable and unsatisfactory scores for each analyte and 
indications of the spread of the results (standard deviation, robust standard 
deviation, mean, median, etc.).  In a well-behaved system there would be few 
outliers and the results would all be close to the assigned value (i.e. the robust 
standard deviation should be similar to acceptable variation), with no more than 
5% unsatisfactory scores. 
It is important to note that the second efficacy measure only conveys how 
closely the participants’ scores were related.  It is not an indication of trueness.  
If a number of laboratories operate similar methods which incorporate similar 
bias the results could be closely clustered around a value which is not the 
assigned value, but the variation in these would be close to that permitted and a 
good efficacy score would be achieved. 
4.1.5 Review 
At the end of each round of testing a review is conducted and any requirements 
for subsequent rounds are identified.  Throughout its many years of operation 
this practice has progressed the refinement and enhancement of the Forensic 
Blood Toxicology PTS to produce the effective and popular accredited scheme 
now offered.  Perhaps as a consequence of the evolutionary nature of the 
scheme, where assessment methods have been adapted as necessary in an 
attempt to maintain the truest reflection of actual laboratory performance, 
formal long term review has not been performed.  Although participants are 
encouraged to monitor their own long term performance, it was considered that 
a long term review of the scheme would be beneficial, “to bring lessons learnt 
to the widest possible audience”, in accordance with VAM Recommendation (f) 
13.48 
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4.2 Aims of the study 
The freely available unaccredited UNODC ICE scheme had been reviewed.  It was 
unknown, however, how this performance compared to an accredited scheme.  
The aims were to assess the effectiveness of the Quartz PTS and compare this to 
ICE to determine whether ICE could develop to an accredited PTS scheme and 
what an appropriate scoring system might be. 
4.3 Methods 
In order to ensure participant anonymity, it was not possible to receive data in 
its raw format.  Rather, data was extracted from the formal summary reports 
dispatched to participants following each round.  Data from rounds 30 in 2007 to 
48 in 2012 were collated in Excel spreadsheets. 
As full processing of standard solutions (sample three) only commenced in round 
39 there were only four rounds of results available, which was insufficient for 
long term review.  This was also true of the blood alcohol tests which only have 
results from five rounds of testing.  The review was therefore focused on 
performance for samples 1 and 2 with standard solution samples and blood 
alcohol tests addressed briefly in isolation. 
As the z-score calculation for sample 2 had not always been performed using a 
percentage of the assigned value, scores could not be compared directly 
between rounds.  Where possible they were recalculated with acceptable 
variation as a fixed percentage of the formulation value, with uncertainty 
considered when necessary.  The percentage SDPA was unsuitable for samples 
which contained analytes at very low concentrations.  As the most appropriate 
scoring could not be applied to these datasets the review was exclusive of these 
and also some datasets which had unknown, but increased, uncertainty. 
Participant measurements had been plotted in the summary reports to 
demonstrate normal distribution, allowing application of z-score performance 
assessment.  It was noted, however, that with less than twenty participants in 
each round deviations from a normal distribution would be difficult to 
identify.132 Where the data was not normally distributed around the assigned 
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value it could be suggested that there was a problem with the assigned value 
and these datasets were excluded (Table 4-2 details excluded data and Table 4-3 
and Table 4-4 provide two examples of why data was excluded).  Table 4-5 lists 
the sample 2 datasets considered by the review with details of the scoring 
originally applied to each analyte in the QUARTZ report and the changes made to 
allow round-to-round comparison. 
 
 
Table 4-2:  Datasets not considered in the long term review 
Substance (mg/l) Round Assigned Value SDPA Homogenous Comments
Zopiclone 0.12 35 Median -0.063 25% Pass Possible degradation
Thioridazine 0.7 40 Median -0.54 20% Pass Possible degradation
Metformin 115.4 43 FV 15% Pass Small dataset
Phenytoin 15 44 Median (12.35)
15% of median + 
uncertainty
Pass Possible degradation
Phenazepam 0.46 48 0.434 20% of 0.434 Pass
Possible degradation.  It is unclear 
w hy the FV w as changed to 0.434.  
There is no clear explanation for this
THC-COOH 0.005 39 FV Robust SD Fail Low  Level
Methamfetamine 0.00487 47 FV Robust SD + uncertainty Pass Low  level
6-MAM 0.05 42 Median -0.02
Rounded from Robust 
SD 0.007 to 0.01  
Pass
Low  Level:  Rounding of the SDPA to 
0.01 has an impact on the number of 
participants w ith satisfactory, 
questionable and unsatisfactory 
results
Norfluoxetine 0.05 47 FV Robust SD  Pass Low  level
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Table 4-3:  Round 35, 
Zopiclone results. 
(Cautionary scores, 
Unacceptable Scores.)  
Formulation value should 
have been 0.12 mg/l but 
quantifications from a 
majority of participants were 
lower.  The advisory group 
commented that some 
degradation may have taken 
place.  The extent of the 
degradation, and whether it 
was equal across all 
samples, was unknown.  The 
robust mean was, therefore, 
used as the assigned value.  
Assigned variation was 25% 
of this, an extra 5% to 
acknowledge the increased 
uncertainty associated with 
the assigned value.  Some 
participants were allocated 
unacceptable or cautionary 
performance when they 
actually had measurements 
closer to the intended 
formulation value than those 
participants who achieved 
the best scores.  The 
participants who appear to 
perform best actually 
measure the analyte of 
interest at half the level 
originally present.  It is not 
known whether what is being 
assessed is the laboratory 
measurement performance or 
degree of degradation across 
the laboratories. 
 
Table 4-4:  Round 40, 
Thioridazine. 
(Cautionary scores, 
Unacceptable Scores.)  Almost 
all participant results were 
lower than the formulation 
value.  Degradation may have 
occurred, although no 
comment was given to this 
effect.  The SDPA was not 
increased in recognition of 
inflated uncertainty although 
the mean was used as 
assigned value in 
acknowledgement that the 
formulation value may not 
have been correct.  The values 
listed illustrate how differently 
participants would have 
scored had the formulation 
value with an increased SPDA 
of 25% been used.
Formulation Value 0.12 mg/l
Median 0.063 mg/l
Participant Values
Z-score 
w ith SDPA 
25% median
Z-score 
w ith SDPA 
25% FV
0.014 -3.27 -3.53
0.03 -2.2 -3
0.04 -1.53 -2.67
0.047 -1.07 -2.43
0.047 -1.07 -2.43
0.05 -0.87 -2.33
0.06 -0.2 -2
0.06 -0.2 -2
0.06 -0.2 -2
0.07 0.47 -1.67
0.091 1.87 -0.97
0.1 2.47 -0.67
0.15 >4 1
Formulation Value  0.7 mg/l
Median 0.054 mg/l
Participant Values
Z-score 
w ith SDPA 
20% median
Z-score 
w ith SDPA 
25% FV
0.31 -2.13 -2.23
0.33 -1.94 -2.11
0.39 -1.39 -1.77
0.4 -1.3 -1.71
0.5 -0.37 -1.14
0.52 -0.19 -1.03
0.56 0.19 -0.8
0.6 0.56 -0.57
0.63 0.83 -0.4
0.66 1.11 -0.23
0.99 4.17 1.66
1.05 4.72 2
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Table 4-5:  Result sets considered for long term review. 
(FV = formulation value, Robust SD = robust standard deviation) 
Substance (mg/l) Round Assigned Value SDPA Homogenous Recalculated Comments
Chlordiazepoxide 1.1 30 FV Robust SD Pass 20%
Dihydrocodeine 0.2 30 FV Robust SD Pass 20%
Lamotrigine 10.13 31 FV Robust SD Pass 15%
Sildenafil 5.05 32 FV Robust SD Pass 20%
Citalopram 0.18 32 FV Robust SD Pass 20%
MDMA 6.0 33 FV Robust SD Pass 20%
MDA 0.08 33 FV Robust SD Pass 25%
Temazepam 0.18 34 FV 20% Pass
Amfetamine 0.60 34 FV 20% Pass
Olanzapine 0.10 35 FV 20% Pass
Chlorpromazine 0.25 35 FV 20% Pass
Venlafaxine 0.40 36 FV 20% Pass
Quetiapine 0.80 36 FV 20% Pass
Tramadol 0.50 37 FV 20% Pass
Methadone 0.80 37 FV 20% Pass
Benzoylecgonine 0.60 38 FV 20% Pass
Cocaine 0.20 38 FV 20% Pass
Methylphenidate 0.10 38 FV 25% Pass
Methadone 0.85 39 FV 20% Pass
Amisulpride 0.3 40 Median (0.40) 20% Pass
Acceptable - May be error w ith FV.  All 
participants measured greater than the 
FV.  The SDPA has been calculated 
acceptably
Oxycodone 0.2 41 FV 20% Pass
Sertraline 0.5 41 FV 20% Pass
Codeine 0.05 42 FV 20% Pass
Morphine 0.13 42 FV 20% Pass
Risperidone 1.8 43 FV 20% Pass
Zolpidem 0.1 44 FV 25% Pass
BZP 0.25 45 0.26 mg/l 20% 0f 0.26 Pass FV and 20%
0.26 mg/l may have been selected as it's 
the median for the GC-MS group.  At 5 of 
15 this w as the most prevalent method.  
It is unclear w hy the FV w as not used
Mephedrone 3.8 45 FV 20% Pass
Clomipramine 0.228 46 FV 20% Pass
Flecainide 0.100 46 FV 20% Pass
Propanol 0.100 46 FV 25% Pass
Fluoxetine 0.128 47 FV Robust SD Pass 20% Unclear w hy Robust SD w as used
Cyclizine 0.098 48 FV 25% Pass
Propoxyphene 0.206 48 FV 20% Pass
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4.4 Results 
4.4.1 Participation 
 
Table 4-6:  Participation from rounds 30 to 48  
The percentage of laboratories returning results for each sample is given as the proportion 
of laboratories returning results i.e. the number of participants.  For samples 3 and 4 the 
percentage total is calculated only for those rounds which included these samples. 
Table 4-6 details the participation rate of the QUARTZ PTS.  Rounds with 
reduced participation may simply be the consequence of laboratories returning 
results after the deadline for inclusion in the summary report.  This cannot be 
ascertained.  As a consequence of laboratories not having a permanent unique 
laboratory reference number and in the absence of a look-up table for each 
round, it was impossible to monitor individual laboratory participation.   The 
number of consistent participants could not be identified nor could it be 
identified when laboratories opted out of, or joined, particular rounds, although 
data was available for later rounds but not for the entire period of the review.  
A slight dip in general performance could be expected with the enrolment of 
new participants.  This anonymised review precluded true assessment of the 
relationship between participation and performance. 
Year Round
Number of 
Applicants
Number of 
Participants
2007 30 20 18 17 94% 17 94% - - - -
2008 31 20 17 15 88% 14 82% - - - -
2008 32 21 18 17 94% 17 94% - - - -
2008 33 20 18 15 83% 17 94% - - - -
2008 34 19 18 14 78% 18 100% - - - -
2009 35 19 16 14 88% 16 100% 9 56% - -
2009 36 20 18 18 100% 16 89% - - - -
2009 37 20 17 16 94% 17 100% 10 59% - -
2009 38 ? 17 15 88% 17 100% - - - -
2010 39 ? 19 13 68% 16 84% 11 58% 12 63%
2010 40 ? 16 15 94% 14 88% - - - -
2010 41 ? 21 19 90% 18 86% 12 57% 10 48%
2010 42 ? 18 18 100% 18 100% - - - -
2011 43 ? 17 15 88% 12 71% 11 65% 9 53%
2011 44 ? 19 18 95% 19 100% - - - -
2011 45 ? 20 18 90% 16 80% 13 65% 8 40%
2011 46 ? 19 16 84% 18 95% - - - -
2012 47 ? 19 17 89% 17 89% 11 58% 8 42%
2012 48 ? 19 19 100% 18 95% - - - -
TOTAL 344 309 90% 315 92% 77 60% 47 49%
Labs returning 
Sample 1 
Labs returning 
Sample 2 
Labs returning 
Sample 3 
Labs returning 
Sample 4 
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Table 4-7:  Participation based on sample/analysis type 
(1 = identification, 2 quantitative, 3 standard solution and 4 blood alcohol concentration). 
Participation did appear to be fairly stable, however, ranging from 16 to 21 
participants returning results each round (an average of 18).  Quantification 
samples had the highest participation rate, very closely followed by qualitative 
samples.  It was interesting to observe the distribution of participation across all 
four sample types (Table 4-7).  Some laboratories did not participate with all 
sample types, which could have reflected routine practice.  For example, 
performing the quantification sample 2 analysis but not the sample 3 standard 
solution. 
4.4.2 Analyte frequency 
In order to study performance it was necessary to identify analytes which were 
repeatedly tested to allow comparison of performance between each test.  
Table 4-8 details the frequency of analyte testing.  Only six substances were 
tested three or more times across all sample types (amphetamine, 
benzoylecgonine, cocaine, codeine, methadone and morphine).  Only methadone 
has been included for quantification more than once.  The most tested analyte 
1 Only 2 Only 1 + 2 3 Only 1 + 3 2 + 3 1 +2 + 3 4 Only 1 + 4 2 + 4 3 + 4 1 + 2 + 4 1 + 3 + 4 2 + 3 + 4 1 + 2 + 3 + 4
30 1 1 16
31 3 2 12
32 1 1 16
33 1 3 14
34 4 14
35 1 1 6 1 8
36 2 1 15
37 1 6 10
38 2 15
39 1 1 1 5 3 1 3 4
40 2 1 13
41 1 1 2 7 1 1 3 5
42 18
43 1 1 1 4 2 2 1 5
44 1 18
45 4 1 7 2 1 1 4
46 1 3 15
47 1 4 6 1 2 1 4
48 1 18
Round
Samples Tested by Participants
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group was opioid analgesics, followed by central stimulants then 
antidepressants.  This was due to the large number of analytes in the test panel. 
4.4.3 Qualitative Sample 1 
In earlier rounds the summary reports listed results for each substance 
individually with the method given.  In later rounds substances were merged and 
the analytical method was the focus.  If a laboratory had used more than one 
method to identify all of the drugs present, an official result was counted 
against each analyte for each of the methods used.  This unfairly influenced the 
percentage of correct results.  With more than one analyte present it was often 
necessary for laboratories to apply more than one analytical method to the same 
sample, perhaps using different instrumentation.  Each method would only be 
relevant to the detection of particular analytes although all instrumental 
methods applied were recorded for all analytes and it was not possible to 
distinguish which was the relevant method for each particular analyte.  Thus, in 
the official LGC Quartz reports it was apparent that instrumental methods which 
had not been applied to analytes were recorded to have failed to detect the 
analyte.  ‘Not detected’, rather than ‘not used’ was recorded and counted for 
each of these ‘irrelevant’ methods in the official round summary.  Had it been a 
routine analysis the laboratory would have reported the correct content to their 
client as each analyte was detected by the relevant method.  For this reason, 
where more than one instrumental method was recorded against the same 
laboratory reference number, this was counted as one result (with no “failed to 
detect” unless they did not detect the analyte by either method). 
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Table 4-8:  Analyte Testing Frequency:  (substance groups not tested:  Anticholinergic, 
Bronchodilator, Opioid Antagonist and Carboxyhaemoglobin)
Analyte Group
Number 
of Times 
Tested
Analyte
Number of 
Times 
Tested
Qualitative 
Test
Quantitaive 
Tests
Standard 
Solution
Anaesthetic 1 Ketamine 1 1
Analgesic 2 Paracetamol 2 1 1
Anti-arrhythmic 1 Flecainide 1 1
Anticonvulsant 2 Lamotrigine 1 1
Phenytoin 1 Excluded
Antidepressant 11 Fluoxetine 1 1
Mirtazepine 1 1
Sertraline 1 1
Trazodone 1 1
Citalopram 1 1
Clomipramine 2 1 1
Fluoxetine 1 1
Norfluoxetine 1 1
Sertraline 1 1
Venlafaxine 1 1
Antidiabetic 1 Metformin 1 Excluded
Antihistamine 3 Cyclizine 1 1
Promethazine 1 1
Cyclizine 1 1
Antipsychotic 6 Amisulpride 1 1
Chlorpromazine 1 1
Olanzapine 1 1
Quetiapine 1 1
Risperidone 1 1
Thioridazine 1 Excluded
Calcium antagonist 1 Amlodipine 1 1
Central stimulant 21 Amfetamine 4 2 1 1
Benzoylecgonine 3 2 1
BZP 2 1 1
cocaine 4 2 1 1
MDA 2 1 1
MDMA 2 1 1
Mephedrone 2 1 1
Methamfetamine 1 1
Methylphenidate 1 1
Hypnotic 8 Amobarbital 1 1
GHB 1 1
Secobarbital 1 1
Temazepam 2 1 1
Zopiclone 2 1 Excluded
Zolpidem 1 1
NSAID 2 Diclofenac 1 1
Ibuprofen 1 1
Opiod analgesic 23 Buprenorphine 2 2
Codeine 3 2 1
Dihyrocodeine 2 1 1
Dipipanone 1 1
Fentanyl 1 1
Methadone 3 1 1 1
Morphine 6 3 1 2
Oxycodone 2 1 1
Propoxyphene 1 1
Tramadol 2 1 1
6-MAM 1 1
Psychotropic 1 THC-COOH 1 1
Tranquilliser 7 Chlodiazepoxide 2 1 1
Demoxepam 1 1
Desmethyldiazepam 2 2
Diazepam 1 1
Phenazepam 1 Excluded
Vasodialator sildenafil 1 1
β-Blocker Propranolol 1 1
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A total of 44 qualitative datasets were included for review.  Results from only six 
satisfy the first efficacy measure (EMa) of >95% correct identifications.  The 
number of participants in each round, however, often meant that each 
participant accounted for greater than 5%, so even one error caused the dataset 
to fail the criterion.  85% was therefore considered a more realistic EMa aim (this 
would generally allow for two participants to have false negatives or an 
incorrect identification).  Less than half the datasets (19) achieved this.  Figure 
7 depicts by analyte type and round, the percentage of laboratories with correct 
detection.  There was no indication that performance improved with time.  
Instead there was a suggestion of a general increase in the occurrence of false 
negatives.  In many datasets there were unacceptable numbers of participants 
failing to identify the analyte present.  This was given further attention in this 
review to determine whether the failure to detect was random or if there were 
discernable influencing factors. 
 
Figure 7:  Percentage of participants each round that correctly identified an analyte 
 
Of the ten analyte groups, four were considered to exhibit acceptable 
performance: anaesthetics, antidepressants, antihistamines and tranquilisers.  
There was, however, one exception in the tranquilisers group, demoxepam, 0.36 
mg/l in round 4, which was detected by less than half of the participants 
(31.6%).  Demoxepam is a metabolite of chlordiazepoxide with which 
laboratories performed better.  It would, therefore, appear that participants did 
not fail to detect the metabolite but, rather, may not have performed the 
analysis as this analyte was not part of their routine test battery (which was true 
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for Forensic Medicine and Science, Glasgow University).  The presence and 
satisfactory detection of cocaine in the samples which contained 
benzoylecgonine could perhaps explain the apparently poor performance with 
benzoylecgonine, which is a metabolite of cocaine.  It is possible that 
benzoylecgonine was detected but only cocaine was reported.  Benzoylecgonine 
is the main analyte in cocaine cases and is expected to form part of routine 
testing.  This explanation could also be extended to MDA, a metabolite of MDMA.  
MDMA was present and satisfactorily detected in the sample for which MDA 
detection was poor.  MDA is expected to form part of routine testing as it is a 
drug in its own right, as well as a metabolite of MDMA.  Thus MDA may have been 
detected but only MDMA reported. 
Of the seven analytes grouped under central stimulants cocaine and MDMA were 
the only two to demonstrate satisfactory detection.  The detection of both BZP 
and mephedrone was very poor.  These were relatively new drugs and it is 
assumed they were not detected as they did not form part of the participants’ 
routine test battery.  In addition they would not be detected by immunoassay 
screening and standards were not widely available.  Of greater concern was the 
poor performance for amphetamine in round 43.  It was unclear why three 
laboratories did not recognise amphetamine in the sample.  Amphetamine was 
included in a subsequent sample and a good performance was recorded.  
Amphetamine also scored well in quantitative rounds and there did not appear 
to be any continuing cause for concern.  
Table 4-9 outlines all of the analytes for which there were poor detection levels.  
Six (highlighted) require attention.  There was no clear explanation as to why 
these drugs had poor detection.  The morphine results were concerning, 
although there were other analytes in the opioid analgesics group with 
acceptable performance:  dihydrocodeine, oxycodone and tramadol.  
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Table 4-9:  Analytes with poor detection: those highlighted require attention 
 
Year Round Analyte Comments
Participants 
failing to 
detect
2008 32 Benzoylecgonine 0.5 mg/l 39.4%
2010 39 Benzoylecgonine 25 mg/l 23.1%
2009 37 BZP 0.50 mg/l New 58.8%
2011 43 Mephedrone 0.70 mg/l New 40.0%
2009 37 MDA 0.08 mg/l Metabolite 31.3%
2008 34 Paracetamol 6 mg/l
Possibly not reported due to low, 
therapeutic level 35.7%
2011 46 Amlodipine 0.87 mg/l 56.3%
2010 40 Amobarbital 5.72 mg/l 46.7%
2010 40 Secobarbital 5.83 mg/l 40.0%
2011 43 GHB 491.4 mg/l
Participants may not routinely screen 
for this drug
46.7%
2012 47 Temazepam 0.05 mg/l
Metabolite of diazepam but should 
have been detected
35.3%
2012 48 Zopiclone 0.20 mg/l 68.4%
2010 40 Diclofenac 20.0 mg/l 40.0%
2011 45 Ibuprofen 20 mg/l 38.9%
2009 36 Buprenorphine 0.05 mg/l 41.2%
2011 44 Buprenorphine 0.02 mg/l 36.8%
2009 35 Codeine 1.0 mg/l 0.0%
2010 42 Codeine 0.15 mg/l 15.8%
2009 36
Dicocal(Cyclizine/Dipipano
ne) 23.5% / 29.4%
2008 33 Fentanyl
Not commonly encountered in the 
UK, detection not expected to be 
good.  Incidence of occurrence 
including this analyte served to raise 
awareness.
40.0%
2011 44 Methadone 0.15 mg/l 21.1%
2007 30 Morphine 0.10 mg/l 29.4%
2009 36 Morphine 0.10 mg/l 41.2%
Barbiturates may not be routinely 
screened as use has declined
Central stimulant
Metabolite
Analgesic
Calcium antagonist
Hypnotic
NSAID
These drugs may not be included in 
routine screening
Opioid analgesic
Detection expected to be low; it is 
positive that it has improved on the 
second testing
Round 35 included other opiates and 
codeine might not therefore have 
been a target.  Performance drops in 
Round 42 as there are no opiates 
present and the background directed 
the analysis towards antidepressants
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There were a total of 30 false positives reported across rounds 30 to 48 (listed in 
Appendix 1).  No particular problems were apparent from these results.  Often 
the correct analytes were identified in addition to the false positive.  It was 
therefore possible that these false positives were the result of a contamination 
event which the quality system did not signal.  Alternatively, some may have 
been present in the blood matrix and the blank blood was not screened for every 
analyte.  It was expected that participants had investigated any reported false 
positive results and the assumption was made that they were one-off random 
errors, as it was not possible to determine whether any participants reported 
multiple false positives and could have a true quality issue.  However, this was 
possible for later rounds and there were no apparent problems. 
 
4.4.4 Quantitative Sample 2 
Performance was better for the quantification samples, perhaps because 
participants were advised which analytes were present.  For a limited number of 
rounds, the organisers provided a key to link laboratory reference numbers 
through rounds (but did not give identification).  There were four rounds in 
which it could be identified that a laboratory was not a regular participant 
(appearing to have submitted results in one or two rounds only).  These 
laboratories had achieved very high scores, which influenced the perceived 
performance of dedicated participants.  The results from these laboratories 
were therefore omitted from the review. 
There were a total of 34 analyte quantifications (suitable for comparison), 
mapped by round for proportion of acceptable z-scores in Figure 8, and second 
efficacy measure (EMb) in Figure 9.  It was not possible to identify any definite 
improvement over time, although there was a general increase in the number of 
datasets for which participant results exceeded perceived fit-for-purpose 
performance.   
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Figure 8:  Percentage of acceptable z-scores for each sample 2 analyte in rounds 31 to 48 
 
 
Figure 9:  Efficacy values for each dataset by round. 
Three values exceeded y-axis; β-Blocker Propranol (12.5 in round 46), and two opiate 
datasets tramadol and propoxyphene (7.14 and 6.98  in rounds 37 and 48) 
28 datasets had less than 95% acceptable z-scores.  Again, this appeared to be a 
consequence of the low number of participants, and a target EMa of 85% was 
used.  This is a generous figure as in a well behaved system the chances of 
falling outside of ±3z is remote (0.3% when standard deviation is used as 
acceptable variation),87 although these figures are intended to describe large 
schemes.  Twenty three datasets satisfied this efficacy target.  Unfortunately, 
however, the remaining 11 exceeded this such that attention was necessary 
(listed in Table 4-10). 
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There are three analytes listed in Table 4-10 which, although they display poor 
quantification by participants, were not a real cause for concern.  Clomipramine 
was at a low therapeutic level such that some participants may have considered 
its presence irrelevant within the circumstances of the case and therefore did 
not report it.  Clomipramine had been included in the previous round as a 
sample 3 standard solution test with much better performance (with 95% of 
participants within acceptable limits).  BZP and mephedrone were both quite 
new drugs to have become relevant to forensic toxicological analysis.  Some 
participants advised this was not a drug they would routinely consider and 
therefore did not have validated methods for the analysis.  It is, therefore, not 
surprising that performance was poor with these drugs. 
 
Table 4-10:  Participant performance with quantification samples 
 
There were no clear explanations for the other analytes with poor performance.  
The result for the antipsychotic drug olanzapine was disappointing but most 
concerning was the very poor results for the benzodiazepine tranquiliser 
chlordiazepoxide (likely to be related to the instability of this analyte).  Correct 
detection and quantification of this analyte is pertinent in forensic toxicological 
evaluation.  The dataset for this analyte originated in round 30.  This analyte 
was not included in any subsequent quantification samples and the adoption of 
effective corrective actions by participants, therefore, could not be explored. It 
Anti-arrhythmic 1 1 0
Anticonvulsant 1 - 1 Lamotrigine 21.40% 3 of 14
Sertraline 16.70% 3 of 18
Clomipramine 23.10% 3 of 13 Low  therapeutic range 
Antihistamine 1 - 1 Cyclizine 17.60% 3 of 17
Antipsychotic 5 4 1 Olanzapine 33.30% 4 of 12
BZP 20.00% 3 of 15 New  drug
Mephedrone 16.70% 2 of 12 New  drug
Hypnotic 2 1 1 Zolpidem 17.60% 3 of 17
Opioid analgesic 8 7 1 Methadone 17.60% 3 of 17
Tranquilliser 1 - 1 chlordiazepoxide 33.30% 5 of 15
Vasodilator 1 - 1 sildenafil 25.00% 3 of 12
β-Blocker 1 1 -
Total 34 23 11
CommentsAnalyte Group
Number of 
times tested
Datasets with <15% 
Unsatisfactory
z-scores
Datasets with >15% 
Unsatisfactory
z-scores Unsatisfactory scores
Antidepressant
5 3 2
Central stimulant
8 6 2
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was promising, however, that when it was included as a sample 1 qualitative 
analyte in round 40 it was identified by 90% of participants. 
No details of false positive results were reported as it was not expected that 
directed quantification samples would be screened for the presence of any other 
analytes.  
4.4.5 Participant Methods 
4.4.5.1 Qualitative Sample 1 
 
Figure 10:  Methods used for the analysis of identification samples (test sample 1) 
 
The methods used for identification are depicted in Figure 10 while a more 
detailed account is given in Appendix 2 indicating the percentage of 
unsatisfactory results for each method.  It would appear that the use of GC-MS 
declined, although it was the most used method in almost every round.  It was 
very difficult to study the effectiveness of particular analytical methods, as the 
reporting style of the indentification samples was such that it was not possible 
to differentiate between participants who had not attempted identification for 
certain analytes and those that tried but failed.  For example, in round 36 the 
Chapter 4  99 
 
 
 
datsets for dipipanone and cyclizine were very similar and the same laboratories 
failed to detect either of them, although they identified the opiates also 
present.  This might suggest that the routine procedure for these participants 
did not include screening for basic drugs, although this is unlikely, or else they 
did not continue with further analysis having identified the presence of opiates.  
Of course, it is also possible that their methods were unsatifactory.  
4.4.5.2 Quantitative Sample 2 
A plot of the methods used in each round, Figure 11, indicates that GC-MS was 
the most used method overall, followed by HPLC-MS then HPLC-diode array.  The 
general spread of methods applied in each round did not appear to have changed 
considerably over the review period.  Participants were expected to have 
employed different analytical instrumentation from round to round in order to 
use the most suitable method for the particular analyte.  The tables in Appendix 
3 list the instruments used for quantification along with the number of 
unsatisfactory z-scores for each drug type.  It was not possible to draw any 
conclusions as to the suitability or otherwise of particular instrumental methods. 
 
Figure 11:  Methods used by participants in each round of quantitative testing 
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4.4.6 Standard Solution Sample 3 
Standard solutions were introduced to the testing scheme at round 35.  They 
were instigated on the advice of the advisory panel, with the intention that they 
could provide a diagnostic tool for the detection of the source of errors as a 
result of the wide range of z-scores often encountered for quantitative samples.  
These samples were intended to establish whether errors were introduced 
through pipetting, weighting, etc by reviewing the analysis sequence one step at 
a time.  These samples were not in biological matrices in order to avoid matrix-
derived variations.  The first two samples provided were in methanol and did not 
require extraction, it was not until round 39 that analytes were provided in 
water and participants had to perform extractions.  They were advised of a 
concentration range within which the analyte was present and asked to perform 
their routine extraction and analytical method to determine the concentration 
of the analyte.  A summary of the participant results for the standard solution 
samples is outlined in Table 4-11. 
Participation was relatively low for sample 3, especially when compared with 
the number of laboratories that quantified sample 2.  Sample 3 was introduced 
in order to help laboratories improve their performance when quantifying.  The 
analytes were, therefore, those most typically encountered in a forensic 
toxicology laboratory and the majority of laboratories should routinely analyse 
for these substances.  It was, therefore, disappointing that this opportunity had 
not been fully recognised. 
There were really only four rounds from which performance could be compared 
(shaded in Table 4-11) and, as each round contained a different analyte, varying 
methods may have been utilised in each, thereby hampering comparison.  The 
general level of performance was slightly less than expected in a well-balanced 
system, although this again is expected to be the result of the low participation.  
With larger datasets these performance statistics may improve. 
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4.4.7 Alcohol Sample 4 
The most recent version of the scheme description outlined how scoring of 
alcohol results was carried out.131  For formulation values less than or equal to 
100 mg of alcohol per 100 ml of blood, the SDPA is fixed at 3 mg/100ml.  When 
the alcohol concentration is in excess of 100 mg per 100 ml of blood the SDPA is 
3% of the formulation value.  Previously, the alcohol SDPA was the robust 
standard deviation, preventing comparison between rounds.  Z-scores were 
recalculated for the five alcohol data sets (rounds 39, 41, 43, 45 and 47) using 
the defined acceptable variation values rather than robust standard deviation 
(Table 4-12).  Round 39 was unusual as this was the only round for which all 
participants returned results greater than the formulation value.  In other 
rounds they were almost all lower than the formulation value, which is to be 
expected given the volatility of alcohol.  Alcohol samples were not subjected to 
the same quality control measures as the quantification samples and there may 
have been an undetected error in the formulation value.  Overall, participants 
completing alcohol testing performed well.  The only slight regret was the rather 
low, and apparently declining, participation. 
 
Table 4-12:  Results of alcohol in blood proficiency testing 
 
4.5 Summary 
There were twenty analytes which had been tested more than once across any of 
the three forensic toxicology sample types.  The majority were included once for 
detection and once for quantification.  Good performance across both 
quantification and detection was observed with only six analytes (cocaine, 
MDMA, codeine, dihydrocodeine, oxycodone and tramadol).   
There were two analytes (chlordiazepoxide and sertraline) where detection was 
acceptable but quantification could have been better.  Conversely, five analytes 
Total
39 100 100.00 - 110.00 0.83 11 10 91% 1 9% 0 0%
41 89.9 81.00 - 90.69 1.46 10 7 70% 1 10% 2 20%
43 72 55.00 - 72.20 1.89 9 7 78% 1 11% 1 11%
45 55 48.88 - 56.10 0.89 8 8 100% 0 0% 0 0%
47 60 47.00-60.00 1.17 8 7 88% 1 12% 0 0%
Round
Formulation 
Value (FV) 
mg/100ml
Range 
mg/100ml
SD:RSD
Number of participants
Satisfactory Questionable Unsatisfacotry
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(amphetamine, benzoylecgonine, fluoxetine, MDA and temazepam) were well 
quantified with poor detection.  Although poor performance for detection of 
amphetamine was displayed in round 43, it had markedly improved in round 46 
such that it was very good.  Benzoylecgonine was also included for detection in 
two rounds.  Unfortunately the improvement observed for benzoylecgonine from 
round 32 to 39 was only slight such that an inadequate number of participants 
detected the analyte.  It would be useful to include this analyte in a subsequent 
round as there was some improvement on the second testing.  It is hoped that in 
a third round of testing performance would reach a more acceptable level.   
Other analytes presented poor performance in both qualitative and quantitative 
testing.  The antihistamine cyclizine was the only analyte for which this could be 
concerning.  For other analytes the difficulty had been anticipated but the 
analytes were included to contribute to the educational culture of the PTS, for 
example, BZP and mephedrone, which were new to many laboratories.  These 
analytes, however, should now be re-tested. 
Results suggested that some participants may have problems with the detection 
of methadone and morphine and also their quantification of methadone could be 
improved (Table 4-13).  Sample 3 results were considered for these analytes in 
order to increase the information available given the concerns over 
performance.  Over three rounds of qualitative testing the results for morphine 
have been varied, going from poor to acceptable to bad in round 36.  This could 
indicate that either there is a problem with the detection of morphine, that this 
is a difficult analyte to detect, or that perhaps participants are unaware of when 
to test for this substance.  Qualitative testing is based on a scenario from which 
participant laboratories should identify which drugs are relevant; this could be 
the issue rather than an analytical problem.  Although, it is expected that as 
part of the laboratory STA samples would be subject to an immunoassay screen 
which should identify the possible presence of opiates. 
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Table 4-13:  Performance with methadone and morphine 
 
The quantitative results for morphine are more promising.  The first round of 
testing quantitatively was as a standard solution in round 37, where performance 
was poor, with 20% of participants having a z-score of 3 or more.  In the next 
round this improved and on the third time of testing morphine quantitatively in 
round 42 the results were excellent, with all participants receiving acceptable z-
scores.  This is what proficiency testing aims to achieve.  The difficulty for this 
particular review, however, is that it cannot be confirmed that the participants 
have improved their morphine quantification as we cannot be sure which 
laboratories are participating in each round.  The improvement in the statistics 
could possibly be the results of the laboratories that had difficulty with 
morphine not submitting results. 
Methadone and morphine are both forensically relevant analytes expected to be 
encountered often.  These analytes should be tested frequently to ensure 
laboratories can safeguard these important analytical methods from error. 
4.6 Discussion 
4.6.1 Scheme Organisation 
Given the information provided with the test samples, testing in the scheme 
could be considered directed.  Sample 1 screening is the only undirected test.  
The list of drugs which could be present is known, however, and could, 
Analyte Test
Participants w ith 
Unsatisfactory 
Performance
2009 35 Methadone 1.0 mg/l Standard Solution 0.0%
2009 37 Methadone 0.80 mg/l Quantif ication 17.6%
2010 39 Methadone 0.85 mg/l Quantif ication 12.5%
2011 44 Methadone 0.15 mg/l Qualitative 21.05%
2007 30 Morphine 0.10 mg/l Qualitative 29.41%
2009 35 Morphine 0.10 mg/l Qualitative 7.14%
2009 36 Morphine 0.10 mg/l Qualitative 41.18%
2010 42 Morphine 0.13 mg/l Quantitative 0.0%
2009 37 Morphine 0.20 mg/l Standard Solution 20.0%
2010 39 Morphine 1.00 mg/l Standard Solution 9.1%
Year/Round
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therefore, prevent the reporting of false positives for drugs which are not listed.  
Now that participants have had some experience with this PT, the challenging, 
educational aspect could be maintained, and testing could be made more 
reflective of forensic toxicology routine practice, if the drugs to be quantified 
were not confirmed to participants.  In addition there is an important aspect of 
proficiency which is not currently assessed.  Participants’ comments and 
interpretation are essential in casework.  This is recognised by UKAS through 
interpretation being a feature which can be included in a laboratory 
accreditation scope.  It is accredited separately from analytical methods and it 
should therefore form part of EQA for laboratories which are required to provide 
interpretation of their results.  Having more participants include their 
interpretation for incorporation into the round summary report would also add 
to the educational benefits of the scheme.  This would be particularly effective 
if participant laboratories were encouraged to involve more trainees/less senior 
members of staff to perform the analyses and also review the results, given that 
the scheme allows up to 3 sets of results to be returned.  There is a wealth of 
information, covering a very wide range of drugs, which could benefit the 
education of new staff members, particularly as some of these drugs will not 
often be encountered through everyday casework. 
There was only one recognised instance of a laboratory nominating more than 
one result.  The ability to nominate multiple results, however, does not seem to 
be appropriate for the purpose of a PT which should monitor the performance 
that would be provided to clients by routine processing.  The result which would 
be received by the client should be the only nominated result.  Laboratories 
would still be able to use more methods or analysts for comparison purposes but 
rather than submitting these as nominated official results, they could be scored 
and fed back to the participant but not included in the summary report, or they 
could be scored and monitored by the laboratory using the on-line score 
calculator.  Nominating multiple results does not represent the service received 
by customers who would only be provided one report.  It is possible, however, 
that a client using a laboratory multiple times would receive results that have 
been determined by different operators each time.  Submitting multiple results 
to the PTS allows the laboratory to monitor proficiency of staff.  
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Additionally it was evident from participant comments that they would often 
request standards or develop methods in order to perform testing of analytes 
that were not part of the service routinely offered.  If a participant laboratory 
does not offer a particular analysis, there would be no expectation for them to 
be proficient.  It is commendable and adds to the educational value of the PT 
that participants attempt to develop these methods and carry out the requested 
analyses.  In such instances, however, it would be better if participants 
calculated their own performance score via the on-line calculator (or submit the 
result but not as a nominated value), rather than submitting an official result for 
scoring and reporting as this can complicate perception of peer performance.  
Laboratories routinely offering the service would lose the ability to monitor their 
level of proficiency amongst their peers i.e. other participants who should be 
proficient.  When laboratories nominate results they would not routinely 
provide, it could falsely inflate the apparent performance of those other 
participants for whom the service is routine (and more importantly could have a 
significant influence on proficiency scores if participant results are used in the 
calculation). 
The scheme needs to develop its reporting style to clarify whether a participant 
has claimed proficiency in a test for which they have provided results or whether 
they are attempting a non-routine analysis.  Perhaps participants could be 
requested to indicate on the test menu which of the analytes they include in 
their testing service to clients.  Then only results for these analytes would count 
as official results from the participant and be scored and included in the 
summary statistics. 
It is also recommended that participants be requested to stipulate whether or 
not they have attempted an analysis.   In some instances a ‘not detected’ may 
be recorded when in fact the correct determination is that the test material was 
‘not analysed’ for the particular analyte.  Again this influences the summary 
statistics and can provide unrealistic peer comparison.  There are various 
reasons why an analysis might not be performed: one example could be that the 
sample volume did not permit the analysis.  The extensive range of analytes 
potentially present requires a large number of different analytical methods to be 
employed in order to test for all possible analytes (although the testing should 
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be directed by the accompanying scenario).  With only 10 ml of blood the 
number of these methods which can be utilised is restricted.  In light of this, the 
scheme organisers may wish to consider reducing the number of potential 
analytes.  It could be brought in line with the list of analytes with which the 
Home Office (through the College of Policing) request their laboratories to be 
proficient. 
It was disappointing that some participants who would have been capable did 
not take part in sample 3 analyses.  These participants missed the opportunity to 
refine practices essential for good quantification.  Provided quantification scores 
are acceptable, however, it is understandable that laboratories under pressure 
of high workloads chose not to participate.  Yet a larger peer group for 
comparison would benefit those wishing to monitor/improve these skills.  There 
were also some participants who, in the same round, performed sample three 
quantifications but not sample two.  This could, however, simply result from the 
sample two analyte not being one which the laboratory routinely measures. 
4.6.2 Proficiency with Benzylpiperazine 
It was good to observe the inclusion of the emerging psychoactive substances 
BZP and mephedrone, although performance was poor.  BZP was included as 
both a qualitative and quantitative test.  In round 37 participants were given a 
scenario which involved a fatality outside of a nightclub and advised that 
seizures were experienced by the subject.  As this was a qualitative sample this 
dataset could reflect the number of participants who would be aware of these 
being symptoms of BZP and who were looking for BZP in routine casework.  
Unfortunately only seven of sixteen participants identified the presence of BZP.  
In round 45 BZP was included as a quantification sample and participants were, 
therefore, alerted to its presence and laboratories who would not routinely 
consider this analyte attempted the analysis.  As the number of participants in 
this round was not known it was not possible to determine how many 
laboratories intended to participate but did not complete the analysis.  The 
comments from the participants were interesting and it was difficult to know 
whether many of these laboratories would still have proceeded with BZP 
quantification if it had not been directed as part of a PT.  One laboratory 
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reported that they would not quantify BZP as the concentration was too difficult 
to interpret due to the lack of available data.  This is understandable, at the 
same time, however, it is by performing casework analyses that interpretation 
data can be collated (and perhaps then shared via PT schemes such as this). 
Thus methods for the detection of new designer drugs should be implemented in 
forensic toxicology laboratories.  UNODC, of course, aims to provide these 
methods as well as PT samples. Participants should develop, optimise and 
validate methods for the detection of BZP and mephedrone which are increasing 
in popularity.133 Forensic toxicologists should familiarise themselves with the 
potential effects of these drugs in order that their possible use can be 
recognised from casework information.  Including these drugs in PTSs which 
include a scenario describing typical circumstances of their use is, therefore, an 
excellent means of education to help increase familiarity with new drugs.  BZP 
and mephedrone are not detected by routine immunoassay screening and their 
possible presence must be considered by the toxicologist to signal the 
requirement for analysis.  
4.6.3 Performance Scoring 
Perceived fitness-for-purpose was the most used method of calculating 
acceptable variation.  The SDPA percentages were slighter higher than those 
generally suggested for analytical chemistry laboratories (5%).99  This is in 
keeping with the recommendation that the expert steering committee prescribe 
a fit-for-purpose value for acceptable variation within the particular sector.  
Given poor sample quality and low analyte concentrations in forensic toxicology 
it was not surprising that higher percentages were required.  The percentages 
used, however were determined by reference  laboratories’ performance in 
earlier rounds of the PTS.  These percentages are perhaps too high.  The lowest 
at 15% deems a measurement 30% from the true value as satisfactory and only 
those greater than 45% from the true value to be unacceptable.  This does not 
appear to be appropriate for concentrations which could be given in evidence 
and should, therefore, be beyond reasonable doubt (with known uncertainty).  
At validation 15% from the true value is considered reasonable.  This is only of 
analytes present at significant concentrations, however, as it is understood that 
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higher percentages will be necessary for some very low concentration analytes.  
In forensic toxicology some concentrations can be so low that a high percentage 
difference can be such a small value that it is a negligible difference.  For 
example, at low concentrations there may be no significant toxicological 
difference between the true concentration of the drug and the values equal to 
this concentration plus or minus 50% of it (i.e. 0.05 mg/L, 0.1 mg/L and 0.15 
mg/L may all be therapeutic concentrations).   
Despite the high percentages in the Quartz scheme some analyte concentrations 
were still too low for application of a percentage SDPA method, and for some 
others, doubts that the formulation values were correct prevented use of a 
percentage SDPA.  Robust calculations from participants’ results were used in 
these instances.  Whilst this is an approved method for performance assessment 
this data could not be included in the long term review as the datasets were not 
large enough to counter uncertainties or biases in the values: greater than thirty 
participants would be required.102,132 
The necessity to exclude certain datasets for which the formulation values could 
not be used, highlighted the merit in stability testing.  Although homogeneity 
testing was conducted, stability testing was not.  Ideally the stability of test 
materials should be determined and the deadline for return of results fixed to 
the period for which the analyte remains stable.  Where this has not been 
possible, and degradation is suspected, a test sample retained by LGC could be 
re-analysed to establish the degree of degradation which may have occurred.  
This could then be incorporated within the uncertainty for the formulation value 
and a score calculated which does not depend upon participant data.  
Proficiency scores calculated in such uncertain circumstances cannot benefit the 
participants.  Where this increased uncertainty cannot be avoided or measured, 
it would be expedient to draw participants’ attention to the unreliable nature of 
the assigned scores, and that a different scoring mechanism has been applied.  
Whilst it is always possible to determine the method used to calculate the 
proficiency score from the information contained within the summary report, 
this requires some participant endeavour.  It would be helpful to participants if 
scoring mechanisms for each analyte could be more readily identified, to make 
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the significance of a performance score immediately apparent and ease 
monitoring of performance across rounds. 
4.6.4 General Performance 
Some allowances were made for poor quantification performances if the analyte 
was not one which would have immediate significance given the circumstances 
of the case or there was a low therapeutic level present which might not have 
been considered forensically relevant.  It must be stressed to participants, 
however, that all analytes present are to be reported whether they are at 
therapeutic levels or not.  This is especially important if there could have been a 
delay in recovering a sample and a large portion of the analyte has been lost 
through metabolism. 
As PT scores reflect proficiency for substances experienced daily in the 
laboratory, the infrequently used analytes included in Quartz samples are a 
possible explanation for many of the poor detections.  De Zeeuw 1 found that PT 
reflects proficiency for substances experienced daily in the laboratory; inferior 
quality is expected from less frequently performed methods.  The analytes 
highlighted as problematic for detection should, however, be repeated in future 
rounds.  Fentanyl should also have been repeated in a subsequent round to 
ensure participants had headed the advice of the advisory panel and were paying 
attention to increased occurrence of this drug.  The UNODC World Drug Report 
also recently issued a caution with respect to the increasing popularity of 
fentanyl 133 and the 2011 joint report from EMCDDA and EUROPOL reported the 
presence of fentanyl in Scotland.134 
There was a suggestion in participant performance that the proportion of 
laboratories failing to detect analytes had slightly increased over the period of 
the review.  This could simply be a consequence of increasing numbers of 
analytes, some of which were emerging drugs for which participants did not have 
standards, validated methods, or a good general awareness.   
There were not enough analytes repeatedly tested to provide an indication of 
the influence of participation in the scheme nor was there enough comparable 
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data to establish whether participating in this scheme improved participant 
performance.  Review of the few analytes which have had repeated testing 
under the same sample type, however, does point toward repeated testing 
improving participant performance. 
It is expected that an effective PTS will improve performance through time, 
which has been demonstrated elsewhere.135,136  In this review, performance 
could not be assessed against time as constant participation could not be 
established; individual participation could not be monitored.  Additionally, as 
test analytes were so varied, the usual pattern of performance being poorest in 
early rounds and improving in subsequent rounds before reaching a plateau was 
not expected to fit this scheme.  This in itself, however, is a good indication of 
the effective educational function of the scheme.  Having a large selection of 
test analytes reflects the true possibility of routine casework samples and also 
maintains a challenging aspect to the scheme.  It would appear that satisfactory 
performance scores are not the target of this PTS, rather, the aim is for 
participants to satisfactorily take part and learn from the experience.  After all, 
how a laboratory responds to an unsatisfactory result can infer better dedication 
to quality than a laboratory that consistently achieves satisfactory results.94 
In order to fulfil the function of a PTS, and to be fit-for-purpose, repetitive 
testing is essential.  The scheme offered in the rounds considered in this review, 
lacks the repetition necessary to guard against bias in the everyday 
measurements.  It is not possible for such a varied scheme to effectively monitor 
routine performance unless the laboratory wishes to demonstrate proficiency in 
the ability to detect a wide range of drugs.  Rather, a representative cross-
section of analyses performed should be continuously monitored.  As a PTS is 
intended to satisfy the requirement of external quality assessment, it should 
focus on comprehensive monitoring of the most common tests performed i.e. 
those with greatest volume of casework.   
As these analytes are so frequently encountered a biased method will result in a 
large number of incorrect results being released to clients.  It is, therefore, 
suggested that the sample three standard solution, which had poor uptake, be 
replaced with a test for standard analytes in blood.  This should include the 
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analytes morphine, codeine, diazepam, cannabis, amphetamine, cocaine and 
methadone (over two rounds to ensure sufficient sample volume for all of the 
analyses, such that each analyte could be quantified at least once every year).  
With participants frequently testing for these analytes there would be no 
imposition.  Participation in this part of the scheme should be as easy as simply 
adding the test sample to a routine batch for analysis.  Repeatedly testing the 
same analytes would allow for a scoring system to be developed for any analyte 
expected to be present at very low level, with a fixed value for acceptable 
variation below a specified concentration (in-line with the alcohol scoring 
system).  This would ensure continuous comparability and monitoring between 
rounds. 
Scheme coordinators advised that participants were reluctant to seek advice 
with any of the testing conducted to date, although clearly some participants 
were in need of assistance.  If repetitive testing is employed it will be clearly 
identified which analytes pose problems for participants (or the organisers may 
be able to highlight participants who struggle with particular analytes) and offer 
help in the form of a workshop which is offered to all participants rather than 
singling out and targeting laboratories.  Monitoring of efficacy measures is 
redundant without repetitive testing.  Effectiveness of the scheme cannot be 
assessed, other than establishing that the scheme is ineffective at the task of 
ensuring laboratories reach and maintain a defined target of performance.  It 
would appear that the LGC Quartz forensic blood toxicology PTS format has only 
delivered one of its three aims promised to clients.  Participants can compare 
their performance with peers, however there is no safeguarding against 
undetected errors, and there does not appear to be any evidence of participants 
being provided information on technical issues and methodologies. 
4.7 Conclusion 
A PTS should have clearly defined aims.  The current aim of the QUARTZ 
Forensic Blood Toxicology PTS has education as a key factor, intending to 
motivate and support participants to improve their services.  To provide 
laboratories a more effective external quality control service, which monitors 
method performance, the extent of the analytes tested could be reduced, and 
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testing should be more repetitive.  As performance of participants could not be 
traced through time any participant specific difficulties or requirements could 
not be identified.  It is therefore essential that participants continue to monitor 
their own performance over time (paying attention to scoring mechanism) and 
seek advice through the Technical Scheme Coordinator where they may have 
concerns.
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Chapter 5: Comparison of ICE and QUARTZ EQA 
Schemes  
  
5.1 Review  
Critique of the schemes was restricted by features of both:  ICE by incomplete 
data retrieval and inconsistent participation, and Quartz by inability to identify 
participants between rounds.  In the main, it was not possible to assess 
individual participant performance.  Reviews were, therefore, primarily focused 
on overall performance, laboratory proficiency in general, and competence with 
particular analytes (those which had been repeatedly tested by at least eight 
laboratories).  
The nature of participation was a noticeable difference between the two 
schemes.  It is understood from discussion with the Quartz co-ordinators that 
they have a regular group of participants with small fluctuations.  The average 
number of laboratories to participate in Quartz was 18 (range 16-21), mostly 
from the UK and Europe.  In contrast the ICE scheme is much larger, but 
participation much less regular, averaging 33 laboratories (range 22-65) from 
around the world.  The limited anonymised laboratory identification data for 
later rounds of Quartz made it possible to trace some laboratories who were not 
regular participants (having submitted results in one or two rounds only). These 
laboratories had achieved very high z-scores which influenced the perceived 
performance of dedicated participants (and were omitted from the review, just 
as infrequent participants were not considered in the ICE review).  This 
highlights the importance of being able to carefully monitor participation in 
association with performance statistics.  Large amounts of random participation 
could significantly influence performance statistics, which is unfair to 
committed participants.   
Quartz did have regular participation, yet it still did not satisfy the error 
detection function of a PTS.  ICE testing was less frequent, but with more 
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specimens available for quantitative analysis in each round and a smaller test 
menu, more analytes were tested every year.  Quartz had an extensive test 
menu and included fewer analytes tested every year, thereby accruing less 
analyte repetition.  Analytes were not tested often enough for participants to 
effectively monitor their performance over time.  Quartz round-to-round 
performance was randomly good or bad.  The inclusion of analytes in test 
samples which were not frequently encountered in casework samples, and 
possibly did not feature in laboratory STA procedures was thought to explain the 
large numbers of Quartz data sets presenting less than acceptable identification.  
The inclusion of newly emerging drugs for which few participants would have 
validated methods and for which reference standards were not readily available 
also contributed.   
A common problem in both schemes was participants not following a routine 
method.  Laboratories must only participate in testing of analytes for which they 
offer a service to clients; if they do not offer an analysis they are not expected 
to be proficient.  Submitting a result skews the statistical summary for a round 
and does not allow peers to know their performance relative to others who offer 
this service.  The standard ICE results form has an option of ‘analysis not 
performed’ to make clear that there was no attempt to complete the test rather 
than the result being erroneously recorded as a false negative.  The need for this 
clarity may have been readily perceived by the ICE coordinators because, as an 
international scheme, they were aware that they would encounter different 
laboratory protocols, and laboratories with different drugs of relevance as drug 
use trends and legislation differ between member states.  The ‘not analysed’ 
option is something that other PTSs, including Quartz, should consider.   
The impression given from the long term Quartz review was that laboratories 
were not achieving the target acceptable performance (although overall the 
Quartz participants displayed better performance than ICE).  This was an unfair 
representation and was likely due to frequent inclusion of analytes that were not 
part of routine testing, rather than participants not having good day-to-day 
proficiency.  The most important, high throughput analyses, were not being 
adequately monitored.  Participating in the Quartz scheme did not allow for 
error detection in the most frequently used methods and, therefore, should not 
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be considered by the laboratory, or their clients, as demonstrating suitably 
reliable results.  To provide a fit-for-purpose proficiency test to forensic 
toxicology laboratories repetitive testing of the most relevant analytes (e.g. 
morphine, codeine, diazepam, cannabis, amphetamine, cocaine and methadone) 
is essential.  Only this can ensure laboratories safeguard these important 
analytical methods from error.  As a result of the long-term review QUARTZ are 
now implementing such repetitive testing.   
Only a small proportion of ICE laboratories returned quantifications, whilst 
quantification was the most popular sample type amongst Quartz participants.  
Regular ICE participants were shown to be more likely to perform quantification.  
Achieving more regular participants could help to improve the ICE quantification 
rate.  Quantification may also be improved by ICE now returning a performance 
score to participants which previously it did not.  Participants may not have 
believed it worthwhile to make the extra effort to quantify when they were not 
being scored.  The resources available to many Ice participants makes 
quantification very difficult and in many jurisdictions it is not required, 
particularly as urine concentrations are not very meaningful.  Scoring was 
prevented by the difficulty of assigning acceptable variation with participants of 
such varied abilities.  For review it was set at 5% of the true value, based on 
validation bias being unacceptable greater than ±15%.  This may have been too 
stringent.  Acceptable variation with Quartz was much more lenient with 
participants determinations allowed to vary by up to 75% of the true value 
before they became unacceptable.  This acceptable variation does not seem 
appropriate for measurements which could have serious legal consequences and, 
therefore, not fit for purpose for forensic toxicology laboratories.   
The fact that ICE specimens were urine could also influence whether or not 
quantification was performed.  In general terms, analyte concentrations in urine 
are not particularly useful.  Blood is the preferred matrix for quantification and 
laboratories may not routinely quantify urine specimens.  Laboratories regularly 
performing blood quantifications that do not have access to any other reliable 
form of EQA could perhaps reconstitute the urine specimens with blank blood, 
however, this could introduce more errors to their method and the analytes and 
their concentrations may not be relevant.  It would be preferable if UNODC 
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could provide simply dried analytes at known concentration for blood 
reconstitution and analysis.  The provision of blood samples would be 
impractical for such a large international scheme.   
As Quartz provided blood samples and had regular participants this could explain 
greater uptake of quantification, however, it could also partly be due to the 
analytes being made known to participants; ICE testing was undirected.  A PTS 
aims to bring participants towards a target level of performance, or to maintain 
this if already achieved.  A plot of performance by round could, therefore, be 
predicted to appear as a fairly straight horizontal line within close proximity to 
what has been deemed acceptable.  Yet, even with almost all laboratories 
regularly performing quantification, this prediction was not observed with 
Quartz quantifications.  This is undoubtedly a result of the changing analytes 
across time.  In contrast, repetitive testing in ICE enabled quantification with 
specific analytes, and for individual laboratories to be traced which highlighted 
various issues such as inappropriate methods, analytes of particular difficulty 
and laboratories consistently producing poor performance in need of assistance 
with their IQC.  It is absolutely not a failing of a PTS to have laboratories that do 
not perform to the target standard; quite the reverse.  It is reassuring to have 
these issues identified as UNODC can now provide technical assistance required 
by these laboratories for improvement.  This is the true function of a PTS. 
Whilst repetitive testing is essential in a PTS for error detection and to provide a 
measure by which corrective actions can be monitored, it can enhance 
educational aspects to occasionally feature some less frequently encountered 
analytes; particularly emerging drugs of abuse.  Quartz was very strong on this 
educational feature.  Laboratories that establish proficiency in their accredited 
methods elsewhere could benefit from the varied nature of this scheme to gain 
experience with analytes which are not encountered often or which are 
emerging substances of abuse.  Rather than including these analytes in test 
specimens, ICE coordinators invite participants to report any new substances 
encountered at six months intervals and this information is readily shared.129 
Whilst limitations of these schemes meant that it was not possible to determine 
whether participating in a PTS can improve performance over time, this has 
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been demonstrated elsewhere.135,136  An aspect of PT which ensures 
improvement of performance is sharing of information and experiences amongst 
participants.  Unfortunately it seems that this does not occur.  It has been 
explained by the Quartz co-ordinators that commercial laboratories value 
confidentiality and, therefore, would not approach another laboratory for help 
as this could reveal them to be a laboratory which has performed poorly in a 
round.  Ultimately many participants will be competitors and there is not the 
same motivation for developing together.  A PTS introduced to allow 11 
participants across Europe to collaborate on an oral fluid (OF) research project, 
where participants were simultaneously developing and validating their OF 
methods, provided very positive results.  Participant performance improved with 
each round of testing and there was good CV% across the majority of the 
analytes tested.136  This could be due to participants assisting each other with 
method development and problem solving in order that they all might work 
together to make good progress with their research.  If laboratories will not 
communicate, it is the responsibility of PTS coordinators to interact effectively 
with participants to target those in need and those who perform well, and 
develop means to convey relevant information by a fashion which does not 
identify specific participants.  ICE has been very good at approaching 
laboratories to address education of participants by developing and promoting 
the ICE Portal as a “global reference point and early warning advisory on new 
psychoactive substances”.  Information such as trending observations, analytical 
methods, reference documents and mass spectra are shared.137 
It was interesting that participants in both schemes, at some level, displayed 
difficulty with morphine analysis.  Difficulty with morphine detection was also 
recognised in a published OF PTS review in which coefficient of variation of 
participants measurements reached 161%,138 however, a subsequent PTS 
demonstrated laboratories to have very good proficiency with morphine.136  The 
second scheme had fewer participants and they had been selected for a 
collaborative project presumably on the basis that they were laboratories with 
excellent reputations for quality.  Morphine is an analyte of great importance 
and efforts should be made to more closely monitor this testing and assistance 
should be provided to those participants displaying difficulty.  
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ICE is not a true PTS and is not accredited as a PTS but was more effective as a 
means of external quality assurance.  Still, it may not be recognised as a PTS for 
participant accreditation purposes.  This was also true of the OF PTS set up with 
the clear and specific aim of allowing collaborative studies in the DRUID 
project.136  It was not an accredited PTS but proved extremely successful in 
improving participant performance, such that they achieved target proficiency.  
The Quartz Forensic Blood Toxicology PTS is primarily an educational resource.  
It is a UKAS accredited PTS, yet does not provide participants an effective means 
of monitoring routine laboratory performance.  As many of the participant 
laboratories are ISO 17025 accredited, it is expected that they have a 
supplementary source of EQA as this scheme is not appropriate to demonstrate 
the quality that should be attained by accredited laboratories.  The QMS of an 
accredited laboratory should have served to highlight the failings of this scheme. 
King et al 139 reviewed the influence of accreditation in PT performance.  Only 
48% of the participants accredited by the National Measurement Accreditation 
Service (NAMAS, now known as UKAS), CPA or ISO had a written procedure for 
unsatisfactory performance.  They found no evidence to support accredited 
laboratories having better overall performance than non-accredited laboratories, 
although that study was carried out in 1999 before the introduction of the 
ISO17025 standard, which has greater analytical requirements.   This is not 
surprising as accreditation ensures that a validation has been performed and has 
been demonstrated to suit the needs of the customer.  It is not, however, 
concerned with the specific data and results generated.  The requirement of 
accredited laboratories to have meticulous QMS did have some bearing, 
however, as recovery from a poor performance was generally faster amongst 
accredited laboratories.  Laboratories without accreditation showed the highest 
long-term level of unsatisfactory results. 
5.2 Conclusion 
It is unlikely that a laboratory can find a PTS to mirror exactly all of its casework 
analyses, for example, there is no PTS which replicates drug driving samples 
with the specific road traffic vials.  However, the requirements of the analysis 
should be as closely reproduced in a PTS as possible.   
Chapter 5  120 
 
 
 
Accreditation does not provide evidence in support of the quality of a laboratory 
or PTS and should not direct which PTS a laboratory selects for EQA.  It is the 
responsibility of laboratory management to ensure their EQA is appropriate for 
the purpose for which they are participating (safeguard against bias, familiarity 
with emerging substances, maintain competence with infrequently encountered 
analytes, etc.).  This can be assessed with reference to the PTS protocol, for 
example, the frequency of analyte testing, the analytes included, participation, 
how the true value is defined and the acceptable variation.  An unaccredited 
scheme which is more relevant to the laboratory caseload but which uses sound 
practices, is undoubtedly better than an accredited scheme which does not fulfil 
the laboratory’s particular needs.   
Although there are relatively few forensic toxicology PTSs, all laboratories have 
access to an effective means of bias detection for analytes of greatest forensic 
relevance, in the form of the UNODC ICE, although this is limited to analysis of 
urine.   
Long term review ensures the effectiveness of a PTS scheme and highlights areas 
in which laboratories require improvement and guidance.  This also requires that 
PT providers ensure that they employ a scoring system which realistically 
reflects performance.  It is hoped that more providers are encouraged to more 
closely reflect the complex testing often required by ‘forensic’ laboratories; 
particularly testing of less traditional matrices and poor quality specimens. 
For PTSs to operate effectively providers should equip themselves for long-term 
review by archiving the appropriate data, for example to allow round-by-round 
comparison and by being able to monitor individual participant performance in 
an anonymous way.  And to get the full benefits of a PTS laboratories must be 
dedicated, participate regularly, and monitor their results to ensure the PTS is 
fulfilling the intended purpose. 
It is not correct to assume good quality is present in all analyses, based on a 
good PT record.48,91  It has been suggested that as most laboratories perform 
analyses for a range of substances and the PT cannot be all-encompassing, the 
selection of analytes incorporated should be as wide as possible to achieve a 
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representative cross-section of analyses performed.48  The evidence from Quartz 
is that PTS should have a focused selection of analytes, at least some of the test 
samples should provide regular testing of core analytes, and, if necessary, the 
laboratory should participate in a selection of PTS to ensure enough of the work 
performed is represented.  As new substances are routinely encountered these 
too should be incorporated by EQA.  One such group of substances are the 
piperazines, which are the subject of the next chapter.
  122 
 
 
 
Chapter 6: Validation of a Method to Detect 
Piperazines in Blood  
  
6.1 Piperazines 
Piperazines have been available for many years and gained widespread 
familiarity from 2004 when they were aggressively marketed as safer, cleaner, 
less addictive alternatives to illegal dance drugs and introduced as ‘legal highs’.  
Piperazine ‘party pills’, or piperazine-based social tonics (PBSTs), were 
portrayed as harmless natural highs said to elevate mood, increase mental 
capacity, alertness and energy.  They became popular as ‘dance’ drugs but also 
appealed to shift workers, drivers and students.140,141  At this time piperazines 
were legally available, although claims that piperazines were herbal, natural or 
harmless were erroneous. 
The term ‘piperazines’, when used to describe a class of drugs, covers a range of 
piperazine-derived drugs.  Those commonly encountered are depicted in figure 
1.  They occur in a host of shapes and forms, usually tablets of various colours, 
sometimes with impressed logos to look like ecstasy and less often as powders or 
liquids.142,143,134 
Benzylpiperazine (BZP) given the street name ‘A2’, first emerged as a drug of 
abuse in the United States (1996) and Sweden (1999) 144-146 before seizures were 
progressively recorded worldwide,140,147,148 including throughout the UK.147  The 
former Forensic Science Service (FSS) in England received around four hundred 
piperazine cases per quarter (2008).149 
The piperazine ‘experience’ has been likened to different ATS, though with 
lower potency.150-153  It is understood that the optimum experience is achieved 
by combining different piperazines as this more closely mimics the effects of 
MDMA.152-154  At the height of their popularity there were many blends available 
commercially, for example legal E, Legal X rapture, Frenzy, and Charge’, 
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marketed on-line and in head shops as ecstasy alternatives, having stimulant 
and/or hallucinogenic effects.155 
Originally party pills most often contained BZP, usually in combination with 
other piperazines, however, new varieties minus BZP became popular as BZP 
regulations were introduced.  In many countries, including the UK until 2009, the 
ready availability of these substances, legally purchased rather than being 
‘scored’, may have fostered a false sense of safety.142,155  Legality caused users 
to wrongly assume that the safety of these substances had been tested and that 
they were quality assured with accurately labelled ingredients.142  Naïve users, 
who might never have experimented with drugs were introduced to psychoactive 
substances simply because they were legally available.156  It was feared that the 
use of these substances created a relaxed attitude towards pill use; they 
represented a gateway to experimentation with illegal drugs. 157,142,158  There 
were those who were in favour of legal party pills, however, believing that their 
availability and affordability discouraged the use of ecstasy with severe 
potential for harm. 
The vast majority of piperazines (if not all) arrive in the UK from overseas 
factories, usually Asian (China/Hong Kong/Japan).159  Although BZP can be 
synthesised from benzyl chloride and piperazine mono-hydrochloride, both 
cheap and readily available, it is easier to simply purchase it. 
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Piperazine Reference Structure
Benzylpiperazine BZP
Trifluoromethylphenylpiperazine TFMPP
1-(2-Methylphenylpiperazine) o MPP
1-(3-Methylphenylpiperazine) m MPP
1-(4-Methylphenylpiperazine) p MPP
1-(3-Chlorophenylpiperazine) m CPP
1-(4-Fluorophenylpiperazine) p FPP
1-(2-methoxyphenylpiperazine) o MeOPP
1-(3-Methoxyphenylpiperazine) p MeOPP
1-(3,4-methylenedioxybenzyl)piperazine MDBP
1,4-dibenzylpiperazine DBZP
4-bromo-2,5-dimethoxybenzylpiperazine 2C-B-BZP
 
Table 6-1:  Structures of popular piperazines 
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6.2 Current Piperazine Trends 
Piperazines really came to fruition when efforts to control MDMA production in 
the 2000s meant manufacturers faced a shortage of precursors.133   This resulted 
in some users experiencing difficulty in obtaining ATS due to reduced availability 
and increased cost.  This may have created the demand for alternatives, 
although the demand for these substances, originally introduced as ‘legal highs’, 
was augmented by their appeal to others.   
Ecstasy tablets which remained in circulation were found to be heavily 
adulterated, or with MDMA completely replaced with piperazines.160  The FSS 
reported MDMA and amphetamine were often encountered in combination with 
piperazines and, as the number of MDMA cases steadily declined, they witnessed 
a related rise in the number of piperazine cases.149  Piperazines were the most 
popular ‘legal high’ at this time.  In recent years, however, the market for such 
‘mimic drugs’ has experienced unprecedented growth.   
These mimetics have many descriptors; ‘legal highs’, ‘herbal highs’, ‘research 
chemicals’, and ‘party pills’ have been some of the most popular.  The preferred 
term amongst the scientific community is New Psychoactive Substances (NPS), 
which reflects that some are now illegal and that they may not necessarily have 
a stimulant effect.159  Whilst piperazines have been misused for a number of 
years and are illegal in the UK they are still classified as NPS;137 this term is 
defined by EMCDDA as drugs not listed under the 1971 United Nations Convention 
on Psychotropic Substances but which have effects similar to those which are 
listed.  EMCDDA list piperazines as one of the main groups of NPS.  The rate of 
production of NPS poses great difficulties for regulatory authorities and forensic 
analysts in attempting to identify and control them.161  In 2011 the UK 
Government introduced the Home Office-funded Forensic Early Warning System 
that receives information from UK forensic providers which is forwarded to the 
EMCDDA.  By 2011 eight piperazines had already been notified to the EMCDDA 
early warning system.134  The UK also has a Drugs Early Warning System (DEWS), 
with information from police, prisons, NHS health-boards and more.  Whilst the 
number of newly identified piperazines has declined in recent years, those which 
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have already been reported are continually encountered, often as mimic ecstasy 
which has experienced a resurgence.137 
In 2013 piperazine seizures in the UK were found to have been greater in number 
than MDMA seizures, 162 yet global ATS seizures were at the highest level ever 
recorded.137  A large proportion of seized ‘ecstasy’ contained substances other 
than MDMA.  In 2011, ecstasy tablets which did not contain MDMA mostly 
contained diazepam (569,000) closely followed by piperazines (411,000).163  
Davies et al (2012) observed significant seizures of piperazines (large numbers 
were piperazine blends) with TFMPP most frequently encountered followed by 
BZP.163  This was mirrored by Kuleya and coworkers’ (2014) analysis of ATS, all of 
which contained TFMPP, with BZP also common.164  In 2013 at least 20% of UK 
MDMA contained mCPP; either alone or in combination with other substances.137  
Thus piperazines remain very much of relevance to UK forensic toxicologists.  
Quite recently a number of deaths in Scotland were associated with ‘green 
Rolex’ ecstasy tablets.  Many of these tablets were seized and examined by the 
Scottish Police Authority.  Whilst the main constituent was most often found to 
be para-methoxyamphetamine various other constituents were noted, including 
BZP.165  Despite the wealth of NPS now available, piperazines endure.   
6.2.1 Legal status 
Under the UK Medicines Act of 1968 the sale of BZP products for human use has 
been illegal since March 2007.166  In 2008 the Advisory Council on the Misuse of 
Drugs (ACMD) provided the UK Home Office with advice and recommendations 
for the control of piperazines following the European Council decision to subject 
BZP to ‘control measures and criminal provisions’.149  In December 2009, 
“1-benzylpiperazine and any compound structurally derived from1-
benzylpiperazine or 1-phenylpiperazine by substitution in the 
aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide 
or haloalkyl substituent, whether or not substituted at the second 
nitrogen atom of the piperazine ring with alkly, benzyl, haloalkyl, or 
phenyl substitution”,  
were legislated as Class C under schedule 2, part III of the Misuse of Drugs Act 
(1971) and placed under Schedule 1 of the Misuse of Drugs Regulations (2001) 
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(mCPP is an exception which is under Schedule 4).149,167,168  The ACMD report 
explained that classification of piperazines was based on potential for 
dependence and social harms, however, the impression created by the literature 
(or lack of it), is that the risk posed from piperazines has yet to be fully 
assessed. 
The UK and Australia are the only countries to have banned all piperazine 
analogues.169  Elsewhere some piperazines can be supplied and possessed 
without consequence.  BZP has been controlled in all EU member states since 
2009,170 in the United states since 2002 147,157 and in New Zealand since 2008.171  
New Zealand originally favoured regulation over illegalisation, in an endeavour 
to alleviate high rates of amphetamine use.140,141,146  As popularity of the legal 
drugs soared annual sales were estimated at £24 million, around five million pills 
(2004).171  The use of ecstasy versus party pills, however, increased.146 Party 
pills were consumed in addition to habitual drug use,142 and piperazines were 
illegalised. 
International illegalisation of BZP cultivated demand for non-scheduled 
piperazines and BZP-free party pills.  By 2007 mCPP had become the most 
common piperazine analogue in Europe,127 and the most widely encountered NPS 
since monitoring began in 1997.172  Consequently mCPP was also added to drugs 
legislation in many European countries.148,149 
6.2.2  Relationship to Amphetamines 
In the 1970s BZP was recognised as exhibiting stimulant properties in rats.  With 
prospects as an anti-depressant, human clinical trials were conducted and its 
potential for abuse investigated.  Volunteers experienced in amphetamine use 
who could fluently communicate effects and provide an ‘educated’ view of 
abuse appeal were recruited.  It was during this trial that Campbell et al derived 
the much quoted 10:1 potency ratio.151   Administration of 10 mg of 
dexamphetamine and 100 mg of BZP produced almost equal measured effects or 
‘scores’.  BZP was actually rated more amphetamine-like than dexamphetamine 
indicating significant abuse potential.  Campbell et al abandoned the trials and 
recommended statutory control of BZP. 
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There have been few subsequent studies of piperazines.  As substitutes for MDMA 
piperazines were expected to have similar physiological action.  BZP, however, 
was the only piperazine to exhibit clear stimulant behaviour.154  Similar to 
MDMA, BZP increased heart rate, blood pressure, and auditory vigilance,151,173,174 
whilst other piperazines exerted only mild changes in these functions.148,175  BZP 
has been established chiefly as a dopamine and norephedrine 168 releasing agent 
but also increases serotonin levels by inhibiting synaptic re-uptake, similar to 
amphetamine (and cocaine).144,153,176   TFMPP, mCPP and FPP were recognised to 
release endogenous stores of serotonin from neurons, similar to substituted 
amphetamines (e.g.MDMA),148,152,175,177 although there was no significant release 
of dopamine as observed with MDMA.  Thus no single piperazine was found to 
replicate the pharmacodynamics of MDMA.  Co-administration of BZP/TFMPP, 
however, was different. 
BZP with TFMPP resulted in dopamine production in excess of the sum of both 
drugs taken individually.  It displayed similar neurological action to MDMA, and 
demonstrated the existence of a piperazine interaction.152,153  This effect was 
further investigated by Antia et al 178 with the conclusion that each of these 
drugs inhibit the metabolism of the other, leading to elevated levels of both 
drugs when co-administered.  This synergistic effect could be life-
threatening.140,152 
6.2.3 Toxicity  
6.2.3.1 Acute 
Whilst studies of toxicity associated with piperazines and piperazine blends are 
few, it is documented that severe effects can occur unpredictably and at 
relatively low doses.179-181  User experiences combined with controlled studies 
have identified adverse effects of piperazines to include:  nausea, vomiting, 
tachycardia, hypertension, confusion, agitation, panic attacks, hallucination, 
dissociative symptoms, dryness of the mouth, and problems with urine retention, 
as well as more serious complications such as renal failure, life-threatening 
seizures, multi-organ failure, respiratory depression and psychosis. 
141,151,155,168,173,176,181-185  Symptoms can persist for up to 24 hours and users 
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frequently recount experiencing a severe hangover following piperazine 
use.168,181,183 
There are relatively small numbers of reported piperazine poisonings, however, 
these are expected to be underreported. 186,187  The inability of most routine 
toxicology screening to detect piperazines could contribute to this, as could 
misdiagnosis due to more familiar expectation of amphetamine intoxication 
which presents similar symptoms.150,186,188  Patients may contribute to 
misdiagnosis by wrongly claiming to have consumed ATS, although they have 
unwittingly purchased and consumed piperazines sold in place of an ATS (e.g. 
mimic ecstasy).134,162,184,186,188  In four confirmed cases of piperazine poisoning in 
the UK, patients believed they had purchased MDMA but tests determined they 
had been sold piperazines.173,184  Although there have been no deaths attributed 
to piperazine use, BZP and/or TFMPP featured on 25 UK death certificates from 
2008 to 2012.163 
As piperazine use is considered to be widespread it must be assumed that the 
majority of users do not suffer serious adverse effects.  In an assessment of the 
effects of BZP and TFMPP (individually and combined), however, the Medical 
Research Institute of New Zealand abandoned their trials after only 35 subjects 
had completed testing.  This was due to “the frequency and nature of severe 
reactions” observed.180  This partial trial was enough to demonstrate that at 
recommended doses BZP/TFMPP party pills “result in a high rate of severe 
adverse reactions,” indicating a narrow safety margin in some users, especially 
in blends and at high doses.  During this trial in which subjects were observed to 
suffer severe negative effects, only the recommended dose had been 
administered.  With piperazines promoted as safer alternatives to ATS, the 
perception has been that they are good quality pills but weaker, and users admit 
disregarding safety information and ‘hyper-dosing’.142,174  User surveys revealed 
that when taking piperazines for the first time over 30% of respondents 
consumed more than the labelled dose (usually 2 pills), and others habitually 
consumed 10 or more pills, with occasional greatest consumption around 12 
pills.142,189,190   
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6.2.3.2 Risk of overdose 
Accidental ‘overdose’ could result from users’ difficulty in assessing exactly 
what they have taken.  There can be a number of reasons for this including 
incorrect concentration of active ingredient labelled,155,191 variability of active 
ingredients across brands,189,192 changes in constituents of brands through time, 
and poor labelling which is difficult to interpret.145,193  Labels generally advise 
taking one or two pills and waiting only one hour to assess effects before taking 
more.194  It can take more than one hour for effects to manifest so effects may 
be increased beyond that intended (peak subjective effects around two 
hours).150,168,175  Contrasting this with MDMA, which exerts its effects relatively 
quickly, regular MDMA users accustomed to rapid onset may believe that party 
pills have not had any effect and take more, or resort to MDMA.  Many users 
claim to purposely combine piperazines with ATS to enhance and prolong the 
effects.142,146  Party pills warn against their use with other substances,142 
although the dangers of doing so are not explicit.  mCPP has also been detected 
in cocaine and ketamine;148,155  the pharmacokinetics of mCPP following nasal 
insufflation (which increases potency) are unknown.195   
Slow onset of effects could be responsible for observed intravenous 
administration of piperazines, particularly BZP. 146,155,181,183,196  This could also be 
a result of their having similar effects to ATS but better availability.156  
Intravenous use results in a much higher bioavailability and increased risk of 
serious adverse reactions.  Piperazines are basic making injection painful, so it is 
therefore unlikely that piperazines would become established for intravenous 
use.156 
6.2.3.3 Chronic effects 
Long term effects of piperazine use have not been established.  With similar 
mode of action and physiological effects to ATS,144,155,173 similar consequences of 
long term use may be a reasonable postulation.187,191  MDMA has been shown to 
have potential to cause neurotoxicity and psychobiological problems such as 
depression, obsessive-compulsive disorder and paranoia.197  With such unknown 
potential for long term harm the ACMD assignment of ‘relatively low risk’155 may 
be an underestimate.  The efficacy and potency of piperazines may be lower 
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than ATS but the trend to consume them in large doses and in blends198 means 
that they are potentially as harmful.  There has also been evidence from a small 
number of studies to suggest that regular use of some piperazines/blends could 
lead to dependence.141,151,191,199,200 
6.2.4 Metabolism 
Only four groups have addressed metabolism of piperazines in human subjects.  
Three of these suggest that there is no significant metabolism as large 
concentrations of parent drug (BZP, TFMPP and mCPP) are detected in 
urine.37,176,201  However, Antia et al, the only group to dose humans, identified 
that BZP is extensively metabolised.202   The parent drug and hydroxy 
metabolites (3-OH-BZP slightly in excess of 4-OH-BZP) excreted in urine account 
for only ca. 12.5 % of the total administered dose.  This may indicate low 
bioavailability of BZP, another route of excretion (e.g. billiary), or strong protein 
binding.  Hydroxylated metabolites of BZP (3-OH-BZP and 4-OH-BZP)202 and 
TFMPP (4-OH TFMPP) 203 were also detected in plasma.  BZP metabolites were at 
extremely low levels in comparison to the parent drug (meta 5% and para 3%), 
but 4-OH-TFMPP was detectable in plasma in relatively high abundance, reaching 
a peak concentration almost as high as that of the parent drug.  The metabolic 
interaction of BZP with TFMPP following co-ingestion was demonstrated once 
again, as the metabolites of individual ingestion differed to those of co-
ingestion, with each losing a hydroxylated metabolite (3-OH BZP and 4-OH 
TFMPP respectively).204 
The metabolic pathways of piperazines in human tissue have yet to be 
confirmed, although metabolic dependence of the CYP450 enzyme system is 
expected, with CYP2D6 believed to be the major enzyme responsible for 
catalysing the metabolism of piperazines.178,205  Reliance upon CYP450 
metabolism explains the susceptibility of piperazines to drug-drug interaction.  
Co-ingested piperazines significantly inhibit metabolism, resulting in greater 
toxicity. 183,186,204  It is also expected that co-ingesting a piperazine with another 
CYP2D6, CYP1A2 or CYP3A4 metabolised drug, e.g. MDMA and cocaine, will 
increase toxicity of that drug as the piperazine competes for metabolism.  This 
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could be very dangerous if the competing drug is a medication as this may no 
longer function as it should. 
6.3 Aim 
Following the G8-Roma-Lyon expert group meeting in April 2013,206 the UK 
committed to developing methods for analysis and identification of NPS to allow 
collection and sharing of toxicology data.  It is essential that forensic toxicology 
laboratories develop validated quantification methods.  UNODC have produced a 
guide to the analysis of piperazines in seized materials (2013)207 but not yet for 
biological samples which are more complex. 
Piperazines clearly present a means of driver impairment and pose a significant 
toxicological threat - they are included on the UK and Ireland Association of 
Forensic Toxicologists recommended drugs of abuse panel to be routinely tested 
in forensic toxicology laboratories.208  A method which identifies their use and 
which can quantify the levels present in body fluids (particularly blood) is 
required.   
The aim of this project was to validate a method for the detection and 
quantification in blood of as many ‘relevant’ piperazines as possible.   
6.3.1 Relevant piperazines 
Widespread use of BZP and TFMPP 133 make them most relevant, together with 
mCPP and MeOPP which are given greatest interest in the literature.  ‘Party pill’ 
investigations through time have shown that they contain all four of these 
piperazines in addition to MBZP (methylbenzylpiperazine), DBZP (1,4-
dibenzylpiperazine), pFPP and oMPP 19,193,209; these are therefore, also of 
importance.  UNODC reports the top five piperazines to be mCPP, BZP, TFMPP, 
pFPP, followed by MBZP.  Piperazines most frequently encountered by the FSS in 
the UK were mCPP, BZP, TFMPP, and DBZP.149  These piperazines and mCPCPP 
(1-(3-chlorophenyl)-4-(3-chloropropyl) piperazine) have been reported to the 
EMCDDA/EUROPOL Early Warning System.134  Two further piperazines are known 
to have been in circulation as they have been reported to the UNODC: 2C-B-BZP 
(4-bromo-2,5-dimethoxybenzylpiperazine) and MePP (methylphenylpiperazine). 
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EWS data may not be a true representation of the piperazines in current 
circulation, rather, it may be a reflection of detection methods in place in drugs 
laboratories.  It is likely that some substances have been missed.  The 
piperazines which have been identified, however, are a good set of target 
analytes for a piperazines forensic toxicological method because if these are 
known to be present in drugs seizures they have the potential to be present in 
clinical and post mortem blood samples.  Those piperazines identified in seizures 
are summarised in Table 6-2. 
 
Piperazine Abbreviation Included in Method
Benzylpiperazine BZP P
4-bromo-2,5-dimethoxybenzylpiperazine 2C-B-BZP No; lack of reference standard
 1-(3-Chlorophenyl)-4-(3-chloropropyl) piperazine m CPCPP No; lack of reference standard
1-(3-chlorophenyl)piperazine m CPP P
1-(4-chlorophenyl)piperazine pCPP P
1-(4-Dibenzyl)piperazine DBZP No; impurity of BZP generally at trace levels *
1-(4-fluorophenyl)piperazine pFPP P
Methoxyphenylpiperazine MeOPP P 
methylbenzylpiperazine MBZP No; avoided by users, extremely mild effects **
Methylphenylpiperazine MPP P
Trifluoromethylphenylpiperazine TFMPP P
 
Table 6-2:  Relevant piperazines for toxicological detection * 149   ** 210 
 
6.4 Experimental Section 
6.4.1 Introduction 
The piperazine structure suggests similar chemical properties to amphetamines.  
It was, therefore, hoped that the piperazines could be added to the Forensic 
Medicine and Science (FMS) validated and UKAS-accredited amphetamines GC-MS 
method.  This method, however, proved to be unsuitable and required some 
changes for application to piperazines.  The GC oven temperature programme, 
injection conditions, and derivatisation were investigated.  Careful consideration 
of high volatility of analytes, their basic nature and high polarity was necessary.  
A method such as LC-MS/MS which does not operate at high temperatures, 
requires fewer evaporation steps, and can provide greater specificity could be 
more suited to piperazine analysis.  This was explored through comparison of the 
validation parameters for GC-MS and  LC-MS/MS methods. 
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6.4.2 Reagents and Standards 
All chemicals used, listed in Table 6-1, were of at least analytical reagent grade.  
Deionised water was obtained from the in-house Millipore system. 
 
Table 6-3:  Materials and suppliers 
 
6.4.3 Preparation of Blank Blood 
Validation calibration samples were prepared from expired red blood cell 
pouches supplied with ethical approval from the blood bank at the Western 
Infirmary, Glasgow.  These had been frozen upon receipt.  Before use they were 
fully defrosted and diluted 1:1 with isotonic saline solution (9.5g of sodium 
chloride dissolved in 1L deionised water).  Whole blood was also used, which was 
received frozen and allowed to reach room temperature before use. 
Reagent Supplier
1-(2-methylphenyl)piperazine dihyrdrochloride ACROS Organics
1-(4-methylphenyl)piperazine dihydrochloride ACROS Organics
1-(3-chlorophenyl)piperazine monohydrochloride Alfa Aesar
1-benzylpiperazine Fluka
1-​(4-​Chlorophenyl)​piperazine Sigma Aldrich
1-(2-methoxyphenyl)piperazine Sigma Aldrich
1-(3-Chlorophenyl)-piperazine-d8 Sigma Aldrich
1-(3-trifluoromethylphenyl)piperazine hydrochloride Sigma Aldrich
1-(4-fluorophenyl)piperazine Sigma Aldrich
1-(4-methoxyphenyl)piperazine Sigma Aldrich
1,4-​Dibenzylpiperazine Sigma Aldrich
1-methyl-3-phenyl-piperazine Sigma Aldrich
Benzylpiperazine-d8 dihydrochloride Sigma Aldrich
Heptafluorobutyric anhydride Sigma Aldrich
disodium hydrogen orthophosphate anhydrous VWR
sodium dihydrogen orthophosphate monohydrate VWR
Ammonium Acetate VWR
Sodium chloride BDH Chemical Ltd  
Ammonia Fisher Scientific
Methanol VWR
Dichloromethane VWR
Ethyl acetate VWR
Propan-2-ol VWR
Acetic Acid, Glacial Fisher Scientific
Cleanscreen DAU 200mg/10mL Presearch
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6.4.4 Preparation of Working Standards and Quality Controls 
A mixed internal standard (I.S.) working solution was prepared containing 20 
µg/ml of both BZP-D8 and mCPP-D8.  This was prepared by adding 100 µl of 1 
mg/ml BZP-D8 stock solution and 1 ml of 0.1 mg/ml mCPP-d8 to a 5 ml 
volumetric flask and making up to the mark with methanol.  Limited resources 
meant that some experiments employed only one I.S.  For these a separate 20 
µg/ml BZP-D8 solution was prepared by adding 200 µl of BZP-D8 stock solution to 
a 10 ml volumetric flask and filling to the mark with methanol.   
Each reference standard was prepared as a 1 mg/ml methanol stock solution, 
most being prepared from bulk powders.  2.5 ml of each of the nine stock 
solutions were combined in a 50 ml volumetric flask and filled to the line with 
methanol to produce a 50 µg/ml mixed reference standard intermediate 
solution.  From this intermediate solution mixed reference standards were 
individually prepared (not by serial dilution).  Preparation of the calibration 
standards is outlined in Table 6-4. 
Table 6-4:  Preparation of calibrators 
Blood Concentration ng/ml
(50µl stnd sol to 1 ml blood)
Concentration of standard 
solution µg/ml
ml of  50 µg/ml solution to make 
10ml working solution
5 0.1 0.02
20 0.4 0.08
60 1.2 0.24
100 2.0 0.40
300 6.0 1.20
500 10.0 2.00
1000 20.0 4.00
1500 30.0 6.00
2000 40.0 8.00
 
Quality control samples were prepared by the same means but from different 1 
mg/ml stock solutions.  Practical restrictions meant that for some runs quality 
control samples were from the calibration batch. 
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6.4.5 Sample Preparation 
Calibration standards were prepared by adding 50 µl of piperazines working 
solution and 50 µl of 20 µg/ml internal standard solution to a test-tube before 
adding 5 ml of mixed water:pH6 phosphate buffer (2:1 v:v) and lastly 1 ml of 
blank blood.  This was vortex mixed then centrifuged at 2500 rpm for 10 min.  
Cleanscreen® DAU solid phase extraction cartridges were used for extraction as 
they had previously provided good recovery for amphetamines 30,183,211-213 and 
piperazines 187 (although the recovery was less for mCPP).81  Cartridges were 
conditioned with 3 ml methanol, 3 ml deionised water, then 1 ml pH 6 
phosphate buffer, prior to sample loading.  Cartridges were then washed with 
3ml deionised water, 1 ml 0.1M acetic acid, then 3ml methanol and dried 
thoroughly on full vacuum.  The analytes were eluted with 3 ml freshly prepared 
dichloromethane/isopropanol/concentrated ammonia (78:20:2 v:v:v).  600 µl of 
the extract was removed and dried at room temperature before reconstitution 
with 100 µl of 2 mM ammonium acetate in 5 % methanol for LC-MS/MS. The 
remaining extract was dried at room temperature before derivatisation with 40 
µl of HFBA at 60oC for 30 min.  Excess HFBA was evaporated before 
reconstitution in 40 µl ethyl acetate.  
6.4.6 Optimisation of GC-MS 
6.4.6.1 Derivatisation 
The majority of the piperazine analytes were not suited to GC-MS analysis 
without derivatisation.  Derivatisation of amine and hydroxyl moieties is 
necessary to prevent tailing of peaks and improve sensitivity.  Amines are usually 
derivatised by acylation, using acetic or propionic anhydrides,19 to replace active 
hydrogens which can interact with the stationary phase to negatively affect 
reproducibility and peak shape.214,215  The acetyl group stabilises the piperazine 
ring, producing more characteristic mass spectra.  Structural isomers may still 
have the same fragmentation, however,derivatisation improves chromatographic 
resolution, aiding in differentiation of isomers by retention time.145 
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Pentafluoropropionic anhydride (PFPA) is commonly cited as a derivatising 
reagent for amphetamines (optimum conditions 15 minutes at 50oC 216).  Given 
structural similarity of piperazines to amphetamines it is surprising that the 
application of PFPA to piperazine methods has not previously been reported.  
Three PFPA preparations in ethyl acetate were trialled (1:1 v:v), (2:1 v:v), and 
(3:2 v:v), with 50 µl of these solutions added and allowed to derivatise at a 
range of temperatures for various times.  Excess derivatising reagent was 
removed by evaporation (without heat).  Unfortunately this was not successful 
across all of the piperazines.  Some analytes displayed multiple peaks due to 
varying sites of derivatisation; also, the derivatisation was not reproducible. 
Other derivatising reagents were also trialled: acetic anhydride with pyridine, 
used by Stack et al in their piperazine metabolite investigations 29,186,188,217-220; 
trifluoroacetic anhydride (TFAA), popular for derivatisation of amino and 
hydroxyl groups in forensic and clinical toxicology and used in published 
piperazine methods 144,145,221,222, not always successfully (Tsutsumi et al 221 
problems of reproducibility); N,O-bis(trimethylsilyl)trifluoro-acetamide (BSTFA) 
and heptafluorobutyric anhydride (HFBA).  HFBA produced the most acceptable 
spectra.  Only o/p-MeOPP had two derivative peaks due to derivatisation 
occurring at two locations, but these were only apparent at high concentrations.  
HFBA is expensive and it is preferable for routine methods to use as little as 
possible.  Dilution of HFBA with ethyl acetate was trialled but was found to be 
ineffective.  Sufficient reproducibility of derivatisation by addition of 50 µl of 
undiluted HFBA at 60 oC for 30 minutes was demonstrated by viewing the TIC of 
seven HFBA derivatised aliquots of each of the individual piperazines. 
6.4.6.2 Internal Standard 
Prior to instrumental analysis, internal standards are added at the earliest stage 
to correct for any analyte loss during preparation and analysis.16,38,74  For 
reliable compensation the I.S. must parallel the behaviour of the 
analytes.38,141,198  This also applies to LC-MS/MS analysis in which deuteron-
labelled standards can compensate for matrix effects.  
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Piperazine research methods have generally used ephedrine, therapeutic drugs, 
or other piperazines as internal standards.145,195,223,224  These are not suitable for 
casework methods, although some published casework methods make use of 
them.81,176,187,225  A deuterated piperazine would be preferred, however, these 
can be expensive and difficult to source.  These constraints may render the 
limited number which are available unsuitable for high volume routine 
laboratory analysis.  To overcome this, molecules of similar weight and 
chemistry such as deuterated amphetamine 144 or mescaline 226  have been used.  
These were part of methods with few targets, however, and if analytes are 
eluting over a considerable time, more than one internal standard is necessary.  
Deuterated versions of both BZP and mCPP were obtained for this study.  It 
would be ideal to have a deuterated version of each of the analytes but this was 
not possible.  The best alternative is to have at least two internal standards, one 
which elutes close to the first eluting analyte and another which elutes close to 
the last.  BZP-d8 and mCPP-d8 were quite well placed in the elution to represent 
most of the analytes as shown in Figure 12 for GC-MS method and Figure 13 for 
LC/MS/MS method. 
 
Figure 12:  Placement of internal standards in GC-MS method.  BZP-D8 used for mMPP, BZP, 
pFPP and TFMPP, mCPP-D8 used for pMPP, oMeOPP, pCPP, pMeOPP and mCPP. 
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Figure 13:  Placement of internal standards in LC-MS-MS method.  BZP-D8 used for pMeOPP, 
pFPP, mMPP, oMeOPP and BZP; mCPP-D8 used for pMPP and TFMPP. 
 
6.4.6.3 Injection Conditions 
Sample introduction is a critical step in gas chromatography.227  Splitless 
injection is conventionally held as the best method for analytes present in low 
concentration.  Programmed temperature vaporisation (PTV) is associated with 
large volume injection (LVI) for pre-column focusing, however, its use with 
regular injection volumes could perhaps improve chromatography, as it is 
intended to remove unwanted substances.  PTV could possibly remove excess 
derivatising reagent and solvent to provide larger on-column analyte 
concentration.228  Highly volatile compounds such as piperazines, however, could 
also be purged.  Some preliminary investigation of the potential for PTV for a 
piperazines method was carried out.  The signs were promising with improved 
peak shape and reduced background noise (using PFPA derivatives), however, 
the GC-MS instrument with the required injection port was not available for the 
entire period of the study.    
6.4.6.4 Oven Temperature 
Temperature programmes reported in the literature (Staack et al 188,195,219,229 
Kenyon 230 De Boer 145) and the FMS laboratory routine amphetamine method 
were compared.  Resolution of the piperazines was slightly better with the de 
Boer method and this was the focus of investigations to provide further 
Chapter 6  140 
 
 
 
improvement.  The final temperature programme used an initial temperature of 
90º for 1 min, rising to 180 ºC at 15 ºC/min, then to 240 ºC at 5 º/min and to 
300ºC at 20 ºC/min, which was held for 5 minutes.  The total run time was 27 
minutes. 
6.4.7 GC-MS Method 
1 µl of sample was injected to an Agilent Technologies GC System 7890A, fitted 
with a DB5 column (30 m length, 0.25 mm i.d., 0.25 µm film thickness).  Splitless 
isothermal injection at 250ºC was employed with a valve off time of 0.7 min.  
The carrier gas was helium at a constant flow rate of 1.2 ml/min.  
The GC was linked to an Agilent Technologies 5975C inert XLMSD with Triple-Axis 
Detection.  The ion source temperature was 200oC and the interface 
temperature 250oC.  EI+ mode was used with ionisation energy of 70 eV.  Mass 
spectrometry was in the selected ion monitoring mode, using the ions detailed in 
Table 6-5.  The relationship of these ions to the analyte structure is given in 
Appendix 4: generally the main fragment ions are formed by loss of functional 
groups from the benzene ring and splitting of the piperazine ring.  Peak areas 
were recorded with a ChemStation data system and translated for interpretation 
by the Mass Hunter Quantitative Analysis programme (both supplied by Agilent 
Technologies). 
  
Table 6-5:  Ions for SIM method 
 
Retention 
Index 
Quantifier Ion
m/z
Qualifier Ions 
m/z
1-(3-methylphenyl)piperazine mMPP 1632 372 175, 104
Benzylpiperazine-d8 BZP-d8 1736 380 289, 183
1-(2-methylphenyl)piperazine oMPP 1737 118 **
Benzylpiperazine BZP 1739 281 372, 175
1-(4-fluorophenyl)piperazine pFPP 1742 376 179, 123
Trifluoromethylphenylpiperazine TFMPP 1747 426 200, 229
1-(4-methylphenyl)piperazine pMPP 1804 372 175, 119
1-(2-methoxyphenyl)piperazine oMeOPP 1831 388 191, 120
1-(3-chlorophenyl)piperazine-d8 mCPP-d8 1974 400 203, 171
1-(3-chlorophenyl)piperazine mCPP 1976 392 195, 166
1-(4-methoxyphenyl)piperazine pMeOPP 1978 388 191, 120
1-(4-chlorophenyl)piperazine pCPP 2005 392 195, 166
HFBA Derivatised Analyte
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6.4.8 LC-MS/MS Method Development 
There were practical restrictions on the method development.  In order to 
facilitate maximum usage of the LC-MS/MS, a standard column and mobile phase 
had to be used.  The advantage of such restrictions, however, is that the 
resultant method would be readily incorporated to a busy casework laboratory. 
Each piperazine analyte was ‘characterised’ by direct infusion to the mass 
spectrometer of individual piperazine solutions prepared in 2 mM 50 % methanol 
0.1 % formic acid at a concentration of 1 µg/ml.  The fragmentor voltage was 
optimised to give maximum fragmentation of the precursor ion, and the collision 
energy was optimised for each product ion to give greatest abundance.  The ions 
observed and their relative intensities were recorded.  Each piperazine was then 
introduced to the mass spectrometer in mobile phase via the column to ensure 
the ion intensities recorded at infusion were correct.  The transition with the 
most intense signal was selected for quantification and the next most intense for 
confirmation as detailed in Table 6-6.  The relationships of these ions to the 
piperazine structures are detailed in Appendix 5: they all tended to follow the 
same pattern, with fragmentation of the piperazine ring. 
 
Precursor 
Ion m/z
Fragmentor 
Voltage
Prodcuct 
Ion m/z CE (V)
Prodcuct 
Ion m/z CE (V)
Trifluoromethylphenylpiperazine TFMPP 231.02 160 188.00 21 118.00 44
1-(3-chlorophenyl)piperazine-d8 mCPP-D8 205.00 150 158.00 20 123.00 28
1-(4-chlorophenyl)piperazine pCPP 197.02 135 154.05 18 119.10 25
1-(3-chlorophenyl)piperazine mCPP 197.00 150 153.97 18 118.00 37
1-(2-methoxyphenyl)piperazine oMeOPP 193.00 130 150.00 18 119.95 37
1-(4-methoxyphenyl)piperazine pMeOPP 193.00 135 150.00 17 176.00 15
Benzylpiperazine-d8 BZP-D8 185.10 120 91.00 22 65.00 50
1-(4-fluorophenyl)piperazine pFPP 181.00 145 138.00 18 91.00 30
Benzylpiperazine BZP 177.05 110 91.00 22 85.00 13
1-(3-methylphenyl)piperazine mMpp 177.00 130 134.00 14 160.00 12
1-(2-methylphenyl)piperazine oMPP 177.00 135 134.00 18 118.00 38
1-(4-methylphenyl)piperazine pMPP 177.00 135 134.00 18 118.00 40
Analyte
 
Table 6-6:  Piperazine analyte identification transitions for LC-MS/MS 
 
The analytes were then combined for injection to the LC-MS/MS with the mass 
spectrometer programmed to detect only the first transition for each analyte.  
The highest calibrator concentration 2 µg/ml of blood (4 µg/ml standard for 
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injection) was used to develop a gradient.  Due to the presence of isomers and 
the similarity of each analyte an elaborate gradient was necessary to achieve 
the best separation possible whilst maintaining acceptable peak shapes.  There 
is a long period (7 minutes) before any analytes elute, which is required to 
separate o/pMeOPP.  The stability of peak retention times was assessed to 
ensure enough time was allowed for the column to return to equilibrium at the 
start of the gradient (5% solution of 2 mM acetonitrile in methanol with 95% of 2 
mM acetonitrile in water).   
The second transition for each analyte was then added to the method and 
sensitivity evaluated with non-extracted standards, then with extracted low 
concentration standards.  Dwell time was optimised at 100 ms per step and 
injection volume at 20 µl.   
With the final method determined each analyte was run individually to assess 
interferences.  When each was injected individually there did not appear to be 
any problems of interference.  When combined, however, it was clear that the 
analytes which co-eluted with pFPP were causing interference as a high 
background noise and a large shoulder to the pFPP peak at high concentration.  
All ion transitions identified for pFPP at infusion were trialled but none were 
free of this noise.  Manual integration was necessary to remove the contribution 
from co-eluting analytes.   
When interference was first assessed an aged sample of BZP-d8 was used.  This 
produced a signal for both BZP-D8 and BZP.  Fresh BZP-D8 did not produce any 
signal for BZP.  BZP-D8 is expected to degrade to BZP.  It is, therefore, essential 
to monitor the zero calibrator for any BZP signal.  
6.4.9 LC-MS/MS Method 
A 20 µl aliquot of the extract was injected on a Gemini C18 (5µm 150 x 2.0 mm) 
column fitted with a Gemini C18 (4 x 2.0 mm) guard column maintained at 40ºC.  
The mobile phase consisted of 2 mM ammonium acetate in deionised water (A) 
and 2 mM ammonium acetate in methanol (B) with gradient programmed to give 
5 % A for 4 min, increasing to 30 % A between 4 and 5 min, held until 5.5 min 
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then increased to 70 % by 7 min and held for 0.25 min before increasing to 90 % 
A then reduced to 5 % A for 4.5 min (total run time of 16 min).  Flow rate was 
0.3 ml/min. 
An Agilent Technologies 6420 Triple Quadrupole mass spectrometer with ESI was 
used.  The mobile phase was introduced directly to the ion source without 
splitting.  Analysis was performed in positive ion mode with capillary voltage of 
4 KV, gas temperature 350oC and nitrogen flow 11 l/Min.  The mass spectrometer 
was operated in multiple reaction monitoring (MRM) mode with two transition 
ions, one for quantification and one for confirmation as shown in Table 6-6. 
6.4.10 Validation 
The GC-MS and LC-MS/MS methods were both subject to validation.  Calibration 
response function was assessed over a wide range but restricted to 5 to 2000 
ng/ml of blood for validation.  The peak area ratio of the analyte to an internal 
standard was calculated and plotted against concentration to produce seven 
calibration curves over five non-consecutive days.  A low (60 ng/ml), medium 
(1000 ng/ml) and high (2000 ng/ml) quality control (QC) sample was quantitated 
by each of the calibration curves.  On one of these days, 5 samples at each QC 
concentration were analysed to investigate precision and accuracy of the 
method.  Accuracy was measured by taking account of how different the 
measured value for the spiked blood was to the expected value.  Instances of 
outliers were removed.  Whilst it is desirable to have five values, three is 
acceptable as a minimum;231,232 there were never less than four.   A percentage 
ratio of the difference was reported.  Precision was measured as percentage 
coefficient of variation (CV %).  Repeatability was assessed between results from 
each of the five days.  Acceptability for both accuracy and precision was 
considered to be within 15% (20% at low concentrations). 
Originally LOD and LOQ were estimated by preparation of a special low level 
regression, around the expected range of LOD.  Calculation of the standard error 
of the regression line of x on y provided an estimate of the uncertainty in the 
regression arising from the background noise.  LOD was estimated to be 3 times 
this and LOQ ten times.  This method is only suitable for linear relationships and 
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could not be applied to the GC-MS method which produced quadratic responses 
for all analytes, even at low levels.  LOQ is defined as the value at which 
measurements have satisfactory precision (20%) and accuracy (±20%).  Thus LOD 
and LOQ were estimated through replicate analyses at various concentrations.  
This was also performed for the LC-MS/MS as the estimated values by low level 
regression were not satisfactory in practice.  
Matrix effects (Equation 6-1), recovery (Equation 6-2) and process efficiency 
(Equation 6-3) were calculated using three types of specially prepared standards 
at low, medium and high concentrations in whole blood (as described by 
Matuszewski et al 233).  The standards prepared were, A) non-extracted, B) 
extracted before spiking analytes into the extract, and C) analytes spiked in 
blood prior to extraction.  Five of each type at each concentration were 
analysed.  Only one I.S. was used, BZP-D8.  
  
Equation 6-1:  Calculation of Matrix effect, 85 to 115 % is desirable 
 
 
Equation 6-2: Calculation of Recovery, > 60 % desirable 
 
  
Equation 6-3: Calculation of process efficiency, a method with no errors = 100 % 
 
A study of short-term stability was performed to ensure the analytes remained 
stable over the analysis period.  Low, medium and high concentration spiked 
blood samples were prepared by adding 100 µg/ml mixed piperazine solution to 
50 ml volumetric flasks, adding a little water to dilute the methanol, then filling 
to the line with whole blood, as outlined in Table 6-7.  These were aliquoted and 
divided between the bench top (room temperature 22 ± 2 oC), fridge (4 ± 2 oC) 
and freezer (- 20 ± 2 oC) for storage.  Three aliquots of each concentration were 
extracted, derivatised and analysed immediately while a further 9 at each 
concentration were extracted and placed on the autosampler for three of each 
to be analysed after 24, 48, and 72 hours to assess stability of the derivatised 
Relative Process Efficiency (%) = C/A x 100 
Recovery (%) = C/B x 100 
Matrix Effect (%) = B/A x 100 
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analytes.  Three of each concentration from the bench-top and fridge were also 
analysed after 24, 48 and 72 hours.  Three of each concentration were left in the 
fridge and analysed after one week.  The freezer samples were analysed after 
each of three freeze/thaw cycles (3 at each concentration each time).  
Blood Concentration
Volume of 100 µg/ml 
standard added
60 ng/ml 30 µl
1000 ng/ml 500 µl
2000 ng/ml 1000 µl
 
Table 6-7:  Preparation of stability standards 
 
6.5 Results and Discussion 
6.5.1 GC-MS Validation 
6.5.1.1 Specificity 
The selectivity of the method was demonstrated by comparison of the 
chromatogram of blank blood with that of blank blood spiked with each of the 
piperazine analytes.  Initial full scan analysis verified that the reference 
standards were of sufficient purity for validation and that there were not 
significant impurities present that might interfere with the method.  The 
quantifier and qualifier ions had to be carefully selected, however, as combining 
piperazines in one method meant that they could interfere with the 
quantification of each other when they could not be fully resolved.  All of the 
ions in the spectra of each co-eluting piperazine were noted.  Ions shared by 
piperazines were only used if they had different retention times.  BZP and o-MPP 
could not be distinguished (for quantification or reliable identification) as it was 
not possible to select unique qualifier ions for o-MPP as there were no ions other 
than m/z 118 which were not shared.  As BZP is the more commonly 
encountered analyte o-MPP was omitted from the validation method as having it 
present in the piperazine mixed standard would have caused interference to the 
BZP response.  If a real case sample contained o-MPP and no BZP, this could be 
identified from full scan mass spectra by looking at retention index 1737 for the 
ions 372 (M+), 175, 146,132 and 118.  Quantification of o-MPP would require 
further validation.  If it was recognised that these analytes were often present in 
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combination, additional validation work could be performed to determine 
quantification parameters for the joint presence of BZP and o-MPP. 
6.5.1.2 Calibration Response Function 
All analytes gave quadratic rather than linear calibration curves but with 
acceptable correlations (R2 > 0.99).  Calibrations and average correlation 
coefficients are shown in Figure 14 to Figure 22.  There was no carry-over 
between runs at the highest calibrator concentration. 
 
Figure 14:  Calibration curve for p-FPP (mean R2 0.9994) 
 
 
Figure 15:  Calibration curve for BZP (mean R2 0.9993) 
 
 
Figure 16:  Calibration curve for m-MPP (mean R2 0.9958) 
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Figure 17:  Calibration curve for TFMPP (mean R2 0.9991) 
 
 
Figure 18:  Calibration curve for p-MPP (mean R2 0.9990) 
 
 
Figure 19:  Calibration curve for o-MeOPP (mean R2 0.9986) 
 
 
Figure 20:  Calibration curve for m-CPP (mean R2 0.9988) 
 
 
Figure 21:  Calibration curve for p-MeOPP (mean R2 0.9989) 
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Figure 22:  Calibration curve for p-CPP (mean R2 0.9990) 
 
6.5.1.3 Accuracy 
Measurements of accuracy (bias and precision) for each analyte at low, medium 
and high concentrations are given in Table 6-8.  These are within the acceptable 
limits for all analytes other than m-MPP (not shown).  Despite producing 
calibration curves which appeared to have good concentration/ response 
correlations, the relationships (response functions) were different each time and 
the response produced by QCs often equated to concentrations significantly 
different to those expected.  Thus m-MPP is suitable only for detection, and not 
quantification, by this method.  The measured bias are estimates only as only p-
CPP was measured with a certified reference standard. 
Concentration pCPP pMeOPP mCPP oMeOPP pMPP TFMPP BZP pFPP
Low Bias -18.5% 15.0% -12.4% -17.9% -11.2% 13.9% -2.0% 6.1%
Medium Bias 4.0% -0.8% 7.0% 3.1% -0.2% -9.3% 6.1% -3.3%
High Bias 3.4% -0.1% 4.7% 4.8% 5.7% -7.9% 7.7% -6.3%
Low Precision 9.8% 14.7% 2.1% 16.9% 6.4% 1.9% 3.0% 12.0%
Medium Precision 2.9% 13.3% 1.7% 3.6% 5.9% 11.9% 4.9% 8.8%
High Precision 2.2% 4.3% 2.3% 5.7% 3.7% 9.8% 3.9% 8.0%
Low Between-day-precision 17.0% 12.8% 10.6% 14.1% 10.9% 20.8% 10.1% 15.2%
Medium Between-day-precision 7.9% 9.9% 7.5% 10.5% 6.0% 6.2% 11.6% 10.8%
High Between-day-precision 4.6% 5.0% 4.8% 5.5% 5.2% 5.5% 5.5% 6.3%
 
Table 6-8:  GC-MS Accuracy at low, medium and high concentrations 
 
6.5.1.4 Limits of Detection and Quantification 
Limits of detection calculated by statistical means which take account of the 
standard error on ‘y’ (the response, and thus signal to noise) were all very much 
overestimates of the detection abilities of this method.  This is expected to be 
as a result of the non-linear calibrations.  All analytes were reliably detected 
(acceptable quantifier to qualifier ion ratios) at the lowest calibration standard.  
Thus the limit of detection was set at this concentration, 5 ng/ml of blood, for 
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all analytes.  It was necessary to determine the limit of quantification 
empirically using four replicates at various concentrations to find the 
concentration at which bias and precision were within acceptable limits (20 %).  
The values estimated for limit of quantification are detailed in Table 6-9. 
 pFPP BZP TFMPP pMPP oMeOPP mCPP pMeOPP pCPP
LLOQ ng/ml 20 30 30 30 30 20 30 20  
Table 6-9:  Limits of quantification for piperazines 
 
6.5.2 LC-MS/MS Validation 
6.5.2.1 Specificity 
The specificity of the method was demonstrated by comparison of the 
chromatogram of blank blood with that of blank blood spiked with each of the 
piperazine analytes.  It was not possible to resolve p-CPP and m-CPP.  The 
method could detect and quantify either of these if present in isolation (using 
the parameters outlined in Table 6-6) but as they were both included in the 
calibration solutions they had to be omitted from the LC-MS/MS method 
validation. 
All of the isomers of MPP were well resolved.  Again, due to use of the same 
validation standards for both GC-MS and LC-MS/MS, o-MPP was omitted from the 
validation.  Inclusion would have caused interference in the GC-MS method 
validation.  o-MPP could be included as an analyte of the LC-MS/MS piperazines 
method with further validation. 
LC-MS/MS performance could have been improved by optimisation of the 
chromatographic method.  It would have been desirable to achieve greater 
separation of the analytes in order to include both m- and p-CPP, and to remove 
some of the increased background around p-FPP.  It is possible that a different 
column and mobile phase could have achieved this. 
An SCX (strong cation exchange) column allows for an organic rich mobile phase 
which is advantageous in achieving higher sensitivity in ESI-MS,221,234 and is 
beneficial in improving separation of amines.30,221,234,235  Such columns, however, 
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are expensive and cannot be applied to many methods across the laboratory.  C18 
columns are applicable to many methods and are, therefore, more economical 
for busy laboratories.  There are nine groups that have published LC-MS/MS 
methods which have included piperazines.  Only two have used an SCX 
column,221,222,236 three used polar RP columns,37,218,237  and the majority (four) C18 
columns.203,238-240  These published methods only incorporated up to three 
different piperazines which made separation much easier.  Separation on a C18 
column can be assisted by addition of an acid to the mobile phase.30,221,241  
Reconstituting the piperazine extracts with an acidic mobile phase would mean 
that they were ionised prior to being injected on the LC-MS/MS and could 
increase efficiency of ionisation, although non-volatile acids can cause problems 
for mass spectrometric detection and, where possible, should be avoided.28 
6.5.2.2 Calibration Response Function 
The mean correlation coefficients (R2) of the calibration curves prepared from 
spiked blood had acceptable linearity in the range 5 to 2000 ng/ml of blood for 
all the piperazine analytes (> 0.99).  The best relationship, however, was as a 
quadratic function as demonstrated in Figure 23 to Figure 29 with mean 
correlation coefficients provided.  There was no carry-over at the highest 
calibrator concentration (although carry-over can be unpredictable with LC-
MS/MS). 
 
Figure 23:  Calibration curve for p-MeOPP (mean R2 0.9962) 
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Figure 24:  Calibration curve for m-MPP mean (R2 0.9971) 
 
 
Figure 25:  Calibration curve for p-FPP (mean R2 0.9970) 
 
 
Figure 26:  Calibration curve for BZP (mean R2 0.9972) 
 
 
Figure 27:  Calibration curve for o-MeOPP (mean R2 0.9972) 
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Figure 28:  Calibration curve for p-MPP (mean R2 0.9972) 
 
 
Figure 29:  Calibration curve for TFMPP (mean R2 0.9976) 
 
6.5.2.3 Accuracy 
Measurements of accuracy (bias and precision) for each analyte at low, medium 
and high concentrations are given in Table 6-10. These are within the acceptable 
limits for all analytes.  m-MPP could not be quantified above 1000 ng/ml of 
blood as, although there appeared to be good correlation, the calculated 
concentrations were too far from the true values.   
It was unusual that for both the GC-MS and LC-MS/MS methods m-MPP did not 
have a reliable response:concentration relationship.  It is difficult to determine 
why this might have occurred.  One possibility is that the calibrator and QC 
samples were not prepared to the correct concentrations.  MPP is very 
hydroscopic.  The bulk powder used to prepare samples had been opened for 
some time (years) and it may have had a high water content affecting the final 
concentrations of the prepared samples.  The powder should be thoroughly dried 
to a constant weight, or freshly obtained, and the accuracy experiment repeated 
to determine whether this might be the cause. 
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Concentration pMeOPP mMpp pFPP BZP oMeOPP pMPP TFMPP
Low Bias -5.4% -5.9% -7.7% 11.9% 7.0% -7.7% -9.6%
Medium Bias -0.3% -2.1% -10.3% -7.0% 4.1% -6.2% -9.6%
High Bias -7.0% 3.2% -3.4% 2.6% 2.8% 1.6%
Low Precision 18.4% 10.9% 3.7% 12.9% 15.7% 6.3% 7.9%
Medium Precision 10.2% 9.2% 7.5% 7.1% 7.7% 4.4% 6.0%
High Precision 9.0% 7.0% 4.4% 13.7% 6.4% 3.6%
Low Between-day-precision 7.0% 6.7% 8.9% 11.2% 2.0% 12.7% 12.4%
Medium Between-day-precision 4.3% 9.8% 13.8% 8.8% 11.1% 8.8% 8.8%
High Between-day-precision 2.8% 3.4% 6.4% 3.6% 3.3% 4.0%
 
Table 6-10:  LC-MS/MS Accuracy at low, medium and high concentrations 
 
Although accuracy and precision were within acceptable limits there really 
should be more internal standards for an LC-MS/MS method.   There should be a 
co-eluting internal standard for every analyte (or at least within short “retention 
windows”).44  This would make the method more robust, particularly with 
respect to any matrix effects not yet detected but which may occur in real 
samples (and also to signal drift which is a possibility with LC-MS/MS methods 
242).  It would also help to identify any invalid results, for example, if an error in 
a run caused an analyte which is present not to be detected, it would also be 
expected that the corresponding internal standard would not be detected and 
signal that an error had occurred. 
6.5.2.4 Limits of Detection/Quantification 
Statistically estimated LLOD and LLOQ (Table 6-11) were over-estimates for all 
the piperazine analytes.  The limits for p-FPP were particularly high due to the 
presence of other analytes causing high background interference.  If p-FPP were 
present in a sample without these other piperazines it is expected that the 
detection levels would be reduced.  p-MPP had a higher estimated LLOQ as, out 
of all the piperazines, this gave the weakest signal.  It was determined by 
experimentation that at 50 ng/ml of blood, acceptable limits of bias and 
precision for LLOQ were achieved for all analytes other than p-MeOPP and p-MPP 
which had LLOQs of 60 ng/ml blood.  As all analytes could be readily detected at 
the lowest calibration standard of 5 ng/ml of blood this was determined to be 
the LLOD of all the analytes. 
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Table 6-11:  Statistically-calculated LLOD and LLOQ for LC-MS/MS method 
 
The values of LLOD/LLOQ by this method are slightly better than those attained 
by Moreno et al and Vorce et al (100 ng/ml) although their methods were 
intended for urine where analytes are in greater concentration.37,223  Other 
methods have achieved lower limits,81,239,240 but with fewer analytes and/or a 
smaller concentration range.  In general terms the volume of specimen 
extracted and the volume of the extract injected to the column will influence 
the detection levels.  The volume on-column was investigated for published 
methods and lowest levels typically ranged from 0.17 ng 236 to 1 ng on-
column.37,239  LLOD of 5 ng/ml in the validated method was equivalent to 0.2 ng 
on-column.  This is at the lower end of the range of the published methods, thus 
the LLOD/LLOQ could be reduced by altering the sample volume.  A full 1 ml was 
extracted but only around 200 µl of this was given to the LC-MS/MS method.   
6.5.3 Method Performance  
The results for extraction recovery, matrix effects (ME) and process efficiency 
(PE) by GC/MS are presented in Table 6-12 and by the LC-MS/MS method in Table 
6-13.   
mMPP mCPP pMEOPP pCPP oMeOPP pMPP pFPP TFMPP BZP
Recovery
Low 105.0% 123.6% 94.7% 140.6% 117.4% 141.4% 119.4% 135.5% 105.0%
Medium 102.5% 98.8% 100.7% 108.2% 93.6% 106.4% 110.0% 112.8% 102.5%
High 101.4% 118.3% 119.4% 87.8% 84.4% 78.6% 92.7% 83.7% 103.7%
Matrix Effects
Low 96.0% 55.6% 19.0% 98.5% 66.5% 37.3% 70.7% 110.6% 96.0%
Medium 102.7% 65.0% 52.8% 69.9% 73.2% 72.3% 90.2% 105.1% 102.7%
High 117.6% 82.9% 80.4% 87.0% 91.6% 98.8% 136.1% 140.7% 94.6%
Process Efficiency
Low 100.8% 72.8% 18.0% 138.5% 78.1% 52.7% 84.5% 149.9% 100.8%
Medium 105.2% 64.2% 53.2% 75.6% 68.5% 76.9% 99.2% 118.5% 105.2%
High 119.3% 98.8% 96.0% 76.4% 77.3% 77.6% 126.1% 117.8% 98.1%
 
Table 6-12:  Recovery, matrix effects and process efficiency by GC-MS method. 
 
(ng/ml) mMPP pMeOPP pFPP oMeOPP BZP pMPP TFMPP
LLOQ 18 27 37 22 12 51 32
LOD 6 9 12 7 4 17 10
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  BZP pMeOPP oMeOPP pFPP pMPP TFMPP 
              
Recovery        
low 72.2% 70.3% 106.6% 73.1% 69.7% 58.3% 
medium 90.7% 74.8% 79.4% 77.1% 72.0% 89.5% 
high 77.7% 106.5% 127.5% 80.7% 93.9% 70.1% 
       
Matrix Effects       
low 88.8% 105.0% 112.5% 79.6% 109.5% 119.9% 
medium 95.0% 116.2% 107.7% 102.5% 107.1% 78.9% 
high 116.1% 112.1% 98.5% 108.4% 115.1% 115.0% 
       
Process Efficiency       
low 64.1% 73.9% 120.0% 58.2% 76.3% 69.9% 
medium 86.2% 87.0% 109.8% 79.1% 77.1% 70.6% 
high 90.2% 119.4% 125.7% 108.5% 108.1% 80.6% 
              
Table 6-13:  Recovery, matrix effects and process efficiency by LC-MS/MS method. 
 
6.5.3.1 Extraction Recovery (ER) 
Recovery by both methods was >60 % and, therefore, acceptable.  It was 
notable, however, that although the same extracts were used for both methods 
they produced different values of recovery.  The LC-MS/MS values were typically 
less than the GC-MS values which were often in excess of 100 %.  As 
derivatisation and evaporation were necessary for GC-MS recovery cannot be 
reliably determined.  Evaporation would also have influenced the LC-MS/MS 
results, although without derivatisation, perhaps to a lesser extent.  The high 
values could also be a result of the co-elution by the GC-MS method, although 
ions were carefully selected.  Acceptable bias is indicative of adequate recovery 
for the GC-MS method. 
6.5.3.2 Apparent Matrix Effects (ME) 
The majority of the LC-MS/MS samples were within the desired range of 85 to 
115 % indicating no significant ion enhancement or suppression.  Matrix effects 
are not usually present with GC-MS methods, although many of the GC-MS values 
were outside of the desired range indicating the presences of a (generally 
suppressing) apparent matrix effect.  This could be the result of co-eluting 
siloxane peaks coming from the GC-column stationary phase suppressing 
ionisation but is likely to arise from discrepancies between extracted and 
unextracted standards caused by analyte loss, derivatisation problems, etc.  A 
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greater concentration of analytes was detected in the unextracted standard than 
the extracted standard.  The extracted standard required a greater degree of 
evaporation (extract volume was 3 ml of elution solvent compared with 50 µl of 
methanol containing the unextracted standard) which could be responsible for 
this observation.  Matrix effect is not an important parameter for GC-MS 
validation but if it was necessary to investigate further it could be better 
addressed through comparison of the concentrations obtained from a spiked 
blood extract with that of a spiked water extract.  Alternatively, matrix effect 
could be examined with the standard spiked into the blank extract after it had 
been evaporated, then the volume would be 50 µL of methanol, the same as the 
unextracted standard, and require the same degree of evaporation.  GC-MS 
recoveries were observed to be greater than 100 %.  This is possibly due to the 
lack of derivatised standards, however, it could also be due to both sample 
types compared having the same volume of solvent (3 ml). 
Five analytes were generally unaffected by apparent ME during GC-MS analysis; 
m-MPP, p-CPP, TFMPP, p-FPP and BZP.  p-MPP and o-MeOPP had problems with 
apparent ME at low concentrations.  m-CPP and, in particular, p-MeOPP require 
attention.   
6.5.3.3 Process Efficiency (PE) 
Process efficiencies for both methods were, on the whole, reasonably good.  The 
LC-MS/MS method appeared to have been better for p-MeOPP, o-MeOPP and p-
MPP, and GC-MS/MS better for m-MPP, p-FPP, TFMPP and BZP.  (p/m-CPP could 
not be compared.)  Where process efficiency is low (p-MeOPP, p- and m-CPP in 
GC-MS method) it is, again, possible that this was a factor of loss during 
evaporation where a greater concentration of analyte was detected in a non-
extracted sample than a spiked blood extraction, which would have been subject 
to drying.  In order to have a true determination of process efficiency for GC-MS 
access to derivatised standards of the piperazine analytes would be required, as 
the non-extracted analytes did not represent 100% efficiency as intended. 
It is also possible that the internal standard was unsuitable for the analytes with 
low process efficiency and did not compensate well for losses during 
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evaporation.  It is, therefore, possible that the true process efficiency for these 
analytes within the validated GC-MS method is improved due to the more 
appropriate internal standard.  These measures of method performance are 
generally not required for GC-MS validation, provided accuracy, precision and 
LLOD/LLOQ are suitable, ER, ME and PE are of little significance in a GC-MS 
method validation.57 
With LC-MS/MS methods which do not require evaporation ER, ME and PE are 
generally measured without use of an internal standard as the internal standard 
could compensate for errors intended to be measured.  In order to account for 
errors occurring at the auto-sampler, and other instrument variables (pressure, 
flow, etc), however, an internal standard is necessary.  Thus, ideally, internal 
standard is added immediately prior to injection.  This was not possible for the 
validation of these piperazine methods.  The latest opportunity at which the 
internal standard could be added was after extraction, prior to evaporation. 
6.5.4 Stability 
The piperazine analytes appear to have short-term stability under all of the 
conditions tested.  Some variation in the measurements is to be expected in 
accordance with the trueness of the method (precision and accuracy).  Samples 
subjected to three freeze/thaw cycles and those stored in the fridge for up to 
one week were found to be stable with no significant deviations (greater than 
15%) from the peak area ratios of the freshly prepared and extracted standards, 
Table 6-14.  As samples stored in the fridge were stable, these were used to 
assess the stability of ‘in-process’, autosampler and bench-top samples, Table 
6-15.  There were no apparent short term stability problems. 
 
Table 6-14:  Percentage deviation of peak height area ratios for fridge and freezer stored 
samples to freshly prepared and extracted samples. 
Concentration Storage pFPP BZP pMPP TFMPP oMeOPP mCPP pMeOPP pCPP
Low Fridge 1 week 8.1% 4.4% -1.9% 6.6% -12.9% 0.9% -4.8% -3.5%
Freeze/thaw x3 16.8% 1.8% 5.4% -13.8% -10.7% 7.3% 2.5% -9.8%
Med Fridge 1 week -11.0% -9.4% 11.6% -12.7% 11.1% 11.9% 8.6% 14.4%
Freeze/thaw x3 -7.1% -7.2% -12.5% 3.0% -13.4% 7.0% 5.2% -3.2%
High Fridge 1 week 3.7% -7.5% 12.7% -3.3% 10.6% 13.4% 14.7% 12.3%
Freeze/thaw x3 -13.0% -14.6% -12.7% -9.0% -8.9% -8.5% -5.7% -8.2%
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Table 6-15:  Percentage deviation of peak height area ratios for in-process autosampler and 
bench-top samples compared to refrigerated samples. 
 
Johnson and Botch-Jones,224 demonstrated that BZP and TFMPP could remain 
stable in whole blood for at least fourteen days in the fridge (4oC).  At room 
temperature, however, Botch-Jones found a noticeable decrease in BZP 
concentration after 4 days (although it was stable for up to 14 days), and after 
14 days TFMPP concentration had reduced by 35%.  Thus TFMPP is not expected 
to be stable in blood beyond the 72 hours observed in the current study.  Blood 
thought to contain piperazines should be placed in the freezer as soon as 
possible or could be stored in the fridge at 4 oC for at least 1 week. 
6.5.5 Concentration Range 
There are few publications which detail methods used for detection of 
piperazines in forensic toxicology samples (listed in Table 6-16).  The majority of 
these are LC-MS/MS urine screen methods.  None contain more than four 
piperazines (typically BZP, TFMPP, m-CPP and p-MeOPP).  This is understandable 
with screening methods which incorporate many drugs and have to select those 
which are perceived to be most relevant.  It is, however, strange that two 
screening methods have omitted BZP, generally considered the most relevant 
and prevalent of the group.201,240  It would be advantageous for a dedicated 
piperazines method to detect more than four analytes, and it is disappointing 
that two methods only detected BZP which is rarely expected to be found in 
isolation; BZP and TFMPP would appear to be a minimum requirement.  The 
methods developed and validated here are superior as they include more 
analytes. 
 
Concentration Storage pFPP BZP pMPP TFMPP oMeOPP mCPP pMeOPP pCPP
autosampler LC-MS/MS 72 hours 5.3% 1.5% 13.7% 9.7% -0.1% 12.1%
Autosampler GC-MS 72 hours 18.4% 9.2% 5.1% 18.6% 7.6% 20.9% -10.8% 6.1%
Bench 72 hours 7.5% 0.6% 8.1% 4.5% -1.6% 5.1% 16.6% 5.8%
autosampler LC-MS/MS 72 hours 13.2% 0.1% 2.5% 13.5% 4.1% 13.9%
Autosampler GC-MS 72 hours -10.5% -12.7% -0.8% 6.3% 6.8% 3.9% 3.7% 8.7%
Bench 72 hours -6.9% -6.2% 7.1% -1.5% 11.7% 13.0% 11.3% 12.7%
autosampler LC-MS/MS 72 hours -12.9% -9.0% 5.1% 2.5% 13.6% -9.5%
Autosampler GC-MS 72 hours -1.6% 1.3% 14.7% -10.9% 14.4% 10.0% -6.7% 4.2%
Bench 72 hours 12.9% 10.5% 8.4% 13.6% 13.0% 12.5% 12.0% 11.4%
High
Medium
Low
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Method Matrix Piperazines Relationship Weighting Calibration Range LLOD LLOQ
LC-MS/MS Screening
Swortwood et al Designer drugs screen serum BZP Linear 1/x 10 - 250 ng/ml 10 - 100 pg/ml 10 ng/ml
m CPP Linear 1/x 10 - 250 ng/ml 10 - 100 pg/ml 10 ng/ml
TFMPP Linear 1/x 10 - 250 ng/ml 10 - 100 pg/ml 10 ng/ml
Wolhfarth et al serum BZP 5 ng/ml
MeOPP 2.5 ng/ml
m CPP 1 ng/ml
TFMPP 5 ng/ml
Montesano et al urine FPP Linear  LOQ - 1000 ng/ml 2 ng/ml 6 ng/ml
MeOPP Linear  LOQ - 1000 ng/ml 0.3 - 1 ng/ml 1 - 3 ng/ml
p CPP Linear  LOQ - 1000 ng/ml 2 ng/ml 6 ng/ml
TFMPP Linear  LOQ - 1000 ng/ml 0.2 ng/ml 0.6 ng/ml
Pichini et al Hallucinogenic designer drugs screen urine m CPP Linear  LOQ - 4000 ng/ml 16 ng/ml 53 ng/ml
Nordgren et al Novel substances screen urine BZP 8.8 ng/ml
Strano-Rossi et al Desinger drugs screen Oral fluid BZP quadratic 2 - 1000 ng/ml 2ng/ml
GC/MS Screen
Peters et al plasma BZP Linear 1/x2 5 - 1000 ng/ml 5 ng/ml
TFMPP Linear 1/x2 5 - 1000 ng/ml 5 ng/ml
m CPP Linear 1/x2 5 - 1000 ng/ml 5 ng/ml
Ishida et al Drugs of abuse screen urine BZP Linear 100 - 5000 ng/ml
TFMPP Linear 50 - 5000 ng/ml
m CPP Linear 50 - 5000 ng/ml
p MeOPP Linear 50 - 5000 ng/ml
LC-MS/MS Confirmation
Elliot and Smith Piperazines Blood BZP Linear  312 to 10000 ng/ml 312 ng/ml 500 ng/ml
TFMPP Linear  31 -10000 ng/ml 20 ng/ml 31 ng/ml
Moreno et al Piperazines (HPLC-DAD) urine BZP Linear  1/x2 100 - 5000 ng/ml 100 ng/ml
TFMPP Linear  1/x 100 - 5000 ng/ml 100 ng/ml
m CPP Linear  1/y 100 - 5000 ng/ml 100 ng/ml
p MeOPP Linear  1/x2 100 - 5000 ng/ml 100 ng/ml
Vorce et al Piperazines urine BZP 100 - 5000 ng/ml 100 ng/ml 100 ng/ml
TFMPP 100 - 10000 ng/ml 100 ng/ml 100 ng/ml
GC/MS Confirmation
Dickson et al Piperazines urine BZP Linear 25 - 2000 ng/ml
TFMPP Linear 25 - 2000 ng/ml
m CPP Linear 25 - 2000 ng/ml
Wikstrom et al Benzylpiperazine Blood BZP Linear 20 - 2000 ng/ml
Hair methods
Bassindale and Berezowski Piperazines (LC-MS/MS) Hair BZP Linear
Barroso et al Piperazines (GC-MS) Hair TFMPP Linear 1/x2 0.05 - 4 ng/mg 0.05 ng/mg
mCPP Linear 1/x2 0.05 - 4 ng/mg 0.05 ng/mg
p MeOPP Linear 1/x 0.05 - 4 ng/mg 0.05 ng/mg
Designer amphetamines, tryptamines 
and piperazines screen
Aphetamines and piperazines screen
Amphetamines and piperazines 
screen
 
Table 6-16:  Published forensic toxicology piperazine methods 
 
The best response relationship was quadratic for both the GC-MS and LC-MS/MS 
methods.  While in some instances, it can be possible to overcome a quadratic 
relationship by weighted regression, this was not possible for these methods 
(although only one published method reports a quadratic relationship, 238 
calibration model is likely to be instrument dependant).  It is acknowledged in 
the United Kingdom and Ireland Association of Forensic Toxicologists Forensic 
toxicology laboratory guidelines (2010),19 however, that “some assays are 
inherently non-linear and that the use of quadratic or other mathematical 
models may be necessary”.  It is quite common for LC-MS/MS methods to 
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produce quadratic regressions.243  The calibrations were reproducible, with 
sufficient accuracy and the fact that they are not a linear relationship does not, 
therefore, prevent their application to casework, although careful choice of 
calibrators is necessary, including LLOQ and ULOQ in every run.243 
The lack of controlled experimentation related to the toxicity of the piperazines 
made it difficult to assess relevant concentration range.  There was some 
information available for the more common piperazines.  For example, subjects 
were administered ‘recommended’ doses (from packaging instructions) of BZP 
dihydrochloride and TFMPP dihydrochloride and average peak blood 
concentrations were 589 ng/ml and 41 ng/ml respectively.180  Such controlled 
administration is expected to underestimate peak concentrations found in 
regular users who may consume up to five times as much.189  It is better to have 
the calibration range extend slightly higher, particularly as specimen volume 
may not permit a second, diluted analysis, as occurred with the method 
developed and applied by Swortwood et al which had an upper limit for BZP of 
1000 ng/ml.239  It is not expected that there would be any problem with 
extending the calibration range for either the GC-MS or LC-MS/MS methods.  
During pre-validation both were assessed with a calibration range up to 5 µg/ml.  
A good relationship existed for both although they were quadratic. 
It is also true, however that much lower concentrations will be encountered as 
the result of metabolism or ingestion of a piperazine as the adulterant of 
another drug, where it would be in a much smaller dose.  More realistic 
expectations of concentrations can be gathered from casework analysis where 
clinical BZP concentrations have ranged from 20 to 1,200 ng/ml 144,184 and post 
mortem BZP and TFMPP concentrations ranged from 390 to 1,700 ng/ml, 176,244 
and 50 to 150 ng/mL.176  These post mortem concentrations do not represent 
fatal piperazine levels as the deaths were not attributed to piperazines, other 
drugs were present. 
These figures suggest that the GC-MS validated calibration range is ideal for BZP 
as, whilst the LLOQ does not extend to the lower range observed, the majority 
of samples are expected to fall within the centre of the range, where there is 
less uncertainty associated with the result.  There is only one published GC-MS 
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method for BZP in blood and this has a very similar calibration range.144  The 
validated calibration range for TFMPP is suitable, although it would be 
preferable to extend a little lower (current LLOQ 30 ng/ml).  Many specimens 
may produce results in the range of increased uncertainty.  The highest 
concentration observed and reported in the literature is a relatively low 
concentration (150 ng/ml 176), which if it were measured by this validated 
method, accuracy and bias would be expected to be greater than 15 %.  There 
are no comparable GC-MS methods for the detection of TFMPP in blood, although 
Peters et al have achieved a better calibration range with plasma, LLOQ 5 
ng/ml, but with only three analytes.81  The validated method favours a bigger 
picture of identifying what was present in the blood with limited quantification 
in preference to targeting only a few analytes and quantifying to low 
concentrations.  It is possible that PTV could improve LLOD/LLOQ for piperazines 
present in lower concentrations such as TFMPP.   
The LLOQ for LC-MS/MS is a little too high for TFMPP, however, the method is 
still useful for detection of lower concentration samples as the LLOD was 
sufficient.  There is only one published LC-MS/MS method for piperazines in 
blood, by Elliot and Smith.176  This method achieved an LLOQ for BZP of 500 
ng/ml, which is perhaps a little too high, although allows for an extended upper 
limit of quantification.  Elliot and Smith’s calibration range for TFMPP, however, 
was more suitable for application to casework samples than the method 
developed and validated in this study as it had a lower LLOQ of 31 ng/ml.  Again 
it would appear that the calibration ranges could be more readily tailored to the 
analytes as these were the only two included in the method.  Swortwood et al 
also have a more appropriate TFMPP calibration range for their serum method, 
however, in this instance BZP is compromised as the calibration range for this 
analyte is much too low.239  As previously explained, the calibration range for 
TFMPP could be improved by loading more analyte on-column by extracting a 
larger sample volume or using a larger injection volume.  The injection volume, 
however, was optimised to give the best result for the combination of analytes 
present. 
With fewer analytes, method performance parameters such as LLOD/LLOQ are 
expected to improve.  With GC-MS some of the most abundant analyte ions were 
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shared with other substances which co-eluted and, therefore, could not be used.  
With LC-MS/MS fewer transitions would increase sensitivity.  The common 
practice of consuming piperazines as blends, however, directs that a piperazine 
method should contain as many piperazines as possible.  It would be undesirable 
to remove any of the analytes included in the method to increase sensitivity.  If 
use in routine casework demonstrated that the calibration performance required 
improvement at the lower end (or more analytes were required to be included) 
it might be necessary to split the target analytes and have two runs.  One run 
could be for more abundant analytes such as BZP and another run for those 
present at lower concentrations, such as TFMPP (with greater sample and 
injection volume), although this would require more time and expense.  Use of 
the current LC-MS/MS method as a screen to determine what is present prior to 
quantification by a more developed method could be a more economical 
solution. 
6.5.6 Specificity 
At least eight different sources of blank blood were used across pre-validation 
and validation (with and without internal standards).  No interferences from 
blood were observed for any of the analytes.  Spiked blood, however, is not an 
accurate representation of blood taken from an individual who has used the 
piperazine drugs.  For example there are no metabolites (or other drugs) present 
which could potentially cause interference.  BZP metabolites are expected to be 
present at very low concentrations and should not be a significant problem.  
TFMPP metabolite 4-OH-TFMPP, however, could be almost as concentrated in 
blood as the parent drug TFMPP and it would be sensible to characterise this 
analyte.  As it is not present if TFMPP is co-ingested with a competing substance, 
it should not be included in the detection method, however, simply assessed for 
potential to interfere.  The unavailability of piperazine metabolite standards 
prevented this assessment.  It is not expected to be a problem for the LC-MS/MS 
method which was more specific than the GC-MS method in which many 
substances co-eluted and shared similar fragmentation patterns.  When 
metabolites become available they should be characterised and added to the 
method to allow information gathering from casework samples to aid 
interpretation (by indicating the degree of metabolism). 
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DBZP was not included in the validated method but was characterised to ensure 
it would not affect the quantification of any of the piperazines of interest, as it 
could be present in a specimen as an impurity found with BZP.  This analyte 
elutes much later than the others in both the GC-MS and LC-MS/MS methods. 
Specificity is complicated for piperazines as TFMPP, BZP, and most often, m-CPP 
and o-MeOPP have all been detected as metabolites of therapeutic drugs (usually 
antidepressants).29,145,211,217-220,245-247  In these circumstances detection of the 
parent antidepressant drugs and their other metabolites enables 
differentiation.217  It would, therefore, be prudent to check for other drugs (e.g. 
antidepressants, minor tranquilisers) in samples presenting only one piperazine 
and no other drugs of abuse.  Consumption of a piperazine can only be 
concluded upon demonstration of the absence of antidepressant drugs.145 
In order to complete the specificity study it is necessary to test the method with 
post-mortem blood due to the possibility of there being putrefaction bases which 
could interfere with the analysis of stimulants.90  This was not possible as in 
Scotland post mortem specimens cannot be used for research purposes.  When 
the method is applied to casework this issue can be monitored and the range of 
blood samples tested will increase confidence in the specificity of the methods.  
Validation will not be fully complete until the method has been applied to real 
samples. 
6.6 Discussion of Further Work 
Knowledge of how piperazines are used, and previous testing of amphetamine-
positive specimens,226,248 indicates that all suspected (and confirmed) 
amphetamine cases should be tested for the presence of piperazines.  It would 
be desirable to retrospectively apply the validated methods to casework samples 
(having confirmed LLOD/LLOQ) to identify whether any piperazines had been 
present.  Unfortunately this was not possible as permission has yet to be granted 
by the Procurator Fiscal.  The methods could, however, be applied to any new 
cases received into the laboratory (following some further validation to ensure 
the methods transfer to the routine laboratory instruments).   
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Addition of another round of tests to routine testing does of course incur greater 
expense.  The popularity of these drugs, however, demonstrates that this is 
essential.  In order to keep costs to a minimum it is possible that the LC-MS/MS 
method could be used as a screening method (generally piperazines are not 
detected by immunoassay).  This would require using a small amount of the 
extract.  With no requirement to perform an independent extraction and 
derivatisation, it is a simple additional step in an amphetamines method to 
incorporate a relatively large range of piperazines into routine practice.  The 
GC-MS method would be required for any confirmation, however, due to the lack 
of internal standards relatively high LLOQs for LC-MS/MS analysis of some 
analytes.  Re-extraction and derivatisation would be time consuming and 
expensive, however, worthwhile as the screen would already have demonstrated 
the presence of a piperazine. 
Whilst the sensitivity and process efficiencies achieved by the GC-MS method 
appear, at the moment, to be satisfactory, gathering of case data may suggest 
that greater sensitivity was required for some of the piperazines and there 
would be two means by which this could be explored.  One would be to try 
reducing analyte loss through evaporation by addition of an acid “keeper” prior 
to evaporation as used for amphetamines.12,216,249  The analytes are retained by 
forming the corresponding (non-volatile) salts.  Addition of methanolic 
hydrochloric acid is recommended 12,215 but acetic 249 and tartaric 216 acids have 
also been effective.  The advantage may be outweighed however by the 
expectation that the salts will build-up on the GC inlet or column, reducing 
efficiency and increasing the frequency with which instrument maintenance is 
required.  A second, perhaps more promising, option is to ensure that excess 
HFBA and derivatisation by-product heptafluorobutyric acid, which can result in 
high background and degradation of the column, are removed completely.  It is 
impossible to do this by evaporation without some loss of derivatives.81  It is 
recommended for derivatives to be extracted into hexane and excess HFBA 
removed by phosphate washing.  This could be investigated, however, at the 
moment there is no apparent need and unnecessary processing should be 
avoided to maintain reproducibility and accuracy of results. 
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Upon application of the method to casework, information on the analytes 
present and their concentrations should be collated.  It would be beneficial to 
share this information (perhaps through TIAFT, UKIAFT or the Scottish Poisons 
Information Bureau database TOXBASE).  There are systems in place to notify the 
forensic community what new substances have been encountered but what is 
lacking is data to allow interpretation.  In a UK based PTS respondents cited the 
reason for not performing a BZP analysis was that they would be unable to 
interpret the results (this is detailed in Chapter 4).  It would seem that it is 
necessary to develop the methods and perform testing before this information 
can become available.  Even if information is not shared, routinely performing 
piperazines testing and monitoring results would provide an internal database to 
aid interpretation. 
6.7 Conclusion 
The validated methods are recommended to be applied to all routine 
amphetamine casework; the LC-MS/MS method as a simple screen and the GC-MS 
method for confirmation and quantification.  Results from such tests should be 
collated in an interpretation database.   
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Chapter 7:  Further Validation of The (Preliminary) 
Field Impairment Test 
  
7.1 Introduction 
7.1.1 Driving Under the Influence of Drugs (DUID)   
Psychoactive substances (most illicit and some therapeutic drugs) affect the 
central nervous system to cause impairment of attention and information 
processing: skills required to drive safely.250  The ‘type’ of impairment 
experienced differs across various drug classifications, for example, stimulants 
increase confidence and risk taking while depressants slow responses.  Numerous 
studies have been conducted to try to establish the nature and extent of 
impairment in relation to specific drug classifications.  This extensive literature 
has been reviewed elsewhere.250-263  Conclusions can be inconsistent.  Much of 
the ambiguity arises from the use of different investigative methods.  Each of 
the methods applied to studies of drug impairment have had unavoidable faults.  
For example in experimental studies outcomes are influenced by factors such as 
sample size, ‘safe’ therapeutic dosing, simulated rather than ‘real’ driving, and 
testing of individual skills, rather than driving as a whole.  With epidemiological 
research and surveys, bias can be introduced by the conditions under which data 
is recorded.  Other problems can include having no, or an inappropriate control 
group; method of case selection (e.g. requiring voluntary participation may not 
return a representative sample of the driving population, especially not those 
guilty of DUID, or those experiencing the lifestyle of problem drug use); not 
analysing for all drugs of abuse and alcohol or considering drug interactions; not 
quantifying drugs detected or analysing the correct matrix to indicate recent 
drug use; or, failing to take account of relevant factors in the study 
population.252,264 There are many studies where relevant factors are not 
considered, examples include the reason an accident was serious/fatal (e.g. 
driver not wearing a seatbelt, driver inexperience, road and weather
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conditions), driver’s history of drug use (tolerance), time interval between 
accident and taking of a blood sample, or a drug user’s risk-taking lifestyle 
contributing to traffic accidents.  The Scottish Executive found a relationship 
between ‘sensation-seeking’ and willingness to drive under the influence of 
drugs.265  Many of the respondents who admitted DUID, had also been caught 
breaking the speed limit, had endorsements on their driving licence or had been 
in an accident in the previous five years. 
As a result, the application of these observations to the driving population in 
‘real’ situations is uncertain.266  The exact characteristics of impairment related 
to each drug type are unknown and it is difficult to estimate trends in drug 
driving. 
7.1.1.1 Drugs Detected 
Drugs commonly detected in impaired drivers vary between countries and with 
time.251,267  Studies across Europe have shown cannabis, the most used illegal 
drug,268 and benzodiazepines, the most widely used class of drugs (abused and 
therapeutic), 269 to be most commonly detected in DUID cases.270,269,271-273  
Generally cannabis is most prevalent (in Australia 251,267, Greece 274, Denmark 275, 
Switzerland 275,276, Norway 277,278, Belgium 279 and Canada280).  A factor which 
may have contributed to this, however, is the long detection window in chronic 
users, and the reliance upon detection of the metabolite 11-nor-9-carboxy-THC 
(THC-COOH), rather than active THC which was common place until relatively 
recently.  Thus, it may not be that cannabis is the drug taken most often by 
drivers,, it could just be that cannabis is the drug most commonly detected. 
After cannabis, cocaine is on the whole the most detected illegal drug in 
Europe.273  Cocaine use did not feature extensively in older DUID studies, 
however, widespread recreational use and increased popularity of crack cocaine 
resulted in studies with high occurrences (Switzerland281, England282, and 
Spain283).  Cocaine was the most detected drug in DUID cases in the Metropolitan 
area of England.284  Similar to THC, however, chronic cocaine users sequester 
cocaine in deep body stores and small amounts can leach back into the 
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bloodstream for days after the drug was last used.285  It may, therefore, be 
easier to detect than other DUID substances. 
THC was only the third most common drug detected in Scottish drivers.  
Benzodiazepines, detected in 88% of DUID cases,286 were most prevalent 
followed by opiates (including methadone).258,287,288  The high rate of 
benzodiazepine detection could be a factor in the reliance upon impairment as 
the UK detection method.  It has been found that through observation alone, 
benzodiazepine impairment is easier to detect than other drugs.289 
Across all studies multiple drug (polydrug) use by drivers was evidenced.  Around 
10 % of European instances of DUID involved multiple drug use, although 
prevalence amongst drivers in general was relatively low, 0.4%.290  This was not 
a good indication of the true occurrence in individual countries.  Some had a 
much higher frequency (Norway,278 Australia,251 Belgium,291 and Switzerland 
275,276 all >50 %).  This was true of Scotland where polydrug use was detected in 
63 % of positive samples; benzodiazepines with opioids was most popular (59 % of 
positive samples).287  Combined drug use amongst drivers was less in England 
though, 16%.292  DUI of combined drugs (including alcohol) poses a serious threat 
to drivers and other road users.273  In the majority of accidents involving drivers 
where drugs were present, a combination of psychoactive substances were 
detected.290 
7.1.1.2 Prevalence of Drug Driving in the UK 
The average rate of DUID in Europe was estimated at 1.9% of drivers.  Again, this 
was encompassed in a large range (0.2 to 8.2%), and did not reflect the situation 
within any particular country.273  The UK did not participate in the driving under 
the influence of drugs, alcohol and medicines (DRUID) extensive integrated study 
of European drivers, however, and statistics for DUID in the UK are lacking.  It 
can be misleading to compare crime figures on a year to year basis as there can 
be many latent influences, for examples, changes in legislation which reclassify 
offences, or police/government campaigns which target and raise awareness of 
particular offences.  The statistics available do suggest an increased rate of 
DUID; a tenfold rise from 1985 to 2003,293 and a doubling from 2004 to 2005.294  
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Yet it is still a very low rate and more recently the number of DUID proceedings 
has significantly declined.295  This is likely to be a result of difficulty in obtaining 
evidence for a DUID prosecution rather than a decline in DUID.  When compared 
to alcohol impairment proceedings (of which there are far more) DUID was less 
likely to result in a finding of guilt.286 
A 2008 survey suggested there were in the region of 1.7 million regular drug 
users in the UK 296 (around four hundred thousand problem drug users,297,298 and 
a much higher number of recreational drug users, at least double 298).  It is, 
therefore, expected that this large drug using population will form part of the 
44.8 million UK driving population.299  An assumption supported by the RAC 
foundation survey in which over 45 % of young drivers admitted to having driven 
under the influence of illegal drugs; with one in five doing so every day.300   
DUID has been found to be more socially acceptable than DUI alcohol.273  6% of 
17-39 year olds reported that they had driven under the influence of drugs.265  
68% of RAC survey respondents had travelled in a car driven by a drug-driver,294 
and 12% of respondents in the THINK! road safety survey believed it was 
acceptable to drive after taking Class A drugs (and many more under the 
influence of cannabis).301  Drug use did not alter intent to drive.302  These figures 
depict an alarming attitude and rate of DUID, yet they are expected to be 
underestimated.  Elliot et al tried to characterise DUID in a six year study of 
road traffic fatalities in England and Wales.244  They reported 32% of driver 
fatalities positive for drugs.  Whilst this is a disturbing number it must be 
considered that of these drug positive drivers the most common drugs detected 
were cannabis (it is not specified whether THC or THC-COOH) with a long 
detection window, and “other drugs”, a category which included therapeutics 
such as diabetes medications and paracetamol.  This very high incidence of drugs 
in fatalities did not correspond to government accident statistics where 
accidents were only recorded if a drug was a contributing factor to the cause of 
the accident and not simply present (Table 7-1). 
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Table 7-1:  Road traffic accidents for which drugs or alcohol were a contributing factor. 
 
These figures are not expected to be a close resemblance to the true extent of 
drug driving, however, as they only relate to accidents which the police have 
attended, alcohol has not been detected and the police officer has requested 
blood samples to be analysed.  Even for road traffic fatalities drug analysis is not 
routine due to cost.292  Typically only traffic police officers will receive training 
for the practices to detect drugs (the field impairment test, FIT), although 
general duty officers often attend the scene of an accident (or stop a dangerous 
driver).  Without drug recognition and FIT training these officers may not 
recognise drug behaviours and, therefore, it may not occur to them to request 
toxicology samples.  A decline in laboratory submissions has been reported.288  
This does not necessarily mean that DUID has declined, rather it is likely to be 
the result of police officers who lack confidence and training failing to request 
samples.   
The difficulty in measuring the rate of DUID in the UK stems largely from the 
legislation; impairment by both drugs and alcohol is covered by the same Section 
4 offence.  There are two consequences of this.  The first is that instances of 
DUID cannot be counted as there is no specific charge for this (unlike a Section 5 
alcohol specific offence).  The second is that drugs are only considered where a 
driver is alcohol negative but impairment is still suspected.  This is primarily due 
to the convenience and reliability of the alcohol breath test but it is also more 
economical in terms of police officers’ time and public funds.  The preference 
for the breath test is evidenced by its frequency of use in comparison to FITs, 
Table 7-2.  It has been shown that drugs are frequently present in combination 
with alcohol.303  Testing only for alcohol means substantial DUID is not detected.   
2008 2010 2011 2012
% % % %
Alcohol 6,758 5.1 5,293 4.4 5,384 4.5 4,963 4.3
Drugs (illicit or medicinal) 687 0.5 565 0.5 644 0.5 622 0.5
Alcohol 11 7 9 8
Drugs (illicit or medicinal) 3 2 3 2
Total number of accidents 131,582 120,827 118,403 114,696
Contributing Factor
All road traffic accidents
Percentage fatal accidents
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Many believe the UK should have better monitoring and recording of DUID.286  
This claim has been rejected,304 understood simply as a result of a lack of belief 
that the significant increase in the cost to road policing would be returned by 
increased road safety.  This is impossible to evaluate without knowledge of its 
frequency of occurrence and consequences. 
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7.1.2 Portable Detection Devices 
Policing DUID is very difficult.  Efforts are being made to simplify this task.  It is 
believed that the greatest aid would be a device which could reliably detect a 
range of drugs in oral fluid (OF) by the roadside.257,305  OF testing devices have 
undergone substantial testing.  They lacked necessary reliability (DRUID had a 
sensitivity and specificity target of 80%, ROSITA had target sensitivity 90% and 
accuracy in excess of 95%), were expensive and time consuming; none were 
found suitable for random roadside testing.306   
Many countries are already employing these, possibly inadequate, screening 
devices across parts of Europe, the US and Australia,307 although they are 
insufficient to be accepted in the UK.  In 2012 the Centre for Applied Science 
and Technology, CAST, produced a Guide to Type Approval Procedures for 
Preliminary Drug Testing Devices. 308  This defined criteria for a ‘road-ready’ 
device (these can be police station based) with regards to safety considerations, 
calibration records, storage/operating temperatures, environmental testing 
procedures, target drug concentrations, and repeatability/specificity 
requirements.308  The list of drugs to be detected is limited (of note for example 
is a lack of benzodiazepines, such as alprazolam), and type approval for a 
selection, or even just one of these drugs is possible.   
So far, one police station based device has gained Home Office type approval; 
the Draeger Drug Test 5000 for cannabis (THC).309  It is not, as yet, available in 
UK police stations, however, Sussex police trialled the device over the 2013 
Christmas drink/drug driving campaign.  The findings of this trial were not 
published.  If OF screening is to be rolled-out across the UK it is important that 
the reliability of, and competence to use, such testing can be demonstrated.  
ISO standard ISO 2006 addresses point of care testing, stating the greatest 
uncertainty to be dependence upon the operator; trained police officers are 
expected to perform less successfully than validating laboratory staff.68  Thus, 
devices should be validated by police officers within each police station and 
continually monitored.  Proficiency testing would be expedient.  
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Even with such QA in place, this will only ensure that reliability of the test does 
not fall outside of the acceptable limits set at validation.  It will not endorse OF 
screening as the best means of detecting DUID.  DRUID determined that OF 
screening alone would be deficient.  It could only be an additional aid, not the 
primary method of detection.  Until drug screening devices attain the necessary 
sensitivity, specificity and scope, reliance upon drug detection devices must be 
discouraged as it could result in officers becoming less skilled in the observation 
of signs of impairment.310  Drugs detected by devices will always be limited.  
Without identification of physical signs of impairment, a driver impaired by a 
drug not signalled by a device (either because it was not part of the test battery 
or inadequate sensitivity) could be allowed to continue driving, endangering 
themselves and others.   
Screening with limited abilities (particularly looking for just one drug) could 
reverse any deterrence the device is intended to instil.  Drivers may feel that 
they can ‘get away with it’ when under the influence of a substance which is not 
detected.  Even when impairment is still suspected, it would be of increased 
difficulty to require a driver to provide a blood sample when they have just 
witnessed a negative screening result.  These concerns have been recognised in 
Western Australia where OF screening is performed for MDMA, Methamphetamine 
and THC.  Screening has come to be relied upon and impairment testing is not 
being conducted.  Drivers do not perceive any risk of being detected whilst 
driving under the influence drugs which are not screened.311  In light of the many 
NPS emerging, some taken specifically to evade detection, limiting on-site 
testing to a specific panel of drugs would be a major downfall  (observation of 
clinical signs is vital to direct testing for these substances).  It is essential that 
officers are familiar with, and confident in, the application of FIT. 
7.1.3 Law Related to Driving Under the Influence of Drugs (DUID) 
The legal approach to driving under the influence of drugs varies throughout the 
World.  There are three basic strategies:  impairment, zero-tolerance, and per 
se limits.  Legislation could be based on one or a combination of these.  
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7.1.3.1 Impairment 
Under impairment laws it is not illegal to drive having taken an illegal (or 
impairing prescription) drug.  It only becomes illegal if the drug influences 
ability to drive.  These laws are very difficult to enforce due to the complexity 
of demonstrating that the driver’s ability to drive was affected by the drug. 
Generally, these laws are administered through observation of specific factors 
related to drivers’ co-ordination, balance and/or vital signs.  The most well-
known of these tests, from which others were developed, is that of the US 
standardised field sobriety test (SFST) which is performed at the roadside by a 
patrol officer.  It is followed up with a drug evaluation and classification 
programme (DECP) performed by an officer qualified as a drug recognition 
expert (DRE). 
7.1.3.2 Zero Tolerance 
To simplify the process for conviction of DUID several European countries 
created zero tolerance laws.275,278,312,313  Any amount of an illegal drug in blood is 
an offence; there is no requirement to demonstrate impairment.  Prompt 
sampling is essential.  Guilt is determined by LLOQ of the analytical method 
applied, thus, standardisation is extremely important.277  Either one laboratory 
has to be responsible for all road traffic samples or analytical cut-off limits for 
laboratories need to be set and monitored through proficiency testing and 
audits.  
Zero tolerance is a good solution for drugs which exhibit wide variation between 
blood concentrations and the impairment observed (e.g. amphetamine type 
stimulants), or drugs where tolerance makes limits inappropriate (e.g. opiates 
and benzodiazepines).  A further advantage of zero-tolerance is that new 
substances can easily be added to the legislation (anything classed as illegal).21 
Zero tolerance has not necessarily dispelled the complexities of defining 
impairment.  Problems arise when drivers are found to be influenced by 
therapeutic drugs for which they hold a valid prescription.  Interpretation of 
scheduled prescription drugs which could also be drugs of abuse, like methadone 
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or benzodiazepines, is very difficult.  Expert opinion is required to state whether 
the concentration detected is within the therapeutic range and whether the 
prescription drug has been taken as directed and not abused.314  Some countries 
(e.g. Belgium, Czech Republic, Finland, Germany, Latvia, Luxembourg, and 
Slovakia) combine zero-tolerance for illegal drugs with per se limits for 
prescribed drugs.286  Few people are found guilty of DUID with only a therapeutic 
level of prescription drug present.312  Usually the level far exceeds the 
therapeutic range (20-70% of patients do not take drugs as prescribed 315) or has 
been combined with other substances.264,278,312,313 
7.1.3.3  UK Legislation 
Since the introduction of the Road Traffic Act in 1930, driving under the 
influence legislation in the UK has centred upon impairment.  It is now governed 
by Sections 4 to 11 of the Road Traffic Act 1988 (as amended by S4 of the Road 
Traffic Act 1991).  Amended Section 4(1) is of greatest interest: 
“A person who, when driving or attempting to drive a motor vehicle 
on a road or other public place, is unfit to drive through drink or 
drugs shall be guilty of an offence” 
Section 11 (2) defines ‘drugs’ as any intoxicant other than alcohol.  This could 
include illegal substances, prescribed and over the counter medicines, and, 
herbal remedies. 
Section 4(5) defines ‘unfit’: 
“a person shall be taken to be unfit to drive if his ability to drive 
properly is for the time being impaired”  
This legislation, therefore, renders impairment due to drugs illegal but it does 
not specify what constitutes drug impairment.  Through international scientific 
research it has been possible for alcohol impairment to be stipulated.  Section 5 
outlines prescribed limits for breath, blood and urine above which a person is 
deemed ‘unfit’.  It was desirable for such definitions to be made for drug 
impairment and in 2012 the Crime and Courts Bill (2012) introduced Section 5A 
which made it an offence for a person to have a proportion of a specified 
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controlled drug (any substance specified in part I, II or III of Schedule 2 of the 
Misuse of Drugs Act 1971) present in their urine or blood which exceeds the 
specified limit for that drug (unless it was lawfully possessed and taken as 
prescribed).  With the introduction of this Bill the Department for Transport 
formed an expert panel to define the drugs to be covered by the legislation and 
determine what the limits should be, and how the detection of multiple drugs 
(including alcohol) should be treated.316    
Such definite limits for drugs are untenable.255,317  Drug impairment is more 
complex than alcohol due to factors such as the potential for drug synergies, 
rapid pharmacokinetics of many impairing substances, variable effects of blood 
concentration depending on whether it is rising or falling, and significant intra-
individual susceptibility to drug effects.  Additionally the list of impairing 
substances is too great to be all encompassing.  Thus the experts focused on 
drugs associated with misuse and common therapeutic drugs, and used ‘real-life’ 
situations to estimate blood concentrations believed to represent a risk to road 
safety (by review of epidemiological data).318  This panel was largely composed 
of doctors (psychiatrists) prescribing some of these substances.  There were 
three toxicologists on the panel and they believed the levels had been set too 
high.208  The Government was also of the view that these levels could possibly be 
in disagreement with their zero-tolerance of illegal drug use stance; it could be 
an endorsement that it was alright to take illegal drugs provided “you don’t have 
too much”.319  Zero-tolerance was, therefore, proposed but the difficulties in 
imposing such a law were acknowledged.286   
To discern the best approach a 2nd expert committee was appointed (with more 
toxicologists) and the nation was consulted on what would be favoured out of 
three options: zero-tolerance, the previously recommended per se limits, or a 
compromise of lowest concentration at which a valid and reliable analytical 
result could be obtained (informed by toxicologists).  Consultation closed and 
the result reported in March 2014 that the favoured option was the latter, 
“lowest accidental exposure limit”.320  This has been put to parliament to be 
written into legislation and is expected to in place by autumn 2014.  It will cover 
8 illicit and 8 prescription drugs (given in Table 7-3 together with recommended 
per se limits).  Consultation is ongoing for amphetamine levels.  Interestingly 
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there is a limit for LSD which currently does not feature in the UKIAFT 
recommended routine and driver routine testing panels.208 
 
Table 7-3:  Proposed limits and recommended per se limits for drugs in blood.319,320 
 
The difficulty in implementing prescribed drug levels is that, unlike alcohol, 
drugs are not eliminated at a constant rate.  The concentration at the time of 
driving cannot be reliably back-calculated.  Attention has, therefore, been 
directed towards OF and sweat.  Section 6C of the Road Traffic Act 1988 allows 
for recovery of OF or sweat at the roadside with drivers obliged to provide them 
(Section 7.6).  The problem, however, is that roadside specimens can only be 
used for screening.  Confirmation must be performed with blood to demonstrate 
the drug was having an effect on the body (and not present due to 
contamination), and also because it is not possible to translate an OF or sweat 
concentration to blood for comparison to the prescribed limits (although OF 
limits are expected).  A further complication is the lack of approved sampling 
Proposed
Drug
Alone
 µg/L
when present 
for alcohol  µg/L
Alcohol when 
present mg/100ml
THC     5 * 3 20
Cocaine      80** 40 20
Benzoylecgonine (BZE) 500
Amphetamine 600 300 20
Methamphetamine 200 100 20
MDMA 300 150 20
Ketamine 200 100 20
Morphine 80 40 20
6-monoacetylmorphine 5
Methadone 500 250 20
Diazepam 550 275 20
Oxazepam 300 150 20
Flunitrazepam 300 150 20
Clonazepam 50 25 20
Temazepam 1000 500 20
Lorazepam 100 50 20
Lysergic acid diethylamide (LSD) 1
Concentration in Whole blood
*  Slightly higher than impairment threshold to allow for passive inhalation and THC 
in lipid stores.  THC conc in blood declines rapidly.    EMCDDA recommendation.
**  Very fast elimination of cocaine, rapidly converted to BZE.  BZE level higher than 
impairment to allow for non recent use
Recommedation
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and screening devices.  Thus, for now, this legislation is largely redundant, 
although it does hold great potential with per se limits and zero-tolerance 
having been shown to dramatically increase the number of DUID 
arrests/toxicology submissions in other countries.321-323 
Sections 6A to 6E were added to the RTA in 2003 (under the Railways and 
Transport Safety Act) to increase prosecution of DUID cases.  Section 6B makes 
driver cooperation mandatory, where previously police could only act on 
suspicion of impairment.257  It allows police to test for driver impairment 
through a roadside preliminary impairment test which meets the requirements of 
the Code of Practice issued by the Secretary of State.324  This is the Field 
Impairment Test (FIT), described at 7.1.4.  FIT does not have criteria to pass or 
fail but requires the trained police officer’s discretion to decide whether or not 
a driver is impaired.  Police Officers have expressed difficulty with this 
subjective test.288 
Regardless of the amendments to the RTA, FIT is presently the only available 
method for detection of DUID and will remain essential to road policing for the 
foreseeable future.  Thus the view of the Faculty of Forensic and Legal Medicine 
that; 
“there is no need for a new offence – there is need for better 
application of current legislation”.257 
This view was mirrored by Stephen Collier (who developed the UK FIT); FIT 
should not be replaced but evaluated to identify how it can be improved.286 
7.1.4 The Field Impairment Test  
In order to complete the task of driving safely a driver is required to combine a 
number of skills in close association (for example alertness, motor skills, visual 
acuity, reaction time, judgement and decision making).  The ability to perform 
such skilled tasks is referred to as psychomotor performance.  Impairment of 
psychomotor performance can be evaluated by breaking down the larger task 
into the best approximation of its key component skills and applying a 
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combination of tests to assess each of them.  There are such test available, 
which belong to one of three groups: 325 
1. Perceptual performance tasks Measure acuity of the senses, particularly 
vision and hearing;  
 Usually an estimation of time. 
2. Cognitive performance tasks  Determine intellectual functioning, 
concentration and mental processing; can 
be tested with simple arithmetic or usually 
a task to discriminate a specific signal from 
a selection. 
3. Motor performance tasks evaluate the integrity and function of motor 
pathways; reaction time tests (button press 
in response to a stimulus). 
 
Tests of driving impairment target memory, co-ordination, balance and ability to 
focus and divide attention.  As the nature of impairment can be different across 
drug groups, the assessment of impairment due to drugs requires tasks from 
each group to be combined.  The tests which comprise FIT were originally 
designed to detect alcohol impairment and, therefore, test the key skills 
expected to be influenced by central nervous system CNS depressants.  The 
compilation of tasks may not be broad enough to identify other effects on the 
CNS.   
7.1.4.1 History 
In the 1940s many countries began developing sobriety tests which were at that 
time based on clinical experience (symptoms associate with intoxication) rather 
than scientific principles.326  Later, in 1981, this testing was standardised and 
validated as probable cause that a motorist had a blood alcohol concentration of 
> 0.08 percent.327  Laboratory validations with alcohol are not discussed here as 
alcohol can easily be detected in breath.328  The Standardised Field Sobriety Test 
(SFST) in the USA consists of three tasks: one leg stand (OLS), walk and turn 
(WAT), and an eye examination for horizontal gaze nystagmus (HGN), an 
involuntary movement of the eye.  In the 1970s, the Los Angeles Police 
Department, the International Association of the Chiefs of Police (IACP) and the 
National Highway Traffic Safety Administration joined forces and advanced the 
Standardised Field Sobriety Test to a Drug Evaluation and Classification Program 
(DECP), although the alcohol validation was yet to take place.329-332  Selected 
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police officers were specially trained and certified as Drug Recognition Experts 
(DREs).  DREs follow drug recognition training (DRT) and refer to the Drug 
Evaluation and Classification Program to determine whether drivers show 
impairment and, if so, whether this is due to alcohol or drugs, specifying up to 
two of seven drug categories.329-332  DREs systematically collect and document 
any symptoms of impairment following the 12-step Drug Influence Evaluation 
(DIE), set out below in Figure 30.329-331  A DRE exam may be requested by any 
police officer who witnesses a driver unsatisfactorily complete a roadside 
Standardised Field Sobriety Test.   
 
Figure 30: DRE 12-step procedure 
 
The American Drug Evaluation and Classification Program is the longest 
established drug detection examination protocol in the world and, therefore, the 
most extensively tested.  The 1985 ‘John Hopkins Study’ (Bigelow et al 333) is 
regularly cited as the study which validates the DECP.  This was not a substantial 
study and could not be considered a full validation as the sample size was too 
small and not representative of the driving population, and also, the DREs were 
instructors with a greater knowledge and experience than would generally be 
expected from most DREs.  Assessments of the Drug Evaluation and Classification 
Program are complicated by the aim being to test whether any drug impairment 
was correctly classified, rather than whether the presence of a drug, any drug, 
was correctly asserted.  This explains why the John Hopkins Study is often cited 
as evidence of the DECP having an accuracy of 92%, when the true ability of the 
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test to detect the presence of any drug was found to be much less (only 61%, 
although not explicitly reported).   
This was a reasonable pilot study and a number of studies followed, although 
they were almost all field studies (reviewed elsewhere 334) rather than rigorous 
laboratory validation.  Field studies are not a good measure of the performance 
of the DECP as there are unknown influences such as driver confessions, driver 
being a known drug user, officer being aware of drug trends, physical evidence 
of drug, unknown drug dose administered, time delay to recover sample, urine 
rather than blood/oral fluid, and unknown time since administration.  
Additionally, many studies cannot provide ‘miss rate’ information i.e. how many 
impaired drivers were not detected and was it only high dose drivers detected?  
Eventually more laboratory studies were conducted, although none were able to 
validate the DECP as a reliable means of detecting drug impairment,329,330,332 
focussing instead on correct drug classification.  Drugs which are more easily 
detected can falsely inflate this accuracy.  Heishman et al’s 332 laboratory 
validation focused on drugs which are more difficult to detect, cocaine and 
cannabis.  Only 44% of DRE observations were found to be consistent with 
toxicology, and only 33% of drug impairment (regardless of classification) was 
correctly detected; again this was not emphasised in the report.   
These ‘validations’ were for the entire DECP omitting only the driver interview.  
With far fewer steps and no significant DRT, the SFST initial ‘screen’ is expected 
to be even less accurate.  Its performance is unknown, however, as it has not 
been validated or even rigorously evaluated for detection of drugs other than 
alcohol.  In spite of this, it was the reported ‘success’ of the DECP programme 
which led the UK to adopt a similar strategy.   
In 1997 Scottish police officers travelled to California to be trained in the 
general principles and techniques of the DECP to devise a UK drug influence 
recognition training (DIRT) programme and field impairment test (FIT).310  The 
FIT is performed by a specially trained police officer and if there is  suspicion of 
impairment there will be a follow-up examination performed by a forensic 
medical examiner (FME).  In 1999, 209 Scottish police officers and FMEs were 
DIRT and FIT trained.335  The officers’ course of business FITs were monitored 
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over a two month period.  The vast majority of drivers suspected of impairment 
had positive toxicology (23 of 25, although for at least 11 of these there was 
additional information such as drugs present or a confession) and officers 
concluded that the training was worthwhile.  The study was, therefore, 
extended by trained researchers from the Transport Research laboratory 
(TRL).335  This was a field study which targeted individuals leaving public houses 
believed to be frequented by drug users.  Tests were conducted in a large van 
which meant the full procedure could not be conducted (the ‘walk and turn’ 
task was omitted), and subjects were interviewed in relation to their drug and 
alcohol use, without any threat of arrest.  These deviations from the FIT 
procedure, together with an unrepresentative population sample (only 23 
‘impaired’ participants and the majority aged under 30 years), renders this 
assessment inappropriate as a FIT validation.   
Researchers were instructed not to make a decision as to whether or not 
subjects were impaired, thus, the predictive power and utility of FIT was not 
determined.  The researchers concluded that, without a measure of unimpaired 
ability, FIT was lacking.  They went on, however, to recommend FIT to the 
Association of Chief Police Officers Traffic Committee and in 2000 a two-day 
‘National Drug Drive Training’ course (five days for instructors) became 
available.292,335,336  FIT was subsequently implemented throughout Scotland in 
2002,288 with the reliability still undetermined.  In 2004 the Secretary of State 
for Transport issued a code of practice for preliminary impairment testing; this 
was simply the original FIT with the addition of a pupillary examination (outlined 
below).324  It was a further two years before validation of the UK FIT procedure 
was reported. 
This was not laboratory validation, rather, it was an extensive field study (with 
some of the associated complications, for example, only suspected drivers were 
invited to participate, some toxicology samples were from urine, and for around 
half the samples carboxy-THC was measured rather than THC).  It is accepted, 
however, that this was a reasonably controlled experiment and, without the 
ability to administer illegal drugs, a good alternative.287  It was concluded that 
FIT was a suitable screening tool but improvement was necessary.  Again, the 
major flaw was noted to be the unavailability of a standard measure of ‘not 
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impaired’ to compare to driver’s FIT performance.  Comprehensive validation 
would require establishing ‘normal’ performance from unimpaired drivers.287 
7.1.4.2 Conducting the Field Impairment Test 
FIT is designed to simultaneously assess coordination and cognition.  At the 
beginning of each of the four physical tasks comprising FIT, the officer reads 
specific instructions and provides a demonstration before providing the driver an 
opportunity to declare any disability, injury or illness that may prevent them 
completing the task as required.  The driver’s understanding of the test 
requirement forms part of the assessment.  The driver is required to remember 
precise instructions, which are lengthy to delay the driver undertaking the task.  
The delay before starting the task is increased by the officer’s demonstrations of 
the tasks, as delays increase opportunities to apply DIRT.  The test takes 10-12 
minutes to complete.  Recollection whilst undertaking the task evaluates 
sustained attention and balance in the driver.  The officer remains still and 
stands a short distance from the driver in order not to cause any distraction and 
records any signs of drug use, for example, slurred speech, drowsiness or facial 
itching.  Officers must conduct the tests, sticking rigidly to the standard 
protocol throughout.   
FIT is intended to be a roadside test, however the officer must be mindful of the 
safety of the driver, particularly as they may be under the influence of drink or 
drugs.  An appropriate location should have a hard, level, non-slippery surface, 
be in a well-lit, unobstructed area and away from the public gaze.324  If the 
immediate roadside is unsuitable the test can be conducted at a nearby location 
or at a police station, otherwise due allowance must be given to interpreting the 
driver’s performance.  Officers must also be mindful that it may not be 
appropriate to administer the test if the driver suffers from a medical or mental 
condition which could affect their performance (this includes being elderly or 
obese).337  Environmental conditions such as weather, lighting conditions and 
shoes worn by the driver also need to be considered and recorded.  All results 
and observations are recorded on a specific form (‘FIT Form’ in Scotland or MG 
DDF in England/Wales). 
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7.1.4.3 Pupillary Examination 
 
Figure 31:  Officer performing a pupillary examination 
 
The driver’s eyes are studied to assess whether their pupils are displaying 
constriction or dilation as this can be a symptom of drug use e.g. opiates may 
cause constriction whilst hallucinogens and stimulants are known to cause 
dilation; normal pupil diameter is given to be 3-6.5mm.287,338  A gauge of 
calibrated pupil size is held to the side of the subject’s face as a guide.  
Reddening or watering of the eyes is also recorded. 
7.1.4.4 The Modified Romberg Balance Test (RBT) 
 
Figure 32:  Officer conducting Romberg test 
 
This task is designed to identify temporal disintegration.  The driver is asked to 
estimate the passage of 30 seconds.  An unimpaired person is expected to 
estimate 20 to 40 seconds; less than 20 could signal stimulant use and greater 
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than 40 a CNS depressant or hallucinogen.  Further clues are sought by studying 
the body language of the subject.  The driver is required to stand in a set 
position with their feet together, arms by their side, head tilted back and eyes 
closed (since vision aids balance).  Any deviation from this including swaying, 
stepping or raising their arm(s), raising their head or opening their eyes is 
considered to be a possible sign of impairment. 
When the driver has brought their head forward and indicated that they have 
finished counting, or after they have been stopped by the officer, they are asked 
“How long was that?”.  This tests whether the participant was trying to follow 
the instruction and perhaps made a poor estimate, or if they had not followed 
the instruction and, therefore not made an estimate of 30 seconds. 
7.1.4.5 Walk and Turn (WAT) 
 
Figure 33:  Officer demonstrating walk and turn test 
 
This tests the driver’s motor function (gross body movement, specifically 
balance), ability to process instructions and divide attention.  The driver is 
asked to assume a rather unnatural stance on the line.  They must maintain this 
position whilst receiving instruction and demonstration.  They must then keep 
their arms by their side and walk along a straight line taking nine heel-to-toe 
steps, turn in a specific manner, and take nine heel/toe steps back; counting the 
steps out loud.  Incorrect number of steps, not counting correctly or out loud, 
missing heel-to-toe, turning incorrectly, raising arms, stumbling or swaying are 
all errors. 
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7.1.4.6 One Legged Stand (OLS) 
 
Figure 34:  One legged stand test 
 
The driver is required to raise one leg, straight, 6-8 inches above the ground 
with toes pointing forward, and keep the supporting leg straight.  They should 
maintain this position, count out loud in the manner “1001, 1002, 1003...”, until 
they are instructed to stop (30 seconds).  Repeat with opposite leg.  Signs of 
impairment include hopping, putting foot down, raising arms and not counting 
correctly. 
7.1.4.7 Finger to Nose (FTN) 
 
Figure 35:  Finger to nose test 
 
This is designed to assess proprioception (depth perception and balance).  
Proprioception is the sense that indicates whether the body is moving with 
required effort, as well as where the various parts of the body are located in 
relation to each other.  This is essential in driving as it enables tasks to be  
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performed simultaneously, for example, feet can operate pedals, while hands 
steer and change gears without the driver taking their eyes off the road.   
The driver is asked to close their eyes, tilt their head back and touch their nose 
with the tip of the index finger of each hand on command (left, right, left, right, 
right, left).  Potential signs of impairment include not being able to touch their 
nose as instructed (using wrong hand or touching another part of their face), 
hesitation, swaying, stepping, raising arms, raising head, opening eyes. 
7.1.4.8 Other Observations 
Officers are instructed to note state of clothing, articulation, manner, 
demeanour, memory of recent events and the presence of any paraphernalia 
indicative of drug use on the person or in the car, as well as any other relevant 
observations of behaviour and mental or physical state.339  “Relevant”, however, 
is not defined and this can lead to extensive note-taking as all actions must be 
recorded since what may become relevant to the FME cannot be known in 
advance.   
If OF screening devices can be developed with the required reliability, a positive 
result would negate the requirement for the FME exam.  The screening device 
would be enough to request a blood sample.  This would be helpful in reducing 
the delay between driving and recovery of a blood sample for analysis, however 
screening cannot be all-encompassing.  There are many drugs for which the 
police FIT followed by an FME medical examination are indispensable. 
7.1.5 Interpreting FIT performance 
General demeanour and collective performance observed in all FIT tasks are 
considered by the police officer and a decision made as to whether or not the 
driver appears to be impaired through drugs.  FIT Code of Practice states: 
 “There is no benchmark for pass or failure, nor is there any scoring 
system to indicate relative success.” 
This has been criticised repeatedly as a severe limitation: objective definition of 
impairment is essential.287,310,335,340  In the absence of a scientifically determined 
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definition of FIT impairment legislation relies upon impairment being adduced 
from: 
“evidence of driving… such as the driver weaving on the road or even 
driving too slowly for the conditions” (R v McCall [1974] R.T.R 216) 339 
The difficulty is then in demonstrating that the impairment is due to drugs, as 
amended Section 6B 3 of the Road Traffic Act (1988) states that the preliminary 
impairment test should determine: 
“whether or not his unfitness is likely to be due to drink or drugs” 
The FME can aid this decision by assessing whether there may be a condition 
present other than drug use which could result in impairment.  There is no 
nationally agreed examination protocol for FMEs, although in Scotland the 
results of the medical exam are recorded on an F97 Medical Examination Form 
and will, therefore, usually follow this format.341,342  In England and Wales there 
is a similar pro-forma available. 343  The FME exam will usually consist of the 
same FIT tasks the police officer performed in addition to a more detailed eye 
examination including nystagmus and other vital signs such as blood pressure and 
temperature.   
The FME is not legally required to give an opinion of impairment, and is advised 
against doing so.286  The function of the FME has been clarified in the Court of 
Appeal; they should only opine as to whether or not there may be a condition 
present related to drug use:344 
“the purpose of the medical advice is to provide a protection 
against the invasive requirement of a blood test when there is 
a clear medical explanation of the person’s condition…Insofar 
as it might be different, his condition later at the police station 
is not that to which the investigation is directed…the doctor is 
not limited to the findings of his or her own police station 
examination.” 
 
Thus, it is essential for police officers to take very detailed notes.  Delay 
between police FIT and FME examination could result in the driver no longer 
displaying symptoms of drug impairment.  If the officer has detailed notes which 
indicate possible drug impairment at the road-side, the dissipation of these 
Chapter 7  189 
 
 
 
symptoms are consistent with a condition due to drug use, and the FME may still 
permit a blood sample to be taken.342  Medical evidence is not considered 
essential as there is no requirement on the driver to consent to a medical 
examination.  Cases have been tried on the evidence of a police officer 
(impairment) and toxicologist (presence of a drug) alone, for example Leetham v 
DPP.  QB 488 1998.310,341,345   
The FME must not be omitted from the process, however, as this examination 
provides independent assessment which could exclude any circumstance (e.g. 
fatigue), medical condition (diabetes), disease or injury as a possible cause of 
the impairment; a task that a police officer is not qualified to perform.310,337,341  
Often, an FME will conclude that impairment observed by a police officer was 
not drug-related (around 25% of examinations).287   
Ultimately, it is the responsibility of the court, not the police officer or FME, to 
decide whether at the time of driving there was impairment due to drugs.  As 
the first point of contact, however, the role of the police officer is critical.  
Their observational skills and ability to describe and record their findings for the 
court are vitally important.  Detection is wholly dependent upon police officers’ 
observational skills.  It is believed, however, that many police officers do not 
have sufficient training in this area.287,288  Officers doubt their ability to execute 
FIT effectively; they lack confidence in detecting the symptoms of drug use,288 
are unsure how to complete the required paperwork, and lack conviction in 
requesting toxicology samples.292  This is apparent in the declining Section 4 
toxicology submissions, which increased when FIT was first introduced.288  It may 
also explain why during the Christmas drink/drug driving campaign of 2005, 11 
UK police forces did not perform any FIT tests at all.294  Officers claim a lack of 
regular training is partly to blame.288 
7.1.5.1 Officer’s Competence  
With so many officers expressing concern over their ability to  effectively 
conduct FIT it is clear that their ability to confidently apply FIT must be 
improved.  This should begin with their training.  UK officers’ training consists of 
one day within a longer course.  The morning covers theory and in the afternoon 
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the trainee officer performs two assessed FITs on colleagues.  By contrast, DRE 
certification requires candidates to attend nine days of classroom instruction 
before completing a written examination and performing twelve DECP 
evaluations on arrested individuals with 75% of their conclusions corroborated by 
toxicological findings.332  There are also criteria for decertification and 
reinstatement.346  It is recognised that the DECP in the USA is more complex 
than FIT but they are intended to fulfil the same purpose of detecting 
impairment consequent to drug use.  The UK training, and perhaps complexity of 
the test, is inadequate. 
Involuntary responses, which cannot be learned or controlled, are the best 
diagnostic tests of drug use.329  Symptoms strongly associated with drug use 
include pupil size in darkness, reaction to light, muscle tone, blood pressure and 
systolic blood pressure.329,346  Better accuracy has been found with horizontal 
gaze nystagmus alone than has been recorded for the entire FIT battery (with 
alcohol).  These clinical symptoms are not incorporated by FIT but ought to form 
part of the FME examination. 338   These are more objective measurements than 
the FIT tasks, with better-defined ‘normal’ response.  Incorporating these 
symptoms to roadside FIT would increase the information on which to make an 
assessment and could increase police officers’ confidence with interpretation.  
This would also increase the relevant information available to the FME who is 
often significantly delayed in their evaluation of the driver.  There are few FMEs 
and their priority is assessment of arrestees’ fitness to be detained which can 
mean long delay to DUID cases.  Sir Peter North advised that this often deters 
officers processing a suspected driver, as taking them back to the police station 
is likely to be a waste of their time without an FME available.286  If at least some 
officers were given more extensive training they could be authorised to approve 
a blood sample prior to the FME exam.  It is not possible to omit the FME 
altogether as only a medical expert can properly evaluate anything which affects 
balance, while ensuring the health and wellbeing of the driver.286 
With any subjective examination experience is essential.  One of the key 
recommendations of a major study conducted by the special EU research 
programme, Impaired Motorists, Methods of Roadside Testing and Assessment for 
Licensing (IMMORTAL), was that “police officers need training in personal 
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contact with intoxicated motorists”.347  It would perhaps be more effective if 
after their initial tuition officers had a period of apprenticeship with an 
experienced operator before they were assessed and certified.  It may be 
beneficial to officers if there were a minimum number of FITs to be observed 
following training before they could apply for certification. This would be similar 
to DRE training, in which the American Department of Transport requires 35 
practice tests from different individuals to have been completed over six months 
before the officer is qualified.348  This would acquaint officers with an expected 
range of driver performance.  It could also act as an incentive for more FITs to 
be carried out, as currently FIT is not performed often enough.349   
In Tunbridge et al’s 335 two month FIT evaluation, even when officers were 
freshly trained and at the peak of awareness, 209 officers completed a total of 
only 111 FITs.  Almost half did not perform a single assessment.  FIT is not 
essential to a DUID arrest so many officers chose not to do it, particularly where 
there is other supporting evidence.349  This is at the root of officers lacking 
competence: without regularly performing FIT they lose skills, confidence and 
opportunities to gain experience of observing the range of abilities (both 
impaired and unimpaired).  This is at the heart of Sir Peter North’s 
recommendation that:286 
“The number of FIT tests conducted should increase significantly, 
with forces making it a matter of policy to carry out the test in all 
cases where impaired driving is suspected, notwithstanding a 
negative breathalyser test.” 
It is most concerning that this advice was rejected by the Secretary of State for 
Transport who stated FIT was simply a means of requesting a driver to exit their 
car in order that a police officer can observe their manner and that drug 
impairment would be evident without specialist training.304  This is clearly not 
the case when even those officers who have received specialist training express 
lack of confidence in their ability to determine whether or not a driver is 
impaired.  Perhaps it is hoped that FIT would become obsolete with the 
introduction of screening devices, however, lack of skills is already a significant 
problem which can only be expected to get worse if OF devices come to be 
relied upon.  FITs would be conducted far less often.  Systematic application of 
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FIT to all RTA involved drivers, and those drivers stopped for any suspicious 
activity, as is performed with breath alcohol, would help to increase the range 
of performances observed by officers, increase their confidence and familiarity 
with the FIT SOP. 
Although FIT is accredited (see below) and should, therefore, be a standardised 
procedure, police officers do not always conduct FIT as specified by the SOP.349  
Sergeant Brian Poole, a certified FIT instructor responsible for the development 
of the FIT training programme in Scotland, advised that officers “forget” the 
details of the test, particularly the importance of the specific stance to be 
adopted with heels and toes together and requirement to use the tip of finger 
rather than pad in the finger to nose test.  The full potential of FIT as it is 
currently applied is, therefore, not being realised and the relatively poor 
accuracy measures which were observed when it was first instigated could 
actually now be even lower.  If a standardised system to measure impairment 
were to be developed and used it would be essential that FITs were truly 
standardised and conducted as the SOP instructs.  It is only by this method that 
the defined ‘normal’ performance will apply.  Thus not only is the QMS failing to 
maintain adequate quality assurance for this procedure, it has also failed to 
identify the skills and competencies required by police officers and how 
competencies should be maintained. 
To maintain aptitude for FIT assessment, officers’ training should be continuous 
with regular refresher courses.292  Refresher training would be useful for officers 
who have not had call to perform many FIT assessments, but is also necessary to 
update officers on recognition of emerging substances, particularly with respect 
to ‘legal highs’.  Combining this continuing professional development with 
officers who are being trained for the first time would mean that the officers 
would benefit from shared experience.  Another means of gaining experience 
could be for FIT tests conducted in the field to be video recorded.  This could 
also be helpful to the FME if their examination has been delayed.  In the US 
police routinely video their SFST.  This is to provide evidence in support of their 
opinion in court.  These would provide a good training aid, however, particularly 
when toxicology results have been obtained and it is known whether or not the 
person was impaired by drugs, allowing the officers to observe a range of 
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performances both impaired by drugs and unimpaired could immediately expand 
their experience and confidence. 
The number of FIT-trained officers also needs to be addressed; there are too few 
to be effective.  The last time the number of FIT trained officers was known was 
in a TRL report of 2000.335  There was only one force where more than one third 
of their traffic officers had FIT training.  In Strathclyde where only 5.5% of the 
police officers in the force were on traffic duty, only ten percent of these had 
FIT training.  In the US an alternative to certified DRE training is the Advanced 
Roadside Impairment Driving Enforcement program (ARIDE), a sixteen hour 
training course which can be undertaken by officers who already have SFST 
training to gain additional skills in recognising signs and symptoms of drug use.350  
An on-line version of this course available from late 2012 makes the skills 
required for recognising drugged driving much more accessible to officers.  
Perhaps something like this would be useful in the UK to encourage more 
uncertified officers to consider the possibility that a driver is impaired by drugs. 
7.1.6 FIT Accreditation 
The FIT process is accredited to the management standard ISO 9001(2000).  This 
accreditation standard does not address the reliability of the test result; simply 
that there is documentation in place to map the standardisation of the 
procedure.  It is expected under this standard, however, that the qualification, 
continuous development and competence of staff be stipulated and adequately 
safeguarded.  It is unclear how this accreditation is being monitored when 
officers feel so ill-equipped that they are apprehensive about performing FIT.   
It is unlikely that FIT could attain accreditation to a testing standard; certainly 
not without validation.  Such psychomotor tests lack validity as there are no 
databases to well-define the criteria which constitute impairment.351,352  
Johnston and Ramsey stress the urgency with which objective definition of 
impairment is required, stating that without such standards it is impossible to 
define acceptable performance versus impairment, raising fears that: 340 
“FIT leads to the arrest of people whose only crime is that they 
cannot pass FIT.”340 
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7.2 Aim of the Present Study 
In order to ascertain that there has been a change in a particular behaviour, it is 
essential to have first established the population distribution parameters for 
that behaviour.254  It is impossible to conclude that performance is impaired, or 
has dropped below that which would normally be expected, without knowing 
what is to be expected.  An important stage in validation of a test such as FIT 
should, therefore, be determination of ‘normal’ performance amongst persons 
not under the influence of impairing substances. This has not been done and 
could account for the difficulty officers have expressed with FIT.   
In a survey of Scottish FMEs the majority of respondents expressed a desire for 
an aggregate clinical score from which to determine impairment.337  FMEs with 
little experience were over-represented in this group, suggesting that a scoring 
system was favoured as it would increase confidence and make the process 
easier.  It is considered that such a scoring system could also increase police 
officers’ confidence with FIT. 
In order to aid officers and improve the applicability of FIT, it was proposed that 
the principles of proficiency testing be applied to the robust measures of 
dispersion from a representative sample of the driving population.  In 
proficiency testing schemes, unacceptable performance is defined as a ‘score’ 
more than 3 acceptable variations from the population robust average.  
Acceptable variation can be represented by a measure of variance within the 
population (expected to encompass 99.7 % of the population). 
The aim was, therefore, to complete the initial stages of a FIT validation by 
establishing the number of FIT ‘errors’ displayed by persons not-impaired by 
drugs for development of a PTS-type scoring system for FIT interpretation. 
7.3 Experimental 
7.3.1 Participant Recruitment  
In order to satisfy PT guidelines, when participant data is relied upon to 
generate values for scoring performance, at least 20 to 30 participants are 
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required.102  As Dixon et al 338 identified that age is expected to impact FIT 
performance it was considered appropriate to separate participants into two age 
groups for evaluation; akin to separating laboratories into peer groups according to 
method in a PTS.  Thus a target for recruitment was set at 60 to 80 participants 
across two age groups.   
Prior to recruiting volunteers the Robertson Centre for Biostatistics at the 
University of Glasgow was consulted to determine whether this target would be 
expected to yield meaningful results.  This required some prediction of a likely 
outcome.  To aid this estimate a pilot study was conducted in student tutorials 
where students were required to learn and complete a FIT assessment as part of 
their coursework.  Preliminary data collected from students gave a mean 
number of errors of 2.6. This was assumed an underestimate of the number of 
errors, as the test was not performed under standardised conditions, students 
were testing each other, and did not represent all ages of the driving 
population.  The Robertson Centre for Biostatistics entered mean estimates from 
2.6 up to ten to a purpose-written computer programme to determine that with 
30 to 40 participants in each group the width of the confidence interval around 
the mean would be ± 2 to 3 errors; an acceptable level of certainty for 
performance assessment.   
Ethical approval was granted by the University of Glasgow (project number 
200120039), Faculty of Medicine Ethics Committee.  The study was publicised by 
posters in university buildings and via email to the staff and some students of 
the College of Medicine, Veterinary and Life Sciences, the Department for 
Estates and Buildings and University Central Services.  This allowed for a broad 
selection of participants from within the University, including academics, 
students, janitors, administrative and cleaning staff.  Recruitment was also 
conducted within some other organisations such as solicitors’ offices, where both 
professionals and secretarial staff accepted the invitation to participate.  The 
only requirement for participants was that they were not under the influence of 
any potentially impairing substances and that they did not have any disability or 
illness that would prevent them from holding a normal UK driving license.  By 
this means the sample group did not differ from the general driving population. 
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Before carrying out FIT, each participant was advised of the process they would 
undertake and those willing to continue provided written consent (Participant 
Information form given in Appendix 6).  Each participant completed a short 
questionnaire (Appendix 7) related to potential sources of impairment such as 
injuries, disabilities, being over-tired or other conditions including use of 
medications, alcohol or recreational drugs.  They were confirmed alcohol free 
through breath analysis (using either a standard UK police issue breathalyser or a 
Lion Intoxilyser 600, following manufacturer’s guidelines).  A 1 ml OF sample was 
recovered using a Quantisal® collection device to allow later confirmation that 
participants were not unwittingly under the influence of any substances which 
might have affected their performance in the test.  Participants were provided a 
reference number which was used to maintain anonymity and to identify their 
questionnaire, OF sample and FIT form (Appendix 8). 
7.3.2 Oral Fluid Samples 
The Quantisal® device combined the recovered oral fluid with 3 mL of buffer 
and preservative in the transportation tube.  Oral fluid samples were frozen on 
the day of recovery and allowed to come to room temperature before analysis. 
Before the first analysis the samples were filtered using Quantisal® filters. 
7.3.2.1  Enzyme-Linked Immunosorbent Assay (ELISA)  
 
Table 7-4:  Drugs of abuse screened with cut-off concentrations 
 
All kits and reagents were purchased from Immunalysis.  The drugs of abuse 
which were screened are listed in Table 7-4 together with their cut-off and 
calibrator concentrations.  Calibrators were produced by diluting methanolic 
stock solutions in phosphate buffer saline solution (PBSS), as outlined in Table 
7-5.  The calibrators were diluted 1:4 (0.5 ml:1.5 ml)  in oral fluid buffer before 
Assay Cutt off (ng/ml)
Level 1 Level 2 Level 3 Level 4
Amphetamines 0 25 100 500 25
Benzodiazepines 0 10 60 300 10
Buprenorphine 0 5 20 100 50
Cannabinoids 0 2 10 50 10
Cocaine 0 10 60 300 10
Methadone 0 25 100 500 25
Methamphetamine 0 25 100 500 25
Opiates 0 10 60 300 10
Calibrators (ng/ml)
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addition to the wells of 96-well plates to replicate the dilution of the OF samples 
in the Quantisal® collection devices. 
 
Table 7-5:  Preparation of ELISA calibrators 
 
Four controls were used.  One at 50 % above and one at 50 % below the cut-off 
concentrations.  These were prepared in blank blood as described in Table 7-6; 
the blank blood used in preparation of these was also included as a control.  The 
blood controls were diluted with PBS (250 µl:1000 µl control:PBS).  The final 
control was blank OF. 
 
Table 7-6:  Preparation of ELISA controls 
 
Calibrators, controls and specimens (10 µl) were pipetted in duplicate into the 
wells of the microtiter plates.  100 µl of the relevant enzyme conjugate labelled 
with horseradish peroxidase were added and the plates were left in the dark to 
incubate for one hour.  The wells were washed six times with 300 - 350 µL of 
deionised water using a microtiter plate washer, inverted and ‘slapped’ dry to 
remove residual water.  Tetramethylbenzidine (TMB) Substrate (100 µl) was 
Reference Standard Volume Conc Level 1 µl Level 2 µl Level 3 µl Level 4 µl
amphetamine, methamphetamie and methadone 0 25 100 500
100 µl d-amphetamine 1mg/ml 10 ml 10 µg/ml
100 µl d-methamphetamine 1mg/ml 10 ml 10 µg/ml
1 ml methadone 100 µg/ml 10 ml 10 µg/ml
Oxazepam, benzoylecgonine, morphine 0 10 60 300
1 ml Oxazepam 1mg/ml 10 ml 100 µg/ml
1 ml Oxazepam 100 µg/ml (prepared above) 10 ml 10 µg/ml
1 ml Morphine 100 µg/ml 10 ml 10 µg/ml
1 ml benzoylecgonine 100 µg/ml 10 ml 10 µg/ml
THC-COOH
100 µl 11-nor-9-carbpxy-delta-9-tetrahydrocannabinol 100 µg/ml 10 ml 1 µg/ml 0 20 100 500
Buprenorphine
100 µl buprenorphine 100 µg/ml 10 ml 1 µg/ml 0 50 200 1000
Calibrators Stock solution Working solutions (stock solution in 10 ml PBSS)
Reference Standard
1 ml Ref Stnd in Concentration -50% 50% -50% 50%
Amphetamine (1mg/ml) 10 ml 100 µg/ml 13 ng/ml 38 ng/ml 13 µl 38 µl
Oxazepam (1mg/ml) 100 ml 10 µg/ml 5 ng/ml 15 ng/ml 50 µl 150 µl
Benzoylecgonine (1mg/ml) 100 ml 10 µg/ml 5 ng/ml 15 ng/ml 50 µl 150 µl
Morphine (1mg/ml) 100 ml 10 µg/ml 5 ng/ml 15 ng/ml 50 µl 150 µl
Methadone (1mg/ml) 10 ml 100 µg/ml 13 ng/ml 38 ng/ml 13 µl 38 µl
Methaphetamine (1mg/ml) 10 ml 100 µg/ml 13 ng/ml 38 ng/ml 13 µl 38 µl
THC-COOH (0.1 mg/ml) 10 ml 10 µg/ml 1 ng/ml 3 ng/ml 10 µl 30 µl
Methanolic working solution Control Concentration
Working solution 
in 100 ml blood
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added and the plates were again set aside to incubate in the dark for up to 30 
minutes (monitored and stopped early if dark colouration developed).  The 
reaction was stopped with 1M hydrochloric acid (100 µl).  A negative result was 
indicated by yellow colouration while a positive result was colourless.  The 
absorbance was read at 450nm, without delay, using a microtiter plate reader. 
7.3.2.2 GC-MS Basic Drug Screen 
The entire remaining OF specimen (ca. 995 µl OF in 2850 ml Buffer) was used for 
a basic drug screen which included methadone, amitriptyline, chlorpheniramine, 
chlorpromazine, citalopram, clomipramine, cyclizine, diltiazem, 
diphenhydramine, dothiepin, doxepin, imipramine, lignocaine, metoclopramide, 
mirtazapine, moclobemide, procyclidine, promethazine, propoxyphene, 
sertraline, tramadol, venlafaxine, and zolpidem.  The specimens were extracted 
exactly as described for the piperazine samples (Section 6.4.5), with the 
exception that the 1 ml of blood was replaced with the remaining OF/buffer and 
the internal standard added to these was 50 µl of 10 µg/ml methadone-d9.  The 
entire eluent was dried and reconstituted in 50 µl ethyl acetate (without 
derivatisation). 
1 µl was analysed by splitless isothermal (250 oC) injection to the Db-5 column 
(30 m length, 0.25mm i.d., 0.25 µm film thickness) of the Agilent Technologies 
GC System 7890A coupled to an Agilent Technologies 5975C inert XLMSD with 
Triple-Axis Detection.  The oven temperature programme has an initial 
temperature of 100 oC, which was raised by 8 oC/min to 200 oC and held for 10 
min, then raised to 300 oC at 8 oC/min and held for 5 min, for a total run time of 
40 min.  The carrier gas was helium at 1 ml/min.  The ion source temperature 
was 230 oC and the interface 250 oC.  EI+ mode was used with ionisation energy 
of 70eV.  The MS was operated in full scan mode (from m/z 40 to 550).  Acquired 
data was processed using the Agilent MSD ChemStation E.02.01.1177 (2010) data 
system. 
7.3.3 FIT Observations 
All tests were video recorded and retained for reference.  Participants were 
informed that these would not be held for more than five years and would be 
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deleted at the conclusion of the study. To minimise the influence of variables 
such as weather, lighting conditions, etc. testing took place indoors in a room 
cleared of furniture and anything which might be considered distracting (e.g. 
wall clocks and posters).  A large number of the initial tests (around 60) were 
conducted by Sergeant Brian Poole of Police Scotland who brought his extensive 
experience of conducting FIT.  Sergeant Poole is one of the very few Scotland-
based Police Officers certified to instruct Drug Influence Recognition and 
Preliminary Impairment Testing Techniques.  He authored the Police Scotland 
Drink & Drug Driving Standard Operating Procedure and was therefore, 
considered the ideal person to conduct and ‘score’ the FITs as he could do so in 
accordance with this SOP and exactly as officers are instructed to do in their 
course of duty.   
Sergeant Poole wore his police uniform while he conducted and scored each 
test.  The remaining tests were performed in the same fashion, with a very 
formal approach, by the lead researcher who had observed all of the tests 
conducted by Sergeant Poole.  Participants were read the instructions (as 
scripted in the example FIT form Appendix 8) and asked to complete each of the 
FIT tasks.  If participants could not complete a task or did not wish to attempt it 
they were not required to do so.  Each time a participant made an error it was 
recorded on the FIT form.  The possible errors associated with each task are 
listed on the FIT form and include any deviations from the specific instructions 
such as raising arms, not standing in the correct position, starting the test too 
soon, swaying, stepping out of position and any general indication of loss of 
balance.  There was no limit to the number of errors which could be recorded. 
7.3.4 Data Analysis 
Any errors recorded on the FIT forms were transcribed to Microsoft Excel® 2007 
worksheets to correlate the number and types of errors occurring in each task, 
and for FIT overall.  Microsoft Excel® data analysis functions were used to apply 
statistical tests to the data.  The tests used included those listed below. 
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7.3.4.1 Mann-Whitney U-test 
A robust method to compare two independent sets of non-parametric data, 
which may contain different numbers of measurements (an alternative to the 
between-subjects t-test).87,353  Mann-Whitney U-test is distribution free and most 
suitable to data with outliers and when there are skewed distributions.353  The 
test relies on ranking the data (i.e. the lowest data value is ranked 1, then the 
data values are consecutively numbered in order of increasing value with equal 
values sharing the mean of their ranks).  The entire data is ranked as a whole, 
not in groups.  The ranks for each group are then summed and applied to 
Equation 7-1 as T1 and T2, where n1 and n2 are equal to the number of values in 
each group.  Mann-Whitney U is the lower of the two values.  In order to 
determine whether this is a statistically significant U-value it needs to be 
converted to a z-value by Equation 7-2.  The z-value is checked against a table 
of z-values for significance at the relevant level.  The result reported as the 
probability that the two groups belong to the same population. 
(𝑛1𝑛2 +
𝑛1(𝑛1 + 1)
2
− 𝑇1) or (𝑛1𝑛2 +
𝑛2(𝑛2 + 2)
2
− 𝑇2) 
Equation 7-1:  Mann-Whitney U-test 
 
𝑧 =
𝑛1𝑛2
2 − 𝑈
√(
𝑛1𝑛2
12 )
(𝑛1 + 𝑛2 + 1)
 
Equation 7-2:  Mann-Whitney U-test z-value 
 
7.3.4.2 Kruskal-Wallis H-test 
A robust method to compare more than two independent sets of non-parametric 
data, which may contain different numbers of measurements (an alternative to 
analysis of variance, ANOVA).  It is important that all datasets are compared 
together before isolating groups for direct comparison.  Comparison of smaller 
groups reduces the sample size and increases the likelihood of variance between 
groups.  Thus, the data should be checked as one large set first to identify 
whether there is a statistically significant difference present, before comparing 
groups to try and identify where this difference exists.87  The Kruskal-Wallis test 
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does the initial comparison using data from all of the groups.  It is followed by a 
Kruskal-Wallis post hoc Tukey test which compares two groups at a time to 
identify which have significant differences. 
For Kruskal-Wallis the data in each group should have the same shape of 
distribution (i.e. skewed in the same direction).  The data is pooled and ranked.  
The ranks for each group are added together and the statistic ‘H’ is calculated.  
H roughly follows a chi-squared (Χ2) distribution, Equation 7-3, where each group 
is denoted by A, B, C etc, with the number of values in each nA, nB, nC (N is the 
sum total of these), and rank totals RA, RB, RC. 87   
𝛸2 =
12
𝑁2 + 𝑁
(
𝑅𝐴
2
𝑁𝐴
+
𝑅𝐵
2
𝑁𝐵
+
𝑅𝐶
2
𝑁𝐶
+ ⋯ ) − 3(𝑁 + 1) 
Equation 7-3:  Chi-squared statistic for Kruskal-Wallis test 
 
The significance of H is determined by comparison to tabulated values, the 
degrees of freedom is the number of groups minus 1.  When all of the groups are 
identical H=0.  H gains value when differences exist between the groups and the 
greater the difference between the groups, the greater the value of H.  When H 
exceeds a critical value, at least one group is significantly different to at least 
one other.354  A probability is reported with the H value.  This is the probability 
that random sampling would result in a sum of ranks as far apart as those 
observed, if the groups contained samples from populations with identical 
distributions.355  Thus, the greater the value of ‘p’ the more closely related are 
the groups. 
If a large H value is produced indicative of the presence of a significantly 
different group, a post hoc Tukey HSD test, Equation 7-4, can be used to 
determine which groups have differences.355  The mean ranks of each group are 
calculated.  Any groups for which the difference between their mean ranks is 
greater than the calculated HSD value, can be said to be different. 
𝐻𝑆𝐷 =
𝑞𝛼,𝑘,∞
√2
 √
𝑁(𝑁 + 1)
6𝑛
 
Equation 7-4:  Kruskal Wallis post hoc Tukey test.   
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q = value from q table (with α significance, k number of samples and ∞ degrees of freedom), 
N = total sample size, and n = size of the smallest sample in the analysis.  
7.3.4.3  One Way Analysis of Variance (ANOVA) 
Analysis of variance calculation for the comparison of more than two means to 
determine whether groups are significantly different.  This test applies to 
normally distributed data and may be influenced by outliers.  The null 
hypothesis is that all the means are the same, this is explored by dividing the 
total variation among all the data points into variation within each group and 
variation between each group.353  It requires two values, the mean sum of 
squares error, MSe (equal to the within-condition variation/the total number of 
data points minus the number of groups), and the mean sums of squares 
between conditions, MSb (equal to between-condition variation/the number of 
groups minus one).  If the null hypothesis is true the estimates of MSe and MSb 
should be roughly the same and their ratio should be around 1.  If the 
differences between the groups are larger than expected MSb will be larger than 
MSe. The MSb/MSe ratio is denoted the ‘F’ value and a table of critical F values 
identifies whether the difference between groups is greater than would be 
expected if both groups come from the same population. 
𝐻𝑆𝐷 = 𝑞 √𝑀𝑆𝑒 𝑛 ∗ ⁄  
Equation 7-5:  ANOVA post hoc Tukey test 
n* = the number of values used to calculate the means of interest 
To identify which groups are different requires post hoc testing.  This can be 
done by performing Students t-tests between each group,87  or an ANOVA post 
hoc Tukey Analysis, Equation 7-5.356 
7.4 Results and Discussion 
7.4.1 Toxicology Screening 
The results of the review of participant suitability for the study are presented in 
Table 7-7 and Table 7-8.  The table identifies that a lot of time and effort was 
spent screening participants for possible presence of impairing substances, 
although very few participants were subsequently excluded. 
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One participant produced a positive alcohol breath test, although there was no 
alcohol declared on their questionnaire, and this was later declared as residual 
alcohol from drinking on the previous evening.  This participant’s FIT 
observations were not included for data analysis. 
All 82 participants had negative ELISA screening for amphetamines, 
benzodiazepines, buprenorphine, cocaine, methadone, methamphetamine and 
opiates.  Two participants produced positive cannabinoid ELISA screening.  These 
presumptive positive results could not be confirmed as the entire oral fluid 
sample was required for the basic drugs analysis.  No cannabis use was declared 
on these participants’ questionnaires.    It was possible that these individuals 
were not under the influence of THC, that the positive result was a consequence 
of previous cannabis use, as the metabolite carboxy-THC can remain present and 
detectable after the impairing effects of THC have dissipated.  However, the FIT 
observations from these participants’ were not used, as it could not be 
confirmed whether or not the participants were under the impairing influence of 
THC. 
There was no declared use of any possibly impairing medications and no positive 
results from the basic drug screening which included methadone, amitriptyline, 
chlorpheniramine, chlorpromazine, citalopram, clomipramine, cyclizine, 
diltiazem, diphenhydramine, dothiepin, doxepin, imipramine, lignocaine, 
metoclopramide, mirtazapine, moclobemide, procyclidine, promethazine, 
propoxyphene, sertraline, tramadol, venlafaxine, and zolpidem.  The internal 
standard produced a strong signal in all samples confirming that the system was 
functioning properly, but there were no detectable signals to indicate the 
presence of a basic drug. 
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Table 7-7: Participant screening results (part 1) 
Amphetamines Benzodiazepine Buprenorphine Cannabis Cocaine Methadone Methamphetamine Opiates
1 negative negative negative negative negative negative negative negative negative negative
2 negative negative negative negative negative negative negative negative negative negative
4 Inner ear infection
5 negative negative negative negative negative negative negative negative negative negative
6 negative negative negative negative negative negative negative negative negative negative
7 negative negative negative negative negative negative negative negative negative negative
8 negative negative negative negative negative negative negative negative negative negative
9 negative negative negative negative negative negative negative negative negative negative
10 negative negative negative negative negative negative negative negative negative negative
11 negative negative negative negative negative negative negative negative negative negative
12 negative negative negative negative negative negative negative negative negative negative
15 negative negative negative negative negative negative negative negative negative negative
16 negative negative negative negative negative negative negative negative negative negative
17 negative negative negative negative negative negative negative negative negative negative
18 negative negative negative negative negative negative negative negative negative negative
19 negative negative negative negative negative negative negative negative negative negative
20 negative negative negative negative negative negative negative negative negative negative
21 negative negative negative negative negative negative negative negative negative negative
22 negative negative negative negative negative Positive negative negative negative negative
23 negative negative negative negative negative Positive negative negative negative negative
24 negative negative negative negative negative negative negative negative negative negative
25 negative negative negative negative negative negative negative negative negative negative
26 Vertigo
27 negative negative negative negative negative negative negative negative negative negative
28 negative negative negative negative negative negative negative negative negative negative
29 negative negative negative negative negative negative negative negative negative negative
30 negative negative negative negative negative negative negative negative negative negative
31 negative negative negative negative negative negative negative negative negative negative
32 negative negative negative negative negative negative negative negative negative negative
33 negative negative negative negative negative negative negative negative negative negative
34 negative negative negative negative negative negative negative negative negative negative
35 negative negative negative negative negative negative negative negative negative negative
36 negative negative negative negative negative negative negative negative negative negative
37 negative negative negative negative negative negative negative negative negative negative
40 negative negative negative negative negative negative negative negative negative negative
41 negative negative negative negative negative negative negative negative negative negative
42 negative negative negative negative negative negative negative negative negative negative
43 negative negative negative negative negative negative negative negative negative negative
44 negative negative negative negative negative negative negative negative negative negative
45 negative negative negative negative negative negative negative negative negative negative
46 negative negative negative negative negative negative negative negative negative negative
47 negative negative negative negative negative negative negative negative negative negative
48 negative negative negative negative negative negative negative negative negative negative
49 negative negative negative negative negative negative negative negative negative negative
ELISA Screening
Alcohol Basic drugsParticipant Clinical
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Table 7-8:  Participant Screening Results  (part 2)
Amphetamines Benzodiazepine Buprenorphine Cannabis Cocaine Methadone Methamphetamine Opiates
50 negative negative negative negative negative negative negative negative negative negative
51 negative negative negative negative negative negative negative negative negative negative
52 negative negative negative negative negative negative negative negative negative negative
53 negative negative negative negative negative negative negative negative negative negative
54 negative negative negative negative negative negative negative negative negative negative
55 negative negative negative negative negative negative negative negative negative negative
56 negative negative negative negative negative negative negative negative negative negative
57 negative negative negative negative negative negative negative negative negative negative
58 negative negative negative negative negative negative negative negative negative negative
59 negative negative negative negative negative negative negative negative negative negative
60 negative negative negative negative negative negative negative negative negative negative
61 negative negative negative negative negative negative negative negative negative negative
62 negative negative negative negative negative negative negative negative negative negative
63 negative negative negative negative negative negative negative negative negative negative
64 negative negative negative negative negative negative negative negative negative negative
65 negative negative negative negative negative negative negative negative negative negative
66 negative negative negative negative negative negative negative negative negative negative
67 negative negative negative negative negative negative negative negative negative negative
68 negative negative negative negative negative negative negative negative negative negative
69 negative negative negative negative negative negative negative negative negative negative
70 negative negative negative negative negative negative negative negative negative negative
71 negative negative negative negative negative negative negative negative negative negative
72 negative negative negative negative negative negative negative negative negative negative
73 negative negative negative negative negative negative negative negative negative negative
74 negative negative negative negative negative negative negative negative negative negative
75 negative negative negative negative negative negative negative negative negative negative
76 negative negative negative negative negative negative negative negative negative negative
77 negative negative negative negative negative negative negative negative negative negative
79 negative negative negative negative negative negative negative negative negative negative
82 negative negative negative negative negative negative negative negative negative negative
84 Positive
85 negative negative negative negative negative negative negative negative negative negative
89 negative negative negative negative negative negative negative negative negative negative
90 negative negative negative negative negative negative negative negative negative negative
91 negative negative negative negative negative negative negative negative negative negative
92 negative negative negative negative negative negative negative negative negative negative
93 negative negative negative negative negative negative negative negative negative negative
94 negative negative negative negative negative negative negative negative negative negative
95 negative negative negative negative negative negative negative negative negative negative
96 negative negative negative negative negative negative negative negative negative negative
Participant Alcohol Basic drugs
ELISA Screening
Clinical
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7.4.2 FIT Observations 
Ninety one participants completed a FIT.  Five had to be discounted as they 
could not be considered representative of a normal unimpaired driver (3 failed 
toxicology screening and the others were considered to have possible 
impairment due to severe vertigo and an inner ear infection).  A subset of results 
from 7 participants (4 female and 3 male) were also removed as English was not 
their first language and it could not be differentiated where there was an error 
of performance or an error of understanding due to language difficulty.  The 
final results set consisted of observation of 79 participants, 43 females aged 18 
to 65, and 36 males aged 19 to 72.  In order to satisfy PTS peer group 
requirements when using participants’ data to derive acceptable variation (>30 
participants), participants were separated into two categories; participants aged 
under forty years (n = 41) and those aged forty and over (n = 38).  Participant 
demographics are depicted in Figure 36.   
 
Figure 36:  Participation by age and gender. 
 
The participants were a good representation of the driving population in terms 
of age range and fitness abilities (although there were no unhealthy or 
extremely unfit participants).  Participants were asked to rate their fitness from 
1 (excellent) to 5 (extremely unfit).  The average was 2 (the highest value was 
4). 7 participants removed footwear prior to the test but 3 completed FIT with 
unsuitable footwear.  The participant total error count for each task is listed in 
Table 7-9 followed by the total number of each type of error observed across all 
79 participants.  The total number of errors for each error type does not 
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represent the number of participants making the error as some participants 
recorded multiple occurrences of the same error type. 
   
Table 7-9:  Error count for each FIT task 
Number of errors 
Observed
0 45 57.0%
1 26 32.9%
2 8 10.1%
Median 0
0 17 21.5%
1 22 27.8%
2 13 16.5%
3 9 11.4%
4 9 11.4%
5 1 1.3%
6 2 2.5%
7 5 6.3%
8 0 0.0%
9 1 1.3%
Median 2
0 15 19.0%
1 25 31.6%
2 15 19.0%
3 6 7.6%
4 3 3.8%
5 3 3.8%
6 4 5.1%
7 5 6.3%
8 2 2.5%
9 0 0.0%
10 0 0.0%
11 0 0.0%
17 1 1.3%
Median 1
0 23 29.1%
1 30 38.0%
2 18 22.8%
3 3 3.8%
4 4 5.1%
5 0 0.0%
6 1 1.3%
Median 1
Modified Romberg Test
Walk and Turn Test
One Leg Stand
Finger to Nose Test
Percentage of 
participants 
Number of 
participants
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7.4.3 Pupillary Examination 
Average pupil size was around 5 mm (range 3 to 7 mm).  Normal pupil diameter 
is given to be 3-6.5mm.287,338  There was one participant found to be just outside 
of the normal range.  Studies which have involved the measurement of pupil 
diameter have also recorded normal pupil sizes greater than 6.5 mm,357,358 and 
have found pupil size to be an age-dependent variable.357  Pupil size depends to 
a large extent on lighting conditions (and also other factors such as fatigue and 
emotion). If standard lighting cannot be applied the range of normal diameters is 
expected to be large.357  Pupil diameter has previously been determined not to 
make a significant contribution to the FIT procedure.287  Reaction to changing 
light conditions and the presence of nystagmus are better indicators of drug 
use.329,332,346 
7.4.4 Modified Romberg Test 
 
Table 7-10:  Total errors observed in the modified Romberg balance task 
(At section 7.4.10 consideration was given to what should be a significant error as a more 
lenient scoring method was required.  These errors were not counted in the re-evaluation at 
section 7.4.10) 
This appeared to be the easiest of the tasks as the majority of participants did 
not err, giving a median of 0.  Only 43% of participants made at least one error 
and none made more than 2.  The most common error was the participant not 
1 2.4%
2 4.8%
5 11.9%
1 2.4%
6 14.3%
15 35.7%
1 2.4%
10 23.8%
Sway 3 7.1%
 4 9.5%
3 7.1%
1 2.4%
total errors 42
Error
No of 
observations
% total errors 
observed for 
each task
Raised arms
During Instruction:
Modified Romberg Balance Test 
Had to be stopped
Light sway
Did not reply "30 seconds"
Brought head forward
Moved feet apart
Closed eyes/tilted head before instructed
Did not say "stop"
Swaying:
Slight sway
Slight sway throughout
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saying “stop” after 30 seconds but using some other phrase to signal the end of 
the 30 second period (15 people, 18%).  Next most frequent error was swaying.  
It was difficult to evaluate what was a ‘normal’ level of sway with some 
instances recorded as a slight sway and others simply as sway.  This was further 
complicated by the recording of sway “throughout” rather than having a count 
of how many times the subject was observed to sway.    Other errors regularly 
observed were to tilt the head back and/or close eyes before being instructed to 
do so (6 people, 7.4%) and not to reply “30 seconds” when asked how long the 
participant had been counting (5 people 6.2%).   
The average estimate of 30 seconds was 30 seconds with a range from 18 to 44 
seconds.  This does not include one participant who was still counting after one 
minute and had to be asked to stop.  The guideline on this task is that an 
unimpaired person’s estimate should fall between 20 to 40 seconds.  One subject 
estimated faster than this range and three subjects slower (not including the 
individual who did not stop).  Thus, five participants were outside of the 
specified normal range.  
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7.4.5 Walk and Turn Test 
 
Table 7-11:  Total errors observed in the walk and turn task  
(These errors were not counted in the re-evaluation at section 7.3.5.10) 
The robust average number of participant errors on this task was 2, although 
most people made just one error.  The highest was 9.  The majority (around 89%) 
could not complete this test without error.  Missing heel to toe contact on steps 
and raising arms were most frequently observed errors. 
 
2 1.2%
4 2.5%
1 0.6%
9 5.6%
2 1.2%
8 5.0%
10 6.2%
1 0.6%
4 2.5%
1 0.6%
3 1.9%
1 0.6%
3 1.9%
2 1.2%
54 33.5%
27 16.8%
8 5.0%
19 11.8%
31 19.3%
17 10.6%
19 11.8%
11 6.8%
3 1.9%
3 1.9%
1 0.6%
1 0.6%
total errors 161
Raised arms (total)
No of 
observations
% total errors 
observed for 
each task
Error
Walk and Turn Test
Sway
Took more/less than nine steps
Did not maintian start position
Asked for clarification/confirmation
Stumbled and started again
Stepped off line
Raised arams throughout
Did not count out loud
Counting Error
Stumble
Stumble 
Slight sway
Raised for balance
slightly throughout
throughout
Stepped off 
Turn:
Not as demonstrated
Raised arms
Slight stumble
Swayed
During Instruction:
Raised arams
Sway
Slight sway
Missed heel/toe
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7.4.6 One Leg Stand 
 
Table 7-12:  Total errors observed in the one legged stand task  
(These errors were not counted in the re-evaluation at section 7.3.5.10) 
The robust average number of errors on this task was 1 although the range was 
large, from 19% of participants completing the task without error to one outlier 
with 17 errors.  With the highest number of errors this appeared to be the most 
difficult task  
4 2.1%
3 1.6%
1 0.5%
8 4.2%
1 0.5%
48 25.0%
Sway 34 17.7%
left 21 10.9%
right 13 6.8%
9 4.7%
left 5 2.6%
right 4 2.1%
5 2.6%
left 3 1.6%
right 2 1.0%
15 7.8%
left 9 4.7%
right 6 3.1%
26 13.5%
left 13 6.8%
right 13 6.8%
4 2.1%
left 2 1.0%
right 2 1.0%
27 14.1%
left 17 8.9%
right 10 5.2%
47 24.5%
left 27 14.1%
right 20 10.4%
5 2.6%
left 2 1.0%
right 3 1.6%
3 1.6%
left 0 0.0%
right 3 1.6%
total errors 192
Slight sway
During Instruction:
Stumbled
Swayed throught
Raised arms throughout
Hop
Not looking at foot
Could not complete
Did not point toes/moved foot
Put foot down
Raised arms to balance
Swaying total
Asked for clarification/confirmation
Raised arms
Counting error
Footdown and restarted
Error
No of 
observations
% total errors 
observed for 
each task
One Leg Stand Test
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7.4.7 Finger to Nose Test 
 
Table 7-13:  Total errors observed in the finger to nose task 
 (These errors were not counted in the re-evaluation at section 7.4.10) 
The robust average number of errors on this task was 1.  Around 29% of 
participants completed the task without error.  The maximum number of errors 
was six.  The most frequent error by far was not making contact with the tip of 
the nose, however most people touched a part of their nose, there were only 
two occasions where there was contact with another part of the face.   
7.4.8 Complete FIT Performance 
Only one participant completed all of the FIT tasks without error.  The greatest 
error count was 23.  The robust average number of errors for the group as a 
whole was 4.   
1 1.1%
2 2.1%
1 1.1%
3 3.2%
3 3.2%
2 2.1%
6 6.3%
68 71.6%
2 2.1%
7 7.4%
total errors 95
Used wrong hand
Instructed to take hand down/delay in returning
Missed tip of nose
Missed nose completely
Used finger pads rather than tips
Swayed during instruction
Asked for clarification/confirmation
Swayed during task
Tilted head back/closed eyes before asked
Brought head forward
Finger to nose test
Error
No of 
observations
% total errors 
observed for 
each task
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Table 7-14:  Number of errors for complete FIT by participant age 
 
7.4.9 Influence of Age  
Data was analysed primarily by robust statistics to overcome the influence of 
outliers.  A two sided Grubbs test (95% confidence) identified two outliers among 
the data, one in each of the two age groups.  The presence of outliers posed a 
difficulty in whether or not they should be included in the data analysis.  It was 
considered that they should be included as the participants were known not to 
be under the influence of any impairing substances and, therefore, whilst a 
statistical outlier, still represented a possible performance that could be 
observed from an unimpaired driver.  (The use of robust statistics, however, 
meant that these values had less influence on measures of dispersion.) 
When the participants were divided into just two groups, over and under 40 
years old (Figure 37), age was found to be a statistically significant factor in the 
number of errors incurred by participants (Mann-Whitney P=0.029, sig <0.05, 2 
tailed).  A non-parametric comparison method was considered most appropriate 
in order to include outliers.   
18-27 28-37 38-47 48-57 57+ Under 40Over 40
0 1 1 1
1 2 2 1 2 3 5
2 2 4 2 6 2 8
3 2 5 4 7 4 11
4 2 4 1 6 1 7
5 2 2 1 1 2 4 4 8
6 2 2 4 2 6 8
7 3 2 1 5 1 6
8 2 1 2 1 3 3 6
9 1 1 1
10 1 1 2 1 3 4
11 1 1 1 1 1 3 4
12 1 2 1 2 3
13 1 1 1
14 1 1 1
15 1 1 1
16 2 2 2
17 1 1 1
:
23 1 1 1
Number of participants by age groupNumber 
of errors ALL
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Figure 37:  Dispersion of errors in the age groups over and under 40 years. 
 
To expand upon this finding participants were separated into smaller age groups 
(four groups of ages 18-29, 30-39, 40-49, and 50+), a Kruskal-Wallis test was 
performed.  This did not indicate significant differences in the mean ranks of 
each age group (H = 0.707 and P = 0.872).  The discriminating power of non-
parametric significance tests of more than 2 groups is limited, however, as 
information is lost in substituting data for ranks.  In the interest of maximising 
the information which could be gained from the data, parametric analysis of 
variance (one way ANOVA) was applied and indicated that the mean error in 
each age group did differ significantly with and without outliers (F(2.727) = 
3.125, p = 0.031, sig 0.05 with outliers, and F(2.73) = 3.52, p= 0.019, sig 0.05 
excluding outliers).  Post hoc t-tests, however, did not indicate any of the four 
age groups to be statistically different (the difference between the oldest and 
youngest group was -1.07 and the acceptable difference at 95% confidence 
interval was -3.69 to 1.56).  When Tukey’s test was applied there was an 
indication of a difference in performance between the age groups 30-39 and 50+ 
(HSD(3.16)=3.39, sig 0.05) but only when outliers were not included.  This 
difference was slight and could be related to the small sample size of the 30-39 
age group, particularly as no other differences were found.  If performance in 
FIT was influenced by age it would be expected for the two extreme groups, 
those aged 18 to 29 and those aged 50 and over, to be significantly different.  
They were not. 
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Table 7-15:  Median error count and error range for by age groups  
(* omission of outlier 17 and ** omission of outlier 23).  The robust data is that which is 
relevant, the parametric data is given for comparison only. 
The uncertainty associated with the median of some age groups as shown by the 
confidence interval was large (Table 7-15), indicative of the large spread in the 
number of errors amongst the subjects of the groups.  The large variance could 
be the result of a lack of data: because there is considerable variance in 
performance a larger sample is required in order to capture the true spread of 
performance.  To achieve a sufficient degree of statistical power in studies of 
skills related to driving the European Monitoring Centre for Drugs and Drug 
Addiction recommend more than 18 subjects per group.359  The group aged 40 to 
49 had only 16 participants but the others had greater than 18, suggesting that 
the recommended number of participants should be higher.   
It is possible that with increased observations the range of error rates across 
each group could equalise, although it is not possible to speculate.  The 
confidence related to the medians of just two groups (over and under 40 years, 
each with at least 38 subjects) was more acceptable and supported the 
proposition that drivers over the age of at least 40 are likely to incur more errors 
when performing FIT. It was noted, however, that both groups had considerable 
overlap and the range of each was very large.  The overlap between the error 
ranges for each age group was so great that a comparison of error count and age 
would be ineffective at determining whether or not an individual may be 
impaired.  Reduction of this range had to be addressed in order to try and 
establish a useful baseline performance.  Interpretation of an ‘error’ was 
Age group
No. of 
participants
Median 
Error 
count
Confidence 
Interval 
95%
Inter-quartile 
Range
Mean 
error
Standard 
Deviation
Error 
range
18-29 22 5 2 to 8 2 to 8 5 4 0 to 13
30-39 19 4 3 to 6 3 to 6 2 to 17
18 4 5 2 2 to 12 *
40-49 16 6 2 to 11 2 to 9 6 4 1 to 15
50+ 22 7 5 to 11 5 to 11 3 to 23
21 6 8 4 3 to 16 **
Under 40 41 4 3 to 6 3 to 7 0 to 17
40 4 5 3.1 0 to 13 *
Over 40 38 6 5 to 10 4 to 11 1 to 23
37 6 7 4.4 1 to16 **
All 79 5 4 to 7 3 to 8 0 to 23
78 5 6 4.1 0 to 17 **
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investigated by looking again at the type of errors being observed.  It was found 
that some errors were observed more often than not.  These should therefore 
not be considered indicative of impairment as they were not unusual behaviour 
for unimpaired persons.  It appeared that the scoring applied was overly critical 
and a more conservative approach, where only unusual errors were considered 
significant, could make FIT observations more meaningful.  
7.4.10 Omission of Common Errors 
A significant proportion of UK FMEs had reservations about how FIT was scored, 
believing it to be too harsh.337  Elsewhere officers are trained to be more 
conservative in assessment.  The DECP only allows for each error type to be 
recorded once, even if they are observed to occur several times and allowances 
are made for common error types, for example, an arm raise has to be 
deliberate and higher than six inches.348  It was noted during the testing that 
signs and symptoms could easily be missed due to the extensive note taking 
required.  A more conservative scoring approach could mean slightly less 
recording on the FIT form and increased opportunity got observation of the 
driver. 
The FIT scoring mechanism is subjective and relies upon the discretion of the 
observer.  Some of the errors recorded occurred so frequently that they could be 
considered less indicative of drug impairment than others; they appear to 
constitute normal behaviour when balance is tested.  An example of this is the 
observation of “sway”.  It is understood that an unwarranted, sizable sway, 
disproportionate to that which would ‘normally’ be expected may be a valuable 
observation and should be recorded as an error.  There is, of course, difficulty in 
measuring sway.  There were many instances of “slight” sway recorded, 
however, a slight sway is to be expected.  “Slight sway” was discounted as an 
error. 
Errors which had not been counted but recorded to have occurred “throughout” 
a task were also removed from the second assessment as it could not be 
determined if these were true errors of performance or errors of understanding.  
As FIT tests comprehension and information processing together with balance, 
officers are told not to correct drivers who do not follow the instruction given.  
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Over the course of this research it became apparent that this was not 
appropriate.  The level of impairment is difficult to assess if the balance tests 
are not performed as instructed; slight deviations from the intended position can 
make a task much easier to complete and it is not clear whether the deviation 
from instruction is because the driver has not understood/remembered the 
instruction, or because they are incapable of performing the task as required.  If 
a task is not being undertaken as instructed the officer should correct the driver 
to alert them to this error (recording that they have done so, an error in 
following instruction).  If the driver continues to perform the task incorrectly 
this can be determined a true error and the number of times the instruction is 
violated counted rather than “throughout” to allow a more meaningful score to 
be calculated.  This was most applicable to the error “raised arms”.  
Raising arms slightly to aid balance or having them slightly raised throughout 
(perhaps because the instruction to keep them by the side has been forgotten) is 
quite different to raising them high sharply to prevent a stumble or fall, and 
very different to having them completely outstretched throughout because 
balance is extremely poor.  It should be clear to an observer if arms were raised 
to avoid a stumble or fall as opposed to inadvertently slightly raised by the sides 
throughout a test.  Raised arms throughout should be considered an error of not 
following instruction rather than a balance error if there has been no attempt to 
keep them by the sides.  This was evident from some participants having arms 
raised throughout recorded on their FIT forms in addition to a count of how 
many times the arms were ‘raised’.  Instances of raised arms throughout were 
discounted. 
Similarly the error “not as demonstrated” recorded against the turn in the WAT 
posed interpretive difficulty.  All of the participants against whom this was 
recorded had attempted to perform the turn as demonstrated but made slight 
mistakes such as using the wrong foot or turning in the wrong direction.  Downey 
et al 360 also had difficulty with this fault noting that ‘improper turn’ was not 
considered to be related to drug impairment as it was recorded most often for 
the placebo group.  Errors of turn “not as demonstrated” were, therefore, 
removed.  If there was no attempt to make the turn as instructed, however, 
then this would be countable. 
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The errors that were removed in the conservative assessment are identified in 
Table 7-13 as lighter grey text.   
7.4.11 Updated performance with conservative assessment 
 
Figure 38:  Dispersion of significant errors across groups aged over and under 40 years 
 
 
Figure 39:  Comparison of the percentage of participants making at least one error by the 
original scoring system and with the more conservative scoring  
 
Changing the criteria for what constitutes an error had a significant impact on 
perceived performance.  This change in over-all FIT performance can be seen in 
the changing appearance of the box and whisker plot, Figure 38.  The difference 
was most easily discerned from the new error count for each FIT task, Figure 39 
and Table 7-16.  There was no significant impact on the RBT.  For all the other 
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tasks, however, the proportion of participants now making at least one error 
decreased (RBT from 43.0% to 19%, WAT from 78.5% to 57.0%, OLS from 81.0% to 
45.6% and FTN from 70.9% to 27.8%), median values reduced by one error, and 
the error range decreased.  The decrease in errors for the OLS was so marked 
that it no longer appeared to be the most difficult task.  WAT was most difficult, 
followed by OLS.  RBT was still easiest to complete.  This agrees with previous 
studies which have largely identified OLS and WAT to be most useful FIT tasks 
for detection of drug impairment, and FTN least useful (after pupillary 
examination).287,329,335,361,362  
The original assessment of OLS as the most difficult task correlated well with the 
experience of TRL that it was too sensitive, as most participants failed,335 and 
Oliver et al’s observation that a high proportion of drug negative drivers 
displayed signs of impairment (even though these were composed largely of 
younger drivers).287  Whilst with conservative interpretation the number of errors 
observed was less than those for WAT, OLS was the only task for which there was 
a participant that could not complete the test.  It would therefore seem that 
OLS is actually the most difficult task to perform, although error counts for WAT 
could be expected to be greater as it has an increased number of requirements 
and increased potential for error.  The majority of police surgeons disapproved 
of WAT and OLS as indicators of drug use but far fewer had reservations 
regarding RBT and FTN.337  This could be related to the difficulty unimpaired 
persons have completing WAT and OLS and the much closer range of error counts 
for RBT and FTN (where normal performance and  therefore impairment are 
more readily defined). 
Noting only significant errors is estimated to make OLS more effective at 
detecting impairment, although it remains likely that unimpaired persons could 
experience difficulty.  This highlights the importance of interpreting FIT as a 
whole, rather than looking at performance on individual tasks. 
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Table 7-16:  Participant error counts by task with conservative assessment 
 
Number of errors 
Observed
0 64 81.0%
1 12 15.2%
2 3 3.8%
Median 0
0 34 43.0%
1 15 19.0%
2 11 13.9%
3 6 7.6%
4 5 6.3%
5 1 1.3%
6 5 6.3%
7 1 1.3%
8 1 1.3%
9 0 0.0%
Median 1
0 43 54.4%
1 16 20.3%
2 6 7.6%
3 3 3.8%
4 4 5.1%
5 5 6.3%
6 1 1.3%
7 0 0.0%
8 0 0.0%
9 0 0.0%
10 0 0.0%
11 0 0.0%
14 1 1.3%
Median 0
0 57 72.2%
1 19 24.1%
2 2 2.5%
3 1 1.3%
Median 0
Finger to Nose Test
Number of 
participants
Percentage of 
participants 
Modified Romberg Test
Walk and Turn Test
One Leg Stand
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Table 7-17: Participant total error count by age group with conservative scoring 
 
Following the revised interpretation 14 participants (17.7%) completed FIT 
without error compared with just one before (1.3%), and over half completed 
with 2 or less errors (54.4%) compared with less than a fifth (17.7%) of 
participants.  The error ranges for each task were reduced but performance 
overall still contained some relatively high error counts, Table 7-18, indicating 
that some people who were not under the influence of an impairing substance 
had difficulties in completing FIT.  The largest error count had a relatively small 
reduction from 23 to 19.  The robust average number of errors across all 
participants was 2, with a confidence interval 1 to 4 errors calculated by 
Equation 7-6 and Equation 7-7.363 
When the results were processed as one large group the number of outliers had 
increased from 1 with the original scoring to 4.  There was still only one outlier 
in each of the under 40 and 40+ age groups, however, which suggested that it 
was more appropriate for the data to be divided into these two groups rather 
than being evaluated collectively.  The increased significance of the difference 
between the over and under 40 years groups was confirmed by statistical testing 
(Mann-Whitney P=0.00578, sig <0.05, 2 tailed).  The mean number of errors for 
the under 40 age group was 1 (confidence interval 1 to 2), and for the 40 and 
18-29 30-39 40-49 50+ <40 >40 All
0 4 6 1 3 10 4 14
1 5 6 6 2 11 8 19
2 5 2 1 2 7 3 10
3 2 1 1 1 3 2 5
4 2 1 3 2 3 5 8
5 1 2 1 3 1 4
6 2 1 6 2 7 9
7 1 1 1 1 2
8 2 1 3 3
9
:
:
11 1 1 1
12 1 1 1
13 1 1 1
14 1 1 1
:
19 1 1 1
Age Group
Error Count
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over age group it was considerably higher at 4, but with less precision 
(confidence interval 2 to 6).    
 
Table 7-18:  Number of significant errors by age group: medians and dispersion. 
Outliers removed:  * 14, **19, ***12, 13, 14 and 19 
 
𝑛
2
−
1.96√𝑛
2
  
Equation 7-6:  Lower 95% confidence limit ranked value 
 
1 +
𝑛
2
+
1.96√𝑛
2
  
Equation 7-7:  Upper 95% confidence limit ranked value 
 
It was recognised prior to data analysis that the number of participants could 
only support two peer groups for PT-type FIT scoring (in order that measurement 
of deviation attain sufficient certainty).  The large dispersion of results for the 
over 40 age group, and resulting substantial uncertainty associated with the 
robust average, could indicate that there ought to have been more than two 
peer groups.  Whilst participation was insufficient to allow more, the possibility 
that further observations of unimpaired performance would have a significant 
contribution to the resultant scoring system was re-investigated with 
performance appraisal for four age ranges as before.   
Age group
No. of 
participants
Median 
Error
Confidence 
Interval
Inter-quartile 
Range
Mean 
error
Standard 
Deviation
Error 
range
18-29 22 2 1 to 4 1 to 4 2 2 0 to 7
30-39 19 1 0 to 2 0 to 3 0 to 14
18 1 2 2 0 to 5 *
40-49 16 3 1 to 6 1 to 5 3 3 0 to 8
50+ 23 6 2 to 6 2 to 6 0 to 19
22 6 5 3 0 to 13 **
Under 40 41 1 1 to 2 1 to 3 0 to 14
40 1 2 2 0 to 7 *
Over 40 38 4 2 to 6 1 to 6 0 to 19
37 4 4 3 0 to 13 **
All 79 2 1 to 4 1 to 5 0 to 19
75 2 1 to 5 3 3 0 to 11 ***
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The Kruskal Wallis test determined at least one age group to be significantly 
different to the others (H = 10.251, P = 0.017).  Kruskal Wallis post hoc Tukey 
analysis (using the values in Table 7-19) indicated that the error rates for all four 
age groups were statistically different to each other.  Comparison of the two 
older age groups with the two younger groups produced the greatest differences 
in performance, with the older groups having significantly more errors.  As 
information can be lost with such ranking processes, the ANOVA post hoc Tukey 
analysis was conducted and confirmed that the 50+ age group had statistically 
significantly higher error rate than the youngest group, ages 18-29 years 
(HSD(2.91) = 3.091, sig 0.05), and the next youngest group, ages 30-39 year 
(HSD(2.91) = 3.342).  It was clearer with the revised, conservative scoring system 
that FIT performance deteriorates with age, although when the number of errors 
was plotted against age there was no correlation, Figure 40. 
 
Figure 40:  Relationship between participation age and FIT error count. 
 
Deteriorating performance with age has also been noted by Dixon et al.338  
Performance of alcohol impaired subjects was compared with unimpaired 
subjects. Participants over forty years old were found to have higher levels of 
impairment (both when under the influence of alcohol and when in a placebo 
state).  A substantially higher incidence of false positives was observed with 
subjects over 40 years of age (participants were aged 18-68; 27% false positive 
rate for under 40s and 67% for over 40s).  This was demonstrated to be a 
significant problem, with false positives in the age group 41-50 years said to be 
greater than the number of true positives (exact figures were not given and it 
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was not possible to calculate the accuracy of FIT with this age group).  There 
were also some suggestions in the work of Tunbridge et al at TRL that age could 
be a factor in FIT performance.335  A greater proportion of drivers over 30 were 
found to fail FIT, however the toxicology results were not correlated with FIT 
performance and it could not be ascertained whether age or drug use impacted 
on performance.  Additionally, the majority of subjects were under 30 and the 
over 30 sample size was unreliable.  The analysis of FIT results by Oliver et al 
was the only study not to detect a change in performance with age.  It is 
possible that this was because they were using the less conservative scoring 
method, which failed to detect an age influence in the current study, or it could 
be due to the majority of participants belonging to the under 40 age group. 
 
Table 7-19:  Kruskal Wallis post hoc Tukey analysis data 
 
7.4.12 Scoring System 
A scoring system which works from two different thresholds is required, one for 
drivers under the age of 40 and another for drivers aged 40 and over.  It was 
hoped that acceptable variation could be calculated by robust methods.  The 
lack of variation in performance amongst the younger age group, however, 
meant that most often the robust standard deviation was equal to zero.  This is 
not a useful value for performance scoring.  The alternative means of calculating 
acceptable variation was to remove outliers and use the conventional standard 
deviation.  Standard deviation for each age group, together with the resultant 
acceptable ‘unimpaired’ error counts are detailed in Table 7-20.  It is advised 
that FIT performance as a whole should be the determining factor in whether or 
not a driver is impaired.  Under this condition it is likely that a driver is impaired 
if they are under 40 and make more than 7 (conservative) errors, or aged over 40 
and make more than 15 (conservative) errors.  By this guide one participant 
HSD 
P=0.05
HSD 
p=0.01
18-29 with 30-39 6.85 3.09 3.89
18-29 with 40-49 5.89
18-29 with 50+ 14.93 N = 79
30-39 with 40-49 12.74 n = 16
30-39 with 50+ 21.78 df = 60
40-49 with 50+ 9.04 k = 3
Groups compared Difference in mean ranks
Chapter 7  225 
 
 
under 40 (aged 36, score 8) and one person aged over 40 (age 63, score 19) 
known not to be under the influence of an impairing substance would be wrongly 
suspected.  With some discretion from the officer these are not concerning.  To 
aid with such instances the acceptable error counts for each of the individual 
tasks are provided.  If the over-all FIT score exceeds that expected, each task 
could be independently assessed to determine whether there was perhaps just 
one task with which the driver experienced difficulties and fell outside of the 
normal range; this may be expected with the most difficult task, OLS.  Three 
participants scored outside the unimpaired range for this task (2 <40 and 1 >40).  
For RBT no-one exceeded normal and for WAT and FTN there was one person in 
the <40 age group outside of the predicted range.  It has been suggested that 
impairment should be concluded if the driver is witnessed to be impaired in two 
or more individual tests.360  By this means only one person would have been 
suspected of impairment.  Notably this was one of the participants with 
unsuitable footwear and if allowance was made for this she may not be deemed 
impaired. 
The two participants with error scores beyond the unimpaired range were close 
to the higher end of the age groups; all other unimpaired persons (97%) would be 
correctly diagnosed not to be under the influence of an impairing substance.  It 
seems that perhaps the more pressing problem could be whether or not impaired 
persons would exceed these definitions of “not impaired”. Two studies have 
demonstrated a majority of subjects being wrongly classified as impaired,330 and 
a high incidence of false positive results amongst a large cohort of unimpaired 
subjects who were incapable of passing the test.361  
The wide variation in performance and large range of acceptable errors observed 
in the current study suggest false positives are a real possibility.  This 
phenomenon was well demonstrated by Tiplady et al,364 when the mean change 
in performance from placebo to high dose of ethanol was less than the range of 
placebo performance obtained with a hand-held psychomotor testing device.  
Effectively an individual with good capacity for the task could remain within the 
range of normal performance, giving a performance similar to that of an 
unimpaired person with naturally poor aptitude for the task.  
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The DRE officers conducting the DECP are provided with a matrix which gives a 
broad guide to ‘normal’ measures, for example blood pressure, temperature, 
pupil diameter, the number and type of error to be expected in each physical 
task.  The DRE officers are required to record whether the driver was normal, 
above or below.  The allocations for normal have been questioned with only 
partial agreement.329  15 of the 29 symptoms listed in the matrix were not 
significantly different to a placebo ‘normal’ measure and one was significantly 
different in the opposite direction to that indicated in the DRE matrix.329  The 
wide ranging inter-driver performance suggests that, even with a scoring system, 
police officers may still have difficulty identifying impairment from a single 
measure (i.e. no knowledge of how that particular person would score whilst not 
under the influence of an impairing substance).  Thus the scoring system may 
lack specificity but could remove some of the subjectivity of the FIT process.  It 
could, therefore, provide an effective aid to police officers to increase their 
confidence to administer FIT, seek samples for toxicology testing and arrest 
drivers for DUID.  It could also provide the Crown with statistically justifiable 
evidence of possible impairment to aid management and increase prosecutions 
of such cases.  Under these circumstances, impairment is no longer simply a 
personal opinion.   
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Table 7-20:  Acceptable numbers of errors for unimpaired persons 
 
A limitation to the UK FIT is that it relies on the driver having a good 
understanding of the English language.  As comprehension is a large constituent 
of FIT evaluation, if a driver’s first language is not English more errors are 
anticipated.  It is also possible that the maximum error counts derived from this 
laboratory study were less than would be found by the road-side with English 
speaking drivers.  Impairment can be caused by distractions such as anxiety, 
discomfort and sleep deprivation.  Anxiety was apparent with some of the study 
participants, in particular one who was noted to laugh and sing throughout FIT.  
This could have been mistaken for the influence of a drug.  Most participants 
displayed some signs of nervousness which may well have been exacerbated to 
an impairing extent had FIT been performed under usual roadside circumstances.  
TASK < 40 > 40
Median 1 4
Standard Deviation 1.96 3.45
Outliers omitted from SD 1 (14) 1 (19)
Cautionary error score > 5 > 7
Unacceptable error score > 7 > 15
Median 0 0
Standard Deviation 0.4 0.6
Outliers omitted from SD
Cautionary error score > 1 > 2
Unacceptable error score > 2 > 2
Median 0 1.5
Standard Deviation 1.2 2.22
Outliers omitted from SD 1 (8)
Cautionary error score > 3 > 6
Unacceptable error score > 4 >9
Median 0 1
Standard Deviation 0.85 1.88
Outliers omitted from SD 2 (4 + 5) 1 (14)
Cautionary error score > 2 > 5
Unacceptable error score > 3 > 7
Median 0 0
Standard Deviation 0.57 0.45
Outliers omitted from SD 1 (3)
Cautionary error score > 2 > 1
Unacceptable error score > 2 > 2
FTN
Complete FIT
RBT
WAT
OLS
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To minimise external influences the driver should be made as comfortable as 
possible.  One participant arrived wearing an outdoors coat and advised that 
they might like to remove it as they might find it restrictive.  The vast majority 
of participants were not wearing outdoor clothing which could perhaps have 
slightly biased the results as many drivers would be expected to be wearing a 
coat.  The influence of outdoor clothing and also footwear should be further 
investigated, especially for drivers who may wear a restrictive uniform or 
protective motorcycle apparel.  One participant also asked to remove their 
glasses as their new lenses were causing them some disorientation.   
There are countless issues to be considered when assessing a person’s 
performance in divided attention-type tasks.  Some of these issues are 
immediately apparent such as injury or shock which may result from a road 
traffic accident.  Fatigue is known to affect performance of functions such as 
reaction speed, vigilance, and coordination.365  Studies of circadian rhythms 
have found performance to be poorest in the early morning and late at 
night.366,367  This is mirrored in studies of driving performance, as is 
deterioration of driving during the mid-afternoon (1400-1500 hours) dip in 
wakefulness also.259,366,368  Practical restrictions in the present study meant that 
testing could not be conducted late at night or in the very early hours, however 
testing was conducted over a range of times which included the mid-afternoon 
dip.  Impairment caused by fatigue should be something which the FME can 
address. 
There are some unseen factors, however, which could influence FIT 
performance.  Police Officers have expressed concern that disorders such as 
dyslexia and dyspraxia negatively affect FIT performance.337  This could also be 
true of attention deficit and autistic disorders.  The difficulty with these is that, 
unlike other conditions, an FME may not identify them, particularly as many 
sufferers can be unaware of their condition.337  Many adult drivers will have 
attended school before these conditions were widely recognised and they may 
never have been diagnosed.  
Finally, the scoring system assumes FIT will be performed exactly as directed by 
the SOP.  As different officers apply this to varying degrees, ‘normal’ scores 
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could be officer-specific.  In order for any scoring to be effectively 
implemented, FIT officers must be highly competent in conducting and 
interpreting FIT by a standardised method.  This requires intensive, regular 
training and monitoring. 
7.4.13 Effectiveness of FIT 
Some of the criticism directed towards FIT has been that the tasks involved do 
not directly reflect the act of driving and, therefore, cannot provide evidence 
that driving ability was impaired.  The study of drugs and driving has greatly 
expanded in the time since the introduction of FIT.  There is now a wealth of 
research to demonstrate that drugs impair driving.  The law is also changing such 
that demonstrating impaired driving will no longer be necessary for at least eight 
illegal drugs.  For those drugs not included in the Crime and Courts Bill and 
therefore without prescribed limits, the Section 4 impairment offence will 
remain but case law allows impaired driving to be evidenced by witnessing any 
act of poor driving.  It is now possible, therefore, to dismiss this criticism and 
focus on the true requirement of FIT - to detect a condition that may be due to 
drugs in order that a toxicology sample can be requested following an FME 
excluding other medical causes.  The ability of FIT to do so has been questioned. 
In a study of the Standardised Field Sobriety Test, WAT and OLS were found to 
be particularly sensitive for cannabis use as more participants failed these tasks 
whilst in THC state than in placebo state (age range 21 to 35).360  This study 
explored and demonstrated differences in performance from the same persons 
whilst in various states of intoxication.  This type of study would not be possible 
in the field.  Had the placebo and THC groups not comprised the same subjects, 
the difference may not have been statistically significant.  Additionally, as 
participants completed multiple Standardised Field Sobriety Test assessments 
they were trained to perform the tests, effectively eliminating the 
comprehension and recollection aspects of the assessment.  No significant 
predictive power was discerned by comparisons of DECP indicators between drug 
impaired populations and placebo group.  The DECP test components which are 
used in FIT were determined to be ineffective.329,330 
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UK legislation states that the Secretary of State should aim to ensure that a 
preliminary impairment test is “designed” to indicate whether “unfitness is 
likely to be due to…drugs”.369  The tasks which comprise FIT were not 
specifically designed for the purpose of detection of drug impairment.  FIT tasks 
evolved from observations of alcohol intoxicated individuals and do not appear 
to be very good at detecting drug impairment.  
7.5 Future Work 
Further work is required to determine whether two sets of criteria which define 
impairment in those over and under forty years of age are sufficient, or if 
performance differences across smaller age ranges achieve statistical 
significance.  This would require greater than 30 participants in each range.  The 
uncertainty associated with the median for the over 40 age group was large and 
more observations would be desirable to increase confidence in the proposed 
impairment criteria for drivers over forty.  The influence of time of day must 
also be addressed.  Many drivers who commit DUID offences do so late at night 
or in the early hours of the morning, when impairment in even the normal 
population could be increased.  This could be complicated, however, by the 
possibility that those under the influence of a stimulant would have better than 
baseline performance at this hour due to their fatigue compensation. 
The final scoring system requires to be tested and validated.  Blind testing 
should be performed to determine the specificity, sensitivity and accuracy in 
individuals who are unimpaired or under the influence of intoxicating 
substances.  For any test of impairment to be effective and worthwhile it must 
be demonstrated that there is a significant difference in response between 
impaired and non-impaired drivers.  If this can be determined, a complete FIT 
validation can be launched.  This would require FIT to be observed and scored by 
a number of different officers to ensure robustness of the SOP and scoring 
system, similar to performing an analytical method validation under 
reproducible conditions i.e. applying the same method but on a different 
instrument or with different operators etc.  Applicability of the impairment 
definitions must also be tested on the roadside. 
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7.6 Conclusion 
A conservative approach to FIT interpretation of ‘error’ produced more 
meaningful error counts. Errors should not be recorded to have occurred 
“throughout”, rather a reminder should be given if it appears the instruction has 
not been carried out and then each instance of the fault recorded.  Pupil size 
may not be informative as unimpaired persons were outside of the defined 
normal range.  The defined range for time estimation was also flawed.  WAT and 
OLS were the most difficult FIT tasks and FTN and RBT were the easiest.  
Performance with FIT deteriorates with age, with the decrement becoming 
statistically significant over the age of at least 40 years.  There is large variation 
in the normal performance abilities of individuals, so large that establishing the 
range of normal performance will require many more than 30 subjects in each 
age group to be observed, using small age ranges.  More than two age ranges is 
desirable.  
In order to boost police officers’ confidence in performing FIT and requesting 
toxicology samples, a PTS-type scoring system has been devised which defines 
impairment for English-speaking drivers between the ages of 17 to 39 and 40 
years plus. 
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Chapter 8:  Conclusion 
Consideration of the application of quality assurance to forensic toxicology 
services has revealed some deficiencies.  It is understood that forensic 
toxicology is a sector where the nature of the work, analysing poor quality 
samples for unknown analytes possibly present at very low concentrations, 
means that some allowances are necessary with respect to the quality which can 
be achieved.  Consequently, however, it is a sector within which quality should 
be a primary focus and implemented to the highest degree, particularly as 
results can have very serious legal implications.  There are some areas of 
forensic toxicology where quality needs to be improved. 
Possibly the most difficult area is in keeping pace with the emergence of new 
substances of abuse; the recent surge in NPS has presented a particular struggle.  
Each new substance necessitates development and validation of an analytical 
method.  Review of the Quartz PTS demonstrated the difficulty laboratories 
have with new substances, particularly BZP which belongs to the piperazines 
class of NPS.  Many of these continue to be forensically relevant and it is 
important that forensic toxicology laboratories validate methods for their 
detection to remain effective.  In the absence of an immunoassay screening 
method an LC-MS/MS screening method for piperazines has been validated which 
requires only a small fraction of a routine basic drug extract, preserving the 
majority for other analyses as necessary.  The lack of suitable reference 
standards is a problem for both the GC-MS and LC-MS/MS methods.  Due to the 
possible presence of undetected matrix effects however, the lack of standards is 
particularly troublesome for LC-MS/MS and does not allow for quantification by 
this method.  The internal standards were sufficient that the validated GC-MS 
method can provide quantification for a range of piperazine compounds. 
Different guides from various official bodies cause confusion in knowing whether 
or not a method has been sufficiently validated.  Validation requires laboratories 
to invest time and money to ensure, and demonstrate, that they have a fit-for-
purpose protocol.  Having expended this effort, careful application of internal 
Chapter 8  233 
 
 
quality control is essential to confirm that the method has attained sufficient 
quality and that this is being safeguarded.  It is vital that the suitability of IQC 
procedures is also proven through relevant independent external monitoring.  
This is particularly relevant to the analysis of NPS for which it can be difficult to 
obtain certified reference standards (particularly two sources for independent 
calibrators and controls).  Unfortunately these substances are not often included 
in PTS. 
It is difficult for forensic toxicology laboratories to obtain EQA which is entirely 
suited to their routine workload.  EQA should primarily assist laboratories to 
guard against undetected errors and may additionally provide educational 
benefits.  One scheme may not be enough and a combination may be required to 
achieve the necessary safeguards and maintain learning.  Laboratories need to 
select enough schemes in which to participate to ensure a representative sample 
of their analyses is monitored.  They must determine what they may want to 
achieve from EQA (e.g. bias detection for particular substances or experience 
with emerging substances) and rigorously review scheme protocols to ensure 
participation will satisfy their aims. EQA must be fit-for-purpose.   
This demands laboratories understand PTS scoring systems and how these impact 
upon their perceived performance.  To be fit for the purpose of bias detection a 
scheme must not use a participant-dependent scoring method, but use 
appropriate acceptable variation based on expert opinion.  In order for a PTS to 
be effective in its aim of bias detection, laboratories must participate regularly 
(at least once per year, ideally twice) and pay close attention to their reported 
proficiency.  Where necessary laboratories should recalculate their own 
proficiency score to ensure testing is to a standard appropriate for the needs of 
their clients.  Apart from laboratory managers, less senior staff should also be 
coordinating PT, or at least reviewing PT reports, to gain an appreciation of the 
importance of quality assurance early in their career and benefit from shared 
experience.  This is also helpful in ensuring the quality of results being released 
from the laboratory; it will often be the technical staff who conduct the analysis 
and they should be aware of their own performance. 
As the selection of PTSs available to forensic toxicology laboratories was found 
to be very limited, long term reviews of two quite different forensic toxicology 
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PTSs were conducted and the strengths and weaknesses of both schemes were 
identified via comparison.  Improvements which could be made to both schemes 
to further benefit their participants were highlighted.   
The Quartz Forensic Blood Toxicology Proficiency Testing Scheme was primarily 
an educational resource.  Laboratories that have established their proficiency in 
their most commonly-used methods can benefit from the varied nature of this 
scheme to gain experience with analytes which are not encountered often or 
which are emerging substances of abuse.  In order to provide a safeguard against 
bias this scheme requires more repetitive testing.  Without such testing this 
scheme does not provide participants with an effective means of monitoring 
routine laboratory performance.  The requirement for more focused, frequent, 
testing of the most relevant forensic analytes was brought to the attention of 
the coordinators and is now being actioned. 
UNODC International Collaborative Exercises is in need of more consistent 
participation.  This is outside of the control of the coordinators.  Due to the 
smaller array of potential analytes and, therefore, more repetitive nature of the 
testing ICE was more effective as a means of external quality assurance.  ICE, 
however, is not recognised as a PTS for accreditation purposes, whereas Quartz 
is a UKAS accredited scheme, and also it uses urine rather than whole blood, the 
preferred sample type in post mortem forensic toxicology.  
The reviews demonstrated that accreditation of a PTS is not an endorsement of 
its quality and that an unaccredited scheme can be more suitable for the 
intended purpose of a PTS.  Laboratories should not base selection of EQA on 
accreditation status but on whether or not the analytes tested, the frequency of 
testing and the scoring system applied are appropriate for their needs.  A further 
example of mistaken reliance on accreditation to support fitness-for-purpose 
was demonstrated by the ISO-accredited field impairment test. 
The police FIT has never been fully validated.  The first step in validation of this 
protocol now has been completed.  Acceptable performance in the FIT for 
drivers over and under the age of 40 years has been defined (for drivers 
competent with the English language).  Error counts outside of these acceptable 
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ranges provide police officers reason to pursue further testing with scientific 
justification for this which, if necessary, could be presented to the Court.   
In order that police officers maintain competence with the FIT SOP a form of 
proficiency testing could be introduced which tests their understanding of the 
process and the driver errors which should be recorded.  As the offence of 
driving with levels of prescribed drugs above prescribed limits is soon to be 
enforced, it is also important for fairness to drivers, that toxicology laboratories 
that will perform analysis of drivers’ blood samples be monitored to ensure 
acceptable accuracy at the levels of interest.  As it is anticipated that oral fluid 
could eventually replace blood specimens from drivers, it is promising that oral 
fluid PTS are being developed. 
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Appendix 1:  Quartz False Positives in 
Identification Samples 
 
Table Appendix I, 1:  False positives observed with Quartz identification samples
Round False Positive False Negative
30 Clomipramine Morphine
32 Salicylate + Clozapine
MDMA Benzoylecgonine + cocaine
Lignocane
Lignocane Benzoylecgonine
35 Citalopram
Citalopram
Citalopram
Citalopram
Citalopram
Citalopram
Citalopram
Citalopram Morphine
37 Amphetamine + Methamphetamine BZP + MDA + MDMA
40 Phenobarbital Secobarbital
Butobarbital
41 Promethazine Demoxepam
Methamphetamine Desmethyldiazepam + Demoxepam
Temazepam Demoxepam
Lignocane Desmethyldiazepam + Demoxepam
42 MDMA
44 Mephedrone Buprenorphine
Morphine Buprenorphine
45 Venlafaxine Trazodone
BZP
46 Chlodiazepoxide Amlodipine
47 Paracetamol Morphine
Morphine Ketamine + temazepam
  237 
 
 
Appendix 2: Quartz Participant Identification 
Methods 
 
Table Appendix 2, 1:  Method used for identification of opiates 
 
 
Table Appendix 2, 2:  Method used for identification of basic drugs 
 
 
Table Appendix 2, 3:  Method used for identification of benzodiazepines
Drug Type
Round
Method
LC-MS/MS 1 2 2 1 2 8 1
HPLC-MS 2 2 3 3 7 /2 7 /4 2 1 4 /1 10 /4 41 /11 8 /1
HPLC-Diode Array 1 1 /1 2 2 1 /1 1 2 5 1 16 /2
HPLC-UV Vis 1 1
MS-MS 3 /2 2 3 /2 1 /1 1 /1 1 1 2 14 /6
GC-MS 12 /3 13 /1 9 /3 9 /1 9 6 /3 6 /2 7 5 /2 7 /1 4 /1 87 /17 7
GC-NPD 1 /1 1 /1 2 /2 1 /1
GC-FID 1 /1 1 /1
EIA 1 /1 1 /1
Unknow n/Other 1 1 2 1 5 1 /1
Opiates Group
Analyses/Not detected
Methadone
Total42 44 4430 30 33 35 35 36 36 39 40
Drug Type
Round
Method
LC-MS/MS 2 /2 2 /2 2 2 1 1 3 /2 3 16 /6
HPLC-MS 2 /1 1 2 1 1 4 6 /1 6 /3 5 /1 4 3 5 40 /6
HPLC-Diode Array 1 3 2 2 /1 2 /1 1 3 3 2 1 /1 1 21 /3
HPLC-UV Vis 5 /1 1 6 /1
MS-MS 3 1 1 3 /1 2 /1 2 4 /1 3 3 22 /3
GC-MS 9 9 /5 10 11 /1 11 /1 8 /1 7 /1 6 6 /4 4 /2 6 6 /1 5 98 /16
GC-NPD 1 1 1 1 2 1 7
Unknow n/Other 1 /1 2 2 /2 1 /1 6 /4
Basic Drugs
Total
Analyses/Not detected
4746 484833 34 34 36 36 38 42 45 45
Drug Type
Round
Method
LC-MS/MS 1 1
HPLC-MS 3 3 7 7 /2 7 /4 6 33 /6
HPLC-Diode Array 1 1 5 5 5 /2 17 /2
HPLC-UV Vis 1 /1 1 2 /1
MS-MS 1 /1 1 2 /1 2 2 /2 4 /1 12 /5
GC-MS 9 /1 9 4 4 4 /4 4 /3 34 /8
GC-NPD 1 /1 1 /1
GC-ECD 1 1 1 /1 3 /1
Unknow n/Other 1 /1 1 /1
47 Total
Benzodiazepines
Analyses/Not detected
31 31 41 41 41
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Table Appendix 2, 4:  Method used for identification of ATS, BZP, mephedrone and GHB 
 
 
Table Appendix 2, 5:  Method used for identification of cocaine 
 
 
Table Appendix 2, 6:  Method used for identification of Barbiturates 
 
 
 
Drug Type
Round
Method
LC-MS/MS 1 1 1 1 4 1 1 /1 1
HPLC-MS 2 2 4 /1 4 /2 12 /3 2 /1 4 4 /2
HPLC-Diode Array 1 /1 1 1 2 5 /1 1 /1 1 1 /1
MS-MS 3 3 2 /1 8 /1 3 /2
GC-MS 9 /4 9 /1 7 /1 4 /3 29 /6/9 9 /5 7 /2 7 /3
GC-NPD 1 1 1 /1 1
GC-ECD 1 /1 1 /1
Unknow n/Other 1 /1 2 /2 3 /3 1 /1 1 /1
GHB
Analyses/Not detected Analyses/Not detected
4337 37 46 37 43 43
ATS
Total
BZP Mephedrone
Drug Type
Round
Method
HPLC-MS 3 1 2 2 8
HPLC-Diode Array 2 /1 2 /1 2 2 8 /2
MS-MS 1 2 1 1 5
GC-MS 11 /4 12 /1 7 /3 7 37 /8
Unknow n/Other 1 1 2
Analyses/Not detected
39
Cocaine Group
32 32 39 Total
Drug Type
Round
Method
HPLC-MS 1 1 2 /6
HPLC-Diode Array 2 /1 2 /1 4 /2
MS-MS 1 /1 1 /1 2 /5
GC-MS 8 /2 8 /2 16 /8
GC-FID 1 /1 1 /1 2 /1
Unknow n/Other 2 /1 2 /1 4 /1
Analyses/Not detected
Barbiturates
40 40 41 Total
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Appendix 3: Quartz Participant Quantification 
Methods      
   
 
Table Appendix 3, 1:  Method used for quantification of basic drugs 
 
 
Table Appendix 3, 2:  Method used for quantification of cocaine 
 
 
Table Appendix 3, 3:  Method used for quantification of opiates 
 
 
Table Appendix 3, 4:  Method used for quantification of methadone
Drug Type
Round
Method
LC-MS/MS 1 1 1 1 1 1 1 1 8
HPLC-MS 4 5 6 /1 4 /1 7 /1 4 6 /2 3 9 /1 5 5 /1 4 /2 2 4 4 /1 4 /1 5 81 /11
HPLC-Diode Array 5 /1 4 4 /1 2 3 3 2 /1 3 2 1 3 3 4 /1 4 /1 2 /1 2 47 /6
HPLC-UV Vis 2 1 1 1 1 2 1 /1 1 10 /1
MS-MS 3 /1 1 /1 1 2 2 2 4 3 2 20 /2
GC-MS 3 /2 4 /1 6 1 4 /2 3 /1 3 6 6 /1 3 4 /1 2 /1 6 4 /1 55 /10
GC-NPD 1 2 1 2 1 3 2 12
Unknow n/Other 2 /1 2 1 2 1 /1 8 /2
48 48 Total
Analyses/Unsatisfactory
Basic Drugs
4035 3531 32 32 36 36 41 4338 44 46 46 46
Drug Type
Round
Method
HPLC-MS 2 3 5 3 5 /1 18 /1
HPLC-Diode Array 3 /1 2 1 3 9 /1
MS-MS 1 1 2 4 /1 1 9 /1
GC-MS 11 /1 10 5 5 /2 5 36 /3
GC-NPD 1 1 2 4
Other 1 2 3 6
Analyses/Unsatisfactory
Opiates
30 37 41 42 42 Total
Drug Type
Round
Method
HPLC-MS 3 7 /1 10 /1
HPLC-Diode Array 2 /2 3 5 /2
MS-MS 1 1
GC-MS 11 /1 6 /1 17 /2
Analyses/Unsatisfactory
Methadone
37 38 Total
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Table Appendix 3, 5:  Method used for quantification of benzodiazepines 
 
 
Table Appendix 3, 6:  Method used for quantification of ATS, mephedrone and BZP
Drug Type
Round
Method
HPLC-MS 3 /1 4 7 /1
HPLC-Diode Array 7 6 /1 13 /1
HPLC-UV Vis 1 /1 2 3 /1
MS-MS 2 2
GC-MS 4 /2 2 6 /2
GC-NPD 1 1
Other 1 1
30 34
Bezodiazepines
Analyses/Unsatisfactory
Total
Drug Type BZ
Round 33 33 34 Tot 45 45
Method
LC-MS/MS 1 1 1
HPLC-MS 1 2 3 6 2
HPLC-Diode Array 1 /1 2 /1 1 4 /2 2 /1 1
MS-MS 1 1 2 4 4 /1
GC-MS 11 11 /1 10 /1 43 /2 5 /1 5 /2
GC-NPD 1
Unknow n/Other 1 1 1 /1 3 /1 1 2
Mephedrone
Analyses/Unsatisfactory
Amphetamine Type Stimulants
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Appendix 4: GC-MS Fragmentation of HFBA 
Derivatised Piperazines 
 
Figure Appendix 4, 1:  GC-MS fragmentation of BZP-D8 
 
 
Figure Appendix 4, 2:  GC-MS fragmentation of BZP 
 
 
Figure Appendix 4, 3:  GC-MS fragmentation of p-FPP 
 
 
Figure Appendix 4, 4:  GC-MS fragmentation of TFMPP 
 
 
 
Figure Appendix 4, 5:  GC-MS fragmentation of MPP
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Figure Appendix 4, 6:  GC-MS fragmentation of MeOPP 
 
 
Figure Appendix 4, 7:  GC-MS fragmentation of CPP
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Appendix 5: LC-QqQ Fragmentation of Piperazines 
 
Figure 41:  LC-MS/MS fragmentation of BZP 
 
Figure 42:  LC-MS/MS fragmentation of TFMPP 
 
Figure 43:  LC-MS/MS fragmentation of MPP 
 
Figure 44:  LC-MS/MS fragmentation of MeOPP 
 
Figure 45:  LC-MS/MC fragmentation of CPP 
 
Figure 46:  LC-MS/MS fragmentation of p-FPP
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Appendix 8:  Scottish Field Impairment Test Form 
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